MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01D74B3E.EF6E2E70"

This document is a Single File Web Page, also known as a Web Archive file.  If you are seeing this message, your browser or editor doesn't support Web Archive files.  Please download a browser that supports Web Archive.

------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1252"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:dt=3D"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
2">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 15">
<meta name=3DOriginator content=3D"Microsoft Word 15">
<link rel=3DFile-List href=3D"Karvea_clean_files/filelist.xml">
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"City"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"place"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"PersonName"/>
<!--[if gte mso 9]><xml>
 <o:CustomDocumentProperties>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Enabled dt:dt=3D"strin=
g">true</o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Enabled>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_SetDate dt:dt=3D"strin=
g">2021-05-12T20:18:53Z</o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_=
SetDate>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Method dt:dt=3D"string=
">Standard</o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Method>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Name dt:dt=3D"string">=
0eea11ca-d417-4147-80ed-01a58412c458</o:MSIP_Label_0eea11ca-d417-4147-80ed-=
01a58412c458_Name>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_SiteId dt:dt=3D"string=
">bc9dc15c-61bc-4f03-b60b-e5b6d8922839</o:MSIP_Label_0eea11ca-d417-4147-80e=
d-01a58412c458_SiteId>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_ActionId dt:dt=3D"stri=
ng">f9c34865-cb29-43a3-9b00-8f728be9a8a4</o:MSIP_Label_0eea11ca-d417-4147-8=
0ed-01a58412c458_ActionId>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_ContentBits dt:dt=3D"s=
tring">2</o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_ContentBits>
 </o:CustomDocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
  <o:RemovePersonalInformation/>
  <o:RemoveDateAndTime/>
  <o:TargetScreenSize>800x600</o:TargetScreenSize>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=3DdataStoreItem href=3D"Karvea_clean_files/item0001.xml"
target=3D"Karvea_clean_files/props002.xml">
<link rel=3DdataStoreItem href=3D"Karvea_clean_files/item0003.xml"
target=3D"Karvea_clean_files/props004.xml">
<link rel=3DdataStoreItem href=3D"Karvea_clean_files/item0005.xml"
target=3D"Karvea_clean_files/props006.xml">
<link rel=3DdataStoreItem href=3D"Karvea_clean_files/item0007.xml"
target=3D"Karvea_clean_files/props008.xml">
<link rel=3DthemeData href=3D"Karvea_clean_files/themedata.thmx">
<link rel=3DcolorSchemeMapping href=3D"Karvea_clean_files/colorschememappin=
g.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:HideSpellingErrors/>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:DrawingGridHorizontalSpacing>5.5 pt</w:DrawingGridHorizontalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEve=
ry>
  <w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:UseWord2010TableStyleRules/>
   <w:DontGrowAutofit/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
   <w:DontVertAlignCellWithSp/>
   <w:DontBreakConstrainedForcedTables/>
   <w:DontVertAlignInTxbx/>
   <w:Word11KerningPairs/>
   <w:CachedColBalance/>
  </w:Compatibility>
  <w:DocumentVariables>
   <w:CurrentCoreTemplateVersion>3.0.1.4</w:CurrentCoreTemplateVersion>
   <w:InitialCoreTemplateVersion>1.0</w:InitialCoreTemplateVersion>
  </w:DocumentVariables>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac m:val=3D"off"/>
   <m:dispDef/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapIndent m:val=3D"1440"/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"false"
  DefSemiHidden=3D"false" DefQFormat=3D"false" LatentStyleCount=3D"376">
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"heading 2"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"heading 3"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"heading 4"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"heading 5"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"heading 6"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"heading 7"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"heading 8"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"heading 9"/>
  <w:LsdException Locked=3D"true" Name=3D"toc 1"/>
  <w:LsdException Locked=3D"true" Name=3D"toc 2"/>
  <w:LsdException Locked=3D"true" Name=3D"toc 3"/>
  <w:LsdException Locked=3D"true" Name=3D"toc 4"/>
  <w:LsdException Locked=3D"true" Name=3D"toc 5"/>
  <w:LsdException Locked=3D"true" Name=3D"toc 6"/>
  <w:LsdException Locked=3D"true" Name=3D"toc 7"/>
  <w:LsdException Locked=3D"true" Name=3D"toc 8"/>
  <w:LsdException Locked=3D"true" Name=3D"toc 9"/>
  <w:LsdException Locked=3D"true" SemiHidden=3D"true" UnhideWhenUsed=3D"tru=
e"
   QFormat=3D"true" Name=3D"caption"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" Name=3D"annotation refer=
ence"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" Name=3D"Hyperlink"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"true" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"true" Name=3D"Table Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   Name=3D"Placeholder Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" QFormat=3D"true" Name=3D"=
No Spacing"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true" Name=
=3D"Revision"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" QFormat=3D"true"
   Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" QFormat=3D"true" Name=3D=
"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" QFormat=3D"true"
   Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"19" QFormat=3D"true"
   Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"21" QFormat=3D"true"
   Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"31" QFormat=3D"true"
   Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"32" QFormat=3D"true"
   Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"33" QFormat=3D"true" Name=3D=
"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"37" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" QFormat=3D"true" Name=3D"TOC Heading"/>
  <w:LsdException Locked=3D"false" Priority=3D"41" Name=3D"Plain Table 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"42" Name=3D"Plain Table 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"43" Name=3D"Plain Table 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"44" Name=3D"Plain Table 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"45" Name=3D"Plain Table 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"40" Name=3D"Grid Table Light=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"46" Name=3D"Grid Table 1 Lig=
ht"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k"/>
  <w:LsdException Locked=3D"false" Priority=3D"51" Name=3D"Grid Table 6 Col=
orful"/>
  <w:LsdException Locked=3D"false" Priority=3D"52" Name=3D"Grid Table 7 Col=
orful"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"46" Name=3D"List Table 1 Lig=
ht"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k"/>
  <w:LsdException Locked=3D"false" Priority=3D"51" Name=3D"List Table 6 Col=
orful"/>
  <w:LsdException Locked=3D"false" Priority=3D"52" Name=3D"List Table 7 Col=
orful"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Mention"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Smart Hyperlink"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Hashtag"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Unresolved Mention"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Smart Link"/>
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid=3D"clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=3Dieooui></objec=
t>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-alt:"\FF2D\FF33 \660E\671D";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;
	mso-font-alt:\BC14\D0D5;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\5B8B\4F53;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 680460288 22 0 262145 0;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;
	mso-font-alt:\65B0\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611969 684719354 22 0 1048577 0;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;
	mso-font-alt:"\FF2D\FF33 \30B4\30B7\30C3\30AF";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\B3CB\C6C0;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\9ED1\4F53;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;
	mso-font-alt:\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1610611969 684719354 22 0 1048577 0;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;
	mso-font-alt:\660E\671D;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;
	mso-font-alt:\AD74\B9BC;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1048579 0 0 0 1 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:67110535 0 0 0 159 0;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:65539 0 0 0 1 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:131075 0 0 0 1 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:262147 0 0 0 1 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2097155 0 0 0 1 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:4194307 0 0 0 1 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:1;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536869121 1107305727 33554432 0 415 0;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;
	mso-font-alt:\6E38\30B4\30B7\30C3\30AF;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\7B49\7EBF;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610612033 953122042 22 0 262159 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073732485 9 0 511 0;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073732485 9 0 511 0;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870265 1073741843 0 0 415 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610610945 1073750107 16 0 415 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 33554432 0 0 1 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536858881 -1073711013 9 0 511 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-alt:"Times New Roman";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 134676480 16 0 131073 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;
	mso-font-alt:"Times New Roman";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536859905 -1073711039 9 0 511 0;}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-alt:"MS Gothic";
	mso-font-charset:128;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:0 134676480 16 0 131073 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612049 1073772795 0 0 159 0;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536869121 1107305727 33554432 0 415 0;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073783883 0 0 415 0;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611969 2 0 0 415 0;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 19 0 0 159 0;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536869121 64767 1 0 415 0;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073783883 0 0 415 0;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073783883 0 0 415 0;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610612641 33554497 2048 0 147 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:-536870161 1342185547 0 0 159 0;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 33554432 12288 0 1 0;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 0 0 1 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 8192 0 0 1 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1560281085 0 65536 0 65793 0;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1560281085 0 65536 0 65793 0;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482993 6144 0 0 31 0;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147480833 14699 0 0 191 0;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1879048145 701988091 18 0 524289 0;}
@font-face
	{font-family:"\@Malgun Gothic";
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1879048145 701988091 18 0 524289 0;}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342174545 165641467 18 0 4063677 0;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1342174545 165641467 18 0 4063677 0;}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 65536 64 0 1 0;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:679 684672000 22 0 1048585 0;}
@font-face
	{font-family:"\@Microsoft JhengHei";
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:679 684672000 22 0 1048585 0;}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:679 684672000 22 0 1048585 0;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:679 684672000 22 0 1048585 0;}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147482969 684672000 22 0 1048585 0;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147482969 684672000 22 0 1048585 0;}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147482969 684672000 22 0 1048585 0;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";
	mso-font-charset:136;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147482969 684672000 22 0 1048585 0;}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 -2147483648 0 1 0;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 134217728 0 1 0;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-452972801 -1073717157 41 0 66047 0;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 1073741824 0 1 0;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 718224464 22 0 262175 0;}
@font-face
	{font-family:"\@Microsoft YaHei";
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 718224464 22 0 262175 0;}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 718224464 22 0 262175 0;}
@font-face
	{font-family:"\@Microsoft YaHei UI";
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 718224464 22 0 262175 0;}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 718209040 22 0 262175 0;}
@font-face
	{font-family:"\@Microsoft YaHei Light";
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 718209040 22 0 262175 0;}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 718209040 22 0 262175 0;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";
	mso-font-charset:134;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 718209040 22 0 262175 0;}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 66562 524290 0 1 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 168296456 16 0 1048577 0;}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483613 0 131072 0 1 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:"\@MS UI Gothic";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:"\@MS PGothic";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 256 0 1 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 1024 0 1 0;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130739165 33554506 512 0 1 0;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130739165 33554506 512 0 1 0;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 268435456 0 0 1 0;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:655 0 0 0 159 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:655 0 0 0 159 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073683329 9 0 511 0;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1073800319 33 0 415 0;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483153 33554434 6340736 0 1 0;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073683329 9 0 511 0;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073683329 9 0 511 0;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073683329 9 0 511 0;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483165 302055407 262144 0 1 0;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 680460288 22 0 262145 0;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:643 680460288 22 0 262145 0;}
@font-face
	{font-family:"\@NSimSun";
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:643 680460288 22 0 262145 0;}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:3 168689664 16 0 262145 0;}
@font-face
	{font-family:"\@SimSun-ExtB";
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:3 168689664 16 0 262145 0;}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1671 0 0 0 159 0;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"\@Yu Gothic UI";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"\@Yu Gothic Light";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717749759 22 0 131231 0;}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 268435456 0 0 1 0;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 2048 0 0 159 0;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 17 0;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147475353 -2147483648 8 0 65 0;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147475353 -2147483648 8 0 65 0;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147475353 -2147483648 8 0 65 0;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"MT Extra";
	panose-1:5 5 1 2 1 2 5 2 2 2;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 0 0 0 415 0;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 3 0;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;
	mso-font-charset:2;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Abadi;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 0 0 1 0;}
@font-face
	{font-family:"Abadi Extra Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 0 0 1 0;}
@font-face
	{font-family:Aharoni;
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2051 0 0 0 33 0;}
@font-face
	{font-family:Aldhabi;
	mso-font-charset:178;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147475449 -2147483648 8 0 65 0;}
@font-face
	{font-family:Alef;
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2055 1073741824 0 0 179 0;}
@font-face
	{font-family:"Amasis MT Pro";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610612561 1073750107 0 0 147 0;}
@font-face
	{font-family:"Amasis MT Pro Black";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610612561 1073750107 0 0 147 0;}
@font-face
	{font-family:"Amasis MT Pro Light";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610612561 1073750107 0 0 147 0;}
@font-face
	{font-family:"Amasis MT Pro Medium";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610612561 1073750107 0 0 147 0;}
@font-face
	{font-family:"Amatic SC";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536873487 1073741826 0 0 439 0;}
@font-face
	{font-family:AngsanaUPC;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:Aparajita;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:"Arabic Typesetting";
	mso-font-charset:178;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147475449 -2147483648 8 0 211 0;}
@font-face
	{font-family:"Aref Ruqaa";
	mso-font-charset:178;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147475345 -2147483573 0 0 65 0;}
@font-face
	{font-family:"Arial Nova";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:655 2 0 0 415 0;}
@font-face
	{font-family:"Arial Nova Cond";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:655 2 0 0 415 0;}
@font-face
	{font-family:"Arial Nova Cond Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:655 2 0 0 415 0;}
@font-face
	{font-family:"Arial Nova Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:655 2 0 0 415 0;}
@font-face
	{font-family:Assistant;
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610433 1073750091 0 0 33 0;}
@font-face
	{font-family:"Assistant ExtraBold";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610433 1073750091 0 0 33 0;}
@font-face
	{font-family:"Assistant ExtraLight";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610433 1073750091 0 0 33 0;}
@font-face
	{font-family:"Assistant Light";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610433 1073750091 0 0 33 0;}
@font-face
	{font-family:"Assistant SemiBold";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610433 1073750091 0 0 33 0;}
@font-face
	{font-family:Athiti;
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Athiti ExtraLight";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Athiti Light";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Athiti Medium";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Athiti SemiBold";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Avenir Next LT Pro";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483409 1342185546 0 0 147 0;}
@font-face
	{font-family:"Avenir Next LT Pro Demi";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483409 1342185546 0 0 147 0;}
@font-face
	{font-family:"Avenir Next LT Pro Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612497 1342185547 0 0 147 0;}
@font-face
	{font-family:BatangChe;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:Bembo;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 0 0 1 0;}
@font-face
	{font-family:Bierstadt;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 1 0 0 1 0;}
@font-face
	{font-family:"Bierstadt Display";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 1 0 0 1 0;}
@font-face
	{font-family:Biome;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1592449281 -2147483638 65536 0 415 0;}
@font-face
	{font-family:"Biome Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1592449281 -2147483638 65536 0 415 0;}
@font-face
	{font-family:"Browallia New";
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:BrowalliaUPC;
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:Cavolini;
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-1592449281 -2147483638 65536 0 415 0;}
@font-face
	{font-family:Charmonman;
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:Chonburi;
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:CordiaUPC;
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:Dante;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 0 0 1 0;}
@font-face
	{font-family:DaunPenh;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 65536 0 1 0;}
@font-face
	{font-family:David;
	mso-font-charset:177;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2051 0 0 0 33 0;}
@font-face
	{font-family:Daytona;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147482897 10 0 0 415 0;}
@font-face
	{font-family:"Daytona Condensed";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Daytona Condensed Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Daytona Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"DengXian Light";
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610612033 953122042 22 0 262159 0;}
@font-face
	{font-family:DilleniaUPC;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:DokChampa;
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2097151997 0 0 0 65537 0;}
@font-face
	{font-family:DotumChe;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:"EB Garamond";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 33555475 0 0 415 0;}
@font-face
	{font-family:"EB Garamond ExtraBold";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 33555475 0 0 415 0;}
@font-face
	{font-family:"EB Garamond Medium";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 33555475 0 0 415 0;}
@font-face
	{font-family:"EB Garamond SemiBold";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 33555475 0 0 415 0;}
@font-face
	{font-family:"Elephant Pro";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536871559 2 0 0 415 0;}
@font-face
	{font-family:EucrosiaUPC;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:Euphemia;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483537 74 8192 0 1 0;}
@font-face
	{font-family:Fahkwang;
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Fahkwang ExtraLight";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Fahkwang Light";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Fahkwang Medium";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Fahkwang SemiBold";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:FangSong;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:"Frank Ruhl Libre";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2055 1073741825 0 0 163 0;}
@font-face
	{font-family:"Frank Ruhl Libre Black";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2055 1073741825 0 0 163 0;}
@font-face
	{font-family:"Frank Ruhl Libre Light";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2055 1073741825 0 0 163 0;}
@font-face
	{font-family:"Frank Ruhl Libre Medium";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2055 1073741825 0 0 163 0;}
@font-face
	{font-family:FrankRuehl;
	mso-font-charset:177;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2051 0 0 0 33 0;}
@font-face
	{font-family:FreesiaUPC;
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:"Georgia Pro";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Georgia Pro Black";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Georgia Pro Cond";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Georgia Pro Cond Black";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Georgia Pro Cond Light";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Georgia Pro Cond Semibold";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Georgia Pro Light";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Georgia Pro Semibold";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Gill Sans Nova";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Gill Sans Nova Cond";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Gill Sans Nova Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:Gisha;
	mso-font-charset:177;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147481593 1073741890 0 0 33 0;}
@font-face
	{font-family:"Goudy Type";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:7 1 0 0 147 0;}
@font-face
	{font-family:Grandview;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:"Grandview Display";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610612025 2 0 0 415 0;}
@font-face
	{font-family:Grotesque;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 0 0 1 0;}
@font-face
	{font-family:"Grotesque Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 0 0 1 0;}
@font-face
	{font-family:GulimChe;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:Gungsuh;
	mso-font-charset:129;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:GungsuhChe;
	mso-font-charset:129;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-1342176593 1775729915 48 0 524447 0;}
@font-face
	{font-family:"Hadassah Friedlaender";
	mso-font-charset:177;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:2051 0 0 0 33 0;}
@font-face
	{font-family:Heebo;
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610457 1073741891 0 0 33 0;}
@font-face
	{font-family:"Heebo Black";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610457 1073741891 0 0 33 0;}
@font-face
	{font-family:"Heebo ExtraBold";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610457 1073741891 0 0 33 0;}
@font-face
	{font-family:"Heebo Light";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610457 1073741891 0 0 33 0;}
@font-face
	{font-family:"Heebo Medium";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610457 1073741891 0 0 33 0;}
@font-face
	{font-family:"Heebo Thin";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610610457 1073741891 0 0 33 0;}
@font-face
	{font-family:HGGothicE;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:HGMaruGothicMPRO;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:HGMinchoE;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:HGPGothicE;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:HGPMinchoE;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:HGPSoeiKakugothicUB;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:HGSGothicE;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:HGSMinchoE;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:HGSoeiKakugothicUB;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:HGSSoeiKakugothicUB;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 717745662 18 0 131073 0;}
@font-face
	{font-family:IrisUPC;
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:"Iskoola Pota";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 512 0 1 0;}
@font-face
	{font-family:JasmineUPC;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:KaiTi;
	mso-font-charset:134;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-2147482945 953122042 22 0 262145 0;}
@font-face
	{font-family:Kalinga;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:524291 0 0 0 1 0;}
@font-face
	{font-family:Kartika;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:8388611 0 0 0 1 0;}
@font-face
	{font-family:"Khmer UI";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 65536 0 1 0;}
@font-face
	{font-family:Kigelia;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1609226497 -1040187317 67584 0 415 0;}
@font-face
	{font-family:"Kigelia Arabic";
	mso-font-charset:178;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610603905 -2147483645 8 0 471 0;}
@font-face
	{font-family:"Kigelia Arabic Light";
	mso-font-charset:178;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610603905 -2147483645 8 0 471 0;}
@font-face
	{font-family:"Kigelia Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1609226497 -1040187317 67584 0 415 0;}
@font-face
	{font-family:KodchiangUPC;
	mso-font-charset:222;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:Kokila;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:Krub;
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Krub ExtraLight";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Krub Light";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Krub Medium";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Krub SemiBold";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:Lalezar;
	mso-font-charset:178;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:536879111 0 8 0 467 0;}
@font-face
	{font-family:"Lao UI";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2113929213 0 0 0 1 0;}
@font-face
	{font-family:Leelawadee;
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:"Levenim MT";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2051 0 0 0 33 0;}
@font-face
	{font-family:LilyUPC;
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2130706429 0 0 0 65537 0;}
@font-face
	{font-family:"Mangal Pro";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 1 0 0 1 0;}
@font-face
	{font-family:Meiryo;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791492095 134217746 0 131231 0;}
@font-face
	{font-family:"Meiryo UI";
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791492095 134217746 0 131231 0;}
@font-face
	{font-family:"Microsoft GothicNeo";
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147482945 701998203 16 0 2687135 0;}
@font-face
	{font-family:"Microsoft GothicNeo Light";
	mso-font-charset:129;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147482945 701998203 16 0 2687135 0;}
@font-face
	{font-family:"Microsoft Uighur";
	mso-font-charset:178;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147475453 -2147483648 8 0 65 0;}
@font-face
	{font-family:MingLiU_HKSCS;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611969 684719354 22 0 1048577 0;}
@font-face
	{font-family:Miriam;
	mso-font-charset:177;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2051 0 0 0 33 0;}
@font-face
	{font-family:"Miriam Fixed";
	mso-font-charset:177;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:2051 0 0 0 33 0;}
@font-face
	{font-family:"Miriam Libre";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2055 1073741824 0 0 179 0;}
@font-face
	{font-family:Mitr;
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Mitr ExtraLight";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Mitr Light";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Mitr Medium";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Mitr SemiBold";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Modern Love";
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Modern Love Caps";
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Modern Love Grunge";
	mso-font-charset:0;
	mso-generic-font-family:decorative;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:MoolBoran;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 0 65536 0 1 0;}
@font-face
	{font-family:"MS PMincho";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:Narkisim;
	mso-font-charset:177;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:2051 0 0 0 33 0;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 147 0;}
@font-face
	{font-family:"News Gothic MT";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Nyala;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610612625 0 2048 0 147 0;}
@font-face
	{font-family:OCRB;
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Open Sans";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870161 1073750107 40 0 415 0;}
@font-face
	{font-family:"Open Sans ExtraBold";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870161 1073750107 40 0 415 0;}
@font-face
	{font-family:"Open Sans Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870161 1073750107 40 0 415 0;}
@font-face
	{font-family:"Open Sans SemiBold";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870161 1073750107 40 0 415 0;}
@font-face
	{font-family:"Plantagenet Cherokee";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:3 0 4096 0 1 0;}
@font-face
	{font-family:Posterama;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1592449281 -805298101 65536 0 415 0;}
@font-face
	{font-family:Pridi;
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Pridi ExtraLight";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Pridi Light";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Pridi Medium";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Pridi SemiBold";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:Prompt;
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Prompt Black";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Prompt ExtraBold";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Prompt ExtraLight";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Prompt Light";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Prompt Medium";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Prompt SemiBold";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Prompt Thin";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Quire Sans";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1592449281 -2147483638 65536 0 415 0;}
@font-face
	{font-family:"Quire Sans Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Quire Sans Pro Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Reem Kufi";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Roboto;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1342185563 32 0 415 0;}
@font-face
	{font-family:"Roboto Black";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1342185563 32 0 415 0;}
@font-face
	{font-family:"Roboto Condensed";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1342185563 32 0 415 0;}
@font-face
	{font-family:"Roboto Condensed Light";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1342185563 32 0 415 0;}
@font-face
	{font-family:"Roboto Condensed Medium";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1342185563 32 0 415 0;}
@font-face
	{font-family:"Roboto Light";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1342185563 32 0 415 0;}
@font-face
	{font-family:"Roboto Medium";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1342185563 32 0 415 0;}
@font-face
	{font-family:"Roboto Thin";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1342185563 32 0 415 0;}
@font-face
	{font-family:"Rockwell Light";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 0 0 0 15 0;}
@font-face
	{font-family:"Rockwell Nova";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Rockwell Nova Cond";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Rockwell Nova Cond Light";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Rockwell Nova Extra Bold";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:"Rockwell Nova Light";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 2 0 0 159 0;}
@font-face
	{font-family:Rod;
	mso-font-charset:177;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:2051 0 0 0 33 0;}
@font-face
	{font-family:"Sabon Next LT";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1592449281 -805306357 65536 0 415 0;}
@font-face
	{font-family:"Sagona Book";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Sagona ExtraLight";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Sakkal Majalla";
	mso-font-charset:178;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147475449 -2147483648 8 0 211 0;}
@font-face
	{font-family:"Sanskrit Text";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610579897 0 0 0 1 0;}
@font-face
	{font-family:Seaford;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 1 0 0 1 0;}
@font-face
	{font-family:"Seaford Display";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 1 0 0 1 0;}
@font-face
	{font-family:"Secular One";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2055 1073741824 0 0 179 0;}
@font-face
	{font-family:Selawik;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 147 0;}
@font-face
	{font-family:"Selawik Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 147 0;}
@font-face
	{font-family:"Selawik Semibold";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:7 0 0 0 147 0;}
@font-face
	{font-family:"Shonar Bangla";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:65539 0 0 0 1 0;}
@font-face
	{font-family:"Simplified Arabic";
	mso-font-charset:178;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:8195 -2147483648 8 0 65 0;}
@font-face
	{font-family:"Simplified Arabic Fixed";
	mso-font-charset:178;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:8195 0 8 0 65 0;}
@font-face
	{font-family:"Sitka Banner Semibold";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Display Semibold";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Heading Semibold";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Small Semibold";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Subheading Semibold";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:"Sitka Text Semibold";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-1610611985 1073750091 0 0 415 0;}
@font-face
	{font-family:Skeena;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 1 0 0 1 0;}
@font-face
	{font-family:"Skeena Display";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 1 0 0 1 0;}
@font-face
	{font-family:"Source Code Pro";
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:536871671 33568771 0 0 415 0;}
@font-face
	{font-family:"Source Code Pro Black";
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:536871671 33568771 0 0 415 0;}
@font-face
	{font-family:"Source Code Pro ExtraLight";
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:536871671 33568771 0 0 415 0;}
@font-face
	{font-family:"Source Code Pro Light";
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:536871671 33568771 0 0 415 0;}
@font-face
	{font-family:"Source Code Pro Medium";
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:536871671 33568771 0 0 415 0;}
@font-face
	{font-family:"Source Code Pro Semibold";
	mso-font-charset:0;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:536871671 33568771 0 0 415 0;}
@font-face
	{font-family:"Source Sans Pro";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1610613495 33554433 0 0 415 0;}
@font-face
	{font-family:"Source Sans Pro Black";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1610613495 33554433 0 0 415 0;}
@font-face
	{font-family:"Source Sans Pro ExtraLight";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1610613495 33554433 0 0 415 0;}
@font-face
	{font-family:"Source Sans Pro Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1610613495 33554433 0 0 415 0;}
@font-face
	{font-family:"Source Sans Pro SemiBold";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1610613495 33554433 0 0 415 0;}
@font-face
	{font-family:"Source Serif Pro";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:536871559 33554435 0 0 415 0;}
@font-face
	{font-family:"Source Serif Pro Black";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:536871559 33554435 0 0 415 0;}
@font-face
	{font-family:"Source Serif Pro ExtraLight";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:536871559 33554435 0 0 415 0;}
@font-face
	{font-family:"Source Serif Pro Light";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:536871559 33554435 0 0 415 0;}
@font-face
	{font-family:"Source Serif Pro SemiBold";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:536871559 33554435 0 0 415 0;}
@font-face
	{font-family:"Speak Pro";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Speak Pro Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:STCaiyun;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:1 953090296 22 0 262145 0;}
@font-face
	{font-family:STFangsong;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:647 135200768 16 0 262303 0;}
@font-face
	{font-family:STHupo;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:1 135200768 16 0 262144 0;}
@font-face
	{font-family:STKaiti;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:647 135200768 16 0 262303 0;}
@font-face
	{font-family:STXihei;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:647 135200768 16 0 262303 0;}
@font-face
	{font-family:STXingkai;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:1 135200768 16 0 262144 0;}
@font-face
	{font-family:STXinwei;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:1 135200768 16 0 262144 0;}
@font-face
	{font-family:STZhongsong;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:647 135200768 16 0 262303 0;}
@font-face
	{font-family:"Suez One";
	mso-font-charset:177;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:2055 1073741824 0 0 179 0;}
@font-face
	{font-family:Tenorite;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 1 0 0 1 0;}
@font-face
	{font-family:"Tenorite Display";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147483645 1 0 0 1 0;}
@font-face
	{font-family:"TH SarabunPSK";
	mso-font-charset:222;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:16777219 0 0 0 65809 0;}
@font-face
	{font-family:"The Hand";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"The Hand Black";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"The Hand Extrablack";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"The Hand Light";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"The Serif Hand";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"The Serif Hand Black";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"The Serif Hand Extrablack";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"The Serif Hand Light";
	mso-font-charset:0;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Tisa Offc Serif Pro";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147482905 2 0 0 415 0;}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-2147482905 2 0 0 415 0;}
@font-face
	{font-family:"Trade Gothic Next";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Trade Gothic Next Cond";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Trade Gothic Next Heavy";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Trade Gothic Next Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Traditional Arabic";
	mso-font-charset:178;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:8195 -2147483648 8 0 65 0;}
@font-face
	{font-family:Trirong;
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Trirong Black";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Trirong ExtraBold";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Trirong ExtraLight";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Trirong Light";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Trirong Medium";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Trirong SemiBold";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"Trirong Thin";
	mso-font-charset:222;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:553648135 1 0 0 65939 0;}
@font-face
	{font-family:"UD Digi Kyokasho N-B";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482973 717745402 16 0 131072 0;}
@font-face
	{font-family:"UD Digi Kyokasho N-R";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482973 717745402 16 0 131072 0;}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482973 717745402 16 0 131072 0;}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482973 717745402 16 0 131072 0;}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482973 717745402 16 0 131072 0;}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482973 717745402 16 0 131072 0;}
@font-face
	{font-family:Univers;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 0 0 0 15 0;}
@font-face
	{font-family:"Univers Condensed";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 0 0 0 15 0;}
@font-face
	{font-family:"Univers Condensed Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 0 0 0 15 0;}
@font-face
	{font-family:"Univers Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 0 0 0 15 0;}
@font-face
	{font-family:"Urdu Typesetting";
	mso-font-charset:178;
	mso-generic-font-family:script;
	mso-font-pitch:variable;
	mso-font-signature:8195 -2147483648 8 0 65 0;}
@font-face
	{font-family:Utsaah;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:32771 0 0 0 1 0;}
@font-face
	{font-family:Vani;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:2097155 0 0 0 1 0;}
@font-face
	{font-family:"Verdana Pro";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Verdana Pro Black";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Verdana Pro Cond";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Verdana Pro Cond Black";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Verdana Pro Cond Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Verdana Pro Light";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:"Verdana Pro SemiBold";
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-2147483001 67 0 0 159 0;}
@font-face
	{font-family:Vijaya;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:1048579 0 0 0 1 0;}
@font-face
	{font-family:"Walbaum Display";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Walbaum Display Heavy";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Walbaum Display Light";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Walbaum Display SemiBold";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Walbaum Heading";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Walbaum Text";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147483601 10 0 0 1 0;}
@font-face
	{font-family:"Yu Mincho";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482905 717749503 18 0 131231 0;}
@font-face
	{font-family:"Yu Mincho Demibold";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482905 717749503 18 0 131231 0;}
@font-face
	{font-family:"Yu Mincho Light";
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-2147482905 717749503 18 0 131231 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0in;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
h1
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 1 Char";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	mso-list:l0 level1 lfo1;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	mso-font-kerning:0pt;
	mso-ansi-language:EN-GB;
	mso-bidi-font-weight:normal;}
h2
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 2 Char";
	mso-style-next:Normal;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:2;
	mso-list:l0 level2 lfo1;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-ansi-language:EN-GB;
	mso-bidi-font-weight:normal;}
h3
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 3 Char";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	mso-list:l0 level3 lfo1;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-ansi-language:EN-GB;
	mso-bidi-font-weight:normal;}
h4
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 4 Char";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	mso-list:l0 level4 lfo1;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-ansi-language:EN-GB;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
h5
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 5 Char";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:5;
	mso-list:l0 level5 lfo1;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:normal;}
h6
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 6 Char";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:6;
	mso-list:l0 level6 lfo1;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 7 Char";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:7;
	mso-list:l0 level7 lfo1;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 8 Char";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:8;
	mso-list:l0 level8 lfo1;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 9 Char";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:9;
	mso-list:l0 level9 lfo1;
	font-size:9.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-unhide:no;
	mso-style-link:"Footnote Text Char";
	margin:0in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-unhide:no;
	mso-style-link:"Comment Text Char";
	margin:0in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-unhide:no;
	mso-style-link:"Header Char";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-unhide:no;
	mso-style-link:"Footer Char";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:center 3.0in right 6.0in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
span.MsoFootnoteReference
	{mso-style-parent:"";
	font-family:"Verdana",sans-serif;
	mso-ascii-font-family:Verdana;
	mso-hansi-font-family:Verdana;
	vertical-align:super;}
span.MsoCommentReference
	{mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
span.MsoPageNumber
	{mso-style-unhide:no;
	mso-style-parent:"";
	font-family:"Times New Roman",serif;
	mso-bidi-font-family:"Times New Roman";}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-link:"Endnote Text Char";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{mso-style-update:auto;
	mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l7 level1 lfo4;
	tab-stops:list .5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	font-family:"Times New Roman",serif;
	mso-bidi-font-family:"Times New Roman";
	color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-unhide:no;
	color:#954F72;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-link:"Document Map Char";
	margin:0in;
	mso-pagination:widow-orphan;
	background:navy;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Tahoma",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-unhide:no;
	mso-style-parent:"Comment Text";
	mso-style-link:"Comment Subject Char";
	mso-style-next:"Comment Text";
	margin:0in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-unhide:no;
	mso-style-link:"Balloon Text Char";
	margin:0in;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0in;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParag=
raphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListPar=
agraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagra=
phCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 1";
	mso-ansi-font-size:11.0pt;
	text-transform:uppercase;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 2";
	mso-ansi-font-size:11.0pt;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 3";
	mso-ansi-font-size:12.0pt;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 4";
	mso-ansi-font-size:12.0pt;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 5";
	mso-ansi-font-size:11.0pt;
	font-family:"Arial",sans-serif;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-ansi-language:EN-GB;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 6";
	mso-ansi-font-size:11.0pt;
	font-family:"Arial",sans-serif;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-ansi-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 7";
	mso-ansi-font-size:11.0pt;
	font-family:"Arial",sans-serif;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-ansi-language:EN-GB;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 8";
	mso-ansi-font-size:11.0pt;
	font-family:"Arial",sans-serif;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-ansi-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 9";
	mso-ansi-font-size:9.0pt;
	font-family:"Arial",sans-serif;
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-ansi-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.EMEATableCentered, li.EMEATableCentered, div.EMEATableCentered
	{mso-style-name:"EMEA Table Centered";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	mso-style-next:Normal;
	margin:0in;
	text-align:center;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.EMEATableLeft, li.EMEATableLeft, div.EMEATableLeft
	{mso-style-name:"EMEA Table Left";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.EMEABodyTextIndent, li.EMEABodyTextIndent, div.EMEABodyTextIndent
	{mso-style-name:"EMEA Body Text Indent";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	mso-style-next:"EMEA Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	mso-pagination:widow-orphan;
	mso-list:l1 level1 lfo2;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	mso-style-unhide:no;
	mso-style-link:"EMEA Body Text Char";
	margin:0in;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.EMEATitle, li.EMEATitle, div.EMEATitle
	{mso-style-name:"EMEA Title";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	mso-style-next:"EMEA Body Text";
	margin:0in;
	text-align:center;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.EMEAHeading1NoIndent, li.EMEAHeading1NoIndent, div.EMEAHeading1NoIndent
	{mso-style-name:"EMEA Heading 1 No Indent";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	mso-style-next:"EMEA Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	text-transform:uppercase;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.EMEAHeading3, li.EMEAHeading3, div.EMEAHeading3
	{mso-style-name:"EMEA Heading 3";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	mso-style-next:"EMEA Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.EMEAHeading1, li.EMEAHeading1, div.EMEAHeading1
	{mso-style-name:"EMEA Heading 1";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	mso-style-next:"EMEA Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	text-transform:uppercase;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.EMEAHeading2, li.EMEAHeading2, div.EMEAHeading2
	{mso-style-name:"EMEA Heading 2";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	mso-style-link:"EMEA Heading 2 Char";
	mso-style-next:"EMEA Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.EMEAAddress, li.EMEAAddress, div.EMEAAddress
	{mso-style-name:"EMEA Address";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	mso-style-next:"EMEA Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.EMEAComment, li.EMEAComment, div.EMEAComment
	{mso-style-name:"EMEA Comment";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	margin:0in;
	mso-pagination:widow-orphan no-line-numbers;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Document Map";
	mso-ansi-font-size:1.0pt;
	font-family:"Times New Roman",serif;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;}
p.EMEAHiddenTitlePIL, li.EMEAHiddenTitlePIL, div.EMEAHiddenTitlePIL
	{mso-style-name:"EMEA Hidden Title PIL";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Body Text";
	mso-style-next:"EMEA Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.EMEAHiddenTitlePAC, li.EMEAHiddenTitlePAC, div.EMEAHiddenTitlePAC
	{mso-style-name:"EMEA Hidden Title PAC";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Hidden Title PIL";
	mso-style-next:"EMEA Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	text-transform:uppercase;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.BMSInstructionText
	{mso-style-name:"BMS Instruction Text";
	mso-style-unhide:no;
	mso-style-parent:"";
	mso-ansi-font-size:12.0pt;
	font-family:"Times New Roman",serif;
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	color:red;
	display:none;
	mso-hide:all;
	font-style:italic;
	mso-bidi-font-style:normal;
	text-decoration:none;
	text-underline:none;
	vertical-align:baseline;}
span.EMEASubscript
	{mso-style-name:"EMEA Subscript";
	mso-style-unhide:no;
	mso-style-parent:"";
	mso-ansi-font-size:11.0pt;
	vertical-align:sub;}
span.EMEASuperscript
	{mso-style-name:"EMEA Superscript";
	mso-style-unhide:no;
	mso-style-parent:"";
	mso-ansi-font-size:11.0pt;
	vertical-align:super;}
p.EMEATableHeader, li.EMEATableHeader, div.EMEATableHeader
	{mso-style-name:"EMEA Table Header";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Table Centered";
	margin:0in;
	text-align:center;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:Header;
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:Footer;
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Endnote Text";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;}
p.EMEATitlePAC, li.EMEATitlePAC, div.EMEATitlePAC
	{mso-style-name:"EMEA Title PAC";
	mso-style-unhide:no;
	mso-style-parent:"EMEA Hidden Title PIL";
	mso-style-next:"EMEA Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	border:none;
	mso-border-alt:solid windowtext .5pt;
	padding:0in;
	mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	text-transform:uppercase;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.EMEABodyTextChar
	{mso-style-name:"EMEA Body Text Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"EMEA Body Text";
	mso-ansi-font-size:11.0pt;
	font-family:"Times New Roman",serif;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;}
span.EMEAHeading2Char
	{mso-style-name:"EMEA Heading 2 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"EMEA Heading 2";
	mso-ansi-font-size:11.0pt;
	font-family:"Times New Roman",serif;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Balloon Text";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;
	font-family:"Tahoma",sans-serif;
	mso-ascii-font-family:Tahoma;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	mso-style-unhide:no;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:FR;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Footnote Text";
	mso-fareast-language:EN-US;}
p.news-date, li.news-date, div.news-date
	{mso-style-name:news-date;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Comment Text";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Comment Subject";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;
	font-weight:bold;}
p.bodytextagency, li.bodytextagency, div.bodytextagency
	{mso-style-name:bodytextagency;
	mso-style-priority:99;
	mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;}
p.BodytextAgency0, li.BodytextAgency0, div.BodytextAgency0
	{mso-style-name:"Body text \(Agency\)";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-fareast-font-family:Verdana;
	mso-bidi-font-family:Verdana;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Drafting Notes \(Agency\) Char";
	mso-style-next:"Body text \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:Verdana;
	mso-bidi-font-family:"Times New Roman";
	color:#339966;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.No-numheading1Agency, li.No-numheading1Agency, div.No-numheading1Agency
	{mso-style-name:"No-num heading 1 \(Agency\)";
	mso-style-unhide:no;
	mso-style-next:"Body text \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	mso-fareast-font-family:Verdana;
	mso-bidi-font-family:Arial;
	mso-font-kerning:16.0pt;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;
	font-weight:bold;}
p.No-numheading2Agency, li.No-numheading2Agency, div.No-numheading2Agency
	{mso-style-name:"No-num heading 2 \(Agency\)";
	mso-style-unhide:no;
	mso-style-next:"Body text \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	mso-fareast-font-family:Verdana;
	mso-bidi-font-family:Arial;
	mso-font-kerning:16.0pt;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;
	font-weight:bold;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Drafting Notes \(Agency\)";
	mso-ansi-font-size:11.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-fareast-font-family:Verdana;
	mso-hansi-font-family:"Courier New";
	color:#339966;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Body text \(Agency\)";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-ascii-font-family:Verdana;
	mso-fareast-font-family:Verdana;
	mso-hansi-font-family:Verdana;
	mso-bidi-font-family:Verdana;}
p.BodytextAgencyCarattere, li.BodytextAgencyCarattere, div.BodytextAgencyCa=
rattere
	{mso-style-name:"Body text \(Agency\) Carattere";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Body text \(Agency\) Carattere Carattere";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-fareast-font-family:Verdana;
	mso-bidi-font-family:Verdana;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;}
span.BodytextAgencyCarattereCarattere
	{mso-style-name:"Body text \(Agency\) Carattere Carattere";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Body text \(Agency\) Carattere";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-ascii-font-family:Verdana;
	mso-fareast-font-family:Verdana;
	mso-hansi-font-family:Verdana;
	mso-bidi-font-family:Verdana;}
span.msoIns
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:underline;
	text-underline:single;
	color:teal;}
span.msoDel
	{mso-style-type:export-only;
	mso-style-name:"";
	text-decoration:line-through;
	color:red;}
span.msoChangeProp
	{mso-style-type:export-only;
	mso-style-name:"";}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("Karvea_clean_files/header.htm") fs;
	mso-footnote-continuation-separator:url("Karvea_clean_files/header.htm") f=
cs;
	mso-endnote-separator:url("Karvea_clean_files/header.htm") es;
	mso-endnote-continuation-separator:url("Karvea_clean_files/header.htm") ec=
s;}
@page WordSection1
	{size:595.35pt 841.95pt;
	margin:56.7pt 70.85pt 56.7pt 70.85pt;
	mso-header-margin:36.85pt;
	mso-footer-margin:36.85pt;
	mso-even-footer:url("Karvea_clean_files/header.htm") ef1;
	mso-footer:url("Karvea_clean_files/header.htm") f1;
	mso-first-footer:url("Karvea_clean_files/header.htm") ff1;
	mso-paper-source:0;
	mso-gutter-direction:rtl;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:-5;
	mso-list-template-ids:-1;}
@list l0:level1
	{mso-level-style-link:"Heading 1";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:.1in;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l0:level2
	{mso-level-style-link:"Heading 2";
	mso-level-text:"%1\.%2";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:.1in;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l0:level3
	{mso-level-style-link:"Heading 3";
	mso-level-text:"%1\.%2\.%3";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:.1in;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l0:level4
	{mso-level-style-link:"Heading 4";
	mso-level-text:"%1\.%2\.%3\.%4";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:.1in;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l0:level5
	{mso-level-style-link:"Heading 5";
	mso-level-text:"%1\.%2\.%3\.%4\.%5";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:.1in;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l0:level6
	{mso-level-style-link:"Heading 6";
	mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:.1in;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l0:level7
	{mso-level-style-link:"Heading 7";
	mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:.1in;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l0:level8
	{mso-level-style-link:"Heading 8";
	mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:.1in;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l0:level9
	{mso-level-style-link:"Heading 9";
	mso-level-text:"%1\.%2\.%3\.%4\.%5\.%6\.%7\.%8\.%9";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:0in;
	mso-level-legacy-space:.1in;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l1
	{mso-list-id:-2;
	mso-list-type:simple;
	mso-list-template-ids:-1;}
@list l1:level1
	{mso-level-start-at:0;
	mso-level-style-link:"EMEA Body Text Indent";
	mso-level-text:*;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:0in;
	text-indent:0in;
	mso-bidi-font-family:"Times New Roman";}
@list l2
	{mso-list-id:137890012;
	mso-list-type:hybrid;
	mso-list-template-ids:295586578;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:64.35pt;
	mso-level-number-position:left;
	margin-left:64.35pt;
	text-indent:-.25in;
	font-family:Symbol;
	color:black;}
@list l2:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:100.35pt;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l2:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:136.35pt;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l2:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:172.35pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l2:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:208.35pt;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l2:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:244.35pt;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l2:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:280.35pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l2:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:316.35pt;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l2:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:352.35pt;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l3
	{mso-list-id:308244337;
	mso-list-type:hybrid;
	mso-list-template-ids:313688752 1656274158 67698691 67698693 67698689 6769=
8691 67698693 67698689 67698691 67698693;}
@list l3:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Wingdings;
	color:black;}
@list l3:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l3:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l3:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l3:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l3:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l3:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l3:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l3:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l4
	{mso-list-id:668140906;
	mso-list-type:hybrid;
	mso-list-template-ids:746470228 -1 -1 -1 -1 -1 -1 -1 -1 -1;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Wingdings;
	color:black;}
@list l4:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l4:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l4:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l4:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l4:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l4:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l4:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l4:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l5
	{mso-list-id:671376025;
	mso-list-type:hybrid;
	mso-list-template-ids:-1382536336;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Wingdings;
	color:black;}
@list l5:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l5:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l5:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l5:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l5:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l5:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l5:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l5:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l6
	{mso-list-id:677539538;
	mso-list-type:hybrid;
	mso-list-template-ids:1718545482 1656274158 67698691 67698693 67698689 676=
98691 67698693 67698689 67698691 67698693;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Wingdings;
	color:black;}
@list l6:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l6:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l6:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l6:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l6:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l6:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l6:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l6:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l7
	{mso-list-id:686903956;
	mso-list-type:simple;
	mso-list-template-ids:67698703;}
@list l7:level1
	{mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	mso-bidi-font-family:"Times New Roman";}
@list l8
	{mso-list-id:916325310;
	mso-list-type:hybrid;
	mso-list-template-ids:-2007735938 1656274158 67698691 67698693 67698689 67=
698691 67698693 67698689 67698691 67698693;}
@list l8:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:64.35pt;
	mso-level-number-position:left;
	margin-left:64.35pt;
	text-indent:-.25in;
	font-family:Symbol;
	color:black;}
@list l8:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:100.35pt;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l8:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:136.35pt;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l8:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:172.35pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l8:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:208.35pt;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l8:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:244.35pt;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l8:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:280.35pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l8:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:316.35pt;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l8:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:352.35pt;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l9
	{mso-list-id:1220285722;
	mso-list-type:hybrid;
	mso-list-template-ids:-1787942294 1656274158 67698691 67698693 67698689 67=
698691 67698693 67698689 67698691 67698693;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Wingdings;
	color:black;}
@list l9:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l9:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l9:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l9:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l9:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l9:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l9:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l9:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l10
	{mso-list-id:1223059529;
	mso-list-type:simple;
	mso-list-template-ids:-351632580;}
@list l10:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l11
	{mso-list-id:2041279595;
	mso-list-type:hybrid;
	mso-list-template-ids:-605650260;}
@list l11:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Wingdings;
	color:black;}
@list l11:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l11:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l11:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l11:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l11:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l11:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l11:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l11:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1:level1 lfo2
	{mso-level-start-at:1;
	mso-level-number-format:bullet;
	mso-level-numbering:continue;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:28.35pt;
	mso-level-legacy-space:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	mso-ansi-font-size:5.0pt;
	font-family:"Arial",sans-serif;
	mso-bidi-font-family:"Times New Roman";}
@list l10:level1 lfo5
	{mso-level-numbering:continue;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-family:Wingdings;
	color:windowtext;
	mso-ansi-font-style:normal;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"3074"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DEN-US link=3Dblue vlink=3D"#954F72" style=3D'tab-interval:28.3=
5pt;
word-wrap:break-word'>

<div class=3DWordSection1>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB>ANNEX I</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB>SUMMARY OF PRODUCT CHARACTERISTICS<=
/span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<p class=3DEMEAHeading1><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL P<st1:PersonName w:st=3D"on">RO</st1:PersonName>DUCT</span=
></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg tablets.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>QUAL<st1:PersonName
w:st=3D"on">IT</st1:PersonName>ATIVE AND QUANT<st1:PersonName w:st=3D"on">I=
T</st1:PersonName>ATIVE
COMPO<st1:PersonName w:st=3D"on">S<st1:PersonName w:st=3D"on">I</st1:Person=
Name>T</st1:PersonName>ION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Each tablet contains 75&nbsp;mg =
of
irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Excipient with known effect</=
span></u><span
lang=3DEN-GB>: 15.37&nbsp;mg of lactose monohydrate per tablet.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For the full list of excipients,=
 see
section&nbsp;6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Tablet.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2771 engr=
aved
on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>CLINICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
1<span
style=3D'mso-tab-count:1'> </span>Therapeutic indications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span class=3DSpel=
lE><span
lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB> is indicated in adults=
 for the
treatment of essential hypertension.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>It is also indicated for the tre=
atment
of renal disease in adult patients with hypertension and type&nbsp;2 diabet=
es
mellitus as part of an antihypertensive medicinal product regimen (see sect=
ions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
2<span
style=3D'mso-tab-count:1'> </span>Posology and method of administration=
</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Posology<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. <span class=3DSpellE>Karvea</span> at a dose of 150&nbsp;mg o=
nce
daily generally provides a better 24&nbsp;hour blood pressure control than
75&nbsp;mg. However, initiation of therapy with 75&nbsp;mg could be conside=
red,
particularly in haemodialysed patients and in the elderly over 75&nbsp;year=
s.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients insufficiently contr=
olled with
150&nbsp;mg once daily, the dose of <span class=3DSpellE>Karvea</span> can =
be
increased to 300&nbsp;mg, or other antihypertensive agents can be added (see
sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic =
such
as hydrochlorothiazide has been shown to have an additive effect with <span
class=3DSpellE>Karvea</span> (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In hypertensive type&nbsp;2 diab=
etic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily =
and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The demonstration of renal benef=
it of <span
class=3DSpellE>Karvea</span> in hypertensive type&nbsp;2 diabetic patients =
is
based on studies where irbesartan was used in addition to other
antihypertensive agents, as needed, to reach target blood pressure (see sec=
tions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Special Populations<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Renal
impairment</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4=
).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Hepatic
impairment</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Older
people</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Although consideration should be=
 given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary for <span class=3DSpellE>theolde=
r</span>
people.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Paediatric
population</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The safety and efficacy of <span
class=3DSpellE>Karvea</span> in children aged 0 to 18 has not been establis=
hed.
Currently available data are described in sections 4.8, 5.1, and 5.2 but no
recommendation on a posology can be made.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Method of Administration<o:p>=
</o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For oral use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
3<span
style=3D'mso-tab-count:1'> </span>Contraindications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;=
6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Second and third trimesters of p=
regnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><span style=3D'mso-spacerun:yes'=
></span>The
concomitant use of <span class=3DSpellE>Karvea</span> with <span class=3DSp=
ellE>aliskiren</span>-containing
products is contraindicated in patients with diabetes mellitus or renal
impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup=
>)
(see sections 4.5 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
4<span
style=3D'mso-tab-count:1'> </span>Special warnings and precautions for =
use</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Intravascular
volume depletion</span></u><span lang=3DEN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renovascular hypertension</sp=
an></u><span
lang=3DEN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosi=
s of
the artery to a single functioning kidney are treated with medicinal produc=
ts
that affect the renin-angiotensin-aldosterone system. While this is not
documented with <span class=3DSpellE>Karvea</span>, a similar effect should=
 be
anticipated with angiotensin-II receptor antagonists.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment and kidney
transplantation</span></u><span lang=3DEN-GB>: when <span class=3DSpellE>Ka=
rvea</span>
is used in patients with impaired renal function, a periodic monitoring of
potassium and creatinine serum levels is recommended. There is no experience
regarding the administration of <span class=3DSpellE>Karvea</span> in patie=
nts
with a recent kidney transplantation.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=3DEN-GB>:</span=
><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'> the e=
ffects
of irbesartan both on renal and cardiovascular events were not uniform acro=
ss
all subgroups, in an analysis carried out in the study with patients with
advanced renal disease. In particular, they appeared less favourable in wom=
en
and non-white subjects (see section&nbsp;5.1).<o:p></o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS):<o:p></o:p></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>T</span></u><span lang=3DEN-G=
B>here is
evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor
blockers or <span class=3DSpellE>aliskiren</span> increases the risk of
hypotension, hyperkalaemia and decreased renal function (including acute re=
nal
failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,
angiotensin II receptor blockers or <span class=3DSpellE>aliskiren</span> is
therefore not recommended (see sections 4.5 and 5.1). <span
style=3D'mso-spacerun:yes'></span>If dual blockade therapy is considered
absolutely necessary, this should only occur under specialist supervision a=
nd
subject to frequent close monitoring of renal function, electrolytes and bl=
ood
pressure. ACE-inhibitors and angiotensin II receptor blockers should not be
used concomitantly in patients with diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hyperkalaemia</span></u><span
lang=3DEN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with <span class=3DSpellE>Karvea</span>, especially in the presen=
ce of
renal impairment, overt proteinuria due to diabetic renal disease, and/or h=
eart
failure. Close monitoring of serum potassium in patients at risk is recomme=
nded
(see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypoglycaemia: </span></u><sp=
an
class=3DSpellE><span lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB> m=
ay induce
hypoglycaemia, particularly in diabetic patients. In patients treated with
insulin or antidiabetics an appropriate blood glucose monitoring should be
considered; a dose adjustment of insulin or antidiabetics may be required w=
hen
indicated (see section 4.5).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:
the combination of lithium and <span class=3DSpellE>Karvea</span> is not
recommended (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Aortic and mitral valve steno=
sis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=3DEN-GB>: as w=
ith
other vasodilators, special caution is indicated in patients suffering from
aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</spa=
n></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Primary aldosteronism</span><=
/u><span
lang=3DEN-GB>: patients with primary aldosteronism generally will not respo=
nd to
antihypertensive medicinal products acting through inhibition of the renin-=
angiotensin
system. Therefore, the use of <span class=3DSpellE>Karvea</span> is not rec=
ommended.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>General</span></u><span lang=
=3DEN-GB>:
in patients whose vascular tone and renal function depend predominantly on =
the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients wi=
th
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b style=3D'mso-bidi-font-weigh=
t:
normal'> </b>converting enzyme inhibitors or angiotensin-II receptor
antagonists that affect this system has been associated with acute hypotens=
ion,
azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As wi=
th
any antihypertensive agent, excessive blood pressure decrease in patients w=
ith
ischaemic cardiopathy or ischaemic cardiovascular disease could result in a
myocardial infarction or stroke.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As observed for angiotensin conv=
erting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Pregnancy:</span></u><span
lang=3DEN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not =
be
initiated during pregnancy. </span><span lang=3DEN-GB style=3D'mso-bidi-fon=
t-size:
11.0pt'>Unless continued AIIRA therapy is considered essential, patients
planning pregnancy should be changed to alternative antihypertensive treatm=
ents
which have an established safety profile for use in pregnancy. When pregnan=
cy
is diagnosed, treatment with </span><span lang=3DEN-GB>AIIRAs</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> should be stopped immedia=
tely, and,
if appropriate, alternative therapy should be started (see sections&nbsp;4.3
and&nbsp;4.6).<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Paediatric population</span><=
/u><span
lang=3DEN-GB>: irbesartan has been studied in paediatric populations <span
style=3D'mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>aged 6 to 16=
 years
old</span> but the current data are insufficient to support an extension of=
 the
use in children until further data become available (see sections&nbsp;4.8,=
 5.1
and&nbsp;5.2).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><u><span lang=3DEN-GB>Excipients</span></u><span lang=
=3DFR
style=3D'mso-ansi-language:FR'>:<o:p></o:p></span></p>

<p class=3DEMEABodyText><a name=3D"_Hlk37089325"></a><span class=3DSpellE><=
span
style=3D'mso-bookmark:_Hlk37089325'><span lang=3DFR style=3D'mso-ansi-langu=
age:FR'>Karvea</span></span></span><span
style=3D'mso-bookmark:_Hlk37089325'><span lang=3DFR style=3D'mso-ansi-langu=
age:FR'>&nbsp;75
mg <span class=3DSpellE>tablet</span> <span class=3DSpellE>contains</span> =
lactose.
</span></span><span lang=3DEN-GB>Patients with rare hereditary problems of
galactose intolerance, total lactase deficiency or glucose-galactose
malabsorption should not take this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DFR style=3D'mso-a=
nsi-language:
FR'>Karvea</span></span><span lang=3DFR style=3D'mso-ansi-language:FR'>&nbs=
p;75 mg <span
class=3DSpellE>tablet</span> <span class=3DSpellE>contains</span> sodium. <=
/span><span
lang=3DEN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tab=
let, that
is to say essentially sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>4.5<span style=3D'mso-tab-count:=
1'> </span>Interaction
with other medicinal products and other forms of interaction</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Diuretics and other antihyper=
tensive
agents</span></u><span lang=3DEN-GB>: other antihypertensive agents may inc=
rease
the hypotensive effects of irbesartan; however <span class=3DSpellE>Karvea<=
/span>
has been safely administered with other antihypertensive agents, such as
beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Prior treatment with high dose diuretics may result in volume depletion and=
 a
risk of hypotension when initiating therapy with <span class=3DSpellE>Karve=
a</span>
(see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><span class=3DSpellE><u><span lang=3DEN-GB>Aliskire=
n</span></u></span><u><span
lang=3DEN-GB>-containing products or ACE-inhibitors</span></u><span lang=3D=
EN-GB>: clinical
trial data has shown that dual blockade of the renin-angiotensin-aldosterone
system (RAAS) through the combined use of ACE-inhibitors, angiotensin II
receptor blockers or <span class=3DSpellE>aliskiren</span> is associated wi=
th a
higher frequency of adverse events such as hypotension, hyperkalaemia and
decreased renal function (including acute renal failure) compared to the us=
e of
a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=3DEN-GB>:<i style=3D'mso-b=
idi-font-style:
normal'> </i>based on experience with the use of other medicinal products t=
hat
affect the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or
other medicinal products that may increase serum potassium levels (e.g.&nbs=
p;heparin)
may lead to increases in serum potassium and is, therefore, not recommended
(see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:<i
style=3D'mso-bidi-font-style:normal'> </i>reversible increases in serum lit=
hium
concentrations and toxicity have been reported during concomitant
administration of lithium with angiotensin converting enzyme inhibitors.
Similar effects have been very rarely reported with irbesartan so far.
Therefore, this combination is not recommended (see section&nbsp;4.4). If t=
he
combination proves necessary, careful monitoring of serum lithium levels is
recommended.<i style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span><=
/p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Non-steroidal anti-inflammato=
ry drugs</span></u><span
lang=3DEN-GB>: w<span style=3D'color:black'>hen angiotensin&nbsp;II antagon=
ists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) a=
nd
non-selective NSAIDs), attenuation of the antihypertensive effect may occur=
.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'color:black'><o:p>&nbsp=
;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'color:black'>As with ACE
inhibitors, concomitant use of angiotensin&nbsp;II antagonists and NSAIDs m=
ay
lead to an increased risk of worsening of renal function, including possible
acute renal failure, and an increase in serum potassium, especially in pati=
ents
with poor pre-existing renal function. The combination should be administer=
ed
with caution, especially in the elderly. Patients should be adequately hydr=
ated
and consideration should be given to monitoring renal function after initia=
tion
of concomitant therapy, and periodically thereafter.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Repaglinide:</span></u><span
lang=3DEN-GB style=3D'color:black'> irbesartan has the potential to inhibit=
 OATP1B1.
In a clinical study, it was reported that irbesartan increased the C<sub>ma=
x</sub>
and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3&#8209;fol=
d,
respectively, when administered 1 hour before repaglinide. In another study=
, no
relevant pharmacokinetic interaction was reported, when the two drugs were
co-administered. Therefore, dose adjustment of antidiabetic treatment such =
as
repaglinide may be required (see section 4.4).<o:p></o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Additional information on irb=
esartan
interactions</span></u><span lang=3DEN-GB>: <span style=3D'color:black'>in =
clinical
studies, the pharmacokinetic of irbesartan is not affected by
hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a le=
sser
extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic
interactions were observed when irbesartan was coadministered with warfarin=
, a
medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers suc=
h as
rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The
pharmacokinetic of digoxin was not altered by coadministration of irbesarta=
n.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
6<span
style=3D'mso-tab-count:1'> </span>Fertility, pregnancy and lactation</s=
pan></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Pregnancy</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEABodyText style=3D'border:none;mso-border-alt:solid windowtex=
t .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><span lang=3DEN-GB>The=
 use
of AIIRAs is not recommended during the first trimester of pregnancy (see
section&nbsp;4.4). The use of AIIRAs is contraindicated during the second a=
nd
third trimesters of pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span><=
/p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Epidemiological evidence regardi=
ng the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in
risk cannot be excluded. Whilst there is no controlled epidemiological data=
 on
the risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar ri=
sks
may exist for this class of drugs. Unless continued AIIRA therapy is consid=
ered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for us=
e in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be sto=
pped
immediately, and, if appropriate, alternative therapy should be started.</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Exposure to AIIRA therapy during=
 the
second and third trimesters is known to induce human foetotoxicity (decreas=
ed
renal function, oligohydramnios, skull ossification retardation) and neonat=
al
toxicity (renal failure, hypotension, hyperkalaemia). (See section&nbsp;5.3=
).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Should exposure to AIIRAs have o=
ccurred
from the second trimester of pregnancy, ultrasound check of renal function =
and
skull is recommended.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Infants whose mothers have taken=
 AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3
and&nbsp;4.4).<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Breast-feeding</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Because no information is availa=
ble
regarding the use of <span class=3DSpellE>Karvea</span> during breast-feedi=
ng, <span
class=3DSpellE>Karvea</span> is not recommended and alternative treatments =
with
better established safety profiles during breast-feeding are preferable,
especially while nursing a newborn or preterm infant.</span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>It is unkno=
wn
whether irbesartan or its metabolites are excreted in human milk. <o:p></o:=
p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>Available
pharmacodynamic/toxicological data in rats have shown excretion of irbesart=
an
or its metabolites in milk (for details see 5.3).<span style=3D'color:black=
'><o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Fertility</span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan had no effect upon fe=
rtility
of treated rats and their offspring up to the dose levels inducing the first
signs of parental toxicity (see section 5.3).</span><span style=3D'mso-ansi=
-language:
EN-US'> <o:p></o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
7<span
style=3D'mso-tab-count:1'> </span>Effects on ability to drive and use
machines</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Based on its pharmacodynamic pro=
perties,
irbesartan is unlikely to affect the ability to drive and use machine. When
driving vehicles or operating machines, it should be taken into account that
dizziness or weariness may occur during treatment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
8<span
style=3D'mso-tab-count:1'> </span>Undesirable effects</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>In
placebo-controlled trials in patients with hypertension, the overall incide=
nce
of adverse events did not differ between the irbesartan (56.2%) and the pla=
cebo
groups (56.5%). Discontinuation due to any clinical or laboratory adverse e=
vent
was less frequent for irbesartan-treated patients (3.3%) than for
placebo-treated patients (4.5%). The incidence of adverse events was not
related to dose (in the recommended dose range), gender, age, race, or dura=
tion
of treatment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In diabetic hypertensive patient=
s with
microalbuminuria and normal renal function, orthostatic dizziness and
orthostatic hypotension were reported in 0.5% of the patients
(i.e.,&nbsp;uncommon) but in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The following table presents the=
 adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a s=
tar
(*) refer to the adverse reactions that were additionally reported in &gt; =
2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of adverse reactio=
ns
listed below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>very common (&#8805;&nbsp;1/10);=
 common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very r=
are
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects a=
re
presented in order of decreasing seriousness.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Adverse reactions additionally r=
eported
from postmarketing experience are also listed. <span style=3D'mso-bidi-fon=
t-style:
italic'>These adverse reactions are derived from spontaneous reports.<o:p><=
/o:p></span></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Blood and lymphatic system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>anaemia, thrombocytopenia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Immune system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hypersensitivity reactions such as angioedema, rash, urtic=
aria,
anaphylactic reaction, anaphylactic shock<i style=3D'mso-bidi-font-style:no=
rmal'><u><o:p></o:p></u></i></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Metabolism and nutrition disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hyperkalaemia, hypoglycaemia</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><i style=3D'mso-bidi-=
font-style:
normal'><u><span lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nb=
sp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Nervous system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>dizzine=
ss,
orthostatic dizziness*</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Not known:<span style=3D'mso-tab-count:1'> </span>vertig=
o, headache</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Ear and labyrinth disorder<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>tinnitus</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Cardiac disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>tachycar=
dia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Vascular disorders<i style=3D'mso-bidi-font-style:normal'><o:p=
></o:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;tab-stops:31.5pt .5=
in 1.0in'><span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>orthost=
atic
hypotension*</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>flushing<i
style=3D'mso-bidi-font-style:normal'><u><o:p></o:p></u></i></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Respiratory, thoracic and mediastinal disorders<o:p></o:p></sp=
an></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>cough</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Gastrointestinal disorders<i style=3D'mso-bidi-font-style:norm=
al'><o:p></o:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>nausea/vomiting</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>U=
ncommon:<span
style=3D'mso-tab-count:1'> </span>diarrhoea, dyspepsia/heartburn</span=
></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>N=
ot known:<span
style=3D'mso-tab-count:1'> </span>dysgeusia</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB><=
o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Hepatobiliary disorders<i style=3D'mso-bidi-font-style:normal'=
><o:p></o:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>jaundice</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>hepatitis,
abnormal liver function<i style=3D'mso-bidi-font-style:normal'><u><o:p></o:=
p></u></i></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Skin and subcutaneous tissue disorders<i style=3D'mso-bidi-fon=
t-style:
normal'><o:p></o:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:44.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
1'> </span><span class=3DSpellE>leukocytoclastic</span> vasculitis</s=
pan></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Musculoskeletal and connective tissue disorders<i style=3D'mso=
-bidi-font-style:
normal'><o:p></o:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>musculo=
skeletal
pain*</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:1.0in'><span
lang=3DEN-GB>Not known:<span style=3D'mso-tab-count:1'> </span>arthra=
lgia,
myalgia (in some cases associated with increased plasma creatine kinase <sp=
an
style=3D'mso-tab-count:2'> </span>levels), muscle cramps</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Renal and urinary disorders<i style=3D'mso-bidi-font-style:nor=
mal'><o:p></o:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;page-=
break-after:
avoid;mso-outline-level:1;tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<s=
pan
style=3D'mso-tab-count:1'> </span><span style=3D'mso-tab-count:1'> </=
span>impaired
renal function including cases of renal failure in patients at risk (see
section&nbsp;4.4)</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Reproductive system and breast disorders<i style=3D'mso-bidi-f=
ont-style:
normal'><o:p></o:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'text-align:justify;mso-outline-level:1;tab=
-stops:
1.0in'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </=
span>sexual
dysfunction</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>General disorders and administration site conditions<i
style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>fatigue</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>chest
pain<i style=3D'mso-bidi-font-style:normal'><u><o:p></o:p></u></i></span></=
p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Investigations<i style=3D'mso-bidi-font-style:normal'><o:p></o=
:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Very common:<span style=3D'mso-tab-count:1'>=
 </span>Hyperkalaemia*
occurred more often in diabetic patients treated with irbesartan than with
placebo. In diabetic hypertensive patients with microalbuminuria and normal
renal function, hyperkalaemia (&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>m=
Eq</span>/L)
occurred in 29.4% of the patients in the irbesartan 300&nbsp;mg group and 2=
2%
of the patients in the placebo group. In diabetic hypertensive patients with
chronic renal insufficiency and overt proteinuria, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>mEq</span>/L) occurred in 46.3%=
 of
the patients in the irbesartan group and 26.3% of the patients in the place=
bo
group.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'>=
 </span>significant
increases in plasma creatine kinase were commonly observed (1.7%) in irbesa=
rtan
treated subjects. None of these increases were associated with identifiable
clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treat=
ed
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:0in'><span lang=3DEN-GB><o:p>&nb=
sp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB style=3D'mso-bidi-font-weight=
:bold'>Paediatric
population</span></u><b><span lang=3DEN-GB> <o:p></o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In a randomised trial of
318&nbsp;hypertensive children and adolescents aged 6 to 16&nbsp;years, the
following adverse reactions occurred in the 3-week double-blind phase: head=
ache
(7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week
open-label period of this trial the most frequent laboratory abnormalities
observed were creatinine increases (6.5%) and elevated CK values in 2% of c=
hild
recipients.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of suspected adverse
reactions <o:p></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Reporting suspected adverse reac=
tions
after authorisation of the medicinal product is important. It allows contin=
ued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in Appendix V.</span> </span></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB><o:p>&=
nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
9<span
style=3D'mso-tab-count:1'> </span>Overdose</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Experience in adults exposed to =
doses of
up to 900&nbsp;mg/day for 8&nbsp;weeks revealed no toxicity. The most likely
manifestations of overdose are expected to be hypotension and tachycardia;
bradycardia might also occur from overdose. No specific information is
available on the treatment of overdose with <span class=3DSpellE>Karvea</sp=
an>.
The patient should be closely monitored, and the treatment should be
symptomatic and supportive. Suggested measures include induction of emesis
and/or gastric lavage. Activated charcoal may be useful in the treatment of
overdose. Irbesartan is not removed by haemodialysis.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
1<span
style=3D'mso-tab-count:1'> </span>Pharmacodynamic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Pharmacotherapeutic
group: Angiotensin-II antagonists, plain.</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>ATC&nbsp;code:
C09C&nbsp;A04.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Mechanism of action</span></u=
><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB> <o:p></o:p></span=
></b></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan is a potent, orally a=
ctive,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</s=
ub>
receptor, regardless of the source or route of synthesis of angiotensin-II.=
 The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors resul=
ts in
increases in plasma renin levels and angiotensin-II levels, and a decrease =
in
plasma aldosterone concentration. Serum potassium levels are not significan=
tly
affected by irbesartan alone at the recommended doses. Irbesartan does not
inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also
degrades bradykinin into inactive metabolites. Irbesartan does not require
metabolic activation for its activity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><u><span lang=3DEN-GB style=3D'font-weight:normal'>=
Clinical
efficacy<o:p></o:p></span></u></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension<o:p></=
o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan lowers blood pressure=
 with minimal
change in heart rate. The decrease in blood pressure is dose-related for on=
ce a
day doses with a tendency towards plateau at doses above 300&nbsp;mg. Doses=
 of
150-300&nbsp;mg once daily lower supine or seated blood pressures at trough
(i.e.&nbsp;24&nbsp;hours after dosing) by an average of
8-13/5-8&nbsp;mm&nbsp;Hg (systolic/diastolic) greater than those associated
with placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Peak reduction of blood pressure=
 is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours =
the
reduction of blood pressure was 60-70% of the corresponding peak diastolic =
and
systolic responses at the recommended doses. Once daily dosing with 150&nbs=
p;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosi=
ng
on the same total dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
ct of <span
class=3DSpellE>Karvea</span> is evident within 1-2&nbsp;weeks, with the max=
imal
effect occurring by 4-6&nbsp;weeks after start of therapy. The antihyperten=
sive
effects are maintained during long term therapy. After withdrawal of therap=
y,
blood pressure gradually returns toward baseline. Rebound hypertension has =
not
been observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
cts of
irbesartan and thiazide-type diuretics are additive. In patients not adequa=
tely
controlled by irbesartan alone, the addition of a low dose of
hydrochlorothiazide (12.5&nbsp;mg) to irbesartan once daily results in a
further placebo-adjusted blood pressure reduction at trough of
7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastolic).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The efficacy of <span class=3DSp=
ellE>Karvea</span>
is not influenced by age or gender. As is the case with other medicinal
products that affect the renin-angiotensin system, black hypertensive patie=
nts
have notably less response to irbesartan monotherapy. When irbesartan is
administered concomitantly with a low dose of hydrochlorothiazide (e.g.&nbs=
p;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There is no clinically important=
 effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Paediatric population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><span
lang=3DEN-GB>Reduction of blood pressure with 0.5&nbsp;mg/kg (low), 1.5&nbs=
p;mg/kg
(medium) and 4.5&nbsp;mg/kg (high) target titrated doses of irbesartan was
evaluated in 318 hypertensive or at risk (diabetic, family history of
hypertension) children and adolescents aged 6 to 16&nbsp;years over a three
week period. At the end of the three weeks the mean reduction from baseline=
 in
the primary efficacy variable, trough seated systolic blood pressure (<span
class=3DSpellE>SeSBP</span>) was 11.7&nbsp;mmHg (low dose), 9.3&nbsp;mmHg (=
medium
dose), 13.2&nbsp;mmHg (high dose). No significant difference was apparent b=
etween
these doses. Adjusted mean change of trough seated diastolic blood pressure=
 (<span
class=3DSpellE>SeDBP</span>) was as follows: 3.8&nbsp;mmHg (low dose),
3.2&nbsp;mmHg (medium dose), 5.6&nbsp;mmHg (high dose). Over a subsequent t=
wo
week period where patients were re-randomized to either active medicinal
product or placebo, patients on placebo had increases of 2.4 and 2.0&nbsp;m=
mHg
in <span class=3DSpellE>SeSBP</span> and <span class=3DSpellE>SeDBP</span> =
compared
to +0.1 and -0.3&nbsp;mmHg changes respectively in those on all doses of
irbesartan (see section&nbsp;4.2).</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><span lang=3DEN-GB><o=
:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension and
type&nbsp;2 diabetes with renal disease<o:p></o:p></span></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The Irbesartan Diabetic Nephrop=
athy
Trial (IDNT) shows that irbesartan decreases the progression of renal dise=
ase
in patients with chronic renal insufficiency and overt proteinuria. IDNT wa=
s a
double blind, controlled, morbidity and mortality trial comparing <span
class=3DSpellE>Karvea</span>, amlodipine and placebo. In 1,715&nbsp;hyperte=
nsive
patients with type&nbsp;2 diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day
and serum creatinine ranging from 1.0-3.0&nbsp;mg/dl, the long-term effects
(mean&nbsp;2.6&nbsp;years) of <span class=3DSpellE>Karvea</span> on the
progression of renal disease and all-cause mortality were examined. Patients
were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg <span
class=3DSpellE>Karvea</span></span><span lang=3DEN-GB style=3D'font-family:=
"Times",serif;
mso-bidi-font-family:"Times New Roman"'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=3DEN-GB> as tolerated. Patients in =
all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertens=
ive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo gr=
oup
reached this target blood pressure whereas this figure was 76% and 78% in t=
he
irbesartan and amlodipine groups respectively. Irbesartan significantly red=
uced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary r=
enal
composite endpoint compared to 39% and 41% in the placebo and amlodipine gr=
oups
[20% relative risk reduction versus placebo (p&nbsp;=3D&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=3D&nbsp;0.006)]. Wh=
en the
individual components of the primary endpoint were analysed, no effect in <=
span
class=3DSpellE>all cause</span> mortality was observed, while a positive tr=
end in
the reduction in ESRD and a significant reduction in doubling of serum
creatinine were observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'>Subgroups consisting of gender, race, age, duration =
of
diabetes, baseline blood pressure, serum creatinine, and albumin excretion =
rate
were assessed for treatment effect. In the female and black subgroups which
represented 32% and 26% of the overall study population respectively, a ren=
al
benefit was not evident, </span><span style=3D'mso-ansi-language:EN-US'>alt=
hough
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI w=
as
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identif=
ied.</span><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'><o:p><=
/o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The study of the Effects of Irb=
esartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mell=
itus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with t=
ype&nbsp;2
diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal function
(serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effe=
cts
(2&nbsp;years) of <span class=3DSpellE>Karvea</span> on the progression to
clinical (overt) proteinuria (urinary albumin excretion rate (UAER)
&gt;&nbsp;300&nbsp;mg/day, and an increase in UAER of at least 30% from
baseline). The predefined blood pressure goal was
&#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents (excluding
ACE inhibitors, angiotensin&nbsp;II receptor antagonists and dihydropyridine
calcium blockers) were added as needed to help achieve the blood pressure g=
oal.
While similar blood pressure was achieved in all treatment groups, fewer
subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the placebo (14=
.9%)
or in the irbesartan 150&nbsp;mg group (9.7%) reached the endpoint of overt
proteinuria, demonstrating a 70% relative risk reduction versus placebo
(p&nbsp;=3D&nbsp;0.0004) for the higher dose. An accompanying improvement i=
n the
glomerular filtration rate (GFR) was not observed during the first three mo=
nths
of treatment. The slowing in the progression to clinical proteinuria was
evident as early as three months and continued over the 2&nbsp;year period.
Regression to <span class=3DSpellE>normoalbuminuria</span>
(&lt;&nbsp;30&nbsp;mg/day) was more frequent in the <span class=3DSpellE>Ka=
rvea</span>&nbsp;300&nbsp;mg
group (34%) than in the placebo group (21%).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Dual
blockade of the renin-angiotensin-aldosterone system (RAAS)<o:p></o:p></spa=
n></i></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Two large randomised, controlled=
 trials (ONTARGET
(<span class=3DSpellE>ONgoing</span> Telmisartan Alone and in combination w=
ith
Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs
Nephropathy in Diabetes)) have examined the use of the combination of an
ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study
conducted in patients with a history of cardiovascular or cerebrovascular
disease, or type 2 diabetes mellitus accompanied by evidence of end-organ
damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus =
and
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>These studies have shown no sign=
ificant
beneficial effect on renal and/or cardiovascular outcomes and mortality, wh=
ile
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension =
as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients wi=
th
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ALTITUDE (<span class=3DSpellE>A=
liskiren</span>
Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) =
was
a study designed to test the benefit of adding <span class=3DSpellE>aliskir=
en</span>
to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blo=
cker
in patients with type 2 diabetes mellitus and chronic kidney disease,
cardiovascular disease, or both. The study was terminated early because of =
an
increased risk of adverse outcomes. Cardiovascular death and stroke were bo=
th
numerically more frequent in the <span class=3DSpellE>aliskiren</span> grou=
p than
in the placebo group and adverse events and serious adverse events of inter=
est
(hyperkalaemia, hypotension and renal dysfunction) were more frequently
reported in the <span class=3DSpellE>aliskiren</span> group than in the pla=
cebo
group.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
2<span
style=3D'mso-tab-count:1'> </span>Pharmacokinetic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Absorption</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span>=
</p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Distribution</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Plasma
protein binding is approximately 96%, with negligible binding to cellular b=
lood
components. The volume of distribution is 53-93&nbsp;litres. </span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Biotransformation</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Following
oral or intravenous administration of <sup><span style=3D'position:relative;
top:-1.0pt;mso-text-raise:1.0pt'>14</span></sup>C irbesartan, 80-85% of the
circulating plasma radioactivity is attributable to unchanged irbesartan.
Irbesartan is metabolised by the liver via glucuronide conjugation and
oxidation. The major circulating metabolite is irbesartan glucuronide
(approximately 6%). <i style=3D'mso-bidi-font-style:normal'>In&nbsp;vitro</=
i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.=
</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Linearity / non-linearity<o:p=
></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan exhibits linear and d=
ose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg=
. A
less than proportional increase in oral absorption at doses beyond 600&nbsp=
;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at 1.5-2&nbsp;hours after =
oral
administration. The total body and renal clearance are 157&#8209;176&nbsp;a=
nd
3-3.5&nbsp;ml/min, respectively. The terminal elimination half-life of
irbesartan is 11-15&nbsp;hours. Steady-state plasma concentrations are atta=
ined
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repea=
ted
once-daily dosing. In a study, somewhat higher plasma concentrations of irb=
esartan
were observed in female hypertensive patients. However, there was no differ=
ence
in the half-life and accumulation of irbesartan. No dosage adjustment is
necessary in female patients. Irbesartan AUC and C<span class=3DEMEASubscri=
pt>max</span>
values were also somewhat greater in <span class=3DSpellE>oldersubjects</sp=
an>
(&#8805;&nbsp;65&nbsp;years) than those of young subjects (18-40&nbsp;years=
).
However the terminal half-life was not significantly altered. No dosage
adjustment is necessary in older people.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Elimination</span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan and its metabolites a=
re
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style=3D'position:relative;top:-1.0pt;mso-text=
-raise:
1.0pt'>14</span></sup>C irbesartan, about 20% of the radioactivity is recov=
ered
in the urine, and the remainder in the faeces. Less than 2% of the dose is
excreted in the urine as unchanged irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Paediatric population<o:p></o=
:p></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The pharmacokinetics of irbesart=
an were
evaluated in 23&nbsp;hypertensive children after the administration of sing=
le
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable=
 for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;ye=
ars,
nine children between 6 and 12 years). Results showed that C<span
class=3DEMEASubscript>max</span>, AUC and clearance rates were comparable to
those observed in adult patients receiving 150&nbsp;mg irbesartan daily. A
limited accumulation of irbesartan (18%) in plasma was observed upon repeat=
ed
once daily dosing.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment</span></u></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with renal impairmen=
t or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hepatic impairment</span></u>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significant=
ly
altered.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Studies have not been performed =
in
patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
3<i
style=3D'mso-bidi-font-style:normal'><span style=3D'mso-tab-count:1'> <=
/span></i>Preclinical
safety data</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>There was
no evidence of abnormal systemic or target organ toxicity at clinically rel=
evant
doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/da=
y in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/=
day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product wh=
ich
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/d=
ay).
All of these changes were considered to be caused by the pharmacological ac=
tion
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplas=
ia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There was no evidence of mutagen=
icity, <span
class=3DSpellE>clastogenicity</span> or carcinogenicity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Fertility and reproductive perfo=
rmance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), inclu=
ding
mortality at the highest dose. No significant effects on the number of corp=
ora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit fo=
etuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Animal studies with irbesartan s=
howed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significa=
nt
maternal toxicity, including mortality. No teratogenic effects were observe=
d in
the rat or rabbit.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
1<span
style=3D'mso-tab-count:1'> </span>List of excipients</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Microcrystalline
cellulose</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Croscarmellose sodium</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Lactose monohydrate</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Magnesium stearate</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Colloidal hydrated silica</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Pregelatinised maize starch</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Poloxamer&nbsp;188</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
2<span
style=3D'mso-tab-count:1'> </span>Incompatibilities</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><span
lang=3DEN-GB>Not applicable.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
3<span
style=3D'mso-tab-count:1'> </span>Shelf life</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>3&nbsp;years.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
4<span
style=3D'mso-tab-count:1'> </span>Special precautions for storage</span=
></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><span
lang=3DEN-GB>Do not store above 30C.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'margin-left:0in;text-indent:0in;mso-outlin=
e-level:
1'><span lang=3DEN-GB>6.5<span style=3D'mso-tab-count:1'> </span>Nature=
 and
contents of container</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 14&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 28&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 56&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 98&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 56&nbsp;x&nbsp;1&nbsp=
;tablet
in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><span lang=3DEN-GB>No=
t all pack
sizes may be marketed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
6<span
style=3D'mso-tab-count:1'> </span>Special precautions for disposal</spa=
n></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Any
unused medicinal product or waste material should be disposed of in accorda=
nce
with local requirements.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>7.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION HOLDER<o:p>=
</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>8.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION NUMBERS<o:p=
></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'text-align:justify'><span lang=3DNO-BOK
style=3D'mso-ansi-language:NO-BOK'>EU/1/97/049/001-003<br>
EU/1/97/049/010<br>
EU/1/97/049/013</span><span lang=3DSL style=3D'mso-ansi-language:SL'><o:p><=
/o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>DATE
OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Date of first authorisation: 27 =
August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>10.<span style=3D'mso-tab-count:=
1'> </span>DATE
OF REVISION OF THE TEXT</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icinal
product is available on the website of the European Medicines Agency http:/=
/www.ema.europa.eu</span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-bidi-font-size:12.0pt'=
><o:p>&nbsp;</o:p></span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<p class=3DEMEAHeading1><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg tablets.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Each tablet contains 150&nbsp;mg=
 of
irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Excipient with known effect</=
span></u><span
lang=3DEN-GB>: 30.75&nbsp;mg of lactose monohydrate per tablet.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For the full list of excipients,=
 see
section&nbsp;6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Tablet.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2772 engr=
aved
on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>CLINICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
1<span
style=3D'mso-tab-count:1'> </span>Therapeutic indications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span class=3DSpel=
lE><span
lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB> is indicated in adults=
 for the
treatment of essential hypertension.</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>It is also indicated for the tre=
atment
of renal disease in adult patients with hypertension and type&nbsp;2 diabet=
es
mellitus as part of an antihypertensive medicinal product regimen (see sect=
ions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
2<span
style=3D'mso-tab-count:1'> </span>Posology and method of administration=
</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Posology<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. <span class=3DSpellE>Karvea</span> at a dose of 150&nbsp;mg o=
nce
daily generally provides a better 24&nbsp;hour blood pressure control than
75&nbsp;mg. However, initiation of therapy with 75&nbsp;mg could be conside=
red,
particularly in haemodialysed patients and in the elderly over 75&nbsp;year=
s.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients insufficiently contr=
olled
with 150&nbsp;mg once daily, the dose of <span class=3DSpellE>Karvea</span>=
 can be
increased to 300&nbsp;mg, or other antihypertensive agents can be added (see
sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic =
such
as hydrochlorothiazide has been shown to have an additive effect with <span
class=3DSpellE>Karvea</span> (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In hypertensive type&nbsp;2 diab=
etic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily =
and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The demonstration of renal benef=
it of <span
class=3DSpellE>Karvea</span> in hypertensive type&nbsp;2 diabetic patients =
is
based on studies where irbesartan was used in addition to other
antihypertensive agents, as needed, to reach target blood pressure (see sec=
tions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Special Populations<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Renal
impairment</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4=
).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Hepatic
impairment</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Older
people</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Although consideration should be=
 given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary for older people.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Paediatric
population</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The safety and efficacy of <span
class=3DSpellE>Karvea</span> in children aged 0 to 18 has not been establis=
hed.
Currently available data are described in sections 4.8, 5.1, and 5.2 but no
recommendation on a posology can be made.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Method of Administration<o:p>=
</o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For oral use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
3<span
style=3D'mso-tab-count:1'> </span>Contraindications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;=
6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Second and third trimesters of p=
regnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><span style=3D'mso-spacerun:yes'=
></span>The
concomitant use of <span class=3DSpellE>Karvea</span> with <span class=3DSp=
ellE>aliskiren</span>-containing
products is contraindicated in patients with diabetes mellitus or renal
impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup=
>)
(see sections 4.5 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
4<span
style=3D'mso-tab-count:1'> </span>Special warnings and precautions for =
use</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Intravascular
volume depletion</span></u><span lang=3DEN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renovascular hypertension</sp=
an></u><span
lang=3DEN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosi=
s of
the artery to a single functioning kidney are treated with medicinal produc=
ts
that affect the renin-angiotensin-aldosterone system. While this is not
documented with <span class=3DSpellE>Karvea</span>, a similar effect should=
 be
anticipated with angiotensin-II receptor antagonists.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment and kidney
transplantation</span></u><span lang=3DEN-GB>: when <span class=3DSpellE>Ka=
rvea</span>
is used in patients with impaired renal function, a periodic monitoring of
potassium and creatinine serum levels is recommended. There is no experience
regarding the administration of <span class=3DSpellE>Karvea</span> in patie=
nts
with a recent kidney transplantation.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=3DEN-GB>:</span=
><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'> the e=
ffects
of irbesartan both on renal and cardiovascular events were not uniform acro=
ss
all subgroups, in an analysis carried out in the study with patients with
advanced renal disease. In particular, they appeared less favourable in wom=
en
and non-white subjects (see section&nbsp;5.1).<o:p></o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS</span></u><span lang=3DEN-GB>): =
<u>t</u>here
is evidence that the concomitant use of ACE-inhibitors, angiotensin II rece=
ptor
blockers or <span class=3DSpellE>aliskiren</span> increases the risk of
hypotension, hyperkalaemia and decreased renal function (including acute re=
nal
failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,
angiotensin II receptor blockers or <span class=3DSpellE>aliskiren</span> is
therefore not recommended (see sections 4.5 and 5.1). <span
style=3D'mso-spacerun:yes'></span>If dual blockade therapy is considered
absolutely necessary, this should only occur under specialist supervision a=
nd
subject to frequent close monitoring of renal function, electrolytes and bl=
ood
pressure. ACE-inhibitors and angiotensin II receptor blockers should not be
used concomitantly in patients with diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hyperkalaemia</span></u><span
lang=3DEN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with <span class=3DSpellE>Karvea</span>, especially in the presen=
ce of
renal impairment, overt proteinuria due to diabetic renal disease, and/or h=
eart
failure. Close monitoring of serum potassium in patients at risk is recomme=
nded
(see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypoglycaemia: </span></u><sp=
an
class=3DSpellE><span lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB> m=
ay induce
hypoglycaemia, particularly in diabetic patients. In patients treated with
insulin or antidiabetics an appropriate blood glucose monitoring should be
considered; a dose adjustment of insulin or antidiabetics may be required w=
hen
indicated (see section 4.5).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:
the combination of lithium and <span class=3DSpellE>Karvea</span> is not
recommended (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Aortic and mitral valve steno=
sis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=3DEN-GB>: as w=
ith
other vasodilators, special caution is indicated in patients suffering from
aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</spa=
n></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Primary aldosteronism</span><=
/u><span
lang=3DEN-GB>: patients with primary aldosteronism generally will not respo=
nd to
antihypertensive medicinal products acting through inhibition of the
renin-angiotensin system. Therefore, the use of <span class=3DSpellE>Karvea=
</span>
is not recommended.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>General</span></u><span lang=
=3DEN-GB>:
in patients whose vascular tone and renal function depend predominantly on =
the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients wi=
th
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b style=3D'mso-bidi-font-weigh=
t:
normal'> </b>converting enzyme inhibitors or angiotensin-II receptor
antagonists that affect this system has been associated with acute hypotens=
ion,
azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As wi=
th
any antihypertensive agent, excessive blood pressure decrease in patients w=
ith
ischaemic cardiopathy or ischaemic cardiovascular disease could result in a
myocardial infarction or stroke.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As observed for angiotensin conv=
erting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Pregnancy:</span></u><span
lang=3DEN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not =
be
initiated during pregnancy. </span><span lang=3DEN-GB style=3D'mso-bidi-fon=
t-size:
11.0pt'>Unless continued AIIRA therapy is considered essential, patients
planning pregnancy should be changed to alternative antihypertensive treatm=
ents
which have an established safety profile for use in pregnancy. When pregnan=
cy
is diagnosed, treatment with </span><span lang=3DEN-GB>AIIRAs</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> should be stopped immedia=
tely,
and, if appropriate, alternative therapy should be started (see
sections&nbsp;4.3 and&nbsp;4.6).<o:p></o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Paediatric population</span><=
/u><span
lang=3DEN-GB>: irbesartan has been studied in paediatric populations <span
style=3D'mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>aged 6 to 16=
 years
old</span> but the current data are insufficient to support an extension of=
 the
use in children until further data become available (see sections&nbsp;4.8,=
 5.1
and&nbsp;5.2).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><u><span lang=3DEN-GB>Excipients</span></u><span lang=
=3DFR
style=3D'mso-ansi-language:FR'>:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DFR style=3D'mso-a=
nsi-language:
FR'>Karvea</span></span><span lang=3DFR style=3D'mso-ansi-language:FR'>&nbs=
p;150 mg
<span class=3DSpellE>tablet</span> <span class=3DSpellE>contains</span> lac=
tose. </span><span
lang=3DEN-GB>Patients with rare hereditary problems of galactose intoleranc=
e,
total lactase deficiency or glucose-galactose malabsorption should not take
this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DFR style=3D'mso-a=
nsi-language:
FR'>Karvea</span></span><span lang=3DFR style=3D'mso-ansi-language:FR'>&nbs=
p;150 mg
<span class=3DSpellE>tablet</span> <span class=3DSpellE>contains</span> sod=
ium. </span><span
lang=3DEN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tab=
let, that
is to say essentially sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>4.5<span style=3D'mso-tab-count:=
1'> </span>Interaction
with other medicinal products and other forms of interaction</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Diuretics and other antihyper=
tensive
agents</span></u><span lang=3DEN-GB>: other antihypertensive agents may inc=
rease
the hypotensive effects of irbesartan; however <span class=3DSpellE>Karvea<=
/span>
has been safely administered with other antihypertensive agents, such as
beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Prior treatment with high dose diuretics may result in volume depletion and=
 a
risk of hypotension when initiating therapy with <span class=3DSpellE>Karve=
a</span>
(see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><span class=3DSpellE><u><span lang=3DEN-GB>Aliskire=
n</span></u></span><u><span
lang=3DEN-GB>-containing <span class=3DSpellE>productsand</span> <span
class=3DSpellE>ACE-inhibitors<span style=3D'text-decoration:none;text-under=
line:
none'>:.clinical</span></span></span></u><span lang=3DEN-GB> trial data has=
 shown
that dual blockade of the renin-angiotensin-aldosterone system (RAAS) throu=
gh
the combined use of ACE-inhibitors, angiotensin II receptor blockers or <sp=
an
class=3DSpellE>aliskiren</span> is associated with a higher frequency of ad=
verse
events such as hypotension, hyperkalaemia and decreased renal function
(including acute renal failure) compared to the use of a single RAAS-acting
agent (see sections 4.3, 4.4 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Potassium supplements and pot=
assium-sparing
diuretics</span></u><span lang=3DEN-GB>:<i style=3D'mso-bidi-font-style:nor=
mal'> </i>based
on experience with the use of other medicinal products that affect the reni=
n-angiotensin
system, concomitant use of potassium-sparing diuretics, potassium supplemen=
ts,
salt substitutes containing potassium or other medicinal products that may
increase serum potassium levels (e.g.&nbsp;heparin) may lead to increases in
serum potassium and is, therefore, not recommended (see section&nbsp;4.4).<=
/span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:<i
style=3D'mso-bidi-font-style:normal'> </i>reversible increases in serum lit=
hium
concentrations and toxicity have been reported during concomitant
administration of lithium with angiotensin converting enzyme inhibitors.
Similar effects have been very rarely reported with irbesartan so far.
Therefore, this combination is not recommended (see section&nbsp;4.4). If t=
he
combination proves necessary, careful monitoring of serum lithium levels is
recommended.<i style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span><=
/p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Non-steroidal anti-inflammato=
ry drugs</span></u><span
lang=3DEN-GB>: w<span style=3D'color:black'>hen angiotensin&nbsp;II antagon=
ists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) a=
nd
non-selective NSAIDs), attenuation of the antihypertensive effect may occur=
.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'color:black'>As with ACE
inhibitors, concomitant use of angiotensin&nbsp;II antagonists and NSAIDs m=
ay
lead to an increased risk of worsening of renal function, including possible
acute renal failure, and an increase in serum potassium, especially in pati=
ents
with poor pre-existing renal function. The combination should be administer=
ed
with caution, especially in the elderly. Patients should be adequately hydr=
ated
and consideration should be given to monitoring renal function after initia=
tion
of concomitant therapy, and periodically thereafter.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Repaglinide:</span></u><span
lang=3DEN-GB style=3D'color:black'> irbesartan has the potential to inhibit=
 OATP1B1.
In a clinical study, it was reported that irbesartan increased the C<sub>ma=
x</sub>
and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3&#8209;fol=
d,
respectively, when administered 1 hour before repaglinide. In another study=
, no
relevant pharmacokinetic interaction was reported, when the two drugs were
co-administered. Therefore, dose adjustment of antidiabetic treatment such =
as
repaglinide may be required (see section 4.4).<o:p></o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Additional information on irb=
esartan
interactions</span></u><span lang=3DEN-GB>: <span style=3D'color:black'>in =
clinical
studies, the pharmacokinetic of irbesartan is not affected by hydrochloroth=
iazide.
Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by
glucuronidation. No significant pharmacokinetic or pharmacodynamic interact=
ions
were observed when irbesartan was coadministered with warfarin, a medicinal
product metabolised by CYP2C9. The effects of CYP2C9 inducers such as
rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The
pharmacokinetic of digoxin was not altered by coadministration of irbesarta=
n.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
6<span
style=3D'mso-tab-count:1'> </span>Fertility, pregnancy and lactation</s=
pan></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Pregnancy</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEABodyText style=3D'border:none;mso-border-alt:solid windowtex=
t .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><span lang=3DEN-GB>The=
 use
of AIIRAs is not recommended during the first trimester of pregnancy (see
section&nbsp;4.4). The use of AIIRAs is contraindicated during the second a=
nd
third trimesters of pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span><=
/p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Epidemiological evidence regardi=
ng the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in
risk cannot be excluded. Whilst there is no controlled epidemiological data=
 on
the risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar ri=
sks
may exist for this class of drugs. Unless continued AIIRA therapy is consid=
ered
essential, patients planning pregnancy should be changed to alternative ant=
ihypertensive
treatments which have an established safety profile for use in pregnancy. W=
hen
pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately=
, and,
if appropriate, alternative therapy should be started.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Exposure to AIIRA therapy during=
 the
second and third trimesters is known to induce human foetotoxicity (decreas=
ed
renal function, oligohydramnios, skull ossification retardation) and neonat=
al
toxicity (renal failure, hypotension, hyperkalaemia). (See section&nbsp;5.3=
).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Should exposure to AIIRAs have o=
ccurred
from the second trimester of pregnancy, ultrasound check of renal function =
and
skull is recommended.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Infants whose mothers have taken=
 AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3
and&nbsp;4.4).<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Breast-feeding</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Because no information is availa=
ble
regarding the use of <span class=3DSpellE>Karvea</span> during breast-feedi=
ng, <span
class=3DSpellE>Karvea</span> is not recommended and alternative treatments =
with
better established safety profiles during breast-feeding are preferable,
especially while nursing a newborn or preterm infant.</span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>It is unkno=
wn
whether irbesartan or its metabolites are excreted in human milk. <o:p></o:=
p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>Available
pharmacodynamic/toxicological data in rats have shown excretion of irbesart=
an
or its metabolites in milk (for details see 5.3).<span style=3D'color:black=
'><o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Fertility</span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan had no effect upon fe=
rtility
of treated rats and their offspring up to the dose levels inducing the first
signs of parental toxicity (see section 5.3).</span><span style=3D'mso-ansi=
-language:
EN-US'> <o:p></o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
7<span
style=3D'mso-tab-count:1'> </span>Effects on ability to drive and use m=
achines</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Based on its pharmacodynamic pro=
perties,
irbesartan is unlikely to affect the ability to drive and use <span
class=3DSpellE>machnes</span>. When driving vehicles or operating machines,=
 it
should be taken into account that dizziness or weariness may occur during
treatment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
8<span
style=3D'mso-tab-count:1'> </span>Undesirable effects</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>In
placebo-controlled trials in patients with hypertension, the overall incide=
nce
of adverse events did not differ between the irbesartan (56.2%) and the pla=
cebo
groups (56.5%). Discontinuation due to any clinical or laboratory adverse e=
vent
was less frequent for irbesartan-treated patients (3.3%) than for
placebo-treated patients (4.5%). The incidence of adverse events was not
related to dose (in the recommended dose range), gender, age, race, or dura=
tion
of treatment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In diabetic hypertensive patient=
s with
microalbuminuria and normal renal function, orthostatic dizziness and
orthostatic hypotension were reported in 0.5% of the patients
(i.e.,&nbsp;uncommon) but in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The following table presents the=
 adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a s=
tar
(*) refer to the adverse reactions that were additionally reported in &gt; =
2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of adverse reactio=
ns
listed below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>very common (&#8805;&nbsp;1/10);=
 common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very r=
are
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects a=
re
presented in order of decreasing seriousness.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Adverse reactions additionally r=
eported
from postmarketing experience are also listed. <span style=3D'mso-bidi-fon=
t-style:
italic'>These adverse reactions are derived from spontaneous reports.<o:p><=
/o:p></span></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Blood and lymphatic system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>anaemia, thrombocytopenia </span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Immune system disorders<i style=3D'mso-bidi-font-style:normal'=
><o:p></o:p></i></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hypersensitivity reactions such as angioedema, rash, urtic=
aria,
anaphylactic reaction, anaphylactic shock<i style=3D'mso-bidi-font-style:no=
rmal'><u><o:p></o:p></u></i></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Metabolism and nutrition disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hyperkalaemia, hypoglycaemia</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><i style=3D'mso-bidi-=
font-style:
normal'><u><span lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nb=
sp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Nervous system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>dizzine=
ss,
orthostatic dizziness*</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Not known:<span style=3D'mso-tab-count:1'> </span>vertig=
o, headache</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Ear and labyrinth disorder<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>tinnitus</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Cardiac disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>tachycar=
dia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Vascular disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;tab-stops:31.5pt .5=
in 1.0in'><span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>orthost=
atic
hypotension*</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>flushing<i
style=3D'mso-bidi-font-style:normal'><u><o:p></o:p></u></i></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Respiratory, thoracic and mediastinal disorders<o:p></o:p></sp=
an></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>cough</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Gastrointestinal disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>nausea/vomiting</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>U=
ncommon:<span
style=3D'mso-tab-count:1'> </span>diarrhoea, dyspepsia/heartburn</span=
></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>N=
ot known:<span
style=3D'mso-tab-count:1'> </span>dysgeusia</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB><=
o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Hepatobiliary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>jaundice</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>hepatitis,
abnormal liver function<i style=3D'mso-bidi-font-style:normal'><u><o:p></o:=
p></u></i></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Skin and subcutaneous tissue disorders<o:p></o:p></span></u></=
p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:44.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
1'> </span><span class=3DSpellE>leukocytoclastic</span> vasculitis</s=
pan></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Musculoskeletal and connective tissue disorders<o:p></o:p></sp=
an></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>musculo=
skeletal
pain*</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;mso-o=
utline-level:
1;tab-stops:1.0in'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-coun=
t:1'> </span>arthralgia,
myalgia (in some cases associated with increased plasma creatine kinase lev=
els),
muscle cramps</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Renal and urinary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;page-=
break-after:
avoid;mso-outline-level:1;tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<s=
pan
style=3D'mso-tab-count:1'> </span><span style=3D'mso-tab-count:1'> </=
span>impaired
renal function including cases of renal failure in patients at risk (see
section&nbsp;4.4)</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Reproductive system and breast disorders</span></u></p>

<p class=3DEMEABodyText style=3D'text-align:justify;mso-outline-level:1;tab=
-stops:
1.0in'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </=
span>sexual
dysfunction</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>General disorders and administration site conditions<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>fatigue</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>chest
pain<i style=3D'mso-bidi-font-style:normal'><u><o:p></o:p></u></i></span></=
p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DEN-GB><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Investigations<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Very common:<span style=3D'mso-tab-count:1'>=
 </span>Hyperkalaemia*
occurred more often in diabetic patients treated with irbesartan than with
placebo. In diabetic hypertensive patients with microalbuminuria and normal
renal function, hyperkalaemia (&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>m=
Eq</span>/L)
occurred in 29.4% of the patients in the irbesartan 300&nbsp;mg group and 2=
2%
of the patients in the placebo group. In diabetic hypertensive patients with
chronic renal insufficiency and overt proteinuria, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>mEq</span>/L) occurred in 46.3%=
 of
the patients in the irbesartan group and 26.3% of the patients in the place=
bo
group.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'>=
 </span>significant
increases in plasma creatine kinase were commonly observed (1.7%) in irbesa=
rtan
treated subjects. None of these increases were associated with identifiable
clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treat=
ed
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:0in'><span lang=3DEN-GB><o:p>&nb=
sp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB style=3D'mso-bidi-font-weight=
:bold'>Paediatric
population</span></u><b><span lang=3DEN-GB> <o:p></o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In a randomised trial of
318&nbsp;hypertensive children and adolescents aged 6 to 16&nbsp;years, the
following adverse reactions occurred in the 3-week double-blind phase: head=
ache
(7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week
open-label period of this trial the most frequent laboratory abnormalities
observed were creatinine increases (6.5%) and elevated CK values in 2% of c=
hild
recipients.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of suspected adverse
reactions <o:p></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Reporting suspected adverse reac=
tions
after authorisation of the medicinal product is important. It allows contin=
ued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in Appendix V.</span> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
9<span
style=3D'mso-tab-count:1'> </span>Overdose</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Experience in adults exposed to =
doses of
up to 900&nbsp;mg/day for 8&nbsp;weeks revealed no toxicity. The most likely
manifestations of overdose are expected to be hypotension and tachycardia;
bradycardia might also occur from overdose. No specific information is
available on the treatment of overdose with <span class=3DSpellE>Karvea</sp=
an>.
The patient should be closely monitored, and the treatment should be
symptomatic and supportive. Suggested measures include induction of emesis
and/or gastric lavage. Activated charcoal may be useful in the treatment of
overdose. Irbesartan is not removed by haemodialysis.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
1<span
style=3D'mso-tab-count:1'> </span>Pharmacodynamic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Pharmacotherapeutic
group: Angiotensin-II antagonists, plain.</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>ATC&nbsp;code:
C09C&nbsp;A04.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Mechanism of action</span></u=
><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB> <o:p></o:p></span=
></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan is a potent, orally a=
ctive, selective
angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is expected to
block all actions of angiotensin-II mediated by the AT<sub>1</sub> receptor,
regardless of the source or route of synthesis of angiotensin-II. The selec=
tive
antagonism of the angiotensin-II (AT<sub>1</sub>) receptors results in
increases in plasma renin levels and angiotensin-II levels, and a decrease =
in
plasma aldosterone concentration. Serum potassium levels are not significan=
tly
affected by irbesartan alone at the recommended doses. Irbesartan does not
inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also
degrades bradykinin into inactive metabolites. Irbesartan does not require
metabolic activation for its activity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><u><span lang=3DEN-GB style=3D'font-weight:normal'>=
Clinical
efficacy<o:p></o:p></span></u></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension<o:p></=
o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan lowers blood pressure=
 with minimal
change in heart rate. The decrease in blood pressure is dose-related for on=
ce a
day doses with a tendency towards plateau at doses above 300&nbsp;mg. Doses=
 of
150-300&nbsp;mg once daily lower supine or seated blood pressures at trough
(i.e.&nbsp;24&nbsp;hours after dosing) by an average of
8-13/5-8&nbsp;mm&nbsp;Hg (systolic/diastolic) greater than those associated
with placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Peak reduction of blood pressure=
 is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours =
the
reduction of blood pressure was 60-70% of the corresponding peak diastolic =
and
systolic responses at the recommended doses. Once daily dosing with 150&nbs=
p;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosi=
ng on
the same total dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
ct of <span
class=3DSpellE>Karvea</span> is evident within 1-2&nbsp;weeks, with the max=
imal
effect occurring by 4-6&nbsp;weeks after start of therapy. The antihyperten=
sive
effects are maintained during long term therapy. After withdrawal of therap=
y,
blood pressure gradually returns toward baseline. Rebound hypertension has =
not
been observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
cts of
irbesartan and thiazide-type diuretics are additive. In patients not adequa=
tely
controlled by irbesartan alone, the addition of a low dose of
hydrochlorothiazide (12.5&nbsp;mg) to irbesartan once daily results in a
further placebo-adjusted blood pressure reduction at trough of
7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastolic).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The efficacy of <span class=3DSp=
ellE>Karvea</span>
is not influenced by age or gender. As is the case with other medicinal
products that affect the renin-angiotensin system, black hypertensive patie=
nts
have notably less response to irbesartan monotherapy. When irbesartan is
administered concomitantly with a low dose of hydrochlorothiazide (e.g.&nbs=
p;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There is no clinically important=
 effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Paediatric population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><span
lang=3DEN-GB>Reduction of blood pressure with 0.5&nbsp;mg/kg (low),
1.5&nbsp;mg/kg (medium) and 4.5&nbsp;mg/kg (high) target titrated doses of
irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family
history of hypertension) children and adolescents aged 6 to 16&nbsp;years o=
ver
a three week period. At the end of the three weeks the mean reduction from
baseline in the primary efficacy variable, trough seated systolic blood
pressure (<span class=3DSpellE>SeSBP</span>) was 11.7&nbsp;mmHg (low dose),
9.3&nbsp;mmHg (medium dose), 13.2&nbsp;mmHg (high dose). No significant
difference was apparent between these doses. Adjusted mean change of trough
seated diastolic blood pressure (<span class=3DSpellE>SeDBP</span>) was as
follows: 3.8&nbsp;mmHg (low dose), 3.2&nbsp;mmHg (medium dose), 5.6&nbsp;mm=
Hg
(high dose). Over a subsequent two week period where patients were
re-randomized to either active medicinal product or placebo, patients on
placebo had increases of 2.4 and 2.0&nbsp;mmHg in <span class=3DSpellE>SeSB=
P</span>
and <span class=3DSpellE>SeDBP</span> compared to +0.1 and -0.3&nbsp;mmHg c=
hanges
respectively in those on all doses of irbesartan (see section&nbsp;4.2).</s=
pan></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><span lang=3DEN-GB><o=
:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension and
type&nbsp;2 diabetes with renal disease<o:p></o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The Irbesartan Diabetic Nephrop=
athy
Trial (IDNT) shows that irbesartan decreases the progression of renal dise=
ase
in patients with chronic renal insufficiency and overt proteinuria. IDNT wa=
s a
double blind, controlled, morbidity and mortality trial comparing <span
class=3DSpellE>Karvea</span>, amlodipine and placebo. In 1,715&nbsp;hyperte=
nsive
patients with type&nbsp;2 diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day
and serum creatinine ranging from 1.0-3.0&nbsp;mg/dl, the long-term effects
(mean&nbsp;2.6&nbsp;years) of <span class=3DSpellE>Karvea</span> on the
progression of renal disease and all-cause mortality were examined. Patients
were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg <span
class=3DSpellE>Karvea</span></span><span lang=3DEN-GB style=3D'font-family:=
"Times",serif;
mso-bidi-font-family:"Times New Roman"'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=3DEN-GB> as tolerated. Patients in =
all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertens=
ive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo gr=
oup
reached this target blood pressure whereas this figure was 76% and 78% in t=
he
irbesartan and amlodipine groups respectively. Irbesartan significantly red=
uced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary r=
enal
composite endpoint compared to 39% and 41% in the placebo and amlodipine gr=
oups
[20% relative risk reduction versus placebo (p&nbsp;=3D&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=3D&nbsp;0.006)]. Wh=
en the
individual components of the primary endpoint were analysed, no effect in <=
span
class=3DSpellE>all cause</span> mortality was observed, while a positive tr=
end in
the reduction in ESRD and a significant reduction in doubling of serum
creatinine were observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'>Subgroups consisting of gender, race, age, duration =
of
diabetes, baseline blood pressure, serum creatinine, and albumin excretion =
rate
were assessed for treatment effect. In the female and black subgroups which
represented 32% and 26% of the overall study population respectively, a ren=
al
benefit was not evident, </span><span style=3D'mso-ansi-language:EN-US'>alt=
hough
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI w=
as
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identif=
ied.</span><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'><o:p><=
/o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The study of the Effects of Irb=
esartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mell=
itus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with
type&nbsp;2 diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal
function (serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effe=
cts
(2&nbsp;years) of <span class=3DSpellE>Karvea</span> on the progression to
clinical (overt) proteinuria (urinary albumin excretion rate (UAER)
&gt;&nbsp;300&nbsp;mg/day, and an increase in UAER of at least 30% from
baseline). The predefined blood pressure goal was
&#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents (excluding
ACE inhibitors, angiotensin&nbsp;II receptor antagonists and dihydropyridine
calcium blockers) were added as needed to help achieve the blood pressure g=
oal.
While similar blood pressure was achieved in all treatment groups, fewer
subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the placebo (14=
.9%)
or in the irbesartan 150&nbsp;mg group (9.7%) reached the endpoint of overt
proteinuria, demonstrating a 70% relative risk reduction versus placebo
(p&nbsp;=3D&nbsp;0.0004) for the higher dose. An accompanying improvement i=
n the
glomerular filtration rate (GFR) was not observed during the first three mo=
nths
of treatment. The slowing in the progression to clinical proteinuria was
evident as early as three months and continued over the 2&nbsp;year period.
Regression to <span class=3DSpellE>normoalbuminuria</span>
(&lt;&nbsp;30&nbsp;mg/day) was more frequent in the <span class=3DSpellE>Ka=
rvea</span>&nbsp;300&nbsp;mg
group (34%) than in the placebo group (21%).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Dual
blockade of the renin-angiotensin-aldosterone system (RAAS)<o:p></o:p></spa=
n></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Two large randomised, controlled=
 trials
(ONTARGET (<span class=3DSpellE>ONgoing</span> Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Vete=
rans
Affairs Nephropathy in Diabetes)) have examined the use of the combination =
of
an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a st=
udy
conducted in patients with a history of cardiovascular or cerebrovascular
disease, or type 2 diabetes mellitus accompanied by evidence of end-organ
damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus =
and
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>These studies have shown no sign=
ificant
beneficial effect on renal and/or cardiovascular outcomes and mortality, wh=
ile
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension =
as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients wi=
th
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ALTITUDE (<span class=3DSpellE>A=
liskiren</span>
Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) =
was
a study designed to test the benefit of adding <span class=3DSpellE>aliskir=
en</span>
to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blo=
cker
in patients with type 2 diabetes mellitus and chronic kidney disease,
cardiovascular disease, or both. The study was terminated early because of =
an
increased risk of adverse outcomes. Cardiovascular death and stroke were bo=
th
numerically more frequent in the <span class=3DSpellE>aliskiren</span> grou=
p than
in the placebo group and adverse events and serious adverse events of inter=
est
(hyperkalaemia, hypotension and renal dysfunction) were more frequently
reported in the <span class=3DSpellE>aliskiren</span> group than in the pla=
cebo
group.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
2<span
style=3D'mso-tab-count:1'> </span>Pharmacokinetic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Absorption<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span>=
</p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Distribution<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Plasma
protein binding is approximately 96%, with negligible binding to cellular b=
lood
components. The volume of distribution is 53-93&nbsp;litres. </span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Biotransformation<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Following
oral or intravenous administration of <sup><span style=3D'position:relative;
top:-1.0pt;mso-text-raise:1.0pt'>14</span></sup>C irbesartan, 80-85% of the
circulating plasma radioactivity is attributable to unchanged irbesartan.
Irbesartan is metabolised by the liver via glucuronide conjugation and
oxidation. The major circulating metabolite is irbesartan glucuronide
(approximately 6%). <i style=3D'mso-bidi-font-style:normal'>In&nbsp;vitro</=
i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.=
</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Linearity/ non-linearity<o:p>=
</o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan exhibits linear and d=
ose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg=
. A
less than proportional increase in oral absorption at doses beyond 600&nbsp=
;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at 1.5-2&nbsp;hours after =
oral
administration. The total body and renal clearance are 157-176&nbsp;and
3-3.5&nbsp;ml/min, respectively. The terminal elimination half-life of irbe=
sartan
is 11-15&nbsp;hours. Steady-state plasma concentrations are attained within
3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repea=
ted
once-daily dosing. In a study, somewhat higher plasma concentrations of
irbesartan were observed in female hypertensive patients. However, there wa=
s no
difference in the half-life and accumulation of irbesartan. No dosage
adjustment is necessary in female patients. Irbesartan AUC and C<span
class=3DEMEASubscript>max</span> values were also somewhat greater in <span
class=3DSpellE>oldersubjects</span> (&#8805;&nbsp;65&nbsp;years) than those=
 of
young subjects (18-40&nbsp;years). However the terminal half-life was not
significantly altered. No dosage adjustment is necessary in older people.</=
span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Elimination<o:p></o:p></span>=
</u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan and its metabolites a=
re
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style=3D'position:relative;top:-1.0pt;mso-text=
-raise:
1.0pt'>14</span></sup>C irbesartan, about 20% of the radioactivity is recov=
ered
in the urine, and the remainder in the faeces. Less than 2% of the dose is
excreted in the urine as unchanged irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Paediatric population<o:p></o=
:p></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The pharmacokinetics of irbesart=
an were
evaluated in 23&nbsp;hypertensive children after the administration of sing=
le
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable=
 for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;ye=
ars,
nine children between 6 and 12 years). Results showed that C<span
class=3DEMEASubscript>max</span>, AUC and clearance rates were comparable to
those observed in adult patients receiving 150&nbsp;mg irbesartan daily. A
limited accumulation of irbesartan (18%) in plasma was observed upon repeat=
ed
once daily dosing.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment</span></u></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with renal impairmen=
t or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hepatic impairment</span></u>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significant=
ly
altered.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Studies have not been performed =
in
patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
3<i
style=3D'mso-bidi-font-style:normal'><span style=3D'mso-tab-count:1'> <=
/span></i>Preclinical
safety data</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/da=
y in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/=
day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product wh=
ich
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/d=
ay).
All of these changes were considered to be caused by the pharmacological ac=
tion
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplas=
ia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There was no evidence of mutagen=
icity, <span
class=3DSpellE>clastogenicity</span> or carcinogenicity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Fertility and reproductive perfo=
rmance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), inclu=
ding
mortality at the highest dose. No significant effects on the number of corp=
ora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit fo=
etuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Animal studies with irbesartan s=
howed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significa=
nt
maternal toxicity, including mortality. No teratogenic effects were observe=
d in
the rat or rabbit.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
1<span
style=3D'mso-tab-count:1'> </span>List of excipients</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Microcrystalline
cellulose</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Croscarmellose sodium</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Lactose monohydrate</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Magnesium stearate</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Colloidal hydrated silica</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Pregelatinised maize starch</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Poloxamer&nbsp;188</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
2<span
style=3D'mso-tab-count:1'> </span>Incompatibilities</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><span
lang=3DEN-GB>Not applicable.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
3<span
style=3D'mso-tab-count:1'> </span>Shelf life</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>3&nbsp;years.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
4<span
style=3D'mso-tab-count:1'> </span>Special precautions for storage</span=
></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><span
lang=3DEN-GB>Do not store above 30C.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'margin-left:0in;text-indent:0in;mso-outlin=
e-level:
1'><span lang=3DEN-GB>6.5<span style=3D'mso-tab-count:1'> </span>Nature=
 and
contents of container</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 14&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 28&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 56&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 98&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 56&nbsp;x&nbsp;1&nbsp=
;tablet
in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><span lang=3DEN-GB>No=
t all pack
sizes may be marketed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
6<span
style=3D'mso-tab-count:1'> </span>Special precautions for disposal</spa=
n></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Any
unused medicinal product or waste material should be disposed of in accorda=
nce
with local requirements.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>7.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION HOLDER<o:p>=
</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>8.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION NUMBERS<o:p=
></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'text-align:justify'><span lang=3DNO-BOK
style=3D'mso-ansi-language:NO-BOK'>EU/1/97/049/004-006<br>
EU/1/97/049/011<br>
EU/1/97/049/014</span><span lang=3DSL style=3D'mso-ansi-language:SL'><o:p><=
/o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>DATE
OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Date of first authorisation: 27 =
August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>10.<span style=3D'mso-tab-count:=
1'> </span>DATE
OF REVISION OF THE TEXT</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-bidi-font-size:12.0pt'=
><o:p>&nbsp;</o:p></span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<p class=3DEMEAHeading1><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg tablets.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Each tablet contains 300&nbsp;mg=
 of
irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Excipient with known effect</=
span></u><span
lang=3DEN-GB>: 61.50&nbsp;mg of lactose monohydrate per tablet.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For the full list of excipients,=
 see
section&nbsp;6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Tablet.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2773 engr=
aved
on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>CLINICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
1<span
style=3D'mso-tab-count:1'> </span>Therapeutic indications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span class=3DSpel=
lE><span
lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB> is indicated in adults=
 for the
treatment of essential hypertension.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>It is also indicated for the tre=
atment
of renal disease in adult patients with hypertension and type&nbsp;2 diabet=
es
mellitus as part of an antihypertensive medicinal product regimen (see sect=
ions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
2<span
style=3D'mso-tab-count:1'> </span>Posology and method of administration=
</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Posology<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. <span class=3DSpellE>Karvea</span> at a dose of 150&nbsp;mg o=
nce
daily generally provides a better 24&nbsp;hour blood pressure control than
75&nbsp;mg. However, initiation of therapy with 75&nbsp;mg could be conside=
red,
particularly in haemodialysed patients and in the elderly over 75&nbsp;year=
s.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients insufficiently contr=
olled
with 150&nbsp;mg once daily, the dose of <span class=3DSpellE>Karvea</span>=
 can
be increased to 300&nbsp;mg, or other antihypertensive agents can be added =
(see
sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic =
such
as hydrochlorothiazide has been shown to have an additive effect with <span
class=3DSpellE>Karvea</span> (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In hypertensive type&nbsp;2 diab=
etic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily =
and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The demonstration of renal benef=
it of <span
class=3DSpellE>Karvea</span> in hypertensive type&nbsp;2 diabetic patients =
is
based on studies where irbesartan was used in addition to other
antihypertensive agents, as needed, to reach target blood pressure (see sec=
tions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Special Populations<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Renal
impairment</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4=
).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Hepatic
impairment</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Older
people</span></i><span lang=3DEN-GB> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Although consideration should be=
 given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary for older people.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Paediatric
population</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The safety and efficacy of <span
class=3DSpellE>Karvea</span> in children aged 0 to 18 has not been establis=
hed.
Currently available data are described in sections 4.8, 5.1, and 5.2 but no
recommendation on a posology can be made.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Method of Administration<o:p>=
</o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For oral use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
3<span
style=3D'mso-tab-count:1'> </span>Contraindications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;=
6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Second and third trimesters of p=
regnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The concomitant use of <span
class=3DSpellE>Karvea</span> with <span class=3DSpellE>aliskiren</span>-con=
taining
products is contraindicated in patients with diabetes mellitus or renal
impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup=
>)
(see sections 4.5 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
4<span
style=3D'mso-tab-count:1'> </span>Special warnings and precautions for =
use</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Intravascular
volume depletion</span></u><span lang=3DEN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renovascular hypertension</sp=
an></u><span
lang=3DEN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosi=
s of
the artery to a single functioning kidney are treated with medicinal produc=
ts
that affect the renin-angiotensin-aldosterone system. While this is not
documented with <span class=3DSpellE>Karvea</span>, a similar effect should=
 be
anticipated with angiotensin-II receptor antagonists.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment and kidney
transplantation</span></u><span lang=3DEN-GB>: when <span class=3DSpellE>Ka=
rvea</span>
is used in patients with impaired renal function, a periodic monitoring of
potassium and creatinine serum levels is recommended. There is no experience
regarding the administration of <span class=3DSpellE>Karvea</span> in patie=
nts
with a recent kidney transplantation.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=3DEN-GB>:</span=
><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'> the e=
ffects
of irbesartan both on renal and cardiovascular events were not uniform acro=
ss
all subgroups, in an analysis carried out in the study with patients with
advanced renal disease. In particular, they appeared less favourable in wom=
en and
non-white subjects (see section&nbsp;5.1).<o:p></o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS):</span></u><span lang=3DEN-GB> =
there
is evidence that the concomitant use of ACE-inhibitors, angiotensin II rece=
ptor
blockers or <span class=3DSpellE>aliskiren</span> increases the risk of
hypotension, hyperkalaemia and decreased renal function (including acute re=
nal
failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,
angiotensin II receptor blockers or <span class=3DSpellE>aliskiren</span> is
therefore not recommended (see sections 4.5 and 5.1). <span
style=3D'mso-spacerun:yes'></span>If dual blockade therapy is considered
absolutely necessary, this should only occur under specialist supervision a=
nd
subject to frequent close monitoring of renal function, electrolytes and bl=
ood
pressure. ACE-inhibitors and angiotensin II receptor blockers should not be=
 used
concomitantly in patients with diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hyperkalaemia</span></u><span
lang=3DEN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with <span class=3DSpellE>Karvea</span>, especially in the presen=
ce of
renal impairment, overt proteinuria due to diabetic renal disease, and/or h=
eart
failure. Close monitoring of serum potassium in patients at risk is recomme=
nded
(see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypoglycaemia</span></u><span
lang=3DEN-GB>: <span class=3DSpellE>Karvea</span> may induce hypoglycaemia,
particularly in diabetic patients. In patients treated with insulin or
antidiabetics an appropriate blood glucose monitoring should be considered;=
 a dose
adjustment of insulin or antidiabetics may be required when indicated (see =
section
4.5).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:
the combination of lithium and <span class=3DSpellE>Karvea</span> is not
recommended (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Aortic and mitral valve steno=
sis, obstructive
hypertrophic cardiomyopathy</span></u><span lang=3DEN-GB>: as with other
vasodilators, special caution is indicated in patients suffering from aorti=
c or
mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Primary aldosteronism</span><=
/u><span
lang=3DEN-GB>: patients with primary aldosteronism generally will not respo=
nd to
antihypertensive medicinal products acting through inhibition of the renin-=
angiotensin
system. Therefore, the use of <span class=3DSpellE>Karvea</span> is not
recommended.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>General</span></u><span lang=
=3DEN-GB>:
in patients whose vascular tone and renal function depend predominantly on =
the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients wi=
th
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b style=3D'mso-bidi-font-weigh=
t:
normal'> </b>converting enzyme inhibitors or angiotensin-II receptor antago=
nists
that affect this system has been associated with acute hypotension, azotaem=
ia,
oliguria, or rarely acute renal failure (see section 4.5). As with any
antihypertensive agent, excessive blood pressure decrease in patients with
ischaemic cardiopathy or ischaemic cardiovascular disease could result in a
myocardial infarction or stroke.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As observed for angiotensin conv=
erting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Pregnancy:</span></u><span
lang=3DEN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not =
be
initiated during pregnancy. </span><span lang=3DEN-GB style=3D'mso-bidi-fon=
t-size:
11.0pt'>Unless continued AIIRA therapy is considered essential, patients
planning pregnancy should be changed to alternative antihypertensive treatm=
ents
which have an established safety profile for use in pregnancy. When pregnan=
cy
is diagnosed, treatment with </span><span lang=3DEN-GB>AIIRAs</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> should be stopped immedia=
tely,
and, if appropriate, alternative therapy should be started (see
sections&nbsp;4.3 and&nbsp;4.6).<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Paediatric population</span><=
/u><span
lang=3DEN-GB>: irbesartan has been studied in paediatric populations <span
style=3D'mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>aged 6 to 16=
 years
old</span> but the current data are insufficient to support an extension of=
 the
use in children until further data become available (see sections&nbsp;4.8,=
 5.1
and&nbsp;5.2).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><u><span lang=3DEN-GB>Excipients</span></u><span lang=
=3DFR
style=3D'mso-ansi-language:FR'>:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DFR style=3D'mso-a=
nsi-language:
FR'>Karvea</span></span><span lang=3DFR style=3D'mso-ansi-language:FR'>&nbs=
p;300 mg
<span class=3DSpellE>tablet</span> <span class=3DSpellE>contains</span> lac=
tose. </span><span
lang=3DEN-GB>Patients with rare hereditary problems of galactose intoleranc=
e,
total lactase deficiency or glucose-galactose malabsorption should not take
this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DFR style=3D'mso-a=
nsi-language:
FR'>Karvea</span></span><span lang=3DFR style=3D'mso-ansi-language:FR'>&nbs=
p;300 mg
<span class=3DSpellE>tablet</span> <span class=3DSpellE>contains</span> sod=
ium. </span><span
lang=3DEN-GB>This medicine contains less than 1 mmol sodium (23 mg) per tab=
let, that
is to say essentially sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>4.5<span style=3D'mso-tab-count:=
1'> </span>Interaction
with other medicinal products and other forms of interaction</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Diuretics and other antihyper=
tensive
agents</span></u><span lang=3DEN-GB>: other antihypertensive agents may inc=
rease
the hypotensive effects of irbesartan; however <span class=3DSpellE>Karvea<=
/span>
has been safely administered with other antihypertensive agents, such as
beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Prior treatment with high dose diuretics may result in volume depletion and=
 a risk
of hypotension when initiating therapy with <span class=3DSpellE>Karvea</sp=
an>
(see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><span class=3DSpellE><u><span lang=3DEN-GB>Aliskire=
n</span></u></span><u><span
lang=3DEN-GB>-containing products or ACE-inhibitors</span></u><span lang=3D=
EN-GB>: clinical
trial data has shown that dual blockade of the renin-angiotensin-aldosterone
system (RAAS) through the combined use of ACE-inhibitors, angiotensin II re=
ceptor
blockers or <span class=3DSpellE>aliskiren</span> is associated with a high=
er
frequency of adverse events such as hypotension, hyperkalaemia and decreased
renal function (including acute renal failure) compared to the use of a sin=
gle
RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=3DEN-GB>:<i style=3D'mso-b=
idi-font-style:
normal'> </i>based on experience with the use of other medicinal products t=
hat
affect the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or
other medicinal products that may increase serum potassium levels
(e.g.&nbsp;heparin) may lead to increases in serum potassium and is, theref=
ore,
not recommended (see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:<i
style=3D'mso-bidi-font-style:normal'> </i>reversible increases in serum lit=
hium
concentrations and toxicity have been reported during concomitant administr=
ation
of lithium with angiotensin converting enzyme inhibitors. Similar effects h=
ave
been very rarely reported with irbesartan so far. Therefore, this combinati=
on
is not recommended (see section&nbsp;4.4). If the combination proves necess=
ary,
careful monitoring of serum lithium levels is recommended.<i style=3D'mso-b=
idi-font-style:
normal'><o:p></o:p></i></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Non-steroidal anti-inflammato=
ry drugs</span></u><span
lang=3DEN-GB>: w<span style=3D'color:black'>hen angiotensin&nbsp;II antagon=
ists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) a=
nd
non-selective NSAIDs), attenuation of the antihypertensive effect may occur=
.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'color:black'>As with ACE
inhibitors, concomitant use of angiotensin&nbsp;II antagonists and NSAIDs m=
ay
lead to an increased risk of worsening of renal function, including possible
acute renal failure, and an increase in serum potassium, especially in pati=
ents
with poor pre-existing renal function. The combination should be administer=
ed
with caution, especially in the elderly. Patients should be adequately hydr=
ated
and consideration should be given to monitoring renal function after initia=
tion
of concomitant therapy, and periodically thereafter.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Repaglinide:</span></u><span
lang=3DEN-GB style=3D'color:black'> irbesartan has the potential to inhibit=
 OATP1B1.
In a clinical study, it was reported that irbesartan increased the <span
class=3DSpellE>C<sub>max</sub></span> and AUC of repaglinide (substrate of
OATP1B1) by 1.8-fold and 1.3&#8209;fold, respectively, when administered 1 =
hour
before repaglinide. In another study, no relevant pharmacokinetic interacti=
on was
reported, when the two drugs were co-administered. Therefore, dose adjustme=
nt of
antidiabetic treatment such as repaglinide may be required (see section 4.4=
).<o:p></o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Additional information on irb=
esartan
interactions</span></u><span lang=3DEN-GB>: <span style=3D'color:black'>in =
clinical
studies, the pharmacokinetic of irbesartan is not affected by
hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a le=
sser
extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic
interactions were observed when irbesartan was <span class=3DSpellE>coadmin=
istered</span>
with warfarin, a medicinal product metabolised by CYP2C9. The effects of CY=
P2C9
inducers such as rifampicin on the pharmacokinetic of irbesartan have not b=
een
evaluated. The pharmacokinetic of digoxin was not altered by coadministrati=
on
of irbesartan.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
6<span
style=3D'mso-tab-count:1'> </span>Fertility, pregnancy and lactation</s=
pan></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Pregnancy</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEABodyText style=3D'border:none;mso-border-alt:solid windowtex=
t .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><span lang=3DEN-GB>The=
 use
of AIIRAs is not recommended during the first trimester of pregnancy (see
section&nbsp;4.4). The use of AIIRAs is contraindicated during the second a=
nd
third trimesters of pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span><=
/p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Epidemiological evidence regardi=
ng the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in=
 risk
cannot be excluded. Whilst there is no controlled epidemiological data on t=
he
risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar risks =
may
exist for this class of drugs. Unless continued AIIRA therapy is considered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for us=
e in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be sto=
pped
immediately, and, if appropriate, alternative therapy should be started.</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Exposure to AIIRA therapy during=
 the
second and third trimesters is known to induce human <span class=3DSpellE>f=
oetotoxicity</span>
(decreased renal function, oligohydramnios, skull ossification retardation)=
 and
neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section=
&nbsp;5.3).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Should exposure to AIIRAs have o=
ccurred
from the second trimester of pregnancy, ultrasound check of renal function =
and
skull is recommended.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Infants whose mothers have taken=
 AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3 and&nbsp;=
4.4).<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Breast-feeding</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Because no information is availa=
ble regarding
the use of <span class=3DSpellE>Karvea</span> during breast-feeding, <span
class=3DSpellE>Karvea</span> is not recommended and alternative treatments =
with
better established safety profiles during breast-feeding are preferable,
especially while nursing a <span class=3DSpellE>newborn</span> or preterm i=
nfant.</span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>It is unkno=
wn whether
irbesartan or its metabolites are excreted in human milk. <o:p></o:p></span=
></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>Available
pharmacodynamic/toxicological data in rats have shown excretion of irbesart=
an
or its metabolites in milk (for details see 5.3).<span style=3D'color:black=
'><o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Fertility</span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan had no effect upon fe=
rtility
of treated rats and their offspring up to the dose levels inducing the first
signs of parental toxicity (see section 5.3).</span><span style=3D'mso-ansi=
-language:
EN-US'> <o:p></o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
7<span
style=3D'mso-tab-count:1'> </span>Effects on ability to drive and use
machines</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Based on its pharmacodynamic pro=
perties,
irbesartan is unlikely to affect the <span class=3DSpellE>abilityto</span> =
drive
and use machine. When driving vehicles or operating machines, it should be
taken into account that dizziness or weariness may occur during treatment.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
8<span
style=3D'mso-tab-count:1'> </span>Undesirable effects</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>In
placebo-controlled trials in patients with hypertension, the overall incide=
nce
of adverse events did not differ between the irbesartan (56.2%) and the pla=
cebo
groups (56.5%). Discontinuation due to any clinical or laboratory adverse e=
vent
was less frequent for irbesartan-treated patients (3.3%) than for
placebo-treated patients (4.5%). The incidence of adverse events was not
related to dose (in the recommended dose range), gender, age, race, or dura=
tion
of treatment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In diabetic hypertensive patient=
s with
microalbuminuria and normal renal function, orthostatic dizziness and
orthostatic hypotension were reported in 0.5% of the patients (i.e.,&nbsp;u=
ncommon)
but in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The following table presents the=
 adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a s=
tar
(*) refer to the adverse reactions that were additionally reported in &gt; =
2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of adverse reactio=
ns
listed below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>very common (&#8805;&nbsp;1/10);=
 common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very r=
are
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects a=
re
presented in order of decreasing seriousness.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Adverse reactions additionally r=
eported
from postmarketing experience are also listed. <span style=3D'mso-bidi-fon=
t-style:
italic'>These adverse reactions are derived from spontaneous reports.<o:p><=
/o:p></span></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Blood and lymphatic system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>anaemia, thrombocytopenia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Immune system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hypersensitivity reactions such as angioedema, rash, urtic=
aria,
anaphylactic reaction, anaphylactic shock<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Metabolism and nutrition disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hyperkalaemia, hypoglycaemia</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><u><span lang=3DEN-GB=
><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Nervous system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>dizzine=
ss,
orthostatic dizziness*</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Not known:<span style=3D'mso-tab-count:1'> </span>vertig=
o, headache</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Ear and labyrinth disorder<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>tinnitus</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Cardiac disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>tachycar=
dia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Vascular disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;tab-stops:31.5pt .5=
in 1.0in'><span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>orthost=
atic
hypotension*</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>flushing<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Respiratory, thoracic and mediastinal disorders<o:p></o:p></sp=
an></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>cough</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Gastrointestinal disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>nausea/vomiting</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>U=
ncommon:<span
style=3D'mso-tab-count:1'> </span>diarrhoea, dyspepsia/heartburn</span=
></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>N=
ot known:<span
style=3D'mso-tab-count:1'> </span>dysgeusia</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB><=
o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Hepatobiliary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>jaundice</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>hepatitis,
abnormal liver function<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Skin and subcutaneous tissue disorders<o:p></o:p></span></u></=
p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:44.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
1'> </span><span class=3DSpellE>leukocytoclastic</span> vasculitis</s=
pan></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Musculoskeletal and connective tissue disorders<o:p></o:p></sp=
an></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>musculo=
skeletal
pain*</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;mso-o=
utline-level:
1;tab-stops:.5in 1.0in'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab=
-count:
1'> </span>arthralgia, myalgia (in some cases associated with increas=
ed
plasma creatine kinase levels), muscle cramps</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Renal and urinary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;page-=
break-after:
avoid;mso-outline-level:1;tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<s=
pan
style=3D'mso-tab-count:1'> </span><span style=3D'mso-tab-count:1'> </=
span>impaired
renal function including cases of renal failure in patients at risk (see
section&nbsp;4.4)</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Reproductive system and breast disorders<o:p></o:p></span></u>=
</p>

<p class=3DEMEABodyText style=3D'text-align:justify;mso-outline-level:1;tab=
-stops:
1.0in'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </=
span>sexual
dysfunction</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>General disorders and administration site conditions<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>fatigue</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>chest
pain<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Investigations<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Very common:<span style=3D'mso-tab-count:1'>=
 </span>Hyperkalaemia*
occurred more often in diabetic patients treated with irbesartan than with
placebo. In diabetic hypertensive patients with microalbuminuria and normal
renal function, hyperkalaemia (&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>m=
Eq</span>/L)
occurred in 29.4% of the patients in the irbesartan 300&nbsp;mg group and 2=
2%
of the patients in the placebo group. In diabetic hypertensive patients with
chronic renal insufficiency and overt proteinuria, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>mEq</span>/L) occurred in 46.3%=
 of
the patients in the irbesartan group and 26.3% of the patients in the place=
bo
group.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'>=
 </span>significant
increases in plasma creatine kinase were commonly observed (1.7%) in irbesa=
rtan
treated subjects. None of these increases were associated with identifiable
clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treat=
ed
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:0in'><span lang=3DEN-GB><o:p>&nb=
sp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB style=3D'mso-bidi-font-weight=
:bold'>Paediatric
population</span></u><b><span lang=3DEN-GB> <o:p></o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In a randomised trial of
318&nbsp;hypertensive children and adolescents aged 6 to 16&nbsp;years, the
following adverse reactions occurred in the 3-week double-blind phase: head=
ache
(7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week
open-label period of this trial the most frequent laboratory abnormalities
observed were creatinine increases (6.5%) and elevated CK values in 2% of c=
hild
recipients.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of suspected adverse
reactions <o:p></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Reporting suspected adverse reac=
tions
after authorisation of the medicinal product is important. It allows contin=
ued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in Appendix V.</span> </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB><o:p>&=
nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
9<span
style=3D'mso-tab-count:1'> </span>Overdose</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Experience in adults exposed to =
doses of
up to 900&nbsp;mg/day for 8&nbsp;weeks revealed no toxicity. The most likely
manifestations of overdose are expected to be hypotension and tachycardia;
bradycardia might also occur from overdose. No specific information is
available on the treatment of overdose with <span class=3DSpellE>Karvea</sp=
an>.
The patient should be closely monitored, and the treatment should be
symptomatic and supportive. Suggested measures include induction of emesis
and/or gastric lavage. Activated charcoal may be useful in the treatment of
overdose. Irbesartan is not removed by haemodialysis.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
1<span
style=3D'mso-tab-count:1'> </span>Pharmacodynamic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Pharmacotherapeutic
group: Angiotensin-II antagonists, plain.</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>ATC&nbsp;code:
C09C&nbsp;A04.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Mechanism of action</span></u=
><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB> <o:p></o:p></span=
></b></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan is a potent, orally a=
ctive,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</s=
ub>
receptor, regardless of the source or route of synthesis of angiotensin-II.=
 The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors resul=
ts
in increases in plasma renin levels and angiotensin-II levels, and a decrea=
se
in plasma aldosterone concentration. Serum potassium levels are not
significantly affected by irbesartan alone at the recommended doses. Irbesa=
rtan
does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II
and also degrades bradykinin into inactive metabolites. Irbesartan does not
require metabolic activation for its activity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><u><span lang=3DEN-GB style=3D'font-weight:normal'>=
Clinical
efficacy<o:p></o:p></span></u></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i><span
lang=3DEN-GB>Hypertension<o:p></o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan lowers blood pressure=
 with minimal
change in heart rate. The decrease in blood pressure is dose-related for on=
ce a
day doses with a tendency towards plateau at doses above 300&nbsp;mg. Doses=
 of
150-300&nbsp;mg once daily lower supine or seated blood pressures at trough
(i.e.&nbsp;24&nbsp;hours after dosing) by an average of
8-13/5-8&nbsp;mm&nbsp;Hg (systolic/diastolic) greater than those associated
with placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Peak reduction of blood pressure=
 is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours =
the
reduction of blood pressure was 60-70% of the corresponding peak diastolic =
and
systolic responses at the recommended doses. Once daily dosing with 150&nbs=
p;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosi=
ng
on the same total dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
ct of <span
class=3DSpellE>Karvea</span> is evident within 1-2&nbsp;weeks, with the max=
imal
effect occurring by 4-6&nbsp;weeks after start of therapy. The antihyperten=
sive
effects are maintained during long term therapy. After withdrawal of therap=
y,
blood pressure gradually returns toward baseline. Rebound hypertension has =
not
been observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
cts of
irbesartan and thiazide-type diuretics are additive. In patients not adequa=
tely
controlled by irbesartan alone, the addition of a low dose of
hydrochlorothiazide (12.5&nbsp;mg) to irbesartan once daily results in a
further placebo-adjusted blood pressure reduction at trough of
7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastolic).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The efficacy of <span class=3DSp=
ellE>Karvea</span>
is not influenced by age or gender. As is the case with other medicinal
products that affect the renin-angiotensin system, black hypertensive patie=
nts
have notably less response to irbesartan monotherapy. When irbesartan is
administered concomitantly with a low dose of hydrochlorothiazide (e.g.&nbs=
p;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There is no clinically important=
 effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Paediatric population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><span
lang=3DEN-GB>Reduction of blood pressure with 0.5&nbsp;mg/kg (low),
1.5&nbsp;mg/kg (medium) and 4.5&nbsp;mg/kg (high) target titrated doses of
irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family
history of hypertension) children and adolescents aged 6 to 16&nbsp;years o=
ver
a three week period. At the end of the three weeks the mean reduction from
baseline in the primary efficacy variable, trough seated systolic blood
pressure (<span class=3DSpellE>SeSBP</span>) was 11.7&nbsp;mmHg (low dose),
9.3&nbsp;mmHg (medium dose), 13.2&nbsp;mmHg (high dose). No significant
difference was apparent between these doses. Adjusted mean change of trough
seated diastolic blood pressure (<span class=3DSpellE>SeDBP</span>) was as
follows: 3.8&nbsp;mmHg (low dose), 3.2&nbsp;mmHg (medium dose), 5.6&nbsp;mm=
Hg
(high dose). Over a subsequent two week period where patients were
re-randomized to either active medicinal product or placebo, patients on
placebo had increases of 2.4 and 2.0&nbsp;mmHg in <span class=3DSpellE>SeSB=
P</span>
and <span class=3DSpellE>SeDBP</span> compared to +0.1 and -0.3&nbsp;mmHg c=
hanges
respectively in those on all doses of irbesartan (see section&nbsp;4.2).</s=
pan></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><span lang=3DEN-GB><o=
:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension and
type&nbsp;2 diabetes with renal disease<o:p></o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The Irbesartan Diabetic Nephrop=
athy
Trial (IDNT) shows that irbesartan decreases the progression of renal dise=
ase
in patients with chronic renal insufficiency and overt proteinuria. IDNT wa=
s a
double blind, controlled, morbidity and mortality trial comparing <span
class=3DSpellE>Karvea</span>, amlodipine and placebo. In 1,715&nbsp;hyperte=
nsive
patients with type&nbsp;2 diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day
and serum creatinine ranging from 1.0-3.0&nbsp;mg/dl, the long-term effects
(mean&nbsp;2.6&nbsp;years) of <span class=3DSpellE>Karvea</span> on the
progression of renal disease and all-cause mortality were examined. Patients
were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg <span
class=3DSpellE>Karvea</span></span><span lang=3DEN-GB style=3D'font-family:=
"Times",serif;
mso-bidi-font-family:"Times New Roman"'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=3DEN-GB> as tolerated. Patients in =
all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertens=
ive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo gr=
oup
reached this target blood pressure whereas this figure was 76% and 78% in t=
he
irbesartan and amlodipine groups respectively. Irbesartan significantly red=
uced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary r=
enal
composite endpoint compared to 39% and 41% in the placebo and amlodipine gr=
oups
[20% relative risk reduction versus placebo (p&nbsp;=3D&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=3D&nbsp;0.006)]. Wh=
en the
individual components of the primary endpoint were analysed, no effect in <=
span
class=3DSpellE>all cause</span> mortality was observed, while a positive tr=
end in
the reduction in ESRD and a significant reduction in doubling of serum
creatinine were observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'>Subgroups consisting of gender, race, age, duration =
of diabetes,
baseline blood pressure, serum creatinine, and albumin excretion rate were
assessed for treatment effect. In the female and black subgroups which
represented 32% and 26% of the overall study population respectively, a ren=
al
benefit was not evident, </span><span style=3D'mso-ansi-language:EN-US'>alt=
hough
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI w=
as
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identif=
ied.</span><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'><o:p><=
/o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The study of the Effects of Irb=
esartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mell=
itus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with
type&nbsp;2 diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal
function (serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effe=
cts
(2&nbsp;years) of <span class=3DSpellE>Karvea</span> on the progression to
clinical (overt) proteinuria (urinary albumin excretion rate (UAER)
&gt;&nbsp;300&nbsp;mg/day, and an increase in UAER of at least 30% from
baseline). The predefined blood pressure goal was
&#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents (excluding
ACE inhibitors, angiotensin&nbsp;II receptor antagonists and dihydropyridine
calcium blockers) were added as needed to help achieve the blood pressure g=
oal.
While similar blood pressure was achieved in all treatment groups, fewer
subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the placebo (14=
.9%)
or in the irbesartan 150&nbsp;mg group (9.7%) reached the endpoint of overt
proteinuria, demonstrating a 70% relative risk reduction versus placebo
(p&nbsp;=3D&nbsp;0.0004) for the higher dose. An accompanying improvement i=
n the
glomerular filtration rate (GFR) was not observed during the first three mo=
nths
of treatment. The slowing in the progression to clinical proteinuria was
evident as early as three months and continued over the 2&nbsp;year period.
Regression to <span class=3DSpellE>normoalbuminuria</span>
(&lt;&nbsp;30&nbsp;mg/day) was more frequent in the <span class=3DSpellE>Ka=
rvea</span>&nbsp;300&nbsp;mg
group (34%) than in the placebo group (21%).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Dual
blockade of the renin-angiotensin-aldosterone system (RAAS)<o:p></o:p></spa=
n></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Two large randomised, controlled=
 trials (ONTARGET
(<span class=3DSpellE>ONgoing</span> Telmisartan Alone and in combination w=
ith
Ramipril Global Endpoint Trial) and NEPHRON-D (The Veterans Affairs Nephrop=
athy
in Diabetes)) have examined the use of the combination of an ACE-inhibitor =
with
an angiotensin II receptor blocker. ONTARGET was a study conducted in patie=
nts
with a history of cardiovascular or cerebrovascular disease, or type 2 diab=
etes
mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a st=
udy
in patients with type 2 diabetes mellitus and diabetic nephropathy.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB>These studies have shown no sign=
ificant
beneficial effect on renal and/or cardiovascular outcomes and mortality, wh=
ile
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension =
as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients wi=
th
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ALTITUDE (<span class=3DSpellE>A=
liskiren</span>
Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) =
was
a study designed to test the benefit of adding <span class=3DSpellE>aliskir=
en</span>
to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blo=
cker
in patients with type 2 diabetes mellitus and chronic kidney disease,
cardiovascular disease, or both. The study was terminated early because of =
an
increased risk of adverse outcomes. Cardiovascular death and stroke were bo=
th
numerically more frequent in the <span class=3DSpellE>aliskiren</span> grou=
p than
in the placebo group and adverse events and serious adverse events of inter=
est
(hyperkalaemia, hypotension and renal dysfunction) were more frequently
reported in the <span class=3DSpellE>aliskiren</span> group than in the pla=
cebo
group.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
2<span
style=3D'mso-tab-count:1'> </span>Pharmacokinetic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Absorption<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span>=
</p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Distribution<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Plasma
protein binding is approximately 96%, with negligible binding to cellular b=
lood
components. The volume of distribution is 53-93&nbsp;litres. </span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Biotransformation<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Following
oral or intravenous administration of <sup><span style=3D'position:relative;
top:-1.0pt;mso-text-raise:1.0pt'>14</span></sup>C irbesartan, 80-85% of the
circulating plasma radioactivity is attributable to unchanged irbesartan.
Irbesartan is metabolised by the liver via glucuronide conjugation and
oxidation. The major circulating metabolite is irbesartan glucuronide
(approximately 6%). <i style=3D'mso-bidi-font-style:normal'>In&nbsp;vitro</=
i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.=
</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Linearity / non-linearity<o:p=
></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan exhibits linear and d=
ose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg=
. A
less than proportional increase in oral absorption at doses beyond 600&nbsp=
;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at 1.5-2&nbsp;hours after =
oral
administration. The total body and renal clearance are 157-176&nbsp;and
3-3.5&nbsp;ml/min, respectively. The terminal elimination half-life of
irbesartan is 11-15&nbsp;hours. Steady-state plasma concentrations are atta=
ined
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repea=
ted
once-daily dosing. In a study, somewhat higher plasma concentrations of irb=
esartan
were observed in female hypertensive patients. However, there was no differ=
ence
in the half-life and accumulation of irbesartan. No dosage adjustment is
necessary in female patients. Irbesartan AUC and <span class=3DSpellE>C<span
class=3DEMEASubscript>max</span></span> values were also somewhat greater i=
n <span
class=3DSpellE>oldersubjects</span> (&#8805;&nbsp;65&nbsp;years) than those=
 of
young subjects (18-40&nbsp;years). However the terminal half-life was not
significantly altered. No dosage adjustment is necessary in older people.</=
span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Elimination<o:p></o:p></span>=
</u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan and its metabolites a=
re
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style=3D'position:relative;top:-1.0pt;mso-text=
-raise:
1.0pt'>14</span></sup>C irbesartan, about 20% of the radioactivity is recov=
ered
in the urine, and the remainder in the faeces. Less than 2% of the dose is
excreted in the urine as unchanged irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Paediatric population<o:p></o=
:p></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The pharmacokinetics of irbesart=
an were
evaluated in 23&nbsp;hypertensive children after the administration of sing=
le
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable=
 for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;ye=
ars,
nine children between 6 and 12 years). Results showed that <span class=3DSp=
ellE>C<span
class=3DEMEASubscript>max</span></span>, AUC and clearance rates were compa=
rable
to those observed in adult patients receiving 150&nbsp;mg irbesartan daily.=
 A
limited accumulation of irbesartan (18%) in plasma was observed upon repeat=
ed
once daily dosing.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment</span></u></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with renal impairmen=
t or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hepatic impairment</span></u>=
<span
lang=3DEN-GB>:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significant=
ly
altered.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Studies have not been performed =
in
patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
3<i
style=3D'mso-bidi-font-style:normal'><span style=3D'mso-tab-count:1'> <=
/span></i>Preclinical
safety data</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/da=
y in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/=
day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product wh=
ich
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/d=
ay).
All of these changes were considered to be caused by the pharmacological ac=
tion
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplas=
ia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There was no evidence of mutagen=
icity, <span
class=3DSpellE>clastogenicity</span> or carcinogenicity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Fertility and reproductive perfo=
rmance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), inclu=
ding
mortality at the highest dose. No significant effects on the number of corp=
ora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit fo=
etuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Animal studies with irbesartan s=
howed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significa=
nt
maternal toxicity, including mortality. No teratogenic effects were observe=
d in
the rat or rabbit.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
1<span
style=3D'mso-tab-count:1'> </span>List of excipients</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Microcrystalline
cellulose</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Croscarmellose sodium</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Lactose monohydrate</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Magnesium stearate</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Colloidal hydrated silica</span>=
</p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Pregelatini=
sed</span></span><span
lang=3DEN-GB> maize starch</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Poloxamer&nbsp;188</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
2<span
style=3D'mso-tab-count:1'> </span>Incompatibilities</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><span
lang=3DEN-GB>Not applicable.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
3<span
style=3D'mso-tab-count:1'> </span>Shelf life</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>3&nbsp;years.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
4<span
style=3D'mso-tab-count:1'> </span>Special precautions for storage</span=
></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><span
lang=3DEN-GB>Do not store above 30C.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'margin-left:0in;text-indent:0in;mso-outlin=
e-level:
1'><span lang=3DEN-GB>6.5<span style=3D'mso-tab-count:1'> </span>Nature=
 and
contents of container</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 14&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 28&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 56&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 98&nbsp;tablets in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 56&nbsp;x&nbsp;1&nbsp=
;tablet
in PVC/PVDC/Aluminium perforated unit dose blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><span lang=3DEN-GB>No=
t all pack
sizes may be marketed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
6<span
style=3D'mso-tab-count:1'> </span>Special precautions for disposal</spa=
n></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Any
unused medicinal product or waste material should be disposed of in accorda=
nce
with local requirements.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>7.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION HOLDER<o:p>=
</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>8.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION NUMBERS<o:p=
></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'text-align:justify'><span lang=3DNO-BOK
style=3D'mso-ansi-language:NO-BOK'>EU/1/97/049/007-009<br>
EU/1/97/049/012<br>
EU/1/97/049/015</span><span lang=3DSL style=3D'mso-ansi-language:SL'><o:p><=
/o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>DATE
OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Date of first authorisation: 27 =
August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>10.<span style=3D'mso-tab-count:=
1'> </span>DATE
OF REVISION OF THE TEXT</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-bidi-font-size:12.0pt'=
><o:p>&nbsp;</o:p></span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<p class=3DEMEAHeading1><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg film-coated tablets.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Each film-coated tablet contains=
 75&nbsp;mg
of irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Excipient with known effect</=
span></u><span
lang=3DEN-GB>: 25.50&nbsp;mg of lactose monohydrate per film-coated tablet.=
</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For the full list of excipients,=
 see
section&nbsp;6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Film-coated
tablet.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2871 engr=
aved
on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>CLINICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
1<span
style=3D'mso-tab-count:1'> </span>Therapeutic indications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span class=3DSpel=
lE><span
lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB> is indicated in adults=
 for the
treatment of essential hypertension.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>It is also indicated for the tre=
atment
of renal disease in adult patients with hypertension and type&nbsp;2 diabet=
es
mellitus as part of an antihypertensive medicinal product regimen (see sect=
ions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
2<span
style=3D'mso-tab-count:1'> </span>Posology and method of administration=
</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Posology<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. <span class=3DSpellE>Karvea</span> at a dose of 150&nbsp;mg o=
nce
daily generally provides a better 24&nbsp;hour blood pressure control than
75&nbsp;mg. However, initiation of therapy with 75&nbsp;mg could be conside=
red,
particularly in <span class=3DSpellE>haemodialysed</span> patients and in t=
he
elderly over 75&nbsp;years.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients insufficiently contr=
olled
with 150&nbsp;mg once daily, the dose of <span class=3DSpellE>Karvea</span>=
 can
be increased to 300&nbsp;mg, or other antihypertensive agents can be added =
(see
sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic =
such
as hydrochlorothiazide has been shown to have an additive effect with <span
class=3DSpellE>Karvea</span> (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In hypertensive type&nbsp;2 diab=
etic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily =
and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The demonstration of renal benef=
it of <span
class=3DSpellE>Karvea</span> in hypertensive type&nbsp;2 diabetic patients =
is
based on studies where irbesartan was used in addition to other
antihypertensive agents, as needed, to reach target blood pressure (see sec=
tions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Special Populations<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Renal
impairment</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4=
).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Hepatic
impairment</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Older
people</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Although consideration should be=
 given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary for older people.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Paediatric
population</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The safety and efficacy of <span
class=3DSpellE>Karvea</span> in children aged 0 to 18 has not been establis=
hed.
Currently available data are described in section 4.8, 5.1 and 5.2 but no
recommendation on a posology can be made.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Method of Administration<o:p>=
</o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For oral use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
3<span
style=3D'mso-tab-count:1'> </span>Contraindications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;=
6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Second and third trimesters of p=
regnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><span style=3D'mso-spacerun:yes'=
></span>The
concomitant use of <span class=3DSpellE>Karvea</span> with <span class=3DSp=
ellE>aliskiren</span>-containing
products is contraindicated in patients with diabetes mellitus or renal
impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup=
>)
(see sections 4.5 and 5.1).</span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB><o=
:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
4<span
style=3D'mso-tab-count:1'> </span>Special warnings and precautions for =
use</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Intravascular
volume depletion</span></u><span lang=3DEN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renovascular hypertension</sp=
an></u><span
lang=3DEN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosi=
s of
the artery to a single functioning kidney are treated with medicinal produc=
ts
that affect the renin-angiotensin-aldosterone system. While this is not
documented with <span class=3DSpellE>Karvea</span>, a similar effect should=
 be
anticipated with angiotensin-II receptor antagonists.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment and kidney
transplantation</span></u><span lang=3DEN-GB>: when <span class=3DSpellE>Ka=
rvea</span>
is used in patients with impaired renal function, a periodic monitoring of
potassium and creatinine serum levels is recommended. There is no experience
regarding the administration of <span class=3DSpellE>Karvea</span> in patie=
nts
with a recent kidney transplantation.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=3DEN-GB>:</span=
><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'> the e=
ffects
of irbesartan both on renal and cardiovascular events were not uniform acro=
ss
all subgroups, in an analysis carried out in the study with patients with
advanced renal disease. In particular, they appeared less favourable in wom=
en
and non-white subjects (see section&nbsp;5.1).<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS):</span></u><span lang=3DEN-GB> =
there
is evidence that the concomitant use of ACE-inhibitors, angiotensin II rece=
ptor
blockers or <span class=3DSpellE>aliskiren</span> increases the risk of
hypotension, hyperkalaemia and decreased renal function (including acute re=
nal
failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,
angiotensin II receptor blockers or <span class=3DSpellE>aliskiren</span> is
therefore not recommended (see sections 4.5 and 5.1). <span
style=3D'mso-spacerun:yes'></span>If dual blockade therapy is considered
absolutely necessary, this should only occur under specialist supervision a=
nd
subject to frequent close monitoring of renal function, electrolytes and bl=
ood
pressure. ACE-inhibitors and angiotensin II receptor blockers should not be
used concomitantly in patients with diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hyperkalaemia</span></u><span
lang=3DEN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with <span class=3DSpellE>Karvea</span>, especially in the presen=
ce of
renal impairment, overt proteinuria due to diabetic renal disease, and/or h=
eart
failure. Close monitoring of serum potassium in patients at risk is recomme=
nded
(see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypoglycaemia: </span></u><sp=
an
class=3DSpellE><span lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB> m=
ay induce
hypoglycaemia, particularly in diabetic patients. In patients treated with
insulin or antidiabetics an appropriate blood glucose monitoring should be
considered; a dose adjustment of insulin or antidiabetics may be required w=
hen
indicated (see section 4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:
the combination of lithium and <span class=3DSpellE>Karvea</span> is not
recommended (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Aortic and mitral valve steno=
sis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=3DEN-GB>: as w=
ith
other vasodilators, special caution is indicated in patients suffering from
aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Primary aldosteronism</span><=
/u><span
lang=3DEN-GB>: patients with primary aldosteronism generally will not respo=
nd to
antihypertensive medicinal products acting through inhibition of the
renin-angiotensin system. Therefore, the use of <span class=3DSpellE>Karvea=
</span>
is not recommended.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>General</span></u><span lang=
=3DEN-GB>:
in patients whose vascular tone and renal function depend predominantly on =
the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients wi=
th
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b style=3D'mso-bidi-font-weigh=
t:
normal'> </b>converting enzyme inhibitors or angiotensin-II receptor
antagonists that affect this system has been associated with acute hypotens=
ion,
azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As wi=
th
any antihypertensive agent, excessive blood pressure decrease in patients w=
ith
ischaemic cardiopathy or ischaemic cardiovascular disease could result in a
myocardial infarction or stroke.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As observed for angiotensin conv=
erting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are app=
arently
less effective in lowering blood pressure in black people than in non-black=
s,
possibly because of higher prevalence of low-renin states in the black
hypertensive population (see section&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Pregnancy:</span></u><span
lang=3DEN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not =
be
initiated during pregnancy. </span><span lang=3DEN-GB style=3D'mso-bidi-fon=
t-size:
11.0pt'>Unless continued AIIRA therapy is considered essential, patients
planning pregnancy should be changed to alternative antihypertensive treatm=
ents
which have an established safety profile for use in pregnancy. When pregnan=
cy
is diagnosed, treatment with </span><span lang=3DEN-GB>AIIRAs</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> should be stopped immedia=
tely,
and, if appropriate, alternative therapy should be started (see
sections&nbsp;4.3 and&nbsp;4.6).<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Paediatric population</span><=
/u><span
lang=3DEN-GB>: irbesartan has been studied in paediatric populations <span
style=3D'mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>aged 6 to 16=
 years
old</span> but the current data are insufficient to support an extension of=
 the
use in children until further data become available (see sections&nbsp;4.8,=
 5.1
and&nbsp;5.2).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><u><span lang=3DEN-GB>Excipients</span></u><span lang=
=3DFR
style=3D'mso-ansi-language:FR'>:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75 mg film-coated tablet contains lactose. Patients with=
 rare
hereditary problems of galactose intolerance, total lactase deficiency or
glucose-galactose malabsorption should not take this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75 mg film-coated tablet contains sodium. This medicine =
contains
less than 1 mmol sodium (23 mg) per tablet, that is to say essentially
sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
5<span
style=3D'mso-tab-count:1'> </span>Interaction with other medicinal prod=
ucts
and other forms of interaction</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Diuretics and other antihyper=
tensive
agents</span></u><span lang=3DEN-GB>: other antihypertensive agents may inc=
rease
the hypotensive effects of irbesartan; however <span class=3DSpellE>Karvea<=
/span>
has been safely administered with other antihypertensive agents, such as
beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Prior treatment with high dose diuretics may result in volume depletion and=
 a
risk of hypotension when initiating therapy with <span class=3DSpellE>Karve=
a</span>
(see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><u><span lang=3DEN-GB>Aliskire=
n</span></u></span><u><span
lang=3DEN-GB>-containing products or ACE-inhibitors</span></u><span lang=3D=
EN-GB>: clinical
trial data has shown that dual blockade of the renin-angiotensin-aldosterone
system (RAAS) through the combined use of ACE-inhibitors, angiotensin II
receptor blockers or <span class=3DSpellE>aliskiren</span> is associated wi=
th a
higher frequency of adverse events such as hypotension, hyperkalaemia and
decreased renal function (including acute renal failure) compared to the us=
e of
a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=3DEN-GB>:<i style=3D'mso-b=
idi-font-style:
normal'> </i>based on experience with the use of other medicinal products t=
hat
affect the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or
other medicinal products that may increase serum potassium levels
(e.g.&nbsp;heparin) may lead to increases in serum potassium and is, theref=
ore,
not recommended (see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:<i
style=3D'mso-bidi-font-style:normal'> </i>reversible increases in serum lit=
hium
concentrations and toxicity have been reported during concomitant
administration of lithium with angiotensin converting enzyme inhibitors.
Similar effects have been very rarely reported with irbesartan so far.
Therefore, this combination is not recommended (see section&nbsp;4.4). If t=
he
combination proves necessary, careful monitoring of serum lithium levels is
recommended.</span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></i></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Non-steroidal anti-inflammato=
ry drugs</span></u><span
lang=3DEN-GB>: <span style=3D'color:black'>when angiotensin&nbsp;II antagon=
ists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e=
. selective
COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) and
non-selective NSAIDs), attenuation of the antihypertensive effect may occur=
.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'color:black'>As with ACE
inhibitors, concomitant use of angiotensin&nbsp;II antagonists and NSAIDs m=
ay
lead to an increased risk of worsening of renal function, including possible
acute renal failure, and an increase in serum potassium, especially in pati=
ents
with poor pre-existing renal function. The combination should be administer=
ed
with caution, especially in the elderly. Patients should be adequately hydr=
ated
and consideration should be given to monitoring renal function after initia=
tion
of concomitant therapy, and periodically thereafter.<b style=3D'mso-bidi-fo=
nt-weight:
normal'><i style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></b></span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Repaglinide:</span></u><span
lang=3DEN-GB style=3D'color:black'> irbesartan has the potential to inhibit=
 OATP1B1.
In a clinical study, it was reported that irbesartan increased the <span
class=3DSpellE>C<sub>max</sub></span> and AUC of repaglinide (substrate of
OATP1B1) by 1.8-fold and 1.3&#8209;fold, respectively, when administered 1 =
hour
before repaglinide. In another study, no relevant pharmacokinetic interacti=
on was
reported, when the two drugs were co-administered. Therefore, dose adjustme=
nt of
antidiabetic treatment such as repaglinide may be required (see section 4.4=
).<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Additional information on irb=
esartan
interactions</span></u><span lang=3DEN-GB>: <span style=3D'color:black'>in =
clinical
studies, the pharmacokinetic of irbesartan is not affected by hydrochloroth=
iazide.
Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucur=
onidation.
No significant pharmacokinetic or pharmacodynamic interactions were observed
when irbesartan was <span class=3DSpellE>coadministered</span> with warfari=
n, a
medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers suc=
h as
rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The
pharmacokinetic of digoxin was not altered by coadministration of irbesarta=
n.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
6<span
style=3D'mso-tab-count:1'> </span>Fertility, pregnancy and lactation</s=
pan></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Pregnancy</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEABodyText style=3D'border:none;mso-border-alt:solid windowtex=
t .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><span lang=3DEN-GB>The=
 use
of AIIRAs is not recommended during the first trimester of pregnancy (see s=
ection&nbsp;4.4).
The use of AIIRAs is contraindicated during the second and third trimesters=
 of
pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Epidemiological evidence regardi=
ng the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in
risk cannot be excluded. Whilst there is no controlled epidemiological data=
 on
the risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar ri=
sks
may exist for this class of drugs. Unless continued AIIRA therapy is consid=
ered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for us=
e in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be sto=
pped
immediately, and, if appropriate, alternative therapy should be started.</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Exposure to AIIRA therapy during=
 the
second and third trimesters is known to induce human <span class=3DSpellE>f=
oetotoxicity</span>
(decreased renal function, oligohydramnios, skull ossification retardation)=
 and
neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See
section&nbsp;5.3).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Should exposure to AIIRAs have o=
ccurred from
the second trimester of pregnancy, ultrasound check of renal function and s=
kull
is recommended.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Infants whose mothers have taken=
 AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3
and&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Breast-feeding</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Because no information is availa=
ble regarding
the use of <span class=3DSpellE>Karvea</span> during breast-feeding, <span
class=3DSpellE>Karvea</span> is not recommended and alternative treatments =
with
better established safety profiles during breast-feeding are preferable,
especially while nursing a <span class=3DSpellE>newborn</span> or preterm i=
nfant.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>It is unknown whether irbesartan=
 or its
metabolites are excreted in human milk. </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Available pharmacodynamic/toxico=
logical
data in rats have shown excretion of irbesartan or its metabolites in milk =
(for
details see 5.3).</span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Fertility</span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>Irbesartan =
had no
effect upon fertility of treated rats and their offspring up to the dose le=
vels
inducing the first signs of parental toxicity (see section 5.3). <o:p></o:p=
></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>4.7<span style=3D'mso-tab-count:=
1'> </span>Effects
on ability to drive and use machines</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Based on
its pharmacodynamic properties, irbesartan is unlikely to affect the abilit=
y to
drive and use machines. When driving vehicles or operating machines, it sho=
uld
be taken into account that dizziness or weariness may occur during treatmen=
t.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
8<span
style=3D'mso-tab-count:1'> </span>Undesirable effects</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In placebo-controlled trials in =
patients
with hypertension, the overall incidence of adverse events did not differ
between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuat=
ion
due to any clinical or laboratory adverse event was less frequent for
irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).
The incidence of adverse events was not related to dose (in the recommended
dose range), gender, age, race, or duration of treatment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In diabetic hypertensive patient=
s with microalbuminuria
and normal renal function, orthostatic dizziness and orthostatic hypotension
were reported in 0.5% of the patients (i.e.,&nbsp;uncommon) but in excess of
placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The following table presents the=
 adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a s=
tar
(*) refer to the adverse reactions that were additionally reported in &gt; =
2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of adverse reactio=
ns
listed below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>very common (&#8805;&nbsp;1/10);=
 common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very r=
are
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects a=
re
presented in order of decreasing seriousness.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Adverse reactions additionally r=
eported
from postmarketing experience are also listed. <span style=3D'mso-bidi-fon=
t-style:
italic'>These adverse reactions are derived from spontaneous reports.<o:p><=
/o:p></span></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Blood and lymphatic system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>anaemia, thrombocytopenia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Immune system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:1.0in'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count:=
1'> </span>hypersensitivity
reactions such as angioedema, rash, urticaria, anaphylactic reaction,
anaphylactic shock<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Metabolism and nutrition disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hyperkalaemia, hypoglycaemia</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Nervous system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>dizzine=
ss,
orthostatic dizziness*</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Not known:<span style=3D'mso-tab-count:1'> </span>vertig=
o, headache</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Ear and labyrinth disorder<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>tinnitus</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Cardiac disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>tachycar=
dia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Vascular disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;tab-stops:31.5pt .5=
in 1.0in'><span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>orthost=
atic
hypotension*</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>flushing<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><u><span lang=3DEN-GB=
><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Respiratory, thoracic and mediastinal disorders<o:p></o:p></sp=
an></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>cough</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Gastrointestinal disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>nausea/vomiting</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>U=
ncommon:<span
style=3D'mso-tab-count:1'> </span>diarrhoea, dyspepsia/heartburn</span=
></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>N=
ot known:<span
style=3D'mso-tab-count:1'> </span>dysgeusia</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB><=
o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Hepatobiliary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>jaundice</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>hepatitis,
abnormal liver function<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Skin and subcutaneous tissue disorders<o:p></o:p></span></u></=
p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:44.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
1'> </span><span class=3DSpellE>leukocytoclastic</span> vasculitis</s=
pan></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Musculoskeletal and connective tissue disorders <o:p></o:p></s=
pan></u></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>C=
ommon:<span
style=3D'mso-tab-count:1'> </span>musculoskeletal pain*</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;mso-o=
utline-level:
1;tab-stops:.5in 1.0in'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab=
-count:
1'> </span>arthralgia, myalgia (in some cases associated with increas=
ed
plasma creatine kinase levels), muscle cramps</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Renal and urinary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;page-=
break-after:
avoid;mso-outline-level:1;tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<s=
pan
style=3D'mso-tab-count:1'> </span><span style=3D'mso-tab-count:1'> </=
span>impaired
renal function including cases of renal failure in patients at risk (see
section&nbsp;4.4)</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB><=
o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'text-align:justify;page-break-after:avoid;
mso-outline-level:1'><u><span lang=3DEN-GB>Reproductive system and breast
disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB>Uncomm=
on:<span
style=3D'mso-tab-count:1'> </span>sexual dysfunction</span></p>

<p class=3DEMEABodyText style=3D'text-align:justify;mso-outline-level:1;tab=
-stops:
1.0in'><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>General disorders and administration site conditions<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>fatigue</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>chest
pain<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Investigations<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Very common:<span style=3D'mso-tab-count:1'>=
 </span>Hyperkalaemia*
occurred more often in diabetic patients treated with irbesartan than with
placebo. In diabetic hypertensive patients with microalbuminuria and normal
renal function, hyperkalaemia (&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>m=
Eq</span>/L)
occurred in 29.4% of the patients in the irbesartan 300&nbsp;mg group and 2=
2%
of the patients in the placebo group. In diabetic hypertensive patients with
chronic renal insufficiency and overt proteinuria, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>mEq</span>/L) occurred in 46.3%=
 of
the patients in the irbesartan group and 26.3% of the patients in the place=
bo
group.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'>=
 </span>significant
increases in plasma creatine kinase were commonly observed (1.7%) in irbesa=
rtan
treated subjects. None of these increases were associated with identifiable
clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treat=
ed
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><i style=3D'mso-bidi-=
font-style:
normal'><u><span lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nb=
sp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB style=3D'mso-bidi-font-weight=
:bold'>Paediatric
population</span></u><span lang=3DEN-GB style=3D'mso-bidi-font-weight:bold'=
><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-bidi-font-weight:bo=
ld'>I</span><span
lang=3DEN-GB>n a randomised trial of 318&nbsp;hypertensive children and
adolescents aged 6 to 16&nbsp;years, the following adverse reactions occurr=
ed
in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%),
dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this tr=
ial
the most frequent laboratory abnormalities observed were creatinine increas=
es
(6.5%) and elevated CK values in 2% of child recipients.</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB><o:p>&=
nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of suspected adverse
reactions <o:p></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Reporting suspected adverse reac=
tions
after authorisation of the medicinal product is important. It allows contin=
ued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in Appendix V.</span> </span></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB><o:p>&=
nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
9<span
style=3D'mso-tab-count:1'> </span>Overdose</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Experience
in adults exposed to doses of up to 900&nbsp;mg/day for 8&nbsp;weeks reveal=
ed
no toxicity. The most likely manifestations of overdose are expected to be
hypotension and tachycardia; bradycardia might also occur from overdose. No
specific information is available on the treatment of overdose with <span
class=3DSpellE>Karvea</span>. The patient should be closely monitored, and =
the
treatment should be symptomatic and supportive. Suggested measures include
induction of emesis and/or gastric lavage. Activated charcoal may be useful=
 in
the treatment of overdose. Irbesartan is not removed by haemodialysis.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
1<span
style=3D'mso-tab-count:1'> </span>Pharmacodynamic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Pharmacotherapeutic group:
Angiotensin-II antagonists, plain.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ATC&nbsp;code: C09C&nbsp;A04.</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Mechanism of action<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan is a potent, orally a=
ctive,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</s=
ub>
receptor, regardless of the source or route of synthesis of angiotensin-II.=
 The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors resul=
ts
in increases in plasma renin levels and angiotensin-II levels, and a decrea=
se
in plasma aldosterone concentration. Serum potassium levels are not
significantly affected by irbesartan alone at the recommended doses. Irbesa=
rtan
does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II
and also degrades bradykinin into inactive metabolites. Irbesartan does not
require metabolic activation for its activity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><u><span lang=3DEN-GB style=3D'font-weight:normal'>=
Clinical
efficacy</span></u></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension<o:p></=
o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan lowers blood pressure=
 with
minimal change in heart rate. The decrease in blood pressure is dose-related
for once a day doses with a tendency towards plateau at doses above
300&nbsp;mg. Doses of 150-300&nbsp;mg once daily lower supine or seated blo=
od
pressures at trough (i.e.&nbsp;24&nbsp;hours after dosing) by an average of
8-13/5-8&nbsp;mm&nbsp;Hg (systolic/diastolic) greater than those associated
with placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Peak reduction of blood pressure=
 is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours =
the
reduction of blood pressure was 60-70% of the corresponding peak diastolic =
and
systolic responses at the recommended doses. Once daily dosing with 150&nbs=
p;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosi=
ng
on the same total dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
ct of <span
class=3DSpellE>Karvea</span> is evident within 1-2&nbsp;weeks, with the max=
imal
effect occurring by 4-6&nbsp;weeks after start of therapy. The antihyperten=
sive
effects are maintained during long term therapy. After withdrawal of therap=
y, blood
pressure gradually returns toward baseline. Rebound hypertension has not be=
en
observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
cts of
irbesartan and thiazide-type diuretics are additive. In patients not adequa=
tely
controlled by irbesartan alone, the addition of a low dose of
hydrochlorothiazide (12.5&nbsp;mg) to irbesartan once daily results in a
further placebo-adjusted blood pressure reduction at trough of
7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastolic).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The efficacy of <span class=3DSp=
ellE>Karvea</span>
is not influenced by age or gender. As is the case with other medicinal
products that affect the renin-angiotensin system, black hypertensive patie=
nts
have notably less response to irbesartan monotherapy. When irbesartan is
administered concomitantly with a low dose of hydrochlorothiazide (e.g.&nbs=
p;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There is no clinically important=
 effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Paediatric population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Reduction of blood pressure with
0.5&nbsp;mg/kg (low), 1.5&nbsp;mg/kg (medium) and 4.5&nbsp;mg/kg (high) tar=
get
titrated doses of irbesartan was evaluated in 318&nbsp;hypertensive or at r=
isk
(diabetic, family history of hypertension) children and adolescents aged 6 =
to
16&nbsp;years over a three week period. At the end of the three weeks the m=
ean
reduction from baseline in the primary efficacy variable, trough seated
systolic blood pressure (<span class=3DSpellE>SeSBP</span>) was 11.7&nbsp;m=
mHg
(low dose), 9.3&nbsp;mmHg (medium dose), 13.2&nbsp;mmHg (high dose). No
significant difference was apparent between these doses. Adjusted mean chan=
ge
of trough seated diastolic blood pressure (<span class=3DSpellE>SeDBP</span=
>) was
as follows: 3.8&nbsp;mmHg (low dose), 3.2&nbsp;mmHg (medium dose),
5.6&nbsp;mmHg (high dose). Over a subsequent two week period where patients
were re-randomized to either active medicinal product or placebo, patients =
on
placebo had increases of 2.4 and 2.0&nbsp;mmHg in <span class=3DSpellE>SeSB=
P</span>
and <span class=3DSpellE>SeDBP</span> compared to +0.1 and -0.3&nbsp;mmHg c=
hanges
respectively in those on all doses of irbesartan (see section&nbsp;4.2).</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension and
type&nbsp;2 diabetes with renal disease<o:p></o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The Irbesartan Diabetic Nephrop=
athy
Trial (IDNT) shows that irbesartan decreases the progression of renal dise=
ase
in patients with chronic renal insufficiency and overt proteinuria. IDNT wa=
s a
double blind, controlled, morbidity and mortality trial comparing <span
class=3DSpellE>Karvea</span>, amlodipine and placebo. In 1,715&nbsp;hyperte=
nsive
patients with type&nbsp;2 diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day
and serum creatinine ranging from 1.0-3.0&nbsp;mg/dl, the long-term effects
(mean&nbsp;2.6&nbsp;years) of <span class=3DSpellE>Karvea</span> on the
progression of renal disease and all-cause mortality were examined. Patients
were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg <span
class=3DSpellE>Karvea</span></span><span lang=3DEN-GB style=3D'font-family:=
"Times",serif;
mso-bidi-font-family:"Times New Roman"'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=3DEN-GB> as tolerated. Patients in =
all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertens=
ive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo gr=
oup
reached this target blood pressure whereas this figure was 76% and 78% in t=
he
irbesartan and amlodipine groups respectively. Irbesartan significantly red=
uced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary r=
enal
composite endpoint compared to 39% and 41% in the placebo and amlodipine gr=
oups
[20% relative risk reduction versus placebo (p&nbsp;=3D&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=3D&nbsp;0.006)]. Wh=
en the
individual components of the primary endpoint were analysed, no effect in <=
span
class=3DSpellE>all cause</span> mortality was observed, while a positive tr=
end in
the reduction in ESRD and a significant reduction in doubling of serum
creatinine were observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'>Subgroups consisting of gender, race, age, duration =
of
diabetes, baseline blood pressure, serum creatinine, and albumin excretion =
rate
were assessed for treatment effect. In the female and black subgroups which
represented 32% and 26% of the overall study population respectively, a ren=
al
benefit was not evident, </span><span style=3D'mso-ansi-language:EN-US'>alt=
hough
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI w=
as
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identif=
ied.</span><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'><o:p><=
/o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The study of the Effects of Irb=
esartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mell=
itus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with t=
ype&nbsp;2
diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal function
(serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effe=
cts
(2&nbsp;years) of <span class=3DSpellE>Karvea</span> on the progression to
clinical (overt) proteinuria (urinary albumin excretion rate (UAER)
&gt;&nbsp;300&nbsp;mg/day, and an increase in UAER of at least 30% from
baseline). The predefined blood pressure goal was
&#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents (excluding
ACE inhibitors, angiotensin&nbsp;II receptor antagonists and dihydropyridin=
e calcium
blockers) were added as needed to help achieve the blood pressure goal. Whi=
le
similar blood pressure was achieved in all treatment groups, fewer subjects=
 in
the irbesartan 300&nbsp;mg group (5.2%) than in the placebo (14.9%) or in t=
he
irbesartan 150&nbsp;mg group (9.7%) reached the endpoint of overt proteinur=
ia,
demonstrating a 70% relative risk reduction versus placebo
(p&nbsp;=3D&nbsp;0.0004) for the higher dose. An accompanying improvement i=
n the
glomerular filtration rate (GFR) was not observed during the first three mo=
nths
of treatment. The slowing in the progression to clinical proteinuria was
evident as early as three months and continued over the 2&nbsp;year period.
Regression to <span class=3DSpellE>normoalbuminuria</span>
(&lt;&nbsp;30&nbsp;mg/day) was more frequent in the <span class=3DSpellE>Ka=
rvea</span>&nbsp;300&nbsp;mg
group (34%) than in the placebo group (21%).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Dual
blockade of the renin-angiotensin-aldosterone system (RAAS)<o:p></o:p></spa=
n></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Two large randomised, controlled=
 trials
(ONTARGET (<span class=3DSpellE>ONgoing</span> Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Vete=
rans
Affairs Nephropathy in Diabetes)) have examined the use of the combination =
of
an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a st=
udy
conducted in patients with a history of cardiovascular or cerebrovascular
disease, or type 2 diabetes mellitus accompanied by evidence of end-organ
damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus =
and
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>These studies have shown no sign=
ificant
beneficial effect on renal and/or cardiovascular outcomes and mortality, wh=
ile
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension =
as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients wi=
th
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ALTITUDE (<span class=3DSpellE>A=
liskiren</span>
Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) =
was
a study designed to test the benefit of adding <span class=3DSpellE>aliskir=
en</span>
to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blo=
cker
in patients with type 2 diabetes mellitus and chronic kidney disease,
cardiovascular disease, or both. The study was terminated early because of =
an
increased risk of adverse outcomes. Cardiovascular death and stroke were bo=
th
numerically more frequent in the <span class=3DSpellE>aliskiren</span> grou=
p that
in the placebo group and adverse events and serious adverse events of inter=
est
(hyperkalaemia, hypotension and renal dysfunction) were more frequently
reported in the <span class=3DSpellE>aliskiren</span> group than in the pla=
cebo
group.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
2<span
style=3D'mso-tab-count:1'> </span>Pharmacokinetic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Absorption<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span>=
</p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Distribution<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Plasma
protein binding is approximately 96%, with negligible binding to cellular b=
lood
components. The volume of distribution is 53&nbsp;-&nbsp;93&nbsp;litres. </=
span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Biotransformation<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Following
oral or intravenous administration of <sup><span style=3D'position:relative;
top:-1.0pt;mso-text-raise:1.0pt'>14</span></sup>C irbesartan, 80-85% of the
circulating plasma radioactivity is attributable to unchanged irbesartan.
Irbesartan is metabolised by the liver via glucuronide conjugation and
oxidation. The major circulating metabolite is irbesartan glucuronide
(approximately 6%). <i style=3D'mso-bidi-font-style:normal'>In&nbsp;vitro</=
i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.=
</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Linearity/non-linearity<o:p><=
/o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan exhibits linear and d=
ose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg=
. A
less than proportional increase in oral absorption at doses beyond 600&nbsp=
;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at
1.5&nbsp;-&nbsp;2&nbsp;hours after oral administration. The total body and
renal clearance are 157&nbsp;-&nbsp;176&nbsp;and 3&nbsp;-&nbsp;3.5&nbsp;ml/=
min,
respectively. The terminal elimination half-life of irbesartan is
11&nbsp;-&nbsp;15&nbsp;hours. Steady-state plasma concentrations are attain=
ed
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repea=
ted
once-daily dosing. In a study, somewhat higher plasma concentrations of
irbesartan were observed in female hypertensive patients. However, there wa=
s no
difference in the half-life and accumulation of irbesartan. No dosage
adjustment is necessary in female patients. Irbesartan AUC and <span
class=3DSpellE>C<span class=3DEMEASubscript>max</span></span> values were a=
lso
somewhat greater in older subjects (&#8805;&nbsp;65&nbsp;years) than those =
of
young subjects (18&nbsp;-&nbsp;40&nbsp;years). However the terminal half-li=
fe
was not significantly altered. No dosage adjustment is necessary in older
people.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Elimination<o:p></o:p></span>=
</u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan and its metabolites a=
re
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style=3D'position:relative;top:-1.0pt;mso-text=
-raise:
1.0pt'>14</span></sup>C irbesartan, about 20% of the radioactivity is recov=
ered
in the urine, and the remainder in the faeces. Less than 2% of the dose is
excreted in the urine as unchanged irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Paediatric population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The pharmacokinetics of irbesart=
an were
evaluated in 23&nbsp;hypertensive children after the administration of sing=
le
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable=
 for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;ye=
ars,
nine children between 6 and 12 years). Results showed that <span class=3DSp=
ellE>C<span
class=3DEMEASubscript>max</span></span>, AUC and clearance rates were compa=
rable
to those observed in adult patients receiving 150&nbsp;mg irbesartan daily.=
 A
limited accumulation of irbesartan (18%) in plasma was observed upon repeat=
ed
once daily dosing.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment</span></u></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with renal impairmen=
t or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesarta=
n are
not significantly altered. Irbesartan is not removed by haemodialysis.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hepatic impairment</span></u>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significant=
ly
altered. </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Studies have not been performed =
in patients
with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
3<i
style=3D'mso-bidi-font-style:normal'><span style=3D'mso-tab-count:1'> <=
/span></i>Preclinical
safety data</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/da=
y in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/=
day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product wh=
ich
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/d=
ay).
All of these changes were considered to be caused by the pharmacological ac=
tion
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplas=
ia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There was no evidence of mutagen=
icity, <span
class=3DSpellE>clastogenicity</span> or carcinogenicity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Fertility and reproductive perfo=
rmance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), inclu=
ding
mortality at the highest dose. No significant effects on the number of corp=
ora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit fo=
etuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Animal studies with irbesartan s=
howed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significa=
nt
maternal toxicity, including mortality. No teratogenic effects were observe=
d in
the rat or rabbit.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
1<span
style=3D'mso-tab-count:1'> </span>List of excipients</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Tablet
core:</span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Lact=
ose
monohydrate<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Micr=
ocrystalline
cellulose<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Cros=
carmellose
sodium<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Hypr=
omellose<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Sili=
con
dioxide<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Magn=
esium
stearate.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Film=
-coating:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Lact=
ose
monohydrate<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Hypr=
omellose<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Tita=
nium
dioxide<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Macr=
ogol 3000<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Carn=
auba wax.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
2<span
style=3D'mso-tab-count:1'> </span>Incompatibilities</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Not applicable.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
3<span
style=3D'mso-tab-count:1'> </span>Shelf life</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>3&nbsp;years.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
4<span
style=3D'mso-tab-count:1'> </span>Special precautions for storage</span=
></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not store above 30C.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'margin-left:0in;text-indent:0in;mso-outlin=
e-level:
1'><span lang=3DEN-GB>6.5<span style=3D'mso-tab-count:1'> </span>Nature=
 and
contents of container</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 14&nbsp;film-coated t=
ablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 28&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 30</span><span lang=
=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial;mso-fareast-l=
anguage:
DE;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'> film-coated table=
ts
in PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 56&nbsp;film-coated t=
ablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 84&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 90</span><span lang=
=3DEN-GB
style=3D'mso-fareast-language:DE'> film-coated tablets in PVC/PVDC/Aluminium
blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 98&nbsp;film-coated t=
ablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 56&nbsp;x&nbsp;1&nbsp;film-coated tablet in PVC/PVDC/Aluminium
perforated unit dose blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><span lang=3DEN-GB>No=
t all pack
sizes may be marketed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
6<span
style=3D'mso-tab-count:1'> </span>Special precautions for disposal</spa=
n></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Any unused medicinal product or =
waste
material should be disposed of in accordance with local requirements.</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>7.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION HOLDER<o:p>=
</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>8.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION NUMBERS<o:p=
></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DSL style=3D'mso-ansi-language:SL'>EU/1=
/97/049/016-020<br>
EU/1/97/049/031<br>
EU/1/97/049/034<br>
EU/1/97/049/037<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>DATE
OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Date of first authorisation: 27 =
August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>10.<span style=3D'mso-tab-count:=
1'> </span>DATE
OF REVISION OF THE TEXT</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<p class=3DEMEAHeading1><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg film-coated tablets.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Each film-coated tablet contains=
 150&nbsp;mg
of irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Excipient with known effect</=
span></u><span
lang=3DEN-GB>: 51.00&nbsp;mg of lactose monohydrate per film-coated tablet.=
</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For the full list of excipients,=
 see
section&nbsp;6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Film-coated
tablet.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2872 engr=
aved
on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>CLINICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
1<span
style=3D'mso-tab-count:1'> </span>Therapeutic indications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span class=3DSpel=
lE><span
lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB> is indicated in adults=
 for the
treatment of essential hypertension.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>It is also indicated for the tre=
atment
of renal disease in adult patients with hypertension and type&nbsp;2 diabet=
es
mellitus as part of an antihypertensive medicinal product regimen (see sect=
ions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
2<span
style=3D'mso-tab-count:1'> </span>Posology and method of administration=
</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Posology<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. <span class=3DSpellE>Karvea</span> at a dose of 150&nbsp;mg o=
nce
daily generally provides a better 24&nbsp;hour blood pressure control than
75&nbsp;mg. However, initiation of therapy with 75&nbsp;mg could be conside=
red,
particularly in <span class=3DSpellE>haemodialysed</span> patients and in t=
he
elderly over 75&nbsp;years.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients insufficiently contr=
olled
with 150&nbsp;mg once daily, the dose of <span class=3DSpellE>Karvea</span>=
 can
be increased to 300&nbsp;mg, or other antihypertensive agents can be added =
(see
sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic =
such
as hydrochlorothiazide has been shown to have an additive effect with <span
class=3DSpellE>Karvea</span> (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In hypertensive type&nbsp;2 diab=
etic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily =
and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The demonstration of renal benef=
it of <span
class=3DSpellE>Karvea</span> in hypertensive type&nbsp;2 diabetic patients =
is
based on studies where irbesartan was used in addition to other
antihypertensive agents, as needed, to reach target blood pressure (see sec=
tions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Special Populations<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Renal
impairment</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4=
).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Hepatic
impairment</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Older
people</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Although consideration should be=
 given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary <span class=3DSpellE>forolder</s=
pan>
people.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Paediatric
population</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The safety and efficacy of <span
class=3DSpellE>Karvea</span> in children aged 0 to 18 has not been establis=
hed.
Currently available data are described in section 4.8, 5.1 and 5.2 but no
recommendation on a posology can be made.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Method of Administration<o:p>=
</o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For oral use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
3<span
style=3D'mso-tab-count:1'> </span>Contraindications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;=
6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Second and third trimesters of p=
regnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The concomitant use of <span
class=3DSpellE>Karvea</span> with <span class=3DSpellE>aliskiren</span>-con=
taining
products is contraindicated in patients with diabetes mellitus or renal
impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup=
>)
(see sections 4.5 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
4<span
style=3D'mso-tab-count:1'> </span>Special warnings and precautions for =
use</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Intravascular
volume depletion</span></u><span lang=3DEN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renovascular hypertension</sp=
an></u><span
lang=3DEN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosi=
s of
the artery to a single functioning kidney are treated with medicinal produc=
ts
that affect the renin-angiotensin-aldosterone system. While this is not
documented with <span class=3DSpellE>Karvea</span>, a similar effect should=
 be
anticipated with angiotensin-II receptor antagonists.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment and kidney
transplantation</span></u><span lang=3DEN-GB>: when <span class=3DSpellE>Ka=
rvea</span>
is used in patients with impaired renal function, a periodic monitoring of
potassium and creatinine serum levels is recommended. There is no experience
regarding the administration of <span class=3DSpellE>Karvea</span> in patie=
nts
with a recent kidney transplantation.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=3DEN-GB>:</span=
><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'> the e=
ffects
of irbesartan both on renal and cardiovascular events were not uniform acro=
ss
all subgroups, in an analysis carried out in the study with patients with
advanced renal disease. In particular, they appeared less favourable in wom=
en
and non-white subjects (see section&nbsp;5.1).<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS): t</span></u><span lang=3DEN-GB=
>here
is evidence that the concomitant use of ACE-inhibitors, angiotensin II rece=
ptor
blockers or <span class=3DSpellE>aliskiren</span> increases the risk of
hypotension, hyperkalaemia and decreased renal function (including acute re=
nal
failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,
angiotensin II receptor blockers or <span class=3DSpellE>aliskiren</span> is
therefore not recommended (see sections 4.5 and 5.1). <span
style=3D'mso-spacerun:yes'></span>If dual blockade therapy is considered
absolutely necessary, this should only occur under specialist supervision a=
nd
subject to frequent close monitoring of renal function, electrolytes and bl=
ood
pressure. ACE-inhibitors and angiotensin II receptor blockers should not be
used concomitantly in patients with diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hyperkalaemia</span></u><span
lang=3DEN-GB>: as with other medicinal products that affect the
renin-angiotensin-aldosterone system, hyperkalaemia may occur during the
treatment with <span class=3DSpellE>Karvea</span>, especially in the presen=
ce of
renal impairment, overt proteinuria due to diabetic renal disease, and/or h=
eart
failure. Close monitoring of serum potassium in patients at risk is recomme=
nded
(see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypoglycaemia</span></u><span
lang=3DEN-GB>: <span class=3DSpellE>Karvea</span> may induce hypoglycaemia,
particularly in diabetic patients. In patients treated with insulin or
antidiabetics an appropriate blood glucose monitoring should be considered;=
 a dose
adjustment of insulin or antidiabetics may be required when indicated (see =
section
4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:
the combination of lithium and <span class=3DSpellE>Karvea</span> is not
recommended (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Aortic and mitral valve steno=
sis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=3DEN-GB>: as w=
ith
other vasodilators, special caution is indicated in patients suffering from
aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Primary aldosteronism</span><=
/u><span
lang=3DEN-GB>: patients with primary aldosteronism generally will not respo=
nd to
antihypertensive medicinal products acting through inhibition of the
renin-angiotensin system. Therefore, the use of <span class=3DSpellE>Karvea=
</span>
is not recommended.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>General</span></u><span lang=
=3DEN-GB>:
in patients whose vascular tone and renal function depend predominantly on =
the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients wi=
th
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b style=3D'mso-bidi-font-weigh=
t:
normal'> </b>converting enzyme inhibitors or angiotensin-II receptor
antagonists that affect this system has been associated with acute hypotens=
ion,
azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As wi=
th
any antihypertensive agent, excessive blood pressure decrease in patients w=
ith
ischaemic cardiopathy or ischaemic cardiovascular disease could result in a
myocardial infarction or stroke.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As observed for angiotensin conv=
erting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Pregnancy:</span></u><span
lang=3DEN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not =
be
initiated during pregnancy. </span><span lang=3DEN-GB style=3D'mso-bidi-fon=
t-size:
11.0pt'>Unless continued AIIRA therapy is considered essential, patients
planning pregnancy should be changed to alternative antihypertensive treatm=
ents
which have an established safety profile for use in pregnancy. When pregnan=
cy
is diagnosed, treatment with </span><span lang=3DEN-GB>AIIRAs</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> should be stopped immedia=
tely,
and, if appropriate, alternative therapy should be started (see
sections&nbsp;4.3 and&nbsp;4.6).<o:p></o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Paediatric population</span><=
/u><span
lang=3DEN-GB>: irbesartan has been studied in paediatric populations <span
style=3D'mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>aged 6 to 16=
 years
old</span> but the current data are insufficient to support an extension of=
 the
use in children until further data become available (see sections&nbsp;4.8,=
 5.1
and&nbsp;5.2).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><u><span lang=3DEN-GB>Excipients</span></u><span lang=
=3DFR
style=3D'mso-ansi-language:FR'>:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150 mg film-coated tablet contains lactose. Patients wit=
h rare
hereditary problems of galactose intolerance, total lactase deficiency or
glucose-galactose malabsorption should not take this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DFR style=3D'mso-a=
nsi-language:
FR'>Karvea</span></span><span lang=3DFR style=3D'mso-ansi-language:FR'>&nbs=
p;150 mg
fil -<span class=3DSpellE>coated</span> <span class=3DSpellE>tablet</span> =
<span
class=3DSpellE>contains</span> sodium. </span><span lang=3DEN-GB>This medic=
ine
contains less than 1 mmol sodium (23 mg) per tablet, that is to say essenti=
ally
sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
5<span
style=3D'mso-tab-count:1'> </span>Interaction with other medicinal prod=
ucts
and other forms of interaction</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Diuretics and other antihyper=
tensive
agents</span></u><span lang=3DEN-GB>: other antihypertensive agents may inc=
rease
the hypotensive effects of irbesartan; however <span class=3DSpellE>Karvea<=
/span>
has been safely administered with other antihypertensive agents, such as
beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Prior treatment with high dose diuretics may result in volume depletion and=
 a
risk of hypotension when initiating therapy with <span class=3DSpellE>Karve=
a</span>
(see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><u><span lang=3DEN-GB>Aliskire=
n</span></u></span><u><span
lang=3DEN-GB>-containing products or ACE-inhibitors</span></u><span lang=3D=
EN-GB>: clinical
trial data has shown that dual blockade of the renin-angiotensin-aldosteron=
e system
(RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor =
blockers
or <span class=3DSpellE>aliskiren</span> is associated with a higher freque=
ncy of
adverse events such as hypotension, hyperkalaemia and decreased renal funct=
ion
(including acute renal failure) compared to the use of a single RAAS-acting
agent (see sections 4.3, 4.4 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=3DEN-GB>:<i style=3D'mso-b=
idi-font-style:
normal'> </i>based on experience with the use of other medicinal products t=
hat
affect the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or
other medicinal products that may increase serum potassium levels (e.g.&nbs=
p;heparin)
may lead to increases in serum potassium and is, therefore, not recommended=
 (see
section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:<i
style=3D'mso-bidi-font-style:normal'> </i>reversible increases in serum lit=
hium
concentrations and toxicity have been reported during concomitant
administration of lithium with angiotensin converting enzyme inhibitors.
Similar effects have been very rarely reported with irbesartan so far.
Therefore, this combination is not recommended (see section&nbsp;4.4). If t=
he
combination proves necessary, careful monitoring of serum lithium levels is
recommended.</span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></i></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Non-steroidal anti-inflammato=
ry drugs</span></u><span
lang=3DEN-GB>: <span style=3D'color:black'>when angiotensin&nbsp;II antagon=
ists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) a=
nd
non-selective NSAIDs), attenuation of the antihypertensive effect may occur=
.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'color:black'>As with AC=
E inhibitors,
concomitant use of angiotensin&nbsp;II antagonists and NSAIDs may lead to an
increased risk of worsening of renal function, including possible acute ren=
al
failure, and an increase in serum potassium, especially in patients with po=
or
pre-existing renal function. The combination should be administered with
caution, especially in the elderly. Patients should be adequately hydrated =
and
consideration should be given to monitoring renal function after initiation=
 of
concomitant therapy, and periodically thereafter.<b style=3D'mso-bidi-font-=
weight:
normal'><i style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></b></span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Repaglinide:</span></u><span
lang=3DEN-GB style=3D'color:black'> irbesartan has the potential to inhibit=
 OATP1B1.
In a clinical study, it was reported that irbesartan increased the <span
class=3DSpellE>C<sub>max</sub></span> and AUC of repaglinide (substrate of
OATP1B1) by 1.8-fold and 1.3&#8209;fold, respectively, when administered 1 =
hour
before repaglinide. In another study, no relevant pharmacokinetic interacti=
on was
reported, when the two drugs were co-administered. Therefore, dose adjustme=
nt of
antidiabetic treatment such as repaglinide may be required (see section 4.4=
).<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Additional information on irb=
esartan
interactions</span></u><span lang=3DEN-GB>: <span style=3D'color:black'>in =
clinical
studies, the pharmacokinetic of irbesartan is not affected by
hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a le=
sser
extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic
interactions were observed when irbesartan was <span class=3DSpellE>coadmin=
istered</span>
with warfarin, a medicinal product metabolised by CYP2C9. The effects of CY=
P2C9
inducers such as rifampicin on the pharmacokinetic of irbesartan have not b=
een
evaluated. The pharmacokinetic of digoxin was not altered by coadministrati=
on
of irbesartan.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
6<span
style=3D'mso-tab-count:1'> </span>Fertility, pregnancy and lactation</s=
pan></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Pregnancy</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEABodyText style=3D'border:none;mso-border-alt:solid windowtex=
t .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><span lang=3DEN-GB>The=
 use
of AIIRAs is not recommended during the first trimester of pregnancy (see
section&nbsp;4.4). The use of AIIRAs is contraindicated during the second a=
nd
third trimesters of pregnancy (see sections&nbsp;4.3 and&nbsp;4.4).</span><=
/p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Epidemiological evidence regardi=
ng the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in
risk cannot be excluded. Whilst there is no controlled epidemiological data=
 on
the risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar ri=
sks
may exist for this class of drugs. Unless continued AIIRA therapy is consid=
ered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for us=
e in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be sto=
pped
immediately, and, if appropriate, alternative therapy should be started.</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Exposure to AIIRA therapy during=
 the
second and third trimesters is known to induce human <span class=3DSpellE>f=
oetotoxicity</span>
(decreased renal function, oligohydramnios, skull ossification retardation)=
 and
neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See
section&nbsp;5.3).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Should exposure to AIIRAs have o=
ccurred
from the second trimester of pregnancy, ultrasound check of renal function =
and
skull is recommended.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Infants whose mothers have taken=
 AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3
and&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Breast-feeding</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Because no information is availa=
ble
regarding the use of <span class=3DSpellE>Karvea</span> during breast-feedi=
ng, <span
class=3DSpellE>Karvea</span> is not recommended and alternative treatments =
with
better established safety profiles during breast-feeding are preferable,
especially while nursing a <span class=3DSpellE>newborn</span> or preterm i=
nfant.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>It is unknown whether irbesartan=
 or its
metabolites are excreted in human milk. </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Available pharmacodynamic/toxico=
logical
data in rats have shown excretion of irbesartan or its metabolites in milk =
(for
details see 5.3).</span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Fertility</span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>Irbesartan =
had no
effect upon fertility of treated rats and their offspring up to the dose le=
vels
inducing the first signs of parental toxicity (see section 5.3). <o:p></o:p=
></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>4.7<span style=3D'mso-tab-count:=
1'> </span>Effects
on ability to drive and use machines</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Based on its
pharmacodynamic properties, irbesartan is unlikely to affect the ability to=
 drive
and use machines. When driving vehicles or operating machines, it should be
taken into account that dizziness or weariness may occur during treatment.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
8<span
style=3D'mso-tab-count:1'> </span>Undesirable effects</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In placebo-controlled trials in =
patients
with hypertension, the overall incidence of adverse events did not differ
between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuat=
ion
due to any clinical or laboratory adverse event was less frequent for
irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).
The incidence of adverse events was not related to dose (in the recommended
dose range), gender, age, race, or duration of treatment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In diabetic hypertensive patient=
s with
microalbuminuria and normal renal function, orthostatic dizziness and ortho=
static
hypotension were reported in 0.5% of the patients (i.e.,&nbsp;uncommon) but=
 in excess
of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The following table presents the=
 adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a s=
tar
(*) refer to the adverse reactions that were additionally reported in &gt; =
2%
of diabetic hypertensive patients with chronic renal insufficiency and overt
proteinuria and in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of adverse reactio=
ns
listed below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>very common (&#8805;&nbsp;1/10);=
 common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very r=
are
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects a=
re
presented in order of decreasing seriousness.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Adverse reactions additionally r=
eported
from postmarketing experience are also listed. <span style=3D'mso-bidi-fon=
t-style:
italic'>These adverse reactions are derived from spontaneous reports.<o:p><=
/o:p></span></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Blood and lymphatic system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>anaemia, thrombocytopenia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Immune system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hypersensitivity reactions such as angioedema, rash, urtic=
aria,
anaphylactic reaction, anaphylactic shock<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Metabolism and nutrition disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hyperkalaemia, hypoglycaemia</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Nervous system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>dizzine=
ss,
orthostatic dizziness*</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Not known:<span style=3D'mso-tab-count:1'> </span>vertig=
o, headache</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Ear and labyrinth disorder<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>tinnitus</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Cardiac disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>tachycar=
dia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Vascular disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;tab-stops:31.5pt .5=
in 1.0in'><span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>orthost=
atic
hypotension*</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>flushing<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><u><span lang=3DEN-GB=
><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Respiratory, thoracic and mediastinal disorders<o:p></o:p></sp=
an></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>cough</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Gastrointestinal disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>nausea/vomiting</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>U=
ncommon:<span
style=3D'mso-tab-count:1'> </span>diarrhoea, dyspepsia/heartburn</span=
></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>N=
ot known:<span
style=3D'mso-tab-count:1'> </span>dysgeusia</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB><=
o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Hepatobiliary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>jaundice</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>hepatitis,
abnormal liver function<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Skin and subcutaneous tissue disorders<o:p></o:p></span></u></=
p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:44.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
1'> </span><span class=3DSpellE>leukocytoclastic</span> vasculitis</s=
pan></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Musculoskeletal and connective tissue disorders <o:p></o:p></s=
pan></u></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>C=
ommon:<span
style=3D'mso-tab-count:1'> </span>musculoskeletal pain*</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;mso-o=
utline-level:
1;tab-stops:.5in 1.0in'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab=
-count:
1'> </span>arthralgia, myalgia (in some cases associated with increas=
ed
plasma creatine kinase levels), muscle cramps</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Renal and urinary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;page-=
break-after:
avoid;mso-outline-level:1;tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<s=
pan
style=3D'mso-tab-count:1'> </span>impaired renal function including c=
ases
of renal failure in patients at risk (see section&nbsp;4.4)</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB><=
o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'text-align:justify;page-break-after:avoid;
mso-outline-level:1'><u><span lang=3DEN-GB>Reproductive system and breast
disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB>Uncomm=
on:<span
style=3D'mso-tab-count:1'> </span>sexual dysfunction</span></p>

<p class=3DEMEABodyText style=3D'text-align:justify;mso-outline-level:1;tab=
-stops:
1.0in'><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>General disorders and administration site conditions<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>fatigue</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>chest
pain<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Investigations<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Very common:<span style=3D'mso-tab-count:1'>=
 </span>Hyperkalaemia*
occurred more often in diabetic patients treated with irbesartan than with
placebo. In diabetic hypertensive patients with microalbuminuria and normal
renal function, hyperkalaemia (&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>m=
Eq</span>/L)
occurred in 29.4% of the patients in the irbesartan 300&nbsp;mg group and 2=
2%
of the patients in the placebo group. In diabetic hypertensive patients with
chronic renal insufficiency and overt proteinuria, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>mEq</span>/L) occurred in 46.3%=
 of
the patients in the irbesartan group and 26.3% of the patients in the place=
bo
group.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'>=
 </span>significant
increases in plasma creatine kinase were commonly observed (1.7%) in irbesa=
rtan
treated subjects. None of these increases were associated with identifiable
clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treat=
ed
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><i style=3D'mso-bidi-=
font-style:
normal'><u><span lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nb=
sp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB style=3D'mso-bidi-font-weight=
:bold'>Paediatric
population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-bidi-font-weight:bo=
ld'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-bidi-font-weight:bo=
ld'>I</span><span
lang=3DEN-GB>n a randomised trial of 318&nbsp;hypertensive children and ado=
lescents
aged 6 to 16&nbsp;years, the following adverse reactions occurred in the 3-=
week
double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%),
cough (0.9%). In the 26-week open-label period of this trial the most frequ=
ent
laboratory abnormalities observed were creatinine increases (6.5%) and elev=
ated
CK values in 2% of child recipients.</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB><o:p>&=
nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of suspected adverse
reactions <o:p></o:p></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Reporting suspected adverse reac=
tions
after authorisation of the medicinal product is important. It allows contin=
ued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in Appendix V.</span> </span></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB><o:p>&=
nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
9<span
style=3D'mso-tab-count:1'> </span>Overdose</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Experience
in adults exposed to doses of up to 900&nbsp;mg/day for 8&nbsp;weeks reveal=
ed
no toxicity. The most likely manifestations of overdose are expected to be
hypotension and tachycardia; bradycardia might also occur from overdose. No
specific information is available on the treatment of overdose with <span
class=3DSpellE>Karvea</span>. The patient should be closely monitored, and =
the
treatment should be symptomatic and supportive. Suggested measures include
induction of emesis and/or gastric lavage. Activated charcoal may be useful=
 in
the treatment of overdose. Irbesartan is not removed by haemodialysis.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
1<span
style=3D'mso-tab-count:1'> </span>Pharmacodynamic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Pharmacotherapeutic group:
Angiotensin-II antagonists, plain.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ATC&nbsp;code: C09C&nbsp;A04.</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Mechanism of action</span></u=
><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB> <o:p></o:p></span=
></b></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan is a potent, orally a=
ctive,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</s=
ub>
receptor, regardless of the source or route of synthesis of angiotensin-II.=
 The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors resul=
ts in
increases in plasma renin levels and angiotensin-II levels, and a decrease =
in
plasma aldosterone concentration. Serum potassium levels are not significan=
tly
affected by irbesartan alone at the recommended doses. Irbesartan does not
inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also
degrades bradykinin into inactive metabolites. Irbesartan does not require
metabolic activation for its activity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><u><span lang=3DEN-GB style=3D'font-weight:normal'>=
Clinical
efficacy</span></u></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension<o:p></=
o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan lowers blood pressure=
 with minimal
change in heart rate. The decrease in blood pressure is dose-related for on=
ce a
day doses with a tendency towards plateau at doses above 300&nbsp;mg. Doses=
 of
150-300&nbsp;mg once daily lower supine or seated blood pressures at trough
(i.e.&nbsp;24&nbsp;hours after dosing) by an average of 8-13/5-8&nbsp;mm&nb=
sp;Hg
(systolic/diastolic) greater than those associated with placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Peak reduction of blood pressure=
 is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours =
the
reduction of blood pressure was 60-70% of the corresponding peak diastolic =
and
systolic responses at the recommended doses. Once daily dosing with 150&nbs=
p;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosi=
ng
on the same total dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
ct of <span
class=3DSpellE>Karvea</span> is evident within 1-2&nbsp;weeks, with the max=
imal
effect occurring by 4-6&nbsp;weeks after start of therapy. The antihyperten=
sive
effects are maintained during long term therapy. After withdrawal of therap=
y,
blood pressure gradually returns toward baseline. Rebound hypertension has =
not
been observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
cts of
irbesartan and thiazide-type diuretics are additive. In patients not adequa=
tely
controlled by irbesartan alone, the addition of a low dose of hydrochloroth=
iazide
(12.5&nbsp;mg) to irbesartan once daily results in a further placebo-adjust=
ed blood
pressure reduction at trough of 7-10/3-6&nbsp;mm&nbsp;Hg (systolic/diastoli=
c).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The efficacy of <span class=3DSp=
ellE>Karvea</span>
is not influenced by age or gender. As is the case with other medicinal
products that affect the renin-angiotensin system, black hypertensive patie=
nts
have notably less response to irbesartan monotherapy. When irbesartan is
administered concomitantly with a low dose of hydrochlorothiazide (e.g.&nbs=
p;12.5&nbsp;mg
daily), the antihypertensive response in black patients approaches that of
white patients.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There is no clinically important=
 effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Paediatric population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Reduction of blood pressure with
0.5&nbsp;mg/kg (low), 1.5&nbsp;mg/kg (medium) and 4.5&nbsp;mg/kg (high) tar=
get
titrated doses of irbesartan was evaluated in 318&nbsp;hypertensive or at r=
isk
(diabetic, family history of hypertension) children and adolescents aged 6 =
to
16&nbsp;years over a three week period. At the end of the three weeks the m=
ean reduction
from baseline in the primary efficacy variable, trough seated systolic blood
pressure (<span class=3DSpellE>SeSBP</span>) was 11.7&nbsp;mmHg (low dose),
9.3&nbsp;mmHg (medium dose), 13.2&nbsp;mmHg (high dose). No significant
difference was apparent between these doses. Adjusted mean change of trough
seated diastolic blood pressure (<span class=3DSpellE>SeDBP</span>) was as =
follows:
3.8&nbsp;mmHg (low dose), 3.2&nbsp;mmHg (medium dose), 5.6&nbsp;mmHg (high
dose). Over a subsequent two week period where patients were re-randomized =
to
either active medicinal product or placebo, patients on placebo had increas=
es
of 2.4 and 2.0&nbsp;mmHg in <span class=3DSpellE>SeSBP</span> and <span
class=3DSpellE>SeDBP</span> compared to +0.1 and -0.3&nbsp;mmHg changes
respectively in those on all doses of irbesartan (see section&nbsp;4.2).</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension and
type&nbsp;2 diabetes with renal disease<o:p></o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The Irbesartan Diabetic Nephrop=
athy
Trial (IDNT) shows that irbesartan decreases the progression of renal dise=
ase
in patients with chronic renal insufficiency and overt proteinuria. IDNT wa=
s a
double blind, controlled, morbidity and mortality trial comparing <span
class=3DSpellE>Karvea</span>, amlodipine and placebo. In 1,715&nbsp;hyperte=
nsive
patients with type&nbsp;2 diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day
and serum creatinine ranging from 1.0-3.0&nbsp;mg/dl, the long-term effects
(mean&nbsp;2.6&nbsp;years) of <span class=3DSpellE>Karvea</span> on the
progression of renal disease and all-cause mortality were examined. Patients
were titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg <span
class=3DSpellE>Karvea</span></span><span lang=3DEN-GB style=3D'font-family:=
"Times",serif;
mso-bidi-font-family:"Times New Roman"'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=3DEN-GB> as tolerated. Patients in =
all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertens=
ive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo gr=
oup
reached this target blood pressure whereas this figure was 76% and 78% in t=
he
irbesartan and amlodipine groups respectively. Irbesartan significantly red=
uced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approxim=
ately
33% of patients in the irbesartan group reached the primary renal composite
endpoint compared to 39% and 41% in the placebo and amlodipine groups [20%
relative risk reduction versus placebo (p&nbsp;=3D&nbsp;0.024) and 23% rela=
tive
risk reduction compared to amlodipine (p&nbsp;=3D&nbsp;0.006)]. When the
individual components of the primary endpoint were analysed, no effect in <=
span
class=3DSpellE>all cause</span> mortality was observed, while a positive tr=
end in
the reduction in ESRD and a significant reduction in doubling of serum
creatinine were observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'>Subgroups consisting of gender, race, age, duration =
of
diabetes, baseline blood pressure, serum creatinine, and albumin excretion =
rate
were assessed for treatment effect. In the female and black subgroups which
represented 32% and 26% of the overall study population respectively, a ren=
al
benefit was not evident, </span><span style=3D'mso-ansi-language:EN-US'>alt=
hough
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI w=
as
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identif=
ied.</span><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'><o:p><=
/o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The study of the Effects of Irb=
esartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mell=
itus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with
type&nbsp;2 diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal
function (serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effe=
cts
(2&nbsp;years) of <span class=3DSpellE>Karvea</span> on the progression to
clinical (overt) proteinuria (urinary albumin excretion rate (UAER)
&gt;&nbsp;300&nbsp;mg/day, and an increase in UAER of at least 30% from
baseline). The predefined blood pressure goal was
&#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents (excluding
ACE inhibitors, angiotensin&nbsp;II receptor antagonists and dihydropyridine
calcium blockers) were added as needed to help achieve the blood pressure g=
oal.
While similar blood pressure was achieved in all treatment groups, fewer
subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the placebo (14=
.9%)
or in the irbesartan 150&nbsp;mg group (9.7%) reached the endpoint of overt
proteinuria, demonstrating a 70% relative risk reduction versus placebo
(p&nbsp;=3D&nbsp;0.0004) for the higher dose. An accompanying improvement i=
n the
glomerular filtration rate (GFR) was not observed during the first three mo=
nths
of treatment. The slowing in the progression to clinical proteinuria was
evident as early as three months and continued over the 2&nbsp;year period.
Regression to <span class=3DSpellE>normoalbuminuria</span> (&lt;&nbsp;30&nb=
sp;mg/day)
was more frequent in the <span class=3DSpellE>Karvea</span>&nbsp;300&nbsp;mg
group (34%) than in the placebo group (21%).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Dual
blockade of the renin-angiotensin-aldosterone system (RAAS)<o:p></o:p></spa=
n></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Two large randomised, controlled=
 trials
(ONTARGET (<span class=3DSpellE>ONgoing</span> Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Vete=
rans
Affairs Nephropathy in Diabetes)) have examined the use of the combination =
of
an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a st=
udy
conducted in patients with a history of cardiovascular or cerebrovascular
disease, or type 2 diabetes mellitus accompanied by evidence of end-organ
damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus =
and
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>These studies have shown no sign=
ificant
beneficial effect on renal and/or cardiovascular outcomes and mortality, wh=
ile
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension =
as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and
angiotensin II receptor blockers.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients wi=
th
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ALTITUDE (<span class=3DSpellE>A=
liskiren</span>
Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) =
was a
study designed to test the benefit of adding <span class=3DSpellE>aliskiren=
</span>
to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blo=
cker
in patients with type 2 diabetes mellitus and chronic kidney disease,
cardiovascular disease, or both. The study was terminated early because of =
an
increased risk of adverse outcomes. Cardiovascular death and stroke were bo=
th
numerically more frequent in the <span class=3DSpellE>aliskiren</span> grou=
p than
in the placebo group and adverse events and serious adverse events of inter=
est
(hyperkalaemia, hypotension and renal dysfunction) were more frequently
reported in the <span class=3DSpellE>aliskiren</span> group than in the pla=
cebo
group.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
2<span
style=3D'mso-tab-count:1'> </span>Pharmacokinetic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Absorption<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span>=
</p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Distribution<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Plasma
protein binding is approximately 96%, with negligible binding to cellular b=
lood
components. The volume of distribution is 53&nbsp;-&nbsp;93&nbsp;litres. </=
span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Biotransformation<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Following
oral or intravenous administration of <sup><span style=3D'position:relative;
top:-1.0pt;mso-text-raise:1.0pt'>14</span></sup>C irbesartan, 80-85% of the
circulating plasma radioactivity is attributable to unchanged irbesartan.
Irbesartan is metabolised by the liver via glucuronide conjugation and
oxidation. The major circulating metabolite is irbesartan glucuronide
(approximately 6%). <i style=3D'mso-bidi-font-style:normal'>In&nbsp;vitro</=
i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.=
</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Linearity / non-linearity<o:p=
></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan exhibits linear and d=
ose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg=
. A
less than proportional increase in oral absorption at doses beyond 600&nbsp=
;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at
1.5&nbsp;-&nbsp;2&nbsp;hours after oral administration. The total body and
renal clearance are 157&nbsp;-&nbsp;176&nbsp;and 3&nbsp;-&nbsp;3.5&nbsp;ml/=
min,
respectively. The terminal elimination half-life of irbesartan is
11&nbsp;-&nbsp;15&nbsp;hours. Steady-state plasma concentrations are attain=
ed
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repea=
ted
once-daily dosing. In a study, somewhat higher plasma concentrations of
irbesartan were observed in female hypertensive patients. However, there wa=
s no
difference in the half-life and accumulation of irbesartan. No dosage
adjustment is necessary in female patients. Irbesartan AUC and <span
class=3DSpellE>C<span class=3DEMEASubscript>max</span></span> values were a=
lso
somewhat greater in older subjects (&#8805;&nbsp;65&nbsp;years) than those =
of
young subjects (18&nbsp;-&nbsp;40&nbsp;years). However the terminal half-li=
fe
was not significantly altered. No dosage adjustment is necessary in older p=
eople.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Elimination<o:p></o:p></span>=
</u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan and its metabolites a=
re eliminated
by both biliary and renal pathways. After either oral or IV administration =
of <sup><span
style=3D'position:relative;top:-1.0pt;mso-text-raise:1.0pt'>14</span></sup>C
irbesartan, about 20% of the radioactivity is recovered in the urine, and t=
he
remainder in the faeces. Less than 2% of the dose is excreted in the urine =
as
unchanged irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Paediatric population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The pharmacokinetics of irbesart=
an were
evaluated in 23&nbsp;hypertensive children after the administration of sing=
le
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable=
 for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;ye=
ars,
nine children between 6 and 12 years). Results showed that <span class=3DSp=
ellE>C<span
class=3DEMEASubscript>max</span></span>, AUC and clearance rates were compa=
rable
to those observed in adult patients receiving 150&nbsp;mg irbesartan daily.=
 A
limited accumulation of irbesartan (18%) in plasma was observed upon repeat=
ed
once daily dosing.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment</span></u></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with renal impairmen=
t or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hepatic impairment</span></u>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significant=
ly
altered. </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Studies have not been performed =
in
patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
3<i
style=3D'mso-bidi-font-style:normal'><span style=3D'mso-tab-count:1'> <=
/span></i>Preclinical
safety data</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/da=
y in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/=
day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product wh=
ich
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at
&#8805;&nbsp;90&nbsp;mg/kg/day, in macaques at &#8805;&nbsp;10&nbsp;mg/kg/d=
ay).
All of these changes were considered to be caused by the pharmacological ac=
tion
of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplas=
ia/
hypertrophy of the renal juxtaglomerular cells does not appear to have any
relevance.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There was no evidence of mutagen=
icity, <span
class=3DSpellE>clastogenicity</span> or carcinogenicity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Fertility and reproductive perfo=
rmance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), inclu=
ding
mortality at the highest dose. No significant effects on the number of corp=
ora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit fo=
etuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Animal studies with irbesartan s=
howed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significa=
nt
maternal toxicity, including mortality. No teratogenic effects were observe=
d in
the rat or rabbit.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
1<span
style=3D'mso-tab-count:1'> </span>List of excipients</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Tablet
core:</span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Lact=
ose
monohydrate<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Micr=
ocrystalline
cellulose<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Cros=
carmellose
sodium<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Hypr=
omellose<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Sili=
con
dioxide<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Magn=
esium
stearate.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Film=
-coating:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Lact=
ose
monohydrate<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Hypr=
omellose<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Tita=
nium
dioxide<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Macr=
ogol 3000<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Carn=
auba wax.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
2<span
style=3D'mso-tab-count:1'> </span>Incompatibilities</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Not applicable.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
3<span
style=3D'mso-tab-count:1'> </span>Shelf life</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>3&nbsp;years.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
4<span
style=3D'mso-tab-count:1'> </span>Special precautions for storage</span=
></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not store above 30C.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'margin-left:0in;text-indent:0in;mso-outlin=
e-level:
1'><span lang=3DEN-GB>6.5<span style=3D'mso-tab-count:1'> </span>Nature=
 and
contents of container</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 14&nbsp;film-coated t=
ablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 28&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 30</span><span lang=
=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial;mso-fareast-l=
anguage:
DE;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'> film-coated table=
ts in
PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 56&nbsp;film-coated t=
ablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 84&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 90</span><span lang=
=3DEN-GB
style=3D'mso-fareast-language:DE'> film-coated tablets in PVC/PVDC/Aluminium
blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 98&nbsp;film-coated t=
ablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 56&nbsp;x&nbsp;1&nbsp;film-coated tablet in PVC/PVDC/Aluminium
perforated unit dose blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><span lang=3DEN-GB>No=
t all pack
sizes may be marketed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
6<span
style=3D'mso-tab-count:1'> </span>Special precautions for disposal</spa=
n></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Any unused medicinal product or =
waste
material should be disposed of in accordance with local requirements.</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>7.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION HOLDER<o:p>=
</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>8.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION NUMBERS<o:p=
></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DSL style=3D'mso-ansi-language:SL'>EU/1=
/97/049/021-025<br>
EU/1/97/049/032<br>
EU/1/97/049/035<br>
EU/1/97/049/038<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>DATE
OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Date of first authorisation: 27 =
August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>10.<span style=3D'mso-tab-count:=
1'> </span>DATE
OF REVISION OF THE TEXT</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<p class=3DEMEAHeading1><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg film-coated tablets.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Each film-coated tablet contains=
 300&nbsp;mg
of irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Excipient with known effect</=
span></u><span
lang=3DEN-GB>: 102.00&nbsp;mg of lactose monohydrate per film-coated tablet=
.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For the full list of excipients,=
 see
section&nbsp;6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Film-coated
tablet.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>White to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2873 engr=
aved
on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>CLINICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
1<span
style=3D'mso-tab-count:1'> </span>Therapeutic indications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span class=3DSpel=
lE><span
lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB> is indicated in adults=
 for the
treatment of essential hypertension.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>It is also indicated for the tre=
atment
of renal disease in adult patients with hypertension and type&nbsp;2 diabet=
es
mellitus as part of an antihypertensive medicinal product regimen (see sect=
ions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
2<span
style=3D'mso-tab-count:1'> </span>Posology and method of administration=
</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Posology<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>The usual
recommended initial and maintenance dose is 150&nbsp;mg once daily, with or
without food. <span class=3DSpellE>Karvea</span> at a dose of 150&nbsp;mg o=
nce
daily generally provides a better 24&nbsp;hour blood pressure control than
75&nbsp;mg. However, initiation of therapy with 75&nbsp;mg could be conside=
red,
particularly in <span class=3DSpellE>haemodialysed</span> patients and in t=
he
elderly over 75&nbsp;years.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients insufficiently contr=
olled
with 150&nbsp;mg once daily, the dose of <span class=3DSpellE>Karvea</span>=
 can
be increased to 300&nbsp;mg, or other antihypertensive agents can be added =
(see
sections 4.3, 4.4, 4.5 and 5.1). In particular, the addition of a diuretic =
such
as hydrochlorothiazide has been shown to have an additive effect with <span
class=3DSpellE>Karvea</span> (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In hypertensive type&nbsp;2 diab=
etic
patients, therapy should be initiated at 150&nbsp;mg irbesartan once daily =
and
titrated up to 300&nbsp;mg once daily as the preferred maintenance dose for
treatment of renal disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The demonstration of renal benef=
it of <span
class=3DSpellE>Karvea</span> in hypertensive type&nbsp;2 diabetic patients =
is
based on studies where irbesartan was used in addition to other
antihypertensive agents, as needed, to reach target blood pressure (see sec=
tions
4.3, 4.4, 4.5 and&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Special Populations<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Renal
impairment</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with impaired renal function. A lower starting dose (75&nbsp;mg)
should be considered for patients undergoing haemodialysis (see section 4.4=
).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Hepatic
impairment</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>No dosage adjustment is necessar=
y in
patients with mild to moderate hepatic impairment. There is no clinical
experience in patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Older
people</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Although consideration should be=
 given
to initiating therapy with 75&nbsp;mg in patients over 75&nbsp;years of age,
dosage adjustment is not usually necessary <span class=3DSpellE>forolder</s=
pan>
people.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Paediatric
population</span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The safety and efficacy of <span
class=3DSpellE>Karvea</span> in children aged 0 to 18 has not been establis=
hed.
Currently available data are described in section 4.8, 5.1 and 5.2 but no
recommendation on a posology can be made.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Method of Administration<o:p>=
</o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For oral use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
3<span
style=3D'mso-tab-count:1'> </span>Contraindications</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;=
6.1.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Second and third trimesters of p=
regnancy
(see sections&nbsp;4.4 and&nbsp;4.6).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The concomitant use of <span
class=3DSpellE>Karvea</span> with <span class=3DSpellE>aliskiren</span>-con=
taining
products is contraindicated in patients with diabetes mellitus or renal
impairment (glomerular filtration rate (GFR) &lt;60 ml/min/1.73m<sup>2</sup=
>) (see
sections 4.5 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
4<span
style=3D'mso-tab-count:1'> </span>Special warnings and precautions for =
use</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Intravascular
volume depletion</span></u><span lang=3DEN-GB>: symptomatic hypotension,
especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction,
diarrhoea or vomiting. Such conditions should be corrected before the
administration of <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renovascular hypertension</sp=
an></u><span
lang=3DEN-GB>: there is an increased risk of severe hypotension and renal
insufficiency when patients with bilateral renal artery stenosis or stenosi=
s of
the artery to a single functioning kidney are treated with medicinal produc=
ts
that affect the renin-angiotensin-aldosterone system. While this is not
documented with <span class=3DSpellE>Karvea</span>, a similar effect should=
 be
anticipated with angiotensin-II receptor antagonists.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment and kidney
transplantation</span></u><span lang=3DEN-GB>: when <span class=3DSpellE>Ka=
rvea</span>
is used in patients with impaired renal function, a periodic monitoring of
potassium and creatinine serum levels is recommended. There is no experience
regarding the administration of <span class=3DSpellE>Karvea</span> in patie=
nts
with a recent kidney transplantation.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypertensive patients with
type&nbsp;2 diabetes and renal disease</span></u><span lang=3DEN-GB>:</span=
><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'> the e=
ffects
of irbesartan both on renal and cardiovascular events were not uniform acro=
ss
all subgroups, in an analysis carried out in the study with patients with
advanced renal disease. In particular, they appeared less favourable in wom=
en
and non-white subjects (see section&nbsp;5.1).<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Dual blockade of the
renin-angiotensin-aldosterone system (RAAS</span></u><span lang=3DEN-GB>): =
there
is evidence that the concomitant use of ACE-inhibitors, angiotensin II rece=
ptor
blockers or <span class=3DSpellE>aliskiren</span> increases the risk of
hypotension, hyperkalaemia and decreased renal function (including acute re=
nal
failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,
angiotensin II receptor blockers or <span class=3DSpellE>aliskiren</span> is
therefore not recommended (see sections 4.5 and 5.1). <span
style=3D'mso-spacerun:yes'></span>If dual blockade therapy is considered
absolutely necessary, this should only occur under specialist supervision a=
nd
subject to frequent close monitoring of renal function, electrolytes and bl=
ood
pressure. ACE-inhibitors and angiotensin II receptor blockers should not be
used concomitantly in patients with diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hyperkalaemia</span></u><span
lang=3DEN-GB>: as with other medicinal products that affect the renin-angio=
tensin-aldosterone
system, hyperkalaemia may occur during the treatment with <span class=3DSpe=
llE>Karvea</span>,
especially in the presence of renal impairment, overt proteinuria due to
diabetic renal disease, and/or heart failure. Close monitoring of serum
potassium in patients at risk is recommended (see section&nbsp;4.5).</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hypoglycaemia</span></u><span
lang=3DEN-GB>: <span class=3DSpellE>Karvea</span> may induce hypoglycaemia,
particularly in diabetic patients. In patients treated with insulin or
antidiabetics an appropriate blood glucose monitoring should be considered;=
 a dose
adjustment of insulin or antidiabetics may be required when indicated (see =
section
4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:
the combination of lithium and <span class=3DSpellE>Karvea</span> is not
recommended (see section&nbsp;4.5).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Aortic and mitral valve steno=
sis,
obstructive hypertrophic cardiomyopathy</span></u><span lang=3DEN-GB>: as w=
ith
other vasodilators, special caution is indicated in patients suffering from=
 aortic
or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Primary aldosteronism</span><=
/u><span
lang=3DEN-GB>: patients with primary aldosteronism generally will not respo=
nd to
antihypertensive medicinal products acting through inhibition of the
renin-angiotensin system. Therefore, the use of <span class=3DSpellE>Karvea=
</span>
is not recommended.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>General</span></u><span lang=
=3DEN-GB>:
in patients whose vascular tone and renal function depend predominantly on =
the
activity of the renin-angiotensin-aldosterone system (e.g.&nbsp;patients wi=
th
severe congestive heart failure or underlying renal disease, including renal
artery stenosis), treatment with angiotensin<b style=3D'mso-bidi-font-weigh=
t:
normal'> </b>converting enzyme inhibitors or angiotensin-II receptor
antagonists that affect this system has been associated with acute hypotens=
ion,
azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As wi=
th
any antihypertensive agent, excessive blood pressure decrease in patients w=
ith
ischaemic cardiopathy or ischaemic cardiovascular disease could result in a
myocardial infarction or stroke.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As observed for angiotensin conv=
erting
enzyme inhibitors, irbesartan and the other angiotensin antagonists are
apparently less effective in lowering blood pressure in black people than in
non-blacks, possibly because of higher prevalence of low-renin states in the
black hypertensive population (see section&nbsp;5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Pregnancy:</span></u><span
lang=3DEN-GB> angiotensin&nbsp;II Receptor Antagonists (AIIRAs) should not =
be
initiated during pregnancy. </span><span lang=3DEN-GB style=3D'mso-bidi-fon=
t-size:
11.0pt'>Unless continued AIIRA therapy is considered essential, patients pl=
anning
pregnancy should be changed to alternative antihypertensive treatments which
have an established safety profile for use in pregnancy. When pregnancy is
diagnosed, treatment with </span><span lang=3DEN-GB>AIIRAs</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> should be stopped immedia=
tely,
and, if appropriate, alternative therapy should be started (see sections&nb=
sp;4.3
and&nbsp;4.6).<o:p></o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Paediatric population</span><=
/u><span
lang=3DEN-GB>: irbesartan has been studied in paediatric populations <span
style=3D'mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>aged 6 to 16=
 years
old</span> but the current data are insufficient to support an extension of=
 the
use in children until further data become available (see sections&nbsp;4.8,=
 5.1
and&nbsp;5.2).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><u><span lang=3DEN-GB>Excipients</span></u><span lang=
=3DFR
style=3D'mso-ansi-language:FR'>:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300 mg film-coated tablet contains lactose. Patients wit=
h rare
hereditary problems of galactose intolerance, total lactase deficiency or
glucose-galactose malabsorption should not take this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300 mg film-coated tablet contains sodium. This medicine
contains less than 1 mmol sodium (23 mg) per tablet, that is to say essenti=
ally
sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
5<span
style=3D'mso-tab-count:1'> </span>Interaction with other medicinal prod=
ucts
and other forms of interaction</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Diuretics and other antihyper=
tensive
agents</span></u><span lang=3DEN-GB>: other antihypertensive agents may inc=
rease
the hypotensive effects of irbesartan; however <span class=3DSpellE>Karvea<=
/span>
has been safely administered with other antihypertensive agents, such as
beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Prior treatment with high dose diuretics may result in volume depletion and=
 a
risk of hypotension when initiating therapy with <span class=3DSpellE>Karve=
a</span>
(see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><u><span lang=3DEN-GB>Aliskire=
n</span></u></span><u><span
lang=3DEN-GB>-containing products or ACE-inhibitors</span></u><span lang=3D=
EN-GB>: clinical
trial data has shown that dual blockade of the renin-angiotensin-aldosterone
system (RAAS) through the combined use of ACE-inhibitors, angiotensin II
receptor blockers or <span class=3DSpellE>aliskiren</span> is associated wi=
th a
higher frequency of adverse events such as hypotension, hyperkalaemia and
decreased renal function (including acute renal failure) compared to the us=
e of
a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Potassium supplements and
potassium-sparing diuretics</span></u><span lang=3DEN-GB>:<i style=3D'mso-b=
idi-font-style:
normal'> </i>based on experience with the use of other medicinal products t=
hat
affect the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or =
other
medicinal products that may increase serum potassium levels (e.g.&nbsp;hepa=
rin)
may lead to increases in serum potassium and is, therefore, not recommended
(see section&nbsp;4.4).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Lithium</span></u><span lang=
=3DEN-GB>:<i
style=3D'mso-bidi-font-style:normal'> </i>reversible increases in serum lit=
hium
concentrations and toxicity have been reported during concomitant
administration of lithium with angiotensin converting enzyme inhibitors.
Similar effects have been very rarely reported with irbesartan so far.
Therefore, this combination is not recommended (see section&nbsp;4.4). If t=
he
combination proves necessary, careful monitoring of serum lithium levels is
recommended.</span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></i></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Non-steroidal anti-inflammato=
ry drugs</span></u><span
lang=3DEN-GB>: <span style=3D'color:black'>when angiotensin&nbsp;II antagon=
ists are
administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.
selective COX-2 inhibitors, acetylsalicylic acid (&gt;&nbsp;3&nbsp;g/day) a=
nd
non-selective NSAIDs), attenuation of the antihypertensive effect may occur=
.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'color:black'><o:p>&nbsp=
;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'color:black'>As with AC=
E inhibitors,
concomitant use of angiotensin&nbsp;II antagonists and NSAIDs may lead to an
increased risk of worsening of renal function, including possible acute ren=
al
failure, and an increase in serum potassium, especially in patients with po=
or
pre-existing renal function. The combination should be administered with
caution, especially in the elderly. Patients should be adequately hydrated =
and
consideration should be given to monitoring renal function after initiation=
 of
concomitant therapy, and periodically thereafter.<b style=3D'mso-bidi-font-=
weight:
normal'><i style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></b></span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Repaglinide:</span></u><span
lang=3DEN-GB style=3D'color:black'> irbesartan has the potential to inhibit=
 OATP1B1.
In a clinical study, it was reported that irbesartan increased the <span
class=3DSpellE>C<sub>max</sub></span> and AUC of repaglinide (substrate of
OATP1B1) by 1.8-fold and 1.3&#8209;fold, respectively, when administered 1 =
hour
before repaglinide. In another study, no relevant pharmacokinetic interacti=
on was
reported, when the two drugs were co-administered. Therefore, dose adjustme=
nt of
antidiabetic treatment such as repaglinide may be required (see section 4.4=
).<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Additional information on irb=
esartan
interactions</span></u><span lang=3DEN-GB>: <span style=3D'color:black'>in =
clinical
studies, the pharmacokinetic of irbesartan is not affected by hydrochloroth=
iazide.
Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucur=
onidation.
No significant pharmacokinetic or pharmacodynamic interactions were observe=
d when
irbesartan was <span class=3DSpellE>coadministered</span> with warfarin, a
medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers suc=
h as
rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The
pharmacokinetic of digoxin was not altered by coadministration of irbesarta=
n.<o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
6<span
style=3D'mso-tab-count:1'> </span>Fertility, pregnancy and lactation</s=
pan></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Pregnancy</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEABodyText style=3D'border:none;mso-border-alt:solid windowtex=
t .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><span lang=3DEN-GB>The=
 use
of AIIRAs is not recommended during the first trimester of pregnancy (see s=
ection&nbsp;4.4).
The use of AIIRAs is contraindicated during the second and third trimesters=
 of pregnancy
(see sections&nbsp;4.3 and&nbsp;4.4).</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Epidemiological evidence regardi=
ng the
risk of teratogenicity following exposure to ACE inhibitors during the first
trimester of pregnancy has not been conclusive; however a small increase in=
 risk
cannot be excluded. Whilst there is no controlled epidemiological data on t=
he
risk with Angiotensin&nbsp;II Receptor Antagonists (AIIRAs), similar risks =
may
exist for this class of drugs. Unless continued AIIRA therapy is considered
essential, patients planning pregnancy should be changed to alternative
antihypertensive treatments which have an established safety profile for us=
e in
pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be sto=
pped
immediately, and, if appropriate, alternative therapy should be started.</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Exposure to AIIRA therapy during=
 the
second and third trimesters is known to induce human <span class=3DSpellE>f=
oetotoxicity</span>
(decreased renal function, oligohydramnios, skull ossification retardation)=
 and
neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section=
&nbsp;5.3).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Should exposure to AIIRAs have o=
ccurred
from the second trimester of pregnancy, ultrasound check of renal function =
and
skull is recommended.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Infants whose mothers have taken=
 AIIRAs
should be closely observed for hypotension (see sections&nbsp;4.3 and&nbsp;=
4.4).</span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Breast-feeding</span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Because no information is availa=
ble
regarding the use of <span class=3DSpellE>Karvea</span> during breast-feedi=
ng, <span
class=3DSpellE>Karvea</span> is not recommended and alternative treatments =
with
better established safety profiles during breast-feeding are preferable,
especially while nursing a <span class=3DSpellE>newborn</span> or preterm i=
nfant.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>It is unknown whether irbesartan=
 or its
metabolites are excreted in human milk. </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Available pharmacodynamic/toxico=
logical
data in rats have shown excretion of irbesartan or its metabolites in milk =
(for
details see 5.3).</span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Fertility</span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>Irbesartan =
had no
effect upon fertility of treated rats and their offspring up to the dose le=
vels
inducing the first signs of parental toxicity (see section 5.3). <o:p></o:p=
></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>4.7<span style=3D'mso-tab-count:=
1'> </span>Effects
on ability to drive and use machines</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Based on
its pharmacodynamic properties, irbesartan is unlikely to affect the abilit=
y to
drive and use machines. When driving vehicles or operating machines, it sho=
uld
be taken into account that dizziness or weariness may occur during treatmen=
t.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
8<span
style=3D'mso-tab-count:1'> </span>Undesirable effects</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In placebo-controlled trials in =
patients
with hypertension, the overall incidence of adverse events did not differ
between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuat=
ion
due to any clinical or laboratory adverse event was less frequent for irbes=
artan-treated
patients (3.3%) than for placebo-treated patients (4.5%). The incidence of
adverse events was not related to dose (in the recommended dose range), gen=
der,
age, race, or duration of treatment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In diabetic hypertensive patient=
s with
microalbuminuria and normal renal function, orthostatic dizziness and
orthostatic hypotension were reported in 0.5% of the patients (i.e.,&nbsp;u=
ncommon)
but in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The following table presents the=
 adverse
drug reactions that were reported in placebo-controlled trials in which
1,965&nbsp;hypertensive patients received irbesartan. Terms marked with a s=
tar
(*) refer to the adverse reactions that were additionally reported in &gt; =
2%
of diabetic hypertensive patients with chronic renal insufficiency and over=
t proteinuria
and in excess of placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of adverse reactio=
ns
listed below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>very common (&#8805;&nbsp;1/10);=
 common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very r=
are
(&lt;&nbsp;1/10,000). Within each frequency grouping, undesirable effects a=
re
presented in order of decreasing seriousness.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Adverse reactions additionally r=
eported
from postmarketing experience are also listed. <span style=3D'mso-bidi-fon=
t-style:
italic'>These adverse reactions are derived from spontaneous reports.<o:p><=
/o:p></span></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p></=
span></i></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Blood and lymphatic system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>anaemia, thrombocytopenia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Immune system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hypersensitivity reactions such as angioedema, rash, urtic=
aria,
anaphylactic reaction, anaphylactic shock<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Metabolism and nutrition disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:55.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
2'> </span>hyperkalaemia, hypoglycaemia</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Nervous system disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>dizzine=
ss,
orthostatic dizziness*</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Not known:<span style=3D'mso-tab-count:1'> </span>vertig=
o,
headache</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Ear and labyrinth disorder<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>tinnitus</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Cardiac disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>tachycar=
dia</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Vascular disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;tab-stops:31.5pt .5=
in 1.0in'><span
lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'> </span>orthost=
atic
hypotension*</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>flushing<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><u><span lang=3DEN-GB=
><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Respiratory, thoracic and mediastinal disorders<o:p></o:p></sp=
an></u></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1;tab-stops:.5in 1.0in'>=
<span
lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:1'> </span>cough</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Gastrointestinal disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>nausea/vomiting</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>U=
ncommon:<span
style=3D'mso-tab-count:1'> </span>diarrhoea, dyspepsia/heartburn</span=
></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>N=
ot known:<span
style=3D'mso-tab-count:1'> </span>dysgeusia</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB><=
o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Hepatobiliary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>jaundice</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab-count=
:1'> </span>hepatitis,
abnormal liver function<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Skin and subcutaneous tissue disorders<o:p></o:p></span></u></=
p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:44.0pt 71.5pt'><span lang=3DEN-GB>Not known:<span style=3D'mso-ta=
b-count:
1'> </span><span class=3DSpellE>leukocytoclastic</span> vasculitis</s=
pan></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Musculoskeletal and connective tissue disorders <o:p></o:p></s=
pan></u></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB>C=
ommon:<span
style=3D'mso-tab-count:1'> </span>musculoskeletal pain*</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;mso-o=
utline-level:
1;tab-stops:.5in 1.0in'><span lang=3DEN-GB>Not known:<span style=3D'mso-tab=
-count:
1'> </span>arthralgia, myalgia (in some cases associated with increas=
ed
plasma creatine kinase levels), muscle cramps</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Renal and urinary disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;page-=
break-after:
avoid;mso-outline-level:1;tab-stops:71.5pt'><span lang=3DEN-GB>Not known:<s=
pan
style=3D'mso-tab-count:1'> </span><span style=3D'mso-tab-count:1'> </=
span>impaired
renal function including cases of renal failure in patients at risk (see
section&nbsp;4.4)</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:.5in 1.0in'><span lang=3DEN-GB><=
o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'text-align:justify;page-break-after:avoid;
mso-outline-level:1'><u><span lang=3DEN-GB>Reproductive system and breast
disorders<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB>Uncomm=
on:<span
style=3D'mso-tab-count:1'> </span>sexual dysfunction</span></p>

<p class=3DEMEABodyText style=3D'text-align:justify;mso-outline-level:1;tab=
-stops:
1.0in'><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>General disorders and administration site conditions<o:p></o:p=
></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-coun=
t:1'> </span>fatigue</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:71.5pt'><span lang=3DEN-GB>Uncommon:<span style=3D'mso-tab-count:=
1'> </span>chest
pain<u><o:p></o:p></u></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Investigations<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Very common:<span style=3D'mso-tab-count:1'>=
 </span>Hyperkalaemia*
occurred more often in diabetic patients treated with irbesartan than with
placebo. In diabetic hypertensive patients with microalbuminuria and normal
renal function, hyperkalaemia (&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>m=
Eq</span>/L)
occurred in 29.4% of the patients in the irbesartan 300&nbsp;mg group and 2=
2%
of the patients in the placebo group. In diabetic hypertensive patients with
chronic renal insufficiency and overt proteinuria, hyperkalaemia
(&#8805;&nbsp;5.5&nbsp;<span class=3DSpellE>mEq</span>/L) occurred in 46.3%=
 of
the patients in the irbesartan group and 26.3% of the patients in the place=
bo
group.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-1.0in;tab-s=
tops:
.5in 1.0in'><span lang=3DEN-GB>Common:<span style=3D'mso-tab-count:1'>=
 </span>significant
increases in plasma creatine kinase were commonly observed (1.7%) in irbesa=
rtan
treated subjects. None of these increases were associated with identifiable
clinical musculoskeletal events.<br>
In 1.7% of hypertensive patients with advanced diabetic renal disease treat=
ed
with irbesartan, a decrease in haemoglobin*, which was not clinically
significant, has been observed.</span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><i style=3D'mso-bidi-=
font-style:
normal'><u><span lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nb=
sp;</span></o:p></span></u></i></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB style=3D'mso-bidi-font-weight=
:bold'>Paediatric
population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-bidi-font-weight:bo=
ld'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-bidi-font-weight:bo=
ld'>I</span><span
lang=3DEN-GB>n a randomised trial of 318&nbsp;hypertensive children and
adolescents aged 6 to 16&nbsp;years, the following adverse reactions occurr=
ed
in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%),
dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this tr=
ial
the most frequent laboratory abnormalities observed were creatinine increas=
es
(6.5%) and elevated CK values in 2% of child recipients.</span></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB><o:p>&=
nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of suspected adverse
reactions <o:p></o:p></span></u></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB><o:p><span style=3D'text-deco=
ration:
 none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Reporting suspected adverse reac=
tions
after authorisation of the medicinal product is important. It allows contin=
ued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in Appendix V.</span> </span></p>

<p class=3DEMEABodyText style=3D'tab-stops:1.0in'><span lang=3DEN-GB><o:p>&=
nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>4.=
9<span
style=3D'mso-tab-count:1'> </span>Overdose</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Experience
in adults exposed to doses of up to 900&nbsp;mg/day for 8&nbsp;weeks reveal=
ed
no toxicity. The most likely manifestations of overdose are expected to be =
hypotension
and tachycardia; bradycardia might also occur from overdose. No specific
information is available on the treatment of overdose with <span class=3DSp=
ellE>Karvea</span>.
The patient should be closely monitored, and the treatment should be
symptomatic and supportive. Suggested measures include induction of emesis
and/or gastric lavage. Activated charcoal may be useful in the treatment of
overdose. Irbesartan is not removed by haemodialysis.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>PHARMACOLOGICAL
PROPERTIES</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
1<span
style=3D'mso-tab-count:1'> </span>Pharmacodynamic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Pharmacotherapeutic group:
Angiotensin-II antagonists, plain.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ATC&nbsp;code: C09C&nbsp;A04.</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Mechanism of action</span></u=
><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB> <o:p></o:p></span=
></b></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan is a potent, orally a=
ctive,
selective angiotensin-II receptor (type AT<sub>1</sub>) antagonist. It is
expected to block all actions of angiotensin-II mediated by the AT<sub>1</s=
ub>
receptor, regardless of the source or route of synthesis of angiotensin-II.=
 The
selective antagonism of the angiotensin-II (AT<sub>1</sub>) receptors resul=
ts
in increases in plasma renin levels and angiotensin-II levels, and a decrea=
se
in plasma aldosterone concentration. Serum potassium levels are not
significantly affected by irbesartan alone at the recommended doses. Irbesa=
rtan
does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II
and also degrades bradykinin into inactive metabolites. Irbesartan does not
require metabolic activation for its activity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><u><span lang=3DEN-GB style=3D'font-weight:normal'>=
Clinical
efficacy</span></u></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension<o:p></=
o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan lowers blood pressure=
 with
minimal change in heart rate. The decrease in blood pressure is dose-related
for once a day doses with a tendency towards plateau at doses above
300&nbsp;mg. Doses of 150-300&nbsp;mg once daily lower supine or seated blo=
od
pressures at trough (i.e.&nbsp;24&nbsp;hours after dosing) by an average of=
 8-13/5-8&nbsp;mm&nbsp;Hg
(systolic/diastolic) greater than those associated with placebo.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Peak reduction of blood pressure=
 is
achieved within 3-6&nbsp;hours after administration and the blood pressure
lowering effect is maintained for at least 24&nbsp;hours. At 24&nbsp;hours =
the
reduction of blood pressure was 60-70% of the corresponding peak diastolic =
and
systolic responses at the recommended doses. Once daily dosing with 150&nbs=
p;mg
produced trough and mean 24&nbsp;hour responses similar to twice daily dosi=
ng
on the same total dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
ct of <span
class=3DSpellE>Karvea</span> is evident within 1-2&nbsp;weeks, with the max=
imal
effect occurring by 4-6&nbsp;weeks after start of therapy. The antihyperten=
sive
effects are maintained during long term therapy. After withdrawal of therap=
y, blood
pressure gradually returns toward baseline. Rebound hypertension has not be=
en observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The blood pressure lowering effe=
cts of
irbesartan and thiazide-type diuretics are additive. In patients not adequa=
tely
controlled by irbesartan alone, the addition of a low dose of hydrochloroth=
iazide
(12.5&nbsp;mg) to irbesartan once daily results in a further placebo-adjust=
ed
blood pressure reduction at trough of 7-10/3-6&nbsp;mm&nbsp;Hg
(systolic/diastolic).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The efficacy of <span class=3DSp=
ellE>Karvea</span>
is not influenced by age or gender. As is the case with other medicinal pro=
ducts
that affect the renin-angiotensin system, black hypertensive patients have
notably less response to irbesartan monotherapy. When irbesartan is
administered concomitantly with a low dose of hydrochlorothiazide
(e.g.&nbsp;12.5&nbsp;mg daily), the antihypertensive response in black pati=
ents
approaches that of white patients.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There is no clinically important=
 effect
on serum uric acid or urinary uric acid secretion.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Paediatric population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Reduction of blood pressure with
0.5&nbsp;mg/kg (low), 1.5&nbsp;mg/kg (medium) and 4.5&nbsp;mg/kg (high) tar=
get
titrated doses of irbesartan was evaluated in 318&nbsp;hypertensive or at r=
isk (diabetic,
family history of hypertension) children and adolescents aged 6 to
16&nbsp;years over a three week period. At the end of the three weeks the m=
ean
reduction from baseline in the primary efficacy variable, trough seated sys=
tolic
blood pressure (<span class=3DSpellE>SeSBP</span>) was 11.7&nbsp;mmHg (low =
dose),
9.3&nbsp;mmHg (medium dose), 13.2&nbsp;mmHg (high dose). No significant
difference was apparent between these doses. Adjusted mean change of trough=
 seated
diastolic blood pressure (<span class=3DSpellE>SeDBP</span>) was as follows:
3.8&nbsp;mmHg (low dose), 3.2&nbsp;mmHg (medium dose), 5.6&nbsp;mmHg (high
dose). Over a subsequent two week period where patients were re-randomized =
to
either active medicinal product or placebo, patients on placebo had increas=
es
of 2.4 and 2.0&nbsp;mmHg in <span class=3DSpellE>SeSBP</span> and <span
class=3DSpellE>SeDBP</span> compared to +0.1 and -0.3&nbsp;mmHg changes res=
pectively
in those on all doses of irbesartan (see section&nbsp;4.2).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB>Hypertension and
type&nbsp;2 diabetes with renal disease<o:p></o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The Irbesartan Diabetic Nephrop=
athy
Trial (IDNT) shows that irbesartan decreases the progression of renal dise=
ase
in patients with chronic renal insufficiency and overt proteinuria. IDNT wa=
s a
double blind, controlled, morbidity and mortality trial comparing <span
class=3DSpellE>Karvea</span>, amlodipine and placebo. In 1,715&nbsp;hyperte=
nsive
patients with type&nbsp;2 diabetes, proteinuria &#8805;&nbsp;900&nbsp;mg/day
and serum creatinine ranging from 1.0-3.0&nbsp;mg/dl, the long-term effects
(mean&nbsp;2.6&nbsp;years) of <span class=3DSpellE>Karvea</span> on the
progression of renal disease and all-cause mortality were examined. Patient=
s were
titrated from 75&nbsp;mg to a maintenance dose of 300&nbsp;mg <span
class=3DSpellE>Karvea</span></span><span lang=3DEN-GB style=3D'font-family:=
"Times",serif;
mso-bidi-font-family:"Times New Roman"'>, from 2.5&nbsp;mg to 10&nbsp;mg
amlodipine, or placebo</span><span lang=3DEN-GB> as tolerated. Patients in =
all
treatment groups typically received between&nbsp;2 and 4&nbsp;antihypertens=
ive
agents (e.g., diuretics, beta&nbsp;blockers, alpha&nbsp;blockers) to reach a
predefined blood pressure goal of &#8804;&nbsp;135/85&nbsp;mmHg or a
10&nbsp;mmHg reduction in systolic pressure if baseline was
&gt;&nbsp;160&nbsp;mmHg. Sixty per cent (60%) of patients in the placebo gr=
oup
reached this target blood pressure whereas this figure was 76% and 78% in t=
he
irbesartan and amlodipine groups respectively. Irbesartan significantly red=
uced
the relative risk in the primary combined endpoint of doubling serum
creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Approximately 33% of patients in the irbesartan group reached the primary r=
enal
composite endpoint compared to 39% and 41% in the placebo and amlodipine gr=
oups
[20% relative risk reduction versus placebo (p&nbsp;=3D&nbsp;0.024) and 23%
relative risk reduction compared to amlodipine (p&nbsp;=3D&nbsp;0.006)]. Wh=
en the
individual components of the primary endpoint were analysed, no effect in <=
span
class=3DSpellE>all cause</span> mortality was observed, while a positive tr=
end in
the reduction in ESRD and a significant reduction in doubling of serum
creatinine were observed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'>Subgroups consisting of gender, race, age, duration =
of
diabetes, baseline blood pressure, serum creatinine, and albumin excretion =
rate
were assessed for treatment effect. In the female and black subgroups which
represented 32% and 26% of the overall study population respectively, a ren=
al
benefit was not evident, </span><span style=3D'mso-ansi-language:EN-US'>alt=
hough
the confidence intervals do not exclude it. As for the secondary endpoint of
fatal and non-fatal cardiovascular events, there was no difference among the
three groups in the overall population, although an increased incidence of
non-fatal MI was seen for women and a decreased incidence of non-fatal MI w=
as
seen in males in the irbesartan group versus the placebo-based regimen. An
increased incidence of non-fatal MI and stroke was seen in females in the
irbesartan-based regimen versus the amlodipine-based regimen, while
hospitalization due to heart failure was reduced in the overall population.
However, no proper explanation for these findings in women has been identif=
ied.</span><span
lang=3DEN-GB style=3D'mso-fareast-language:ES;layout-grid-mode:line'><o:p><=
/o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:ES;
layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The study of the Effects of Irb=
esartan
on Microalbuminuria in Hypertensive Patients with type&nbsp;2 Diabetes Mell=
itus
(IRMA&nbsp;2) shows that irbesartan 300&nbsp;mg delays progression to overt
proteinuria in patients with microalbuminuria. IRMA&nbsp;2 was a
placebo-controlled double blind morbidity study in 590&nbsp;patients with t=
ype&nbsp;2
diabetes, microalbuminuria (30-300&nbsp;mg/day) and normal renal function
(serum creatinine&nbsp;&#8804;&nbsp;1.5&nbsp;mg/dl in males and
&lt;&nbsp;1.1&nbsp;mg/dl in females). The study examined the long-term effe=
cts
(2&nbsp;years) of <span class=3DSpellE>Karvea</span> on the progression to
clinical (overt) proteinuria (urinary albumin excretion rate (UAER)
&gt;&nbsp;300&nbsp;mg/day, and an increase in UAER of at least 30% from
baseline). The predefined blood pressure goal was
&#8804;&nbsp;135/85&nbsp;mmHg. Additional antihypertensive agents (excluding
ACE inhibitors, angiotensin&nbsp;II receptor antagonists and dihydropyridine
calcium blockers) were added as needed to help achieve the blood pressure g=
oal.
While similar blood pressure was achieved in all treatment groups, fewer
subjects in the irbesartan 300&nbsp;mg group (5.2%) than in the placebo (14=
.9%)
or in the irbesartan 150&nbsp;mg group (9.7%) reached the endpoint of overt
proteinuria, demonstrating a 70% relative risk reduction versus placebo
(p&nbsp;=3D&nbsp;0.0004) for the higher dose. An accompanying improvement i=
n the
glomerular filtration rate (GFR) was not observed during the first three mo=
nths
of treatment. The slowing in the progression to clinical proteinuria was
evident as early as three months and continued over the 2&nbsp;year period.
Regression to <span class=3DSpellE>normoalbuminuria</span>
(&lt;&nbsp;30&nbsp;mg/day) was more frequent in the <span class=3DSpellE>Ka=
rvea</span>&nbsp;300&nbsp;mg
group (34%) than in the placebo group (21%).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><i style=3D'mso-bidi-font-style:normal'><span lang=
=3DEN-GB>Dual
blockade of the renin-angiotensin-aldosterone system (RAAS)<o:p></o:p></spa=
n></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Two large randomised, controlled=
 trials
(ONTARGET (<span class=3DSpellE>ONgoing</span> Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Vete=
rans
Affairs Nephropathy in Diabetes)) have examined the use of the combination =
of
an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a st=
udy
conducted in patients with a history of cardiovascular or cerebrovascular
disease, or type 2 diabetes mellitus accompanied by evidence of end-organ
damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus =
and
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>These studies have shown no sign=
ificant
beneficial effect on renal and/or cardiovascular outcomes and mortality, wh=
ile
an increased risk of hyperkalaemia, acute kidney injury and/or hypotension =
as
compared to monotherapy was observed. Given their similar pharmacodynamic
properties, these results are also relevant for other ACE-inhibitors and an=
giotensin
II receptor blockers.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ACE-inhibitors and angiotensin II
receptor blockers should therefore not be used concomitantly in patients wi=
th
diabetic nephropathy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>ALTITUDE (<span class=3DSpellE>A=
liskiren</span>
Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) =
was
a study designed to test the benefit of adding <span class=3DSpellE>aliskir=
en</span>
to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blo=
cker
in patients with type 2 diabetes mellitus and chronic kidney disease,
cardiovascular disease, or both. The study was terminated early because of =
an
increased risk of adverse outcomes. Cardiovascular death and stroke were bo=
th
numerically more frequent in the <span class=3DSpellE>aliskiren</span> grou=
p than
in the placebo group and adverse events and serious adverse events of inter=
est
(hyperkalaemia, hypotension and renal dysfunction) were more frequently
reported in the <span class=3DSpellE>aliskiren</span> group than in the pla=
cebo
group.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
2<span
style=3D'mso-tab-count:1'> </span>Pharmacokinetic properties</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Absorption<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>After
oral administration, irbesartan is well absorbed: studies of absolute
bioavailability gave values of approximately 60-80%. Concomitant food intake
does not significantly influence the bioavailability of irbesartan. </span>=
</p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Distribution<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Plasma
protein binding is approximately 96%, with negligible binding to cellular b=
lood
components. The volume of distribution is 53&nbsp;-&nbsp;93&nbsp;litres. </=
span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><u><span lang=3DEN=
-GB>Biotransformation<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Following
oral or intravenous administration of <sup><span style=3D'position:relative;
top:-1.0pt;mso-text-raise:1.0pt'>14</span></sup>C irbesartan, 80-85% of the
circulating plasma radioactivity is attributable to unchanged irbesartan.
Irbesartan is metabolised by the liver via glucuronide conjugation and
oxidation. The major circulating metabolite is irbesartan glucuronide
(approximately 6%). <i style=3D'mso-bidi-font-style:normal'>In&nbsp;vitro</=
i>
studies indicate that irbesartan is primarily oxidised by the
cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.=
</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><u><span lang=3DEN-GB>Linarity=
</span></u></span><u><span
lang=3DEN-GB> / non-linearity<o:p></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan exhibits linear and d=
ose
proportional pharmacokinetics over the dose range of 10&nbsp;to 600&nbsp;mg=
. A
less than proportional increase in oral absorption at doses beyond 600&nbsp=
;mg
(twice the maximal recommended dose) was observed; the mechanism for this is
unknown. Peak plasma concentrations are attained at
1.5&nbsp;-&nbsp;2&nbsp;hours after oral administration. The total body and
renal clearance are 157&nbsp;-&nbsp;176&nbsp;and 3&nbsp;-&nbsp;3.5&nbsp;ml/=
min,
respectively. The terminal elimination half-life of irbesartan is
11&nbsp;-&nbsp;15&nbsp;hours. Steady-state plasma concentrations are attain=
ed
within 3&nbsp;days after initiation of a once-daily dosing regimen. Limited
accumulation of irbesartan (&lt;&nbsp;20%) is observed in plasma upon repea=
ted
once-daily dosing. In a study, somewhat higher plasma concentrations of
irbesartan were observed in female hypertensive patients. However, there wa=
s no
difference in the half-life and accumulation of irbesartan. No dosage
adjustment is necessary in female patients. Irbesartan AUC and <span
class=3DSpellE>C<span class=3DEMEASubscript>max</span></span> values were a=
lso
somewhat greater in older subjects (&#8805;&nbsp;65&nbsp;years) than those =
of
young subjects (18&nbsp;-&nbsp;40&nbsp;years). However the terminal half-li=
fe
was not significantly altered. No dosage adjustment is necessary in older
people.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Elimination<o:p></o:p></span>=
</u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Irbesartan and its metabolites a=
re
eliminated by both biliary and renal pathways. After either oral or IV
administration of <sup><span style=3D'position:relative;top:-1.0pt;mso-text=
-raise:
1.0pt'>14</span></sup>C irbesartan, about 20% of the radioactivity is recov=
ered
in the urine, and the remainder in the faeces. Less than 2% of the dose is
excreted in the urine as unchanged irbesartan.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB>Paediatric population<o:p></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid;mso-outline-level:1=
'><u><span
lang=3DEN-GB><o:p><span style=3D'text-decoration:none'>&nbsp;</span></o:p><=
/span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The pharmacokinetics of irbesart=
an were
evaluated in 23&nbsp;hypertensive children after the administration of sing=
le
and multiple daily doses of irbesartan (2&nbsp;mg/kg) up to a maximum daily
dose of 150&nbsp;mg for four weeks. Of those 23 children, 21 were evaluable=
 for
comparison of pharmacokinetics with adults (twelve children over 12&nbsp;ye=
ars,
nine children between 6 and 12 years). Results showed that <span class=3DSp=
ellE>C<span
class=3DEMEASubscript>max</span></span>, AUC and clearance rates were compa=
rable
to those observed in adult patients receiving 150&nbsp;mg irbesartan daily.=
 A
limited accumulation of irbesartan (18%) in plasma was observed upon repeat=
ed
once daily dosing.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Renal impairment</span></u></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with renal impairmen=
t or
those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan
are not significantly altered. Irbesartan is not removed by haemodialysis.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Hepatic impairment</span></u>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>In patients with mild to moderate
cirrhosis, the pharmacokinetic parameters of irbesartan are not significant=
ly
altered. </span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Studies have not been performed =
in
patients with severe hepatic impairment.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>5.=
3<i
style=3D'mso-bidi-font-style:normal'><span style=3D'mso-tab-count:1'> <=
/span></i>Preclinical
safety data</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>There was
no evidence of abnormal systemic or target organ toxicity at clinically
relevant doses. In non-clinical safety studies, high doses of irbesartan
(&#8805;&nbsp;250&nbsp;mg/kg/day in rats and &#8805;&nbsp;100&nbsp;mg/kg/da=
y in
macaques) caused a reduction of red blood cell parameters (erythrocytes,
haemoglobin, haematocrit). At very high doses (&#8805;&nbsp;500&nbsp;mg/kg/=
day)
degenerative changes in the kidney (such as interstitial nephritis, tubular
distension, basophilic tubules, increased plasma concentrations of urea and
creatinine) were induced by irbesartan in the rat and the macaque and are
considered secondary to the hypotensive effects of the medicinal product wh=
ich
led to decreased renal perfusion. Furthermore, irbesartan induced
hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &#8805;&nb=
sp;90&nbsp;mg/kg/day,
in macaques at &#8805;&nbsp;10&nbsp;mg/kg/day). All of these changes were
considered to be caused by the pharmacological action of irbesartan. For
therapeutic doses of irbesartan in humans, the hyperplasia/ hypertrophy of =
the
renal juxtaglomerular cells does not appear to have any relevance.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>There was no evidence of mutagen=
icity, <span
class=3DSpellE>clastogenicity</span> or carcinogenicity.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Fertility and reproductive perfo=
rmance
were not affected in studies of male and female rats even at oral doses of
irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), inclu=
ding
mortality at the highest dose. No significant effects on the number of corp=
ora
lutea, implants, or live foetuses were observed. Irbesartan did not affect
survival, development, or reproduction of offspring. Studies in animals
indicate that the radiolabelled irbesartan is detected in rat and rabbit fo=
etuses.
Irbesartan is excreted in the milk of lactating rats.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Animal studies with irbesartan s=
howed
transient toxic effects (increased renal pelvic cavitation, hydroureter or
subcutaneous oedema) in rat foetuses, which were resolved after birth. In
rabbits, abortion or early resorption were noted at doses causing significa=
nt
maternal toxicity, including mortality. No teratogenic effects were observe=
d in
the rat or rabbit.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
PARTICULARS</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
1<span
style=3D'mso-tab-count:1'> </span>List of excipients</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Tablet
core:</span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Lact=
ose
monohydrate<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Micr=
ocrystalline
cellulose<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Cros=
carmellose
sodium<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Hypr=
omellose<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Sili=
con
dioxide<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Magn=
esium
stearate.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Film=
-coating:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Lact=
ose
monohydrate<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Hypr=
omellose<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Tita=
nium
dioxide<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Macr=
ogol 3000<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Carn=
auba wax.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
2<span
style=3D'mso-tab-count:1'> </span>Incompatibilities</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Not applicable.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
3<span
style=3D'mso-tab-count:1'> </span>Shelf life</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>3&nbsp;years.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
4<span
style=3D'mso-tab-count:1'> </span>Special precautions for storage</span=
></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not store above 30C.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'margin-left:0in;text-indent:0in;mso-outlin=
e-level:
1'><span lang=3DEN-GB>6.5<span style=3D'mso-tab-count:1'> </span>Nature=
 and
contents of container</span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 14&nbsp;film-coated t=
ablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 28&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 30</span><span lang=
=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial;mso-fareast-l=
anguage:
DE;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'> film-coated table=
ts
in PVC/PVDC/Aluminium blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 56&nbsp;film-coated t=
ablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 84&nbsp;film-coated tablets in PVC/PVDC/Aluminium blisters.</spa=
n></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 90</span><span lang=
=3DEN-GB
style=3D'mso-fareast-language:DE'> film-coated tablets in PVC/PVDC/Aluminium
blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Cartons of 98&nbsp;film-coated t=
ablets
in PVC/PVDC/Aluminium blisters.<br>
Cartons of 56&nbsp;x&nbsp;1&nbsp;film-coated tablet in PVC/PVDC/Aluminium
perforated unit dose blisters.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'mso-outline-level:1'><span lang=3DEN-GB>No=
t all pack
sizes may be marketed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2 style=3D'mso-outline-level:1'><span lang=3DEN-GB>6.=
6<span
style=3D'mso-tab-count:1'> </span>Special precautions for disposal</spa=
n></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Any unused medicinal product or =
waste
material should be disposed of in accordance with local requirements.</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>7.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION HOLDER<o:p>=
</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'>8.<s=
pan
style=3D'mso-tab-count:1'> </span>MARKETING AUTHORISATION NUMBERS<o:p=
></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DSL style=3D'mso-ansi-language:SL'>EU/1=
/97/049/026-030<br>
EU/1/97/049/033<br>
EU/1/97/049/036<br>
EU/1/97/049/039<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>DATE
OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Date of first authorisation: 27 =
August
1997<br>
Date of latest renewal: 27 August 2007</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>10.<span style=3D'mso-tab-count:=
1'> </span>DATE
OF REVISION OF THE TEXT</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icinal
product is available on the website of the European Medicines Agency
http://www.ema.europa.eu</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'mso-special-character:line-break;page-break-before:always'>
</span>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB>ANNEX II</span></p>

<p class=3DEMEATitle><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle align=3Dleft style=3D'margin-left:85.0pt;text-align:le=
ft;
text-indent:-35.3pt'><span lang=3DEN-GB>A.<span style=3D'mso-tab-count:1'>=
 </span>MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=3DEMEATitle align=3Dleft style=3D'margin-left:85.0pt;text-align:le=
ft;
text-indent:-35.3pt'><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle align=3Dleft style=3D'margin-left:85.0pt;text-align:le=
ft;
text-indent:-35.3pt'><span lang=3DEN-GB>B.<span style=3D'mso-tab-count:1'>=
 </span>CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=3DEMEATitle align=3Dleft style=3D'margin-left:85.0pt;text-align:le=
ft;
text-indent:-35.3pt'><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle align=3Dleft style=3D'margin-left:85.0pt;text-align:le=
ft;
text-indent:-35.3pt'><span lang=3DEN-GB>C.<span style=3D'mso-tab-count:1'>=
 </span>OTHER
CONDITIONS <span style=3D'mso-no-proof:yes'>AND REQUIREMENTS </span>OF THE
MARKETING AUTHORISATION</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle align=3Dleft style=3D'margin-left:85.0pt;text-align:le=
ft;
text-indent:-35.3pt'><span lang=3DEN-GB>D.<span style=3D'mso-tab-count:1'>=
 </span>CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<p class=3DEMEAHeading1><span lang=3DEN-GB>A.<span style=3D'mso-tab-count:1=
'> </span>MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Name and address of the manuf=
acturers
responsible for batch release</span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>Sanof=
i Winthrop
Industrie<br>
1 rue de la Vierge<br>
<span class=3DSpellE>Ambars</span> &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex<br>
France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>Sanof=
i Winthrop
Industrie<br>
30-36 Avenue Gustave Eiffel, BP 7166<br>
F-37071 Tours Cedex 2<br>
France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span class=3DSpellE><span lang=3DFR style=3D'mso-an=
si-language:
FR'>Chinoin</span></span><span lang=3DFR style=3D'mso-ansi-language:FR'> <s=
pan
class=3DSpellE>Private</span> Co. Ltd.<br>
<span class=3DSpellE>Lvai</span> u.5.<br>
2112 <span class=3DSpellE>Veresegyhaz</span><br>
<span class=3DSpellE>Hungary</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>SANO=
FI-AVENTIS,
S.A.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Ctra=
. C-35 (La
Batlloria-Hostalric), km. 63.09<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>17404 <span class=3DSpellE>Riell=
s</span> <span
class=3DSpellE>i</span> <span class=3DSpellE>Viabrea</span> (Girona) - Spai=
n</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The printed package leaflet of t=
he
medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>B.<span style=3D'mso-tab-count:1=
'> </span>CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span><span lang=3DEN-GB
style=3D'font-weight:normal'> <o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Medicinal product subject to med=
ical
prescription.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt'>=
<b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>C.<span style=3D'm=
so-tab-count:
1'> </span>OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION</span></b></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:.25in;text-indent:-.25in;
mso-list:none;tab-stops:list .25in'><b style=3D'mso-bidi-font-weight:normal=
'><span
lang=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText style=3D'margin-left:64.35pt;text-indent:-64.35pt;
page-break-after:avoid;mso-list:l8 level1 lfo6;tab-stops:list 27.5pt'><![if=
 !supportLists]><span
lang=3DEN-GB style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso=
-bidi-font-family:
Symbol;color:black'><span style=3D'mso-list:Ignore'><span style=3D'font:7.=
0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;
</span></span></span><![endif]><b style=3D'mso-bidi-font-weight:normal'><sp=
an
lang=3DEN-GB>Periodic Safety Update Reports (PSURs)<i style=3D'mso-bidi-fon=
t-style:
normal'><span style=3D'color:red'><o:p></o:p></span></i></span></b></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;page-break-after:avoid=
'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB><o:p>&nbsp;</o:p><=
/span></b></p>

<p class=3DEMEABodyText><a name=3D"_Hlk37090071"><span style=3D'mso-bidi-fo=
nt-size:
11.0pt;font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewR=
omanPSMT;
color:black;mso-ansi-language:EN-US'>The requirements for submission o</spa=
n></a><span
style=3D'mso-bookmark:_Hlk37090071'><span style=3D'mso-bidi-font-size:11.0p=
t;
font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSM=
T;
mso-ansi-language:EN-US'>f PSURs</span></span><span style=3D'mso-bookmark:_=
Hlk37090071'></span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-style:italic'=
> for this
medicinal product are set out in the list of Union reference dates (EURD li=
st)
provided for under Article 107c(7) of Directive 2001/83</span><span lang=3D=
EN-GB>/EC</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-style:italic'=
> and any
subsequent updates published on the European medicines web-portal.</span><s=
pan
lang=3DEN-GB style=3D'mso-fareast-language:FR'><o:p></o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB style=3D'mso-fareast-language=
:FR'><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><b style=3D'mso-bidi-=
font-weight:
normal'><span lang=3DEN-GB>D.<span style=3D'mso-tab-count:1'> </span>C=
ONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT<o:p></o:p></span></b></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB style=3D'mso-bidi-font-size:1=
1.0pt;
mso-fareast-language:FR'><o:p><span style=3D'text-decoration:none'>&nbsp;</=
span></o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:64.35pt;text-indent:-64.35pt;
mso-list:l2 level1 lfo7;tab-stops:list 27.5pt'><a name=3D"_BPDC_LN_INS_1002=
"></a><![if !supportLists]><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fare=
ast-font-family:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-fareast-language:FR'><sp=
an
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style=3D'mso-bidi-font-weight:normal'><sp=
an
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt;mso-fareast-language:FR'>Ri=
sk
Management Plan (RMP)<i style=3D'mso-bidi-font-style:normal'><span
style=3D'color:red'><o:p></o:p></span></i></span></b></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><b style=3D'mso-bidi-=
font-weight:
normal'><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt;mso-fareast-l=
anguage:
FR'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0=
pt;
mso-fareast-language:FR'>Not applicable.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0=
pt;
mso-fareast-language:FR'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'mso-special-character:line-break;page-break-before:always'>
</span>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB>ANNEX III</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB>LABELLING AND PACKAGE LEAFLET</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'mso-special-character:line-break;page-break-before:always'>
</span>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB>A. LABELLING</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>PARTICULARS TO APPEAR ON THE OUT=
ER
PACKAGING </span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>OUTER CARTON</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span class=3DSpel=
lE><span
lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB>&nbsp;75&nbsp;mg tablet=
s</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Each
tablet contains: irbesartan 75&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>LIST
OF EXCIPIENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Excipients:
also contains lactose monohydrate. See leaflet for further information.</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>14&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>28&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>56&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>56&nbsp;x&nbsp;1&nbsp;tablets</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>98&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Oral use.
Read the package leaflet before use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>6.<span style=3D'mso-tab-count:1'> </span>SPECIAL WARNIN=
G THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN=
</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Keep out
of the sight and reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>7.<span style=3D'mso-tab-count:1=
'> </span>OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>8.<span style=3D'mso-tab-count:1=
'> </span>EXPIRY
DATE</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>EXP<i
style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Do not
store above 30C.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>10.<span style=3D'mso-tab-count:1'> </span>SPECIAL PRECAUT=
IONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>11.<span style=3D'mso-tab-count:=
1'> </span>NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris&nbsp;-&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>12.<span style=3D'mso-tab-count:=
1'> </span>MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>EU/1/97/049/010 - 14&nbsp;tablets<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/001 - 28&nbsp;<span class=3DSpellE=
>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/002 - 56&nbsp;<span class=3DSpellE=
>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/013 - 56&nbsp;x&nbsp;1&nbsp;<span
class=3DSpellE>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>EU/1/97/049/003 - 98&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>13.<span style=3D'mso-tab-count:=
1'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place><i style=3D'mso-bidi-font-style:normal'=
><span
lang=3DEN-GB><o:p></o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>14.<span style=3D'mso-tab-count:=
1'> </span>GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Medicinal
product subject to medical prescription.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>15.<span style=3D'mso-tab-count:=
1'> </span>INSTRUCTIONS
ON USE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>16.<span style=3D'mso-tab-count:=
1'> </span>Information
in Braille</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> 75&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>17.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER  2D BARCODE</span></b><i style=3D'mso-bid=
i-font-style:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p></o:p></span></i=
></p>

</div>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'>2D barco=
de
carrying the unique identifier included.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>18.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB style=3D'mso-no-pro=
of:yes'><o:p></o:p></span></i></p>

</div>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>PC: <o:p></o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>SN:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>NN:</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'>sano=
fi-aventis
groupe<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DFR style=3D'mso-ansi-language:FR'>3.<s=
pan
style=3D'mso-tab-count:1'> </span>EXPIRY DATE<o:p></o:p></span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'>EXP<i style=3D'mso-bidi-font-style:normal'><=
o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>Other</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB
style=3D'background:silver;mso-highlight:silver'>14&nbsp;-&nbsp;28&nbsp;-&n=
bsp;56&nbsp;-&nbsp;98&nbsp;tablets:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>56&nbsp;x&nbsp;1&nbsp;tablets:</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>PARTICULARS TO APPEAR ON THE OUT=
ER
PACKAGING </span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>OUTER CARTON</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span class=3DSpel=
lE><span
lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB>&nbsp;150&nbsp;mg table=
ts</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Each
tablet contains: irbesartan 150&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>LIST
OF EXCIPIENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Excipients:
also contains lactose monohydrate. See leaflet for further information.</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>14&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>28&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>56&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>56&nbsp;x&nbsp;1&nbsp;tablets</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>98&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Oral use.
Read the package leaflet before use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>6.<span style=3D'mso-tab-count:1'> </span>SPECIAL WARNIN=
G THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN=
</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Keep out
of the sight and reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>7.<span style=3D'mso-tab-count:1=
'> </span>OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>8.<span style=3D'mso-tab-count:1=
'> </span>EXPIRY
DATE</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>EXP<i
style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Do not
store above 30C.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>10.<span style=3D'mso-tab-count:1'> </span>SPECIAL PRECAUT=
IONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>11.<span style=3D'mso-tab-count:=
1'> </span>NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>12.<span style=3D'mso-tab-count:=
1'> </span>MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>EU/1/97/049/011 - 14&nbsp;tablets<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/004 - 28&nbsp;<span class=3DSpellE=
>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/005 - 56&nbsp;<span class=3DSpellE=
>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/014 - 56&nbsp;x&nbsp;1&nbsp;<span
class=3DSpellE>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>EU/1/97/049/006 - 98&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>13.<span style=3D'mso-tab-count:=
1'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place><i style=3D'mso-bidi-font-style:normal'=
><span
lang=3DEN-GB><o:p></o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>14.<span style=3D'mso-tab-count:=
1'> </span>GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Medicinal
product subject to medical prescription.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>15.<span style=3D'mso-tab-count:=
1'> </span>INSTRUCTIONS
ON USE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>16.<span style=3D'mso-tab-count:=
1'> </span>Information
in Braille</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> 150&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>17.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER  2D BARCODE</span></b><i style=3D'mso-bid=
i-font-style:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p></o:p></span></i=
></p>

</div>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'>2D barco=
de
carrying the unique identifier included.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>18.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB style=3D'mso-no-pro=
of:yes'><o:p></o:p></span></i></p>

</div>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>PC: <o:p></o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>SN:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>NN:</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>MINIMUM PARTICULARS TO APPEAR ON=
 BLISTERS
OR STRIPS</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'>sano=
fi-aventis
groupe<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DFR style=3D'mso-ansi-language:FR'>3.<s=
pan
style=3D'mso-tab-count:1'> </span>EXPIRY DATE<o:p></o:p></span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'>EXP<i style=3D'mso-bidi-font-style:normal'><=
o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>Other</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB
style=3D'background:silver;mso-highlight:silver'>14&nbsp;-&nbsp;28&nbsp;-&n=
bsp;56&nbsp;-&nbsp;98&nbsp;tablets:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>56&nbsp;x&nbsp;1&nbsp;tablets:</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>PARTICULARS TO APPEAR ON THE OUT=
ER
PACKAGING </span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>OUTER CARTON</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span class=3DSpel=
lE><span
lang=3DEN-GB>Karvea</span></span><span lang=3DEN-GB>&nbsp;300&nbsp;mg table=
ts</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Each
tablet contains: irbesartan 300&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>LIST
OF EXCIPIENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Excipients:
also contains lactose monohydrate. See leaflet for further information.</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>14&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>28&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>56&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>56&nbsp;x&nbsp;1&nbsp;tablets</s=
pan></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>98&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Oral use.
Read the package leaflet before use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>6.<span style=3D'mso-tab-count:1'> </span>SPECIAL WARNIN=
G THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN=
</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Keep out
of the sight and reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>7.<span style=3D'mso-tab-count:1=
'> </span>OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>8.<span style=3D'mso-tab-count:1=
'> </span>EXPIRY
DATE</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>EXP<i
style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Do not
store above 30C.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>10.<span style=3D'mso-tab-count:1'> </span>SPECIAL PRECAUT=
IONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>11.<span style=3D'mso-tab-count:=
1'> </span>NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>12.<span style=3D'mso-tab-count:=
1'> </span>MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>EU/1/97/049/012 - 14&nbsp;tablets<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/007 - 28&nbsp;<span class=3DSpellE=
>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/008 - 56&nbsp;<span class=3DSpellE=
>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/015 - 56&nbsp;x&nbsp;1&nbsp;<span
class=3DSpellE>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>EU/1/97/049/009 - 98&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>13.<span style=3D'mso-tab-count:=
1'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place><i style=3D'mso-bidi-font-style:normal'=
><span
lang=3DEN-GB><o:p></o:p></span></i></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>14.<span style=3D'mso-tab-count:=
1'> </span>GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Medicinal
product subject to medical prescription.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>15.<span style=3D'mso-tab-count:=
1'> </span>INSTRUCTIONS
ON USE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>16.<span style=3D'mso-tab-count:=
1'> </span>Information
in Braille</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> 300&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>17.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER  2D BARCODE</span></b><i style=3D'mso-bid=
i-font-style:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p></o:p></span></i=
></p>

</div>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'>2D barco=
de
carrying the unique identifier included.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>18.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB style=3D'mso-no-pro=
of:yes'><o:p></o:p></span></i></p>

</div>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>PC: <o:p></o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>SN:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>NN:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'mso-special-character:line-break;page-break-before:always'>
</span>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'>sano=
fi-aventis
groupe<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DFR style=3D'mso-ansi-language:FR'>3.<s=
pan
style=3D'mso-tab-count:1'> </span>EXPIRY DATE<o:p></o:p></span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'>EXP<i style=3D'mso-bidi-font-style:normal'><=
o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>Other</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB
style=3D'background:silver;mso-highlight:silver'>14&nbsp;-&nbsp;28&nbsp;-&n=
bsp;56&nbsp;-&nbsp;98&nbsp;tablets:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>56&nbsp;x&nbsp;1&nbsp;tablets:</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>PARTICULARS TO APPEAR ON THE OUT=
ER PACKAGING
</span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>OUTER CARTON</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg film-coated tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Each
tablet contains: irbesartan 75&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>LIST
OF EXCIPIENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Excipients:
also contains lactose monohydrate. See leaflet for further information.</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>14&nbsp;tablets<br>
28&nbsp;tablets<br>
30&nbsp;tablets<br>
56&nbsp;tablets<br>
56&nbsp;x&nbsp;1&nbsp;tablets<br>
84&nbsp;tablets<br>
90&nbsp;tablets<br>
98&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Oral use. Read the package leafl=
et
before use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>6.<span style=3D'mso-tab-count:1'> </span>SPECIAL WARNIN=
G THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN=
</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Keep out
of the sight and reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>7.<span style=3D'mso-tab-count:1=
'> </span>OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>8.<span style=3D'mso-tab-count:1=
'> </span>EXPIRY
DATE</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>EXP<i
style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Do not store
above 30C.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>10.<span style=3D'mso-tab-count:1'> </span>SPECIAL PRECAUT=
IONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>11.<span style=3D'mso-tab-count:=
1'> </span>NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>12.<span style=3D'mso-tab-count:=
1'> </span>MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>EU/1/97/049/016 - 14&nbsp;tablets<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/017 - 28&nbsp;<span class=3DSpellE=
>tablets</span><br>
EU/1/97/049/034 - 30&nbsp;<span class=3DSpellE>tablets</span><o:p></o:p></s=
pan></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/018 - 56&nbsp;<span class=3DSpellE=
>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/019 - 56&nbsp;x&nbsp;1&nbsp;<span
class=3DSpellE>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DSL style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:SL'>EU/1/97/049/031 - 84</span><span lang=3DFR
style=3D'background:silver;mso-highlight:silver;mso-ansi-language:FR'>&nbsp=
;<span
class=3DSpellE>tablets</span><br>
EU/1/97/049/037 - 90&nbsp;<span class=3DSpellE>tablets</span><o:p></o:p></s=
pan></p>

<p class=3DEMEABodyText><span style=3D'background:silver;mso-highlight:silv=
er;
mso-ansi-language:EN-US'>EU/1/97/049/020 - 98</span><span lang=3DEN-GB
style=3D'background:silver;mso-highlight:silver'>&nbsp;tablets</span><span
style=3D'mso-ansi-language:EN-US'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>13.<span style=3D'mso-tab-count:=
1'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>14.<span style=3D'mso-tab-count:=
1'> </span>GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Medicinal
product subject to medical prescription.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>15.<span style=3D'mso-tab-count:=
1'> </span>INSTRUCTIONS
ON USE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>16.<span style=3D'mso-tab-count:=
1'> </span>information
in braille</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> 75&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>17.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER  2D BARCODE</span></b><i style=3D'mso-bid=
i-font-style:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p></o:p></span></i=
></p>

</div>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'>2D barco=
de
carrying the unique identifier included.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>18.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB style=3D'mso-no-pro=
of:yes'><o:p></o:p></span></i></p>

</div>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>PC: <o:p></o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>SN:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>NN:</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'>sano=
fi-aventis
groupe<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DFR style=3D'mso-ansi-language:FR'>3.<s=
pan
style=3D'mso-tab-count:1'> </span>EXPIRY DATE<o:p></o:p></span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'>EXP<i style=3D'mso-bidi-font-style:normal'><=
o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>OTher</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span style=3D'bac=
kground:
silver;mso-highlight:silver;mso-ansi-language:EN-US'>14&nbsp;-&nbsp;28&nbsp=
;-&nbsp;56&nbsp;-&nbsp;84&nbsp;-&nbsp;98&nbsp;</span><span
lang=3DLT style=3D'background:silver;mso-highlight:silver;mso-ansi-language=
:LT'>tablets:</span><span
lang=3DLT style=3D'mso-ansi-language:LT'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>30&nbsp;-&nbsp;56&nbsp;x&nbsp;1&nbsp;-&nbsp;90&nbsp;tablets:</span>=
</p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>PARTICULARS TO APPEAR ON THE OUT=
ER
PACKAGING </span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>OUTER CARTON</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg film-coated tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Each
tablet contains: irbesartan 150&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>LIST
OF EXCIPIENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Excipients:
also contains lactose monohydrate. See leaflet for further information.</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>14&nbsp;tablets<br>
28&nbsp;tablets<br>
30&nbsp;tablets<br>
56&nbsp;tablets<br>
56&nbsp;x&nbsp;1&nbsp;tablets<br>
84&nbsp;tablets<br>
90&nbsp;tablets<br>
98&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Oral use. Read the package leafl=
et
before use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>6.<span style=3D'mso-tab-count:1'> </span>SPECIAL WARNIN=
G THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN=
</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Keep out
of the sight and reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>7.<span style=3D'mso-tab-count:1=
'> </span>OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>8.<span style=3D'mso-tab-count:1=
'> </span>EXPIRY
DATE</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>EXP<i
style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Do not
store above 30C.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>10.<span style=3D'mso-tab-count:1'> </span>SPECIAL PRECAUT=
IONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>11.<span style=3D'mso-tab-count:=
1'> </span>NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>12.<span style=3D'mso-tab-count:=
1'> </span>MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>EU/1/97/049/021 - 14&nbsp;tablets<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/022 - 28&nbsp;<span class=3DSpellE=
>tablets</span><br>
EU/1/97/049/035 - 30&nbsp;<span class=3DSpellE>tablets</span><o:p></o:p></s=
pan></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/023 - 56&nbsp;<span class=3DSpellE=
>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/024 - 56&nbsp;x&nbsp;1&nbsp;<span
class=3DSpellE>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DSL style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:SL'>EU/1/97/049/032 - 84</span><span lang=3DFR
style=3D'background:silver;mso-highlight:silver;mso-ansi-language:FR'>&nbsp=
;<span
class=3DSpellE>tablets</span><br>
EU/1/97/049/038 - 90&nbsp;<span class=3DSpellE>tablets</span><o:p></o:p></s=
pan></p>

<p class=3DEMEABodyText><span style=3D'background:silver;mso-highlight:silv=
er;
mso-ansi-language:EN-US'>EU/1/97/049/025 - 98</span><span lang=3DEN-GB
style=3D'background:silver;mso-highlight:silver'>&nbsp;tablets</span><span
style=3D'mso-ansi-language:EN-US'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>13.<span style=3D'mso-tab-count:=
1'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>14.<span style=3D'mso-tab-count:=
1'> </span>GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Medicinal
product subject to medical prescription.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>15.<span style=3D'mso-tab-count:=
1'> </span>INSTRUCTIONS
ON USE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>16.<span style=3D'mso-tab-count:=
1'> </span>information
in braille</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> 150&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>17.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER  2D BARCODE</span></b><i style=3D'mso-bid=
i-font-style:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p></o:p></span></i=
></p>

</div>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'>2D barco=
de
carrying the unique identifier included.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>18.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB style=3D'mso-no-pro=
of:yes'><o:p></o:p></span></i></p>

</div>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>PC: <o:p></o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>SN:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>NN:</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'>sano=
fi-aventis
groupe<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DFR style=3D'mso-ansi-language:FR'>3.<s=
pan
style=3D'mso-tab-count:1'> </span>EXPIRY DATE<o:p></o:p></span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'>EXP<i style=3D'mso-bidi-font-style:normal'><=
o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>OTher</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span style=3D'bac=
kground:
silver;mso-highlight:silver;mso-ansi-language:EN-US'>14&nbsp;-&nbsp;28&nbsp=
;-&nbsp;56&nbsp;-&nbsp;84&nbsp;-&nbsp;98&nbsp;</span><span
lang=3DLT style=3D'background:silver;mso-highlight:silver;mso-ansi-language=
:LT'>tablets:</span><span
lang=3DLT style=3D'mso-ansi-language:LT'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>30&nbsp;-&nbsp;56&nbsp;x&nbsp;1&nbsp;-&nbsp;90&nbsp;tablets:</span>=
</p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>PARTICULARS TO APPEAR ON THE OUT=
ER
PACKAGING </span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>OUTER CARTON</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg film-coated tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Each
tablet contains: irbesartan 300&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>LIST
OF EXCIPIENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Excipients:
also contains lactose monohydrate. See leaflet for further information.</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>14&nbsp;tablets<br>
28&nbsp;tablets<br>
30&nbsp;tablets<br>
56&nbsp;tablets<br>
56&nbsp;x&nbsp;1&nbsp;tablets<br>
84&nbsp;tablets<br>
90&nbsp;tablets<br>
98&nbsp;tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>METHOD
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Oral use. Read the package leafl=
et
before use.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>6.<span style=3D'mso-tab-count:1'> </span>SPECIAL WARNIN=
G THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN=
</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Keep out
of the sight and reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>7.<span style=3D'mso-tab-count:1=
'> </span>OTHER
SPECIAL WARNING(S), IF NECESSARY</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>8.<span style=3D'mso-tab-count:1=
'> </span>EXPIRY
DATE</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>EXP<i
style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>9.<span style=3D'mso-tab-count:1=
'> </span>SPECIAL
STORAGE CONDITIONS</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Do not
store above 30C.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC style=3D'margin-left:30.0pt;text-indent:-30.0pt'><s=
pan
lang=3DEN-GB>10.<span style=3D'mso-tab-count:1'> </span>SPECIAL PRECAUT=
IONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>11.<span style=3D'mso-tab-count:=
1'> </span>NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>12.<span style=3D'mso-tab-count:=
1'> </span>MARKETING
AUTHORISATION NUMBER(S)</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>EU/1/97/049/026 - 14&nbsp;tablets<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/027 - 28&nbsp;<span class=3DSpellE=
>tablets</span><br>
EU/1/97/049/036 - 30&nbsp;<span class=3DSpellE>tablets</span><o:p></o:p></s=
pan></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/028 - 56&nbsp;<span class=3DSpellE=
>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:FR'>EU/1/97/049/029 - 56&nbsp;x&nbsp;1&nbsp;<span
class=3DSpellE>tablets</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DSL style=3D'background:silver;mso-high=
light:
silver;mso-ansi-language:SL'>EU/1/97/049/033 - 84</span><span lang=3DFR
style=3D'background:silver;mso-highlight:silver;mso-ansi-language:FR'>&nbsp=
;<span
class=3DSpellE>tablets</span><br>
EU/1/97/049/039 - 90&nbsp;<span class=3DSpellE>tablets</span><o:p></o:p></s=
pan></p>

<p class=3DEMEABodyText><span style=3D'background:silver;mso-highlight:silv=
er;
mso-ansi-language:EN-US'>EU/1/97/049/030 - 98</span><span lang=3DEN-GB
style=3D'background:silver;mso-highlight:silver'>&nbsp;tablets</span><span
style=3D'mso-ansi-language:EN-US'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'><o:p>&nbsp;=
</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>13.<span style=3D'mso-tab-count:=
1'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>14.<span style=3D'mso-tab-count:=
1'> </span>GENERAL
CLASSIFICATION FOR SUPPLY</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Medicinal
product subject to medical prescription.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>15.<span style=3D'mso-tab-count:=
1'> </span>INSTRUCTIONS
ON USE</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>16.<span style=3D'mso-tab-count:=
1'> </span>information
in braille</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> 300&nbsp;mg</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>17.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER  2D BARCODE</span></b><i style=3D'mso-bid=
i-font-style:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p></o:p></span></i=
></p>

</div>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'>2D barco=
de carrying
the unique identifier included.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-no-proof:yes'><o:p>&nb=
sp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DEN-GB style=3D'mso-no-proof:yes'>18.<span style=3D'mso=
-tab-count:
1'> </span>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-GB style=3D'mso-no-pro=
of:yes'><o:p></o:p></span></i></p>

</div>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>PC: <o:p></o:p></span></p>

<p class=3DEMEATitlePAC style=3D'border:none;mso-padding-alt:0in 0in 0in 0i=
n'><span
lang=3DEN-GB style=3D'font-weight:normal'>SN:<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>NN:</span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB style=3D'font-s=
ize:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-f=
ont-family:
"Times New Roman";text-transform:uppercase;mso-ansi-language:EN-GB;mso-fare=
ast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span></b>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg tablets</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>NAME
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'>sano=
fi-aventis
groupe<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DFR style=3D'mso-ansi-language:FR'>3.<s=
pan
style=3D'mso-tab-count:1'> </span>EXPIRY DATE<o:p></o:p></span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DFR
style=3D'mso-ansi-language:FR'>EXP<i style=3D'mso-bidi-font-style:normal'><=
o:p></o:p></i></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>BATCH
NUMBER</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><st1:place w:st=3D=
"on"><span
 lang=3DEN-GB>Lot</span></st1:place></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DEMEATitlePAC><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>OTher</span></p>

</div>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span style=3D'bac=
kground:
silver;mso-highlight:silver;mso-ansi-language:EN-US'>14&nbsp;-&nbsp;28&nbsp=
;-&nbsp;56&nbsp;-&nbsp;84&nbsp;-&nbsp;98&nbsp;</span><span
lang=3DLT style=3D'background:silver;mso-highlight:silver;mso-ansi-language=
:LT'>tablets:</span><span
lang=3DLT style=3D'mso-ansi-language:LT'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Mon<br>
Tue<br>
Wed<br>
Thu<br>
Fri<br>
Sat<br>
Sun</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:silver;mso-h=
ighlight:
silver'>30&nbsp;-&nbsp;56&nbsp;x&nbsp;1&nbsp;-&nbsp;90&nbsp;tablets:</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'mso-special-character:line-break;page-break-before:always'>
</span>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEATitle><span lang=3DEN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'page-break-before:always'>
</span>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Package leaflet: I=
nformation
for the user<o:p></o:p></span></b></p>

<p class=3DEMEATitle><span class=3DSpellE><span lang=3DEN-GB>Karvea</span><=
/span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg tablets</span></p>

<p class=3DEMEATitle><span lang=3DEN-GB style=3D'font-weight:normal'>irbesa=
rtan<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Read all of this leaflet careful=
ly before
you start taking this medicine because it contains important information for
you.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>If you have any further questions, ask your doctor or pharmaci=
st.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>This medicine has been prescribed for you only. Do not pass it=
 on to
others. It may harm them, even if their signs of illness are the same as yo=
urs.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>If you get any side effects, talk to your doctor or pharmacist=
. This
includes any possible side effects not listed in this leaflet. See section =
4.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><u><span lang=3DEN-GB>What is in this leaflet<o:p><=
/o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1'>=
 </span>What
<span class=3DSpellE>Karvea</span> is and what it is used for</span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1'>=
 </span>What
you need to know before you take <span class=3DSpellE>Karvea</span></span><=
/p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1'>=
 </span>How
to take <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1'>=
 </span>Possible
side effects</span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1'>=
 </span>How
to store <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1'>=
 </span>Contents
of the pack and other information</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>1.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>What <span class=3DSpellE>Karvea</span> is and what it is used for<o:=
p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> belongs to a group of medicines known as angiotensin-II recep=
tor
antagonists. Angiotensin-II is a substance produced in the body which binds=
 to
receptors in blood vessels causing them to tighten. This results in an incr=
ease
in blood pressure. <span class=3DSpellE>Karvea</span> prevents the binding =
of
angiotensin-II to these receptors, causing the blood vessels to relax and t=
he
blood pressure to lower. <span class=3DSpellE>Karvea</span> slows the decre=
ase of
kidney function in patients with high blood pressure and type&nbsp;2 diabet=
es.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is used in adult patients</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to treat high blood pressure (<i style=3D'mso-bidi-font-style:=
normal'>essential
hypertension</i>)</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</=
span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>2.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>What you need to know before you take <span class=3DSpellE>Karvea</sp=
an></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Do not take <span class=3DSpellE=
>Karvea</span></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>allergic</=
b> to
irbesartan or any other ingredients of this medicine (listed in section 6)<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>more than =
3 months
pregnant</b>. (It is also better to avoid <span class=3DSpellE>Karvea</span=
> in
early pregnancy  see pregnancy section)</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo5'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>if you have diabet=
es or
impaired kidney function </span></b><span lang=3DEN-GB>and you are treated =
with a
blood pressure lowering medicine containing <span class=3DSpellE>aliskiren<=
/span>.
<i style=3D'mso-bidi-font-style:normal'><span style=3D'color:red'><o:p></o:=
p></span></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Warning and precautions</span></=
p>

<p class=3DEMEAHeading3><span lang=3DEN-GB style=3D'font-weight:normal'>Tal=
k to your
doctor before taking <span class=3DSpellE>Karvea</span> and</span><span
lang=3DEN-GB> if any of the following apply to you:</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you get <b style=3D'mso-bidi-font-weight:normal'>excessive =
vomiting
or diarrhoea</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>ki=
dney
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>he=
art
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you receive <span class=3DSpellE>Karvea</span> for <b
style=3D'mso-bidi-font-weight:normal'>diabetic kidney disease</b>. In this =
case
your doctor may perform regular blood tests, especially for measuring blood
potassium levels in case of poor kidney function</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you develop <b>low blood sugar levels</b> (symptoms may inc=
lude
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>going to h=
ave an
operation</b> (surgery) or <b style=3D'mso-bidi-font-weight:normal'>be given
anaesthetics<o:p></o:p></b></span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l4 level1 lfo13'><![if !supportLists]><span lang=3DEN-GB
style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-f=
ont-family:
Wingdings;color:black'><span style=3D'mso-list:Ignore'><span style=3D'font=
:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>if you are taking any of =
the
following medicines used to treat high blood pressure:</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:1.0in;text-indent:-.25in;
mso-list:l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:"Courier New";mso-fareast-font-family:"Co=
urier New"'><span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>an ACE-inhibitor (for exa=
mple
enalapril, lisinopril, ramipril), in particular if you have diabetes-related
kidney problems.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-.25in;mso-l=
ist:
l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span lang=3DEN-=
GB
style=3D'font-family:"Courier New";mso-fareast-font-family:"Courier New"'><=
span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span class=3DSpellE><span lang=3DEN-GB>alis=
kiren</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>See also information under the h=
eading
Do not take <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. <span class=3DSpellE>Karvea</spa=
n> is
not recommended in early pregnancy, and must not be taken if you are more t=
han
3&nbsp;months pregnant, as it may cause serious harm to your baby if used at
that stage (see pregnancy section).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Children and adolescents</span><=
/p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>This medici=
nal
product should not be used in children and adolescents because the safety a=
nd
efficacy have not&nbsp;yet been&nbsp;fully established.</span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Other medicines and <span class=
=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor or pharmacist i=
f you are
taking, have recently taken or might take any other medicines.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may need to change y=
our dose
and/or to take other precautions:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><span style=3D'mso-spacerun:yes'=
></span>If
you are taking an ACE-inhibitor or <span class=3DSpellE>aliskiren</span> (s=
ee
also information under the headings Do not take <span class=3DSpellE>Karve=
a</span>
and Warnings and precautions).<span style=3D'background:aqua;mso-highligh=
t:
aqua'><o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>You
may need to have blood checks if you take:</span></b></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium supplements</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>salt substitutes containing potassium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium-sparing medicines (such as certain diuretics)</span>=
</p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>medicines containing lithium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3;mso-prop-ch=
ange:
Author 19000000T0000'><![if !supportLists]><span lang=3DEN-GB style=3D'font=
-family:
Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'=
><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>repaglinide (medication u=
sed
for lowering blood sugar levels)</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you take certain painkillers,=
 called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be redu=
ced.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> with food and drink</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> can be taken with or without food.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Pregnancy and breast-feeding</sp=
an></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Pregnancy</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise=
 you
to stop taking <span class=3DSpellE>Karvea</span> before you become pregnan=
t or
as soon as you know you are pregnant and will advise you to take another
medicine instead of <span class=3DSpellE>Karvea</span>. <span class=3DSpell=
E>Karvea</span>
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used a=
fter
the third month of pregnancy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Breast-feeding</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. <span class=3DSpellE>Karve=
a</span>
is not recommended for mothers who are breast-feeding, and your doctor may
choose another treatment for you if you wish to breast-feed, especially if =
your
baby is <span class=3DSpellE>newborn</span>, or was born prematurely.</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Driving and using machines</span=
></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is unlikely to affect your ability to drive or use machines.
However, occasionally dizziness or weariness may occur during treatment of =
high
blood pressure. If you experience these, talk to your doctor before attempt=
ing
to drive or use machines.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains lactose</span></b><span lang=3DEN-GB>. If you have b=
een told
by your doctor that you have an intolerance to some sugars (e.g. lactose),
contact your doctor before taking this medicinal product.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains sodium. </span></b><span lang=3DEN-GB style=3D'mso-b=
idi-font-weight:
bold'>This medicine contains less than 1 mmol sodium (23 mg) per tablet, th=
at
is to say essentially sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>3.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>How to take <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Always take this medicine exactl=
y as
your doctor has told you. Check with your doctor or pharmacist if you are n=
ot
sure.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Method of administration</span><=
/p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is for <b style=3D'mso-bidi-font-weight:normal'>oral use</b>.=
 Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take <span class=3DSpellE>Karvea</span> with or without food. Try to ta=
ke
your daily dose at about the same time each day. It is important that you
continue to take <span class=3DSpellE>Karvea</span> until your doctor tells=
 you
otherwise.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure<o:p></o:p></span></b></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>Th=
e usual
dose is 150&nbsp;mg once a day (two tablets a day). The dose may later be
increased to 300&nbsp;mg (four tablets a day) once daily depending on blood
pressure response.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure and type&nbsp;2 diabetes with kidney disease<o:p></o:p></span></b>=
</p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>In=
 patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg (four tablet=
s a
day) once daily is the preferred maintenance dose for the treatment of
associated kidney disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The doctor may advise a lower do=
se,
especially when starting treatment in certain patients such as those on <b
style=3D'mso-bidi-font-weight:normal'>haemodialysis</b>, or those <b
style=3D'mso-bidi-font-weight:normal'>over the age of 75&nbsp;years.<o:p></=
o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The maximal blood pressure lower=
ing
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Use in children and adolescents<=
/span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> should not be given to children under 18&nbsp;years of age. I=
f a
child swallows some tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you take more <span class=3DS=
pellE>Karvea</span>
than you should</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you forget to take <span
class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally miss a daily=
 dose,
just take the next dose as normal. Do not take a double dose to make up for=
 a
forgotten dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:NL=
'>If you
have any further questions on the use of this medicine, ask your doctor or
pharmacist.</span><span lang=3DEN-GB style=3D'font-size:10.0pt;font-family:=
"TimesNewRoman\,Italic";
mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"TimesNewRoman=
\,Italic";
mso-fareast-language:NL'><o:p></o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>4.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>Possible side effects</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Like all medicines, this medicin=
e can
cause side effects, although not everybody gets them.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Some of these effects may be ser=
ious and
may require medical attention.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As with similar medicines, rare =
cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of=
 the
face, lips and/or tongue have been reported in patients taking irbesartan. =
If
you get any of these symptoms or get short of breath, <b style=3D'mso-bidi-=
font-weight:
normal'>stop taking <span class=3DSpellE>Karvea</span> and contact your doc=
tor
immediately.<o:p></o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of the side effect=
s listed
below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Very common: </span><span lang=
=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt'>may affect more than 1 in 10 people</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Common: may affect up to 1 in 10=
 people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Uncommon: may affect up to 1 in =
100
people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Side
effects reported in clinical studies for patients treated with <span
class=3DSpellE>Karvea</span> were:</span></p>

<p class=3DEMEABodyTextIndent style=3D'page-break-after:avoid;mso-list:l10 =
level1 lfo3'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Very common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-=
size:11.0pt'>may
affect more than 1 in 10 people)</span><span lang=3DEN-GB>: if you suffer f=
rom
high blood pressure and type&nbsp;2 diabetes with kidney disease, blood tes=
ts
may show an increased level of potassium.</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'page-break-after:avoid;mso-list:l10 =
level1 lfo3'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-size:=
11.0pt'>may
affect up to 1 10 people)</span><span lang=3DEN-GB>: dizziness, feeling sic=
k/vomiting,
fatigue and blood tests may show raised levels of an enzyme that measures t=
he
muscle and heart function (creatine kinase enzyme). In patients with high b=
lood
pressure and type&nbsp;2 diabetes with kidney disease, dizziness when getti=
ng up
from a lying or sitting position, low blood pressure when getting up from a
lying or sitting position, pain in joints or muscles and decreased levels o=
f a
protein in the red blood cells (haemoglobin) were also reported.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Uncommon (</span><span lang=3DEN-GB style=3D'mso-bidi-font-siz=
e:11.0pt'>may
affect up to 1 in 100 people)</span><span lang=3DEN-GB>: heart rate increas=
ed,
flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (prob=
lems
with sexual performance), chest pain.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Some undesirable effects have be=
en
reported since marketing of <span class=3DSpellE>Karvea</span>. Undesirable
effects where the frequency is not known are: feeling of spinning, headache,
taste disturbance, ringing in the ears, </span><span lang=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt'>muscle cramps, </span><span lang=3DEN-G=
B>pain
in joints and muscles, </span><span lang=3DEN-GB style=3D'mso-bidi-font-siz=
e:11.0pt'>decreased
number of red blood cells (anaemia  symptoms may include tiredness, headac=
hes,
being short of breath when exercising, dizziness and looking pale),</span><=
span
lang=3DEN-GB> reduced number of platelets, abnormal liver function, increas=
ed
blood potassium levels, impaired kidney function, inflammation of small blo=
od
vessels</span><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> </spa=
n><span
lang=3DEN-GB style=3D'mso-bidi-font-style:italic'>mainly affecting the skin=
</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> (a condition known as <sp=
an
class=3DSpellE>leukocytoclastic</span> vasculitis),</span><span lang=3DEN-G=
B> severe
allergic reactions (anaphylactic shock)</span><span lang=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt'> and </span><span lang=3DEN-GB>low bloo=
d sugar
levels. Uncommon cases of jaundice (yellowing of the skin and/or whites of =
the
eyes) have also been reported.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of side effects<o:p=
></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you get any side effects, tal=
k to
your doctor or pharmacist. This includes any possible side effects not list=
ed
in this leaflet. You can also report side effects directly via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in </span></span><span class=3DMsoHyperlink><span lang=3DES-TRAD
style=3D'mso-bidi-font-size:12.0pt;background:silver;mso-highlight:silver;
mso-ansi-language:ES-TRAD;mso-fareast-language:ZH-CN;mso-no-proof:yes;
text-decoration:none;text-underline:none'>Appendix V</span></span><span
lang=3DEN-GB>. By reporting side <span class=3DSpellE>effects you</span> ca=
n help
provide more information on the safety of this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>5.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>How to store <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Keep this medicine out of the si=
ght and
reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not use this medicine after t=
he expiry
date which is stated on the carton and on the blister after EXP. The expiry
date refers to the last day of that month.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not store above 30C.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not throw away any medicines =
via
wastewater or household waste. Ask your pharmacist how to throw away of
medicines you no longer use. These measures will help protect the environme=
nt.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>6.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>Contents of the pack and other information</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
contains</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>The active substance is irbesartan. Each tablet of <span
class=3DSpellE>Karvea</span>&nbsp;75&nbsp;mg contains 75&nbsp;mg irbesartan=
.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>The other ingredients are microcrystalline cellulose, croscarm=
ellose
sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica,=
 <span
class=3DSpellE>pregelatinised</span> maize starch, and poloxamer&nbsp;188. =
Please
see section 2 <span class=3DSpellE>Karvea</span> contains lactose.</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
looks like and contents of the pack</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg tablets are white to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2771 engr=
aved
on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg tablets are supplied in blister packs of 14, =
28, 56
or 98&nbsp;tablets. <span class=3DSpellE>Unidose</span> blister packs of
56&nbsp;x&nbsp;1&nbsp;tablet for delivery in hospitals are also available.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Not all pack sizes may be market=
ed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Mark=
eting <span
class=3DSpellE>Authorisation</span> Holder:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris&nbsp;-&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Manu=
facturer:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>SANOF=
I&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
<span class=3DSpellE>Ambars</span> &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DEN-GB>SANOFI&nbsp;<st1:City w:st=3D"on"=
>WINTHROP</st1:City>&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;<st1:City w:st=3D"on"><st1:place w:st=3D"on">Tours</st1:place>=
</st1:City>&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France</span></p>

<p class=3DEMEAAddress><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For any information about this m=
edicinal
product, please contact the local representative of the Marketing Authorisa=
tion
Holder.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D624
 style=3D'margin-left:-1.7pt;border-collapse:collapse;mso-table-layout-alt:=
fixed;
 mso-padding-alt:0in 5.4pt 0in 5.4pt'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Be=
lgi/</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'>Belgique</span></b><b><span lang=
=3DMT
  style=3D'mso-ansi-language:MT'>/Belgien</span></b><b><span lang=3DFR-BE
  style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi Belgium</span><span lang=3DFR-BE
  style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>Tl/Tel: <span
  style=3D'layout-grid-mode:line'>+32 (0)2 710 54 00<o:p></o:p></span></spa=
n></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLT style=3D'mso-ansi-language:LT'>Li=
etuva<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>UAB
  sanofi-aventis Lietuva</span><span lang=3DFR style=3D'mso-ansi-language:F=
R'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+370 5
  2755224<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><span class=3DSpellE><b><span lang=3DEN-GB>&#1041;&#=
1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></span><b
  style=3D'mso-bidi-font-weight:normal'><span lang=3DIT style=3D'mso-ansi-l=
anguage:
  IT'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT;mso-no=
-proof:
  yes'>Sanofi Bulgaria EOOD<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  BG;mso-bidi-font-weight:bold'>&#1058;&#1077;&#1083;</span><span lang=3DIT
  style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT;mso-bidi-font-wei=
ght:
  bold'>.</span><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
  BG;mso-bidi-font-weight:bold'>: +</span><span lang=3DIT style=3D'mso-bidi=
-font-size:
  11.0pt;mso-ansi-language:IT;mso-bidi-font-weight:bold'>359 (0)2</span><sp=
an
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial;
  mso-ansi-language:IT'> 970 53 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR-LU style=3D'mso-ansi-language:FR-=
LU'>Luxembourg/Luxemburg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi Belgium <o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-LU style=3D'mso-ansi-language:FR-LU'=
>Tl/Tel: </span><span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;layout-grid-mode:line'>+32 =
(0)2 710
  54 00 (</span><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>Belgiq=
ue/<span
  class=3DSpellE>Belgien</span>)<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DHU style=3D'mso-ansi-language:HU'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>&#=
268;esk
  republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis,
  s.r.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+420 233
  086 111<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DHU style=3D'mso-ansi-language:HU'>Ma=
gyarorszg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>SANOF=
I-AVENTIS Zrt.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel.:=
 +36 1 </span><span
  lang=3DHU style=3D'mso-ansi-language:HU'>505 0050<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Da=
nmark<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i A/S<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+45 45 16
  70 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Ma=
lta<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+39 02 39394275<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>De=
utschland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i-Aventis
  Deutschland GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
0800 52 52
  010<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel. =
aus dem
  Ausland: +49 69 305 21 131<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Ne=
derland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Genzy=
me Europe B.V.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+31 20 245
  4000</span><span lang=3DNL style=3D'mso-ansi-language:NL'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DET style=3D'mso-ansi-language:ET'>Ee=
sti<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Estonia O<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+372 627
  34 88<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>No=
rge<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Norge AS<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+47 67 10
  71 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
917;&#955;&#955;&#940;&#948;&#945;</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  AEBE</span><span lang=3DET style=3D'mso-ansi-language:ET'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'>: +30 210 900 16 00<o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>s=
terreich<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>sanof=
i-aventis
  GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Tel: =
+43 1 80
  185  0<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DES style=3D'mso-ansi-language:ES'>Es=
paa<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>sanof=
i-aventis,
  S.A.<span style=3D'font-variant:small-caps'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tel: =
+34 93 485
  94 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>Po=
lska<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>sanof=
i-aventis
  Sp. z o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel.:=
 +48
  22&nbsp;280 00 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:8;page-break-inside:avoid'>
  <td width=3D312 colspan=3D2 valign=3Dtop style=3D'width:233.9pt;padding:0=
in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Fr=
ance<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
  France</span><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tl: =
0 800 222
  555<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Appel=
 depuis
  ltranger : +33 1 57 63 23 23<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DPT style=3D'mso-ansi-language:PT'>Po=
rtugal<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Sanof=
i -
  Produtos Farmacuticos, Lda<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+351 21 35
  89 400<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:9;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'page-break-after:avoid'><b><span lang=3DIT
  style=3D'mso-fareast-font-family:SimSun;mso-ansi-language:IT'>Hrvatska<o:=
p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:IT'>sanofi-aventis Croatia d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:FR'>Tel: +385 1 600 34 00</span><span lang=3DFR
  style=3D'mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<b
  style=3D'mso-bidi-font-weight:normal'><span lang=3DIT style=3D'mso-bidi-f=
ont-size:
  11.0pt;mso-ansi-language:IT;mso-no-proof:yes'>Romnia<o:p></o:p></span></=
b></p>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<span
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT'>Sanofi=
 Romania
  SRL<span style=3D'mso-no-proof:yes'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  IT;mso-no-proof:yes'>Tel: +40 </span><span lang=3DIT style=3D'mso-bidi-fo=
nt-size:
  11.0pt;mso-ansi-language:IT'>(0) 21 317 31 36<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:10;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Ir=
eland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
  Ireland Ltd. T/A SANOFI<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+353 (0) 1
  403 56 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSL style=3D'mso-ansi-language:SL'>Sl=
ovenija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+386 1 560
  48 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:11;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIS style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:IS'>sland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Vistor hf.</span><span lang=3DIS style=3D'mso-bidi-font-size:11.0pt;
  mso-ansi-language:IS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0p=
t;
  mso-no-proof:yes'>Smi</span><span lang=3DCS style=3D'mso-bidi-font-size:=
11.0pt;
  mso-ansi-language:CS'>: +354 535 7000<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSK style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:SK'>Slovensk republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'>sanofi-</span><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;mso-=
ansi-language:
  CS'>aventis Slovakia </span><span lang=3DSK style=3D'mso-bidi-font-size:1=
1.0pt;
  mso-ansi-language:SK'>s.r.o.</span><span lang=3DCS style=3D'mso-bidi-font=
-size:
  11.0pt;mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Tel: +</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
  SK'>421 2 </span><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>3=
3 100
  100</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-ansi-lan=
guage:
  SK'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:12;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>It=
alia<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Tel</=
span><span
  lang=3DCS style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:CS'>: 800 =
536389</span><span
  lang=3DIT style=3D'mso-ansi-language:IT'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>Su=
omi/Finland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i Oy<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Puh/T=
el: +358
  (0) 201 200 300<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:13;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
922;&#973;&#960;&#961;&#959;&#962;</span></b><b><span
  lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis <span
  class=3DSpellE>Cyprus</span> Ltd.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;:
  +</span><span lang=3DFR style=3D'mso-ansi-language:FR'>357 22 871600<o:p>=
</o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Sv=
erige<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i AB<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+46 (0)8
  634 50 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:14;mso-yfti-lastrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>La=
tvija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>sanof=
i-aventis
  Latvia SIA<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Tel: =
+371 67 33
  24 51<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Un=
ited
  Kingdom<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+44 (0)
  845 372 7101<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <![if !supportMisalignedColumns]>
 <tr height=3D0>
  <td width=3D2 style=3D'border:none'></td>
  <td width=3D310 style=3D'border:none'></td>
  <td width=3D312 style=3D'border:none'></td>
 </tr>
 <![endif]>
</table>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>This
leaflet was last revised in</span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icine is
available on the European Medicines Agency web site: http://www.ema.europa.=
eu/</span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'page-break-before:always'>
</span>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Package leaflet:
Information for the user<o:p></o:p></span></b></p>

<p class=3DEMEATitle><span class=3DSpellE><span lang=3DEN-GB>Karvea</span><=
/span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg tablets</span></p>

<p class=3DEMEATitle><span lang=3DEN-GB style=3D'font-weight:normal'>irbesa=
rtan<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Read all of this leaflet careful=
ly
before you start taking this medicine because it contains important informa=
tion
for you.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>If you have any further questions, ask your doctor or pharmaci=
st.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>This medicine has been prescribed for you only. Do not pass it=
 on to
others. It may harm them, even if their signs of illness are the same as yo=
urs.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>If you get any side effects, talk to your doctor or pharmacist=
. This
includes any possible side effects not listed in this leaflet. See section =
4.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><u><span lang=3DEN-GB>What is in this leaflet<o:p><=
/o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1'>=
 </span>What
<span class=3DSpellE>Karvea</span> is and what it is used for</span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1'>=
 </span>What
you need to know before you take <span class=3DSpellE>Karvea</span></span><=
/p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1'>=
 </span>How
to take <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1'>=
 </span>Possible
side effects</span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1'>=
 </span>How
to store <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1'>=
 </span>Contents
of the pack and other information</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>1.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>What <span class=3DSpellE>Karvea</span> is and what it is used for<o:=
p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> belongs to a group of medicines known as angiotensin-II recep=
tor antagonists.
Angiotensin-II is a substance produced in the body which binds to receptors=
 in
blood vessels causing them to tighten. This results in an increase in blood
pressure. <span class=3DSpellE>Karvea</span> prevents the binding of
angiotensin-II to these receptors, causing the blood vessels to relax and t=
he
blood pressure to lower. <span class=3DSpellE>Karvea</span> slows the decre=
ase of
kidney function in patients with high blood pressure and type&nbsp;2 diabet=
es.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is used in adult patients</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to treat high blood pressure (<i style=3D'mso-bidi-font-style:=
normal'>essential
hypertension</i>)</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</=
span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>2.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>What you need to know before you take <span class=3DSpellE>Karvea</sp=
an></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Do not take <span class=3DSpellE=
>Karvea</span></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>allergic</=
b> to
irbesartan or any other ingredients of this medicine (listed in section 6)<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>more than =
3 months
pregnant</b>. (It is also better to avoid <span class=3DSpellE>Karvea</span=
> in
early pregnancy  see pregnancy section)</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l3 level1 lfo8;tab-stops:list 27.5pt'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings;color:black'><span style=3D'mso-list:Ignore'=
><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>if you have diabet=
es or
impaired kidney function </span></b><span lang=3DEN-GB>and you are treated =
with a
blood pressure lowering medicine containing <span class=3DSpellE>aliskiren<=
/span>.
<i style=3D'mso-bidi-font-style:normal'><span style=3D'color:red'><o:p></o:=
p></span></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Warning and precautions</span></=
p>

<p class=3DEMEAHeading3><span lang=3DEN-GB style=3D'font-weight:normal'>Tal=
k to your
doctor before taking <span class=3DSpellE>Karvea</span> and</span><span
lang=3DEN-GB> if any of the following apply to you:</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you get <b style=3D'mso-bidi-font-weight:normal'>excessive =
vomiting
or diarrhoea</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>ki=
dney
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>he=
art
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you receive <span class=3DSpellE>Karvea</span> for <b
style=3D'mso-bidi-font-weight:normal'>diabetic kidney disease</b>. In this =
case
your doctor may perform regular blood tests, especially for measuring blood
potassium levels in case of poor kidney function</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you develop <b>low blood sugar levels</b> (symptoms may inc=
lude
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>going to h=
ave an
operation</b> (surgery) or <b style=3D'mso-bidi-font-weight:normal'>be given
anaesthetics<o:p></o:p></b></span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l4 level1 lfo13'><![if !supportLists]><span lang=3DEN-GB
style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-f=
ont-family:
Wingdings;color:black'><span style=3D'mso-list:Ignore'><span style=3D'font=
:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>if you are taking any of =
the
following medicines used to treat high blood pressure:</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:1.0in;text-indent:-.25in;
mso-list:l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:"Courier New";mso-fareast-font-family:"Co=
urier New"'><span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>an ACE-inhibitor (for exa=
mple
enalapril, lisinopril, ramipril), in particular if you have diabetes-related
kidney problems.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-.25in;mso-l=
ist:
l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span lang=3DEN-=
GB
style=3D'font-family:"Courier New";mso-fareast-font-family:"Courier New"'><=
span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span class=3DSpellE><span lang=3DEN-GB>alis=
kiren</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>See also information under the h=
eading
Do not take <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. <span class=3DSpellE>Karvea</spa=
n> is
not recommended in early pregnancy, and must not be taken if you are more t=
han
3&nbsp;months pregnant, as it may cause serious harm to your baby if used at
that stage (see pregnancy section).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Children and adolescents</span><=
/p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>This medici=
nal
product should not be used in children and adolescents because the safety a=
nd
efficacy have not&nbsp;yet been&nbsp;fully established.</span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Other medicines and <span class=
=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor or pharmacist i=
f you
are taking, have recently taken or might take any other medicines.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may need to change y=
our dose
and/or to take other precautions:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><span style=3D'mso-spacerun:yes'=
></span>If
you are taking an ACE-inhibitor or <span class=3DSpellE>aliskiren</span> (s=
ee
also information under the headings Do not take <span class=3DSpellE>Karve=
a</span>
and Warnings and precautions).<span style=3D'background:aqua;mso-highligh=
t:
aqua'><o:p></o:p></span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>You
may need to have blood checks if you take:</span></b></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium supplements</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>salt substitutes containing potassium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium-sparing medicines (such as certain diuretics)</span>=
</p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>medicines containing lithium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3;mso-prop-ch=
ange:
Author 19000000T0000'><![if !supportLists]><span lang=3DEN-GB style=3D'font=
-family:
Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'=
><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>repaglinide (medication u=
sed
for lowering blood sugar levels)</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you take certain painkillers,=
 called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be redu=
ced.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> with food and drink</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> can be taken with or without food.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Pregnancy and breast-feeding</sp=
an></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Pregnancy</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise=
 you
to stop taking <span class=3DSpellE>Karvea</span> before you become pregnan=
t or
as soon as you know you are pregnant and will advise you to take another
medicine instead of <span class=3DSpellE>Karvea</span>. <span class=3DSpell=
E>Karvea</span>
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used a=
fter
the third month of pregnancy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Breast-feeding</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. <span class=3DSpellE>Karve=
a</span>
is not recommended for mothers who are breast-feeding, and your doctor may
choose another treatment for you if you wish to breast-feed, especially if =
your
baby is <span class=3DSpellE>newborn</span>, or was born prematurely.</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Driving and using machines</span=
></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is unlikely to affect your ability to drive or use machines.
However, occasionally dizziness or weariness may occur during treatment of =
high
blood pressure. If you experience these, talk to your doctor before attempt=
ing
to drive or use machines.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains lactose</span></b><span lang=3DEN-GB>. If you have b=
een told
by your doctor that you have an intolerance to some sugars (e.g. lactose),
contact your doctor before taking this medicinal product.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains sodium. </span></b><span lang=3DEN-GB style=3D'mso-b=
idi-font-weight:
bold'>This medicine contains less than 1 mmol sodium (23 mg) per tablet, th=
at is
to say essentially sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>3.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>How to take <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Always take this medicine exactl=
y as
your doctor has told you. Check with your doctor or pharmacist if you are n=
ot
sure.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Method of administration</span><=
/p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is for <b style=3D'mso-bidi-font-weight:normal'>oral use</b>.=
 Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take <span class=3DSpellE>Karvea</span> with or without food. Try to ta=
ke
your daily dose at about the same time each day. It is important that you
continue to take <span class=3DSpellE>Karvea</span> until your doctor tells=
 you
otherwise.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure<o:p></o:p></span></b></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>Th=
e usual
dose is 150&nbsp;mg once a day. The dose may later be increased to 300&nbsp=
;mg
(two tablets a day) once daily depending on blood pressure response.</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure and type&nbsp;2 diabetes with kidney disease<o:p></o:p></span></b>=
</p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>In=
 patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg (two tablets=
 a
day) once daily is the preferred maintenance dose for the treatment of
associated kidney disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The doctor may advise a lower do=
se,
especially when starting treatment in certain patients such as those on <b
style=3D'mso-bidi-font-weight:normal'>haemodialysis</b>, or those <b
style=3D'mso-bidi-font-weight:normal'>over the age of 75&nbsp;years.<o:p></=
o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The maximal blood pressure lower=
ing
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Use in children and adolescents<=
/span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> should not be given to children under 18&nbsp;years of age. I=
f a
child swallows some tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you take more <span class=3DS=
pellE>Karvea</span>
than you should</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you forget to take <span
class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally miss a daily=
 dose,
just take the next dose as normal. Do not take a double dose to make up for=
 a
forgotten dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:NL=
'>If you
have any further questions on the use of this medicine, ask your doctor or
pharmacist.</span><span lang=3DEN-GB style=3D'font-size:10.0pt;font-family:=
"TimesNewRoman\,Italic";
mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"TimesNewRoman=
\,Italic";
mso-fareast-language:NL'><o:p></o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>4.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>Possible side effects</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Like all medicines, this medicin=
e can
cause side effects, although not everybody gets them.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Some of these effects may be ser=
ious and
may require medical attention.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As with similar medicines, rare =
cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of=
 the
face, lips and/or tongue have been reported in patients taking irbesartan. =
If
you get any of these symptoms or get short of breath, <b style=3D'mso-bidi-=
font-weight:
normal'>stop taking <span class=3DSpellE>Karvea</span> and contact your doc=
tor
immediately.<o:p></o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'background:yellow;mso-h=
ighlight:
yellow'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of the side effect=
s listed
below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Very common: </span><span lang=
=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt'>may affect more than 1 in 10 people</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Common: may affect up to 1 in 10=
 people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Uncommon: may affect up to 1 in =
100
people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
>Side
effects reported in clinical studies for patients treated with <span
class=3DSpellE>Karvea</span> were:</span></p>

<p class=3DEMEABodyTextIndent style=3D'page-break-after:avoid;mso-list:l10 =
level1 lfo3'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Very common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-=
size:11.0pt'>may
affect more than 1 in 10 people)</span><span lang=3DEN-GB>: if you suffer f=
rom
high blood pressure and type&nbsp;2 diabetes with kidney disease, blood tes=
ts
may show an increased level of potassium.</span></p>

<p class=3DEMEABodyText style=3D'page-break-after:avoid'><span lang=3DEN-GB=
><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'page-break-after:avoid;mso-list:l10 =
level1 lfo3'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-size:=
11.0pt'>may
affect up to 1 10 people)</span><span lang=3DEN-GB>: dizziness, feeling
sick/vomiting, fatigue and blood tests may show raised levels of an enzyme =
that
measures the muscle and heart function (creatine kinase enzyme). In patients
with high blood pressure and type&nbsp;2 diabetes with kidney disease,
dizziness when getting up from a lying or sitting position, low blood press=
ure
when getting up from a lying or sitting position, pain in joints or muscles=
 and
decreased levels of a protein in the red blood cells (haemoglobin) were also
reported.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Uncommon (</span><span lang=3DEN-GB style=3D'mso-bidi-font-siz=
e:11.0pt'>may
affect up to 1 in 100 people)</span><span lang=3DEN-GB>: heart rate increas=
ed,
flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (prob=
lems
with sexual performance), chest pain.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB>Some undesirable effects have been =
reported
since marketing of <span class=3DSpellE>Karvea</span>. Undesirable effects =
where
the frequency is not known are: feeling of spinning, headache, taste
disturbance, ringing in the ears, </span><span lang=3DEN-GB style=3D'mso-bi=
di-font-size:
11.0pt'>muscle cramps, </span><span lang=3DEN-GB>pain in joints and muscles=
, </span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>decreased number of red bl=
ood
cells (anaemia  symptoms may include tiredness, headaches, being short of
breath when exercising, dizziness and looking pale), </span><span lang=3DEN=
-GB>reduced
number of platelets, abnormal liver function, increased blood potassium lev=
els,
impaired kidney function, inflammation of small blood vessels</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> </span><span lang=3DEN-GB
style=3D'mso-bidi-font-style:italic'>mainly affecting the skin</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> (a condition known as <sp=
an
class=3DSpellE>leukocytoclastic</span> vasculitis),</span><span lang=3DEN-GB
style=3D'mso-ansi-language:EN-US'> </span><span style=3D'mso-ansi-language:=
EN-US'>severe
allergic reactions (anaphylactic shock)</span><span style=3D'mso-bidi-font-=
size:
11.0pt'> <span lang=3DEN-GB>and </span></span><span lang=3DEN-GB>low blood =
sugar
levels. Uncommon cases of jaundice (yellowing of the skin and/or whites of =
the
eyes) have also been reported.</span><span style=3D'mso-ansi-language:EN-US=
'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of side effects<o:p=
></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you get any side effects, tal=
k to
your doctor or pharmacist. This includes any possible side effects not list=
ed
in this leaflet. You can also report side effects directly via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in </span></span><span class=3DMsoHyperlink><span lang=3DES-TRAD
style=3D'mso-bidi-font-size:12.0pt;background:silver;mso-highlight:silver;
mso-ansi-language:ES-TRAD;mso-fareast-language:ZH-CN;mso-no-proof:yes;
text-decoration:none;text-underline:none'>Appendix V</span></span><span
lang=3DEN-GB>. By reporting side <span class=3DSpellE>effects you</span> ca=
n help
provide more information on the safety of this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>5.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>How to store <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Keep this medicine out of the si=
ght and
reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not use this medicine after t=
he
expiry date which is stated on the carton and on the blister after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not store above 30C.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not throw away any medicines =
via
wastewater or household waste. Ask your pharmacist how to throw away of
medicines you no longer use. These measures will help protect the environme=
nt.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>6.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>Contents of the pack and other information</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
contains</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>The active substance is irbesartan. Each tablet of <span
class=3DSpellE>Karvea</span>&nbsp;150&nbsp;mg contains 150&nbsp;mg irbesart=
an.</span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'font-family:Wingdings'><s=
pan
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB>The other ingr=
edients
are microcrystalline cellulose, croscarmellose sodium, lactose monohydrate,
magnesium stearate, colloidal hydrated silica, <span class=3DSpellE>pregela=
tinised</span>
maize starch, and poloxamer&nbsp;188. </span><span style=3D'mso-ansi-langua=
ge:
EN-US'>Please see section 2 <span class=3DSpellE>Karvea</span> contains
lactose.<o:p></o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
looks like and contents of the pack</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg tablets are white to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2772 engr=
aved
on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg tablets are supplied in blister packs of 14,=
 28,
56 or 98&nbsp;tablets. <span class=3DSpellE>Unidose</span> blister packs of
56&nbsp;x&nbsp;1&nbsp;tablet for delivery in hospitals are also available.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Not all pack sizes may be market=
ed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Mark=
eting <span
class=3DSpellE>Authorisation</span> Holder:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris -&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Manu=
facturer:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>SANOF=
I&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
<span class=3DSpellE>Ambars</span> &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>SANOF=
I&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France<o:p></o:p></span></=
p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>CHINO=
IN PRIVATE
CO. LTD.<br>
<span class=3DSpellE>Lvai</span> u.5.<br>
2112 <span class=3DSpellE>Veresegyhz</span>&nbsp;-&nbsp;<span class=3DSpel=
lE>Hungary</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For any information about this m=
edicinal
product, please contact the local representative of the Marketing Authorisa=
tion
Holder.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D624
 style=3D'margin-left:-1.7pt;border-collapse:collapse;mso-table-layout-alt:=
fixed;
 mso-padding-alt:0in 5.4pt 0in 5.4pt'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Be=
lgi/</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'>Belgique</span></b><b><span lang=
=3DMT
  style=3D'mso-ansi-language:MT'>/Belgien</span></b><b><span lang=3DFR-BE
  style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi Belgium</span><span lang=3DFR-BE
  style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>Tl/Tel: <span
  style=3D'layout-grid-mode:line'>+32 (0)2 710 54 00<o:p></o:p></span></spa=
n></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLT style=3D'mso-ansi-language:LT'>Li=
etuva<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>UAB
  sanofi-aventis Lietuva</span><span lang=3DFR style=3D'mso-ansi-language:F=
R'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+370 5
  2755224<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><span class=3DSpellE><b><span lang=3DEN-GB>&#1041;&#=
1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></span><b><span
  lang=3DIT style=3D'mso-ansi-language:IT'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT;mso-no=
-proof:
  yes'>Sanofi Bulgaria EOOD<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  BG;mso-bidi-font-weight:bold'>&#1058;&#1077;&#1083;</span><span lang=3DIT
  style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT;mso-bidi-font-wei=
ght:
  bold'>.</span><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
  BG;mso-bidi-font-weight:bold'>: +</span><span lang=3DIT style=3D'mso-bidi=
-font-size:
  11.0pt;mso-ansi-language:IT;mso-bidi-font-weight:bold'>359 (0)2</span><sp=
an
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial;
  mso-ansi-language:IT'> 970 53 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR-LU style=3D'mso-ansi-language:FR-=
LU'>Luxembourg/Luxemburg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi <span class=3DSpellE>Belgium</span> <o:p></=
o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-LU style=3D'mso-ansi-language:FR-LU'=
>Tl/Tel: </span><span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;layout-grid-mode:line'>+32 =
(0)2 710
  54 00 (</span><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>Belgiq=
ue/<span
  class=3DSpellE>Belgien</span>)<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DHU style=3D'mso-ansi-language:HU'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>&#=
268;esk
  republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis,
  s.r.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+420 233
  086 111<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DHU style=3D'mso-ansi-language:HU'>Ma=
gyarorszg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>SANOF=
I-AVENTIS
  Zrt.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel.:=
 +36 1 </span><span
  lang=3DHU style=3D'mso-ansi-language:HU'>505 0050<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Da=
nmark<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i A/S<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+45 45 16
  70 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Ma=
lta<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+39 02
  39394275<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>De=
utschland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i-Aventis
  Deutschland GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
0800 52 52
  010<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel. =
aus dem
  Ausland: +49 69 305 21 131<o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Ne=
derland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Genzy=
me Europe B.V.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+31 20 245
  4000</span><span lang=3DNL style=3D'mso-ansi-language:NL'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DET style=3D'mso-ansi-language:ET'>Ee=
sti<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Estonia O<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+372 627
  34 88<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>No=
rge<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Norge AS<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+47 67 10
  71 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
917;&#955;&#955;&#940;&#948;&#945;</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  AEBE</span><span lang=3DET style=3D'mso-ansi-language:ET'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'>: +30 210 900 16 00<o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>s=
terreich<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>sanof=
i-aventis
  GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Tel: =
+43 1 80
  185  0<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DES style=3D'mso-ansi-language:ES'>Es=
paa<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>sanof=
i-aventis,
  S.A.<span style=3D'font-variant:small-caps'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tel: =
+34 93 485
  94 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>Po=
lska<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>sanof=
i-aventis
  Sp. z o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel.:=
 +48
  22&nbsp;280 00 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:8;page-break-inside:avoid'>
  <td width=3D312 colspan=3D2 valign=3Dtop style=3D'width:233.9pt;padding:0=
in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Fr=
ance<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
  France</span><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tl: =
0 800 222
  555<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Appel=
 depuis
  ltranger : +33 1 57 63 23 23<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DPT style=3D'mso-ansi-language:PT'>Po=
rtugal<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Sanof=
i -
  Produtos Farmacuticos, Lda<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+351 21 35
  89 400<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:9;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'page-break-after:avoid'><b><span lang=3DIT
  style=3D'mso-fareast-font-family:SimSun;mso-ansi-language:IT'>Hrvatska<o:=
p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:IT'>sanofi-aventis Croatia d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:FR'>Tel: +385 1 600 34 00</span><span lang=3DFR
  style=3D'mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<b
  style=3D'mso-bidi-font-weight:normal'><span lang=3DIT style=3D'mso-bidi-f=
ont-size:
  11.0pt;mso-ansi-language:IT;mso-no-proof:yes'>Romnia<o:p></o:p></span></=
b></p>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<span
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT'>Sanofi=
 Romania
  SRL<span style=3D'mso-no-proof:yes'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  IT;mso-no-proof:yes'>Tel: +40 </span><span lang=3DIT style=3D'mso-bidi-fo=
nt-size:
  11.0pt;mso-ansi-language:IT'>(0) 21 317 31 36<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:10;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Ir=
eland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
  Ireland Ltd. T/A SANOFI<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+353 (0) 1
  403 56 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSL style=3D'mso-ansi-language:SL'>Sl=
ovenija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+386 1 560
  48 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:11;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIS style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:IS'>sland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Vistor hf.</span><span lang=3DIS style=3D'mso-bidi-font-size:11.0pt;
  mso-ansi-language:IS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0p=
t;
  mso-no-proof:yes'>Smi</span><span lang=3DCS style=3D'mso-bidi-font-size:=
11.0pt;
  mso-ansi-language:CS'>: +354 535 7000<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSK style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:SK'>Slovensk republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'>sanofi-</span><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;mso-=
ansi-language:
  CS'>aventis Slovakia </span><span lang=3DSK style=3D'mso-bidi-font-size:1=
1.0pt;
  mso-ansi-language:SK'>s.r.o.</span><span lang=3DCS style=3D'mso-bidi-font=
-size:
  11.0pt;mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Tel: +</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
  SK'>421 2 </span><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>3=
3 100
  100</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-ansi-lan=
guage:
  SK'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:12;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>It=
alia<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Tel</=
span><span
  lang=3DCS style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:CS'>: 800 =
536389</span><span
  lang=3DIT style=3D'mso-ansi-language:IT'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>Su=
omi/Finland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i Oy<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Puh/T=
el: +358
  (0) 201 200 300<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:13;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
922;&#973;&#960;&#961;&#959;&#962;</span></b><b><span
  lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis <span
  class=3DSpellE>Cyprus</span> Ltd.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;:
  +</span><span lang=3DFR style=3D'mso-ansi-language:FR'>357 22 871600<o:p>=
</o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Sv=
erige<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i AB<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+46 (0)8
  634 50 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:14;mso-yfti-lastrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>La=
tvija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>sanof=
i-aventis
  Latvia SIA<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Tel: =
+371 67 33
  24 51<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Un=
ited
  Kingdom<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+44 (0)
  845 372 7101<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <![if !supportMisalignedColumns]>
 <tr height=3D0>
  <td width=3D2 style=3D'border:none'></td>
  <td width=3D310 style=3D'border:none'></td>
  <td width=3D312 style=3D'border:none'></td>
 </tr>
 <![endif]>
</table>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>This
leaflet was last revised in</span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icine is
available on the European Medicines Agency web site: http://www.ema.europa.=
eu/</span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'page-break-before:always'>
</span>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Package leaflet:
Information for the user<o:p></o:p></span></b></p>

<p class=3DEMEATitle><span class=3DSpellE><span lang=3DEN-GB>Karvea</span><=
/span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg tablets</span></p>

<p class=3DEMEATitle><span lang=3DEN-GB style=3D'font-weight:normal'>irbesa=
rtan<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Read all of this leaflet careful=
ly
before you start taking this medicine because it contains important informa=
tion
for you.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>If you have any further questions, ask your doctor or pharmaci=
st.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>This medicine has been prescribed for you only. Do not pass it=
 on to
others. It may harm them, even if their signs of illness are the same as yo=
urs.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>If you get any side effects, talk to your doctor or pharmacist=
. This
includes any possible side effects not listed in this leaflet. See section =
4.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><u><span lang=3DEN-GB>What is in this leaflet<o:p><=
/o:p></span></u></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1'>=
 </span>What
<span class=3DSpellE>Karvea</span> is and what it is used for</span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1'>=
 </span>What
you need to know before you take <span class=3DSpellE>Karvea</span></span><=
/p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1'>=
 </span>How
to take <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1'>=
 </span>Possible
side effects</span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1'>=
 </span>How
to store <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt;text-indent:-28.35pt;
tab-stops:28.35pt'><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1'>=
 </span>Contents
of the pack and other information</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>1.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>What <span class=3DSpellE>Karvea</span> is and what it is used for<o:=
p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> belongs to a group of medicines known as angiotensin-II recep=
tor antagonists.
Angiotensin-II is a substance produced in the body which binds to receptors=
 in
blood vessels causing them to tighten. This results in an increase in blood
pressure. <span class=3DSpellE>Karvea</span> prevents the binding of
angiotensin-II to these receptors, causing the blood vessels to relax and t=
he
blood pressure to lower. <span class=3DSpellE>Karvea</span> slows the decre=
ase of
kidney function in patients with high blood pressure and type&nbsp;2 diabet=
es.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is used in adult patients</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to treat high blood pressure (<i style=3D'mso-bidi-font-style:=
normal'>essential
hypertension</i>)</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</=
span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>2.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>What you need to know before you take <span class=3DSpellE>Karvea</sp=
an></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Do not take <span class=3DSpellE=
>Karvea</span></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>allergic</=
b> to
irbesartan or any other ingredients of this medicine (listed in section 6)<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>more than =
3 months
pregnant</b>. (It is also better to avoid <span class=3DSpellE>Karvea</span=
> in
early pregnancy  see pregnancy section)</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l9 level1 lfo9;tab-stops:list 27.5pt'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings;color:black'><span style=3D'mso-list:Ignore'=
><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>if you have diabet=
es or
impaired kidney </span></b><span lang=3DEN-GB>function and you are treated =
with a
blood pressure lowering medicine containing <span class=3DSpellE>aliskiren<=
/span>.<i
style=3D'mso-bidi-font-style:normal'><span style=3D'color:red'><o:p></o:p><=
/span></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Warning and precautions</span></=
p>

<p class=3DEMEAHeading3><span lang=3DEN-GB style=3D'font-weight:normal'>Tal=
k to your
doctor before taking <span class=3DSpellE>Karvea</span> and</span><span
lang=3DEN-GB> if any of the following apply to you:</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you get <b style=3D'mso-bidi-font-weight:normal'>excessive =
vomiting
or diarrhoea</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>ki=
dney
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>he=
art
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you receive <span class=3DSpellE>Karvea</span> for <b
style=3D'mso-bidi-font-weight:normal'>diabetic kidney disease</b>. In this =
case
your doctor may perform regular blood tests, especially for measuring blood
potassium levels in case of poor kidney function</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you develop <b>low blood sugar levels</b> (symptoms may inc=
lude
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>going to h=
ave an
operation</b> (surgery) or <b style=3D'mso-bidi-font-weight:normal'>be given
anaesthetics<o:p></o:p></b></span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l4 level1 lfo13'><![if !supportLists]><span lang=3DEN-GB
style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-f=
ont-family:
Wingdings;color:black'><span style=3D'mso-list:Ignore'><span style=3D'font=
:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>if you are taking any of =
the
following medicines used to treat high blood pressure:</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:1.0in;text-indent:-.25in;
mso-list:l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:"Courier New";mso-fareast-font-family:"Co=
urier New"'><span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>an ACE-inhibitor (for exa=
mple
enalapril, lisinopril, ramipril), in particular if you have diabetes-related
kidney problems.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-.25in;mso-l=
ist:
l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span lang=3DEN-=
GB
style=3D'font-family:"Courier New";mso-fareast-font-family:"Courier New"'><=
span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span class=3DSpellE><span lang=3DEN-GB>alis=
kiren</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>See also information under the h=
eading
Do not take <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. <span class=3DSpellE>Karvea</spa=
n> is
not recommended in early pregnancy, and must not be taken if you are more t=
han
3&nbsp;months pregnant, as it may cause serious harm to your baby if used at
that stage (see pregnancy section).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Children and adolescents</span><=
/p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>This medici=
nal
product should not be used in children and adolescents because the safety a=
nd
efficacy have not&nbsp;yet been&nbsp;fully established.</span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Other medicines and <span class=
=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor or pharmacist i=
f you
are taking, have recently taken or might take any other medicines.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may need to change y=
our dose
and/or to take other precautions:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><span style=3D'mso-spacerun:yes'=
></span>If
you are taking an ACE-inhibitor or <span class=3DSpellE>aliskiren</span> (s=
ee
also information under the headings Do not take <span class=3DSpellE>Karve=
a</span>
and Warnings and precautions).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>You
may need to have blood checks if you take:</span></b></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium supplements</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>salt substitutes containing potassium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium-sparing medicines (such as certain diuretics)</span>=
</p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>medicines containing lithium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3;mso-prop-ch=
ange:
Author 19000000T0000'><![if !supportLists]><span lang=3DEN-GB style=3D'font=
-family:
Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'=
><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>repaglinide (medication u=
sed
for lowering blood sugar levels)</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you take certain painkillers,=
 called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be redu=
ced.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> with food and drink</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> can be taken with or without food.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Pregnancy and breast-feeding</sp=
an></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Pregnancy</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise=
 you
to stop taking <span class=3DSpellE>Karvea</span> before you become pregnan=
t or
as soon as you know you are pregnant and will advise you to take another
medicine instead of <span class=3DSpellE>Karvea</span>. <span class=3DSpell=
E>Karvea</span>
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used a=
fter
the third month of pregnancy.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Breast-feeding</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. <span class=3DSpellE>Karve=
a</span>
is not recommended for mothers who are breast-feeding, and your doctor may
choose another treatment for you if you wish to breast-feed, especially if =
your
baby is <span class=3DSpellE>newborn</span>, or was born prematurely.</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Driving and using machines</span=
></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is unlikely to affect your ability to drive or use machines.
However, occasionally dizziness or weariness may occur during treatment of =
high
blood pressure. If you experience these, talk to your doctor before attempt=
ing
to drive or use machines.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains lactose</span></b><span lang=3DEN-GB>. If you have b=
een told
by your doctor that you have an intolerance to some sugars (e.g. lactose),
contact your doctor before taking this medicinal product.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains sodium. </span></b><span lang=3DEN-GB style=3D'mso-b=
idi-font-weight:
bold'>This medicine contains less than 1 mmol sodium (23 mg) per tablet, th=
at
is to say essentially sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>3.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>How to take <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Always take this medicine exactl=
y as
your doctor has told you. Check with your doctor or pharmacist if you are n=
ot
sure.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Method of administration</span><=
/p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is for <b style=3D'mso-bidi-font-weight:normal'>oral use</b>.=
 Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take <span class=3DSpellE>Karvea</span> with or without food. Try to ta=
ke
your daily dose at about the same time each day. It is important that you
continue to take <span class=3DSpellE>Karvea</span> until your doctor tells=
 you
otherwise.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure<o:p></o:p></span></b></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>Th=
e usual
dose is 150&nbsp;mg once a day. The dose may later be increased to 300&nbsp=
;mg
once daily depending on blood pressure response.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure and type&nbsp;2 diabetes with kidney disease<o:p></o:p></span></b>=
</p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>In=
 patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg once daily is
the preferred maintenance dose for the treatment of associated kidney disea=
se.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The doctor may advise a lower do=
se,
especially when starting treatment in certain patients such as those on <b
style=3D'mso-bidi-font-weight:normal'>haemodialysis</b>, or those <b
style=3D'mso-bidi-font-weight:normal'>over the age of 75&nbsp;years.<o:p></=
o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The maximal blood pressure lower=
ing
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Use in children and adolescents<=
/span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> should not be given to children under 18&nbsp;years of age. I=
f a
child swallows some tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you take more <span class=3DS=
pellE>Karvea</span>
than you should</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you forget to take <span
class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally miss a daily=
 dose,
just take the next dose as normal. Do not take a double dose to make up for=
 a
forgotten dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:NL=
'>If you
have any further questions on the use of this medicine, ask your doctor or
pharmacist.</span><span lang=3DEN-GB style=3D'font-size:10.0pt;font-family:=
"TimesNewRoman\,Italic";
mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"TimesNewRoman=
\,Italic";
mso-fareast-language:NL'><o:p></o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>4.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>Possible side effects</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Like all medicines, this medicin=
e can
cause side effects, although not everybody gets them.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Some of these effects may be ser=
ious and
may require medical attention.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As with similar medicines, rare =
cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of=
 the
face, lips and/or tongue have been reported in patients taking irbesartan. =
If
you get any of these symptoms or get short of breath, <b style=3D'mso-bidi-=
font-weight:
normal'>stop taking <span class=3DSpellE>Karvea</span> and contact your doc=
tor
immediately.<o:p></o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of the side effect=
s listed
below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Very common: </span><span lang=
=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt'>may affect more than 1 in 10 people</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Common: may affect up to 1 in 10=
 people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Uncommon: may affect up to 1 in =
100
people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Side effects reported in clinical
studies for patients treated with <span class=3DSpellE>Karvea</span> were:<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Very common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-=
size:11.0pt'>may
affect more than 1 in 10 people)</span><span lang=3DEN-GB>: if you suffer f=
rom
high blood pressure and type&nbsp;2 diabetes with kidney disease, blood tes=
ts
may show an increased level of potassium.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-size:=
11.0pt'>may
affect up to 1 10 people)</span><span lang=3DEN-GB>: dizziness, feeling
sick/vomiting, fatigue and blood tests may show raised levels of an enzyme =
that
measures the muscle and heart function (creatine kinase enzyme). In patients
with high blood pressure and type&nbsp;2 diabetes with kidney disease,
dizziness when getting up from a lying or sitting position, low blood press=
ure
when getting up from a lying or sitting position, pain in joints or muscles=
 and
decreased levels of a protein in the red blood cells (haemoglobin) were also
reported.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Uncommon (</span><span lang=3DEN-GB style=3D'mso-bidi-font-siz=
e:11.0pt'>may
affect up to 1 in 100 people)</span><span lang=3DEN-GB>: heart rate increas=
ed,
flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (prob=
lems
with sexual performance), chest pain.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB>Some undesirable effects have been =
reported
since marketing of <span class=3DSpellE>Karvea</span>. Undesirable effects =
where
the frequency is not known are: feeling of spinning, headache, taste
disturbance, ringing in the ears, </span><span lang=3DEN-GB style=3D'mso-bi=
di-font-size:
11.0pt'>muscle cramps, </span><span lang=3DEN-GB>pain in joints and muscles=
, </span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>decreased number of red bl=
ood
cells (anaemia  symptoms may include tiredness, headaches, being short of
breath when exercising, dizziness and looking pale), </span><span lang=3DEN=
-GB>reduced
number of platelets, abnormal liver function, increased blood potassium lev=
els,
impaired kidney function, inflammation of small blood vessels</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> </span><span lang=3DEN-GB
style=3D'mso-bidi-font-style:italic'>mainly affecting the skin</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> (a condition known as <sp=
an
class=3DSpellE>leukocytoclastic</span> vasculitis),</span><span lang=3DEN-GB
style=3D'mso-ansi-language:EN-US'> </span><span style=3D'mso-ansi-language:=
EN-US'>severe
allergic reactions (anaphylactic shock)</span><span style=3D'mso-bidi-font-=
size:
11.0pt'> <span lang=3DEN-GB>and </span></span><span lang=3DEN-GB>low blood =
sugar
levels. Uncommon cases of jaundice (yellowing of the skin and/or whites of =
the
eyes) have also been reported.</span><span style=3D'mso-ansi-language:EN-US=
'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of side effects<o:p=
></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you get any side effects, tal=
k to
your doctor or pharmacist. This includes any possible side effects not list=
ed
in this leaflet. You can also report side effects directly via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in </span></span><span class=3DMsoHyperlink><span lang=3DES-TRAD
style=3D'mso-bidi-font-size:12.0pt;background:silver;mso-highlight:silver;
mso-ansi-language:ES-TRAD;mso-fareast-language:ZH-CN;mso-no-proof:yes;
text-decoration:none;text-underline:none'>Appendix V</span></span><span
lang=3DEN-GB>. By reporting side <span class=3DSpellE>effects you</span> ca=
n help provide
more information on the safety of this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>5.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>How to store <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Keep this medicine out of the si=
ght and
reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not use this medicine after t=
he
expiry date which is stated on the carton and on the blister after EXP. The=
 expiry
date refers to the last day of that month.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not store above 30C.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not throw away any medicines =
via
wastewater or household waste. Ask your pharmacist how to throw away of
medicines you no longer use. These measures will help protect the environme=
nt.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1 style=3D'margin-left:0in;text-indent:0in'><span lan=
g=3DEN-GB>6.<span
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB style=3D'=
font-family:
"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman";text-tr=
ansform:
none'>Contents of the pack and other information</span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
contains</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:=
1'> </span></span><span
lang=3DEN-GB>The active substance is irbesartan. Each tablet of <span
class=3DSpellE>Karvea</span>&nbsp;300&nbsp;mg contains 300&nbsp;mg irbesart=
an.</span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'font-family:Wingdings'><s=
pan
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB>The other ingr=
edients
are microcrystalline cellulose, croscarmellose sodium, lactose monohydrate,
magnesium stearate, colloidal hydrated silica, <span class=3DSpellE>pregela=
tinised</span>
maize starch, and poloxamer&nbsp;188. </span><span style=3D'mso-ansi-langua=
ge:
EN-US'>Please see section 2 <span class=3DSpellE>Karvea</span> contains
lactose.<o:p></o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none;tab-stops:28.35pt'><sp=
an
lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
looks like and contents of the pack</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg tablets are white to off-white, biconvex, and
oval-shaped with a heart debossed on one side and the number&nbsp;2773 engr=
aved
on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg tablets are supplied in blister packs of 14,=
 28,
56 or 98&nbsp;tablets. <span class=3DSpellE>Unidose</span> blister packs of
56&nbsp;x&nbsp;1&nbsp;tablet for delivery in hospitals are also available.<=
/span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Not all pack sizes may be market=
ed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Mark=
eting <span
class=3DSpellE>Authorisation</span> Holder:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris</span><span lang=3DFR style=3D'mso-ansi-language:FR'>&nbsp;</=
span><span
lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>-&nbsp;France<o:p></o:p></sp=
an></p>

<p class=3DEMEABodyText><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE=
'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Manu=
facturer:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
<span class=3DSpellE>Ambars</span> &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>SANOF=
I&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France<o:p></o:p></span></=
p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>CHINO=
IN PRIVATE
CO. LTD.<br>
<span class=3DSpellE>Lvai</span> u.5.<br>
2112 <span class=3DSpellE>Veresegyhz</span>&nbsp;-&nbsp;<span class=3DSpel=
lE>Hungary</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For any information about this m=
edicinal
product, please contact the local representative of the Marketing Authorisa=
tion
Holder.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D624
 style=3D'margin-left:-1.7pt;border-collapse:collapse;mso-table-layout-alt:=
fixed;
 mso-padding-alt:0in 5.4pt 0in 5.4pt'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Be=
lgi/</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'>Belgique</span></b><b><span lang=
=3DMT
  style=3D'mso-ansi-language:MT'>/Belgien</span></b><b><span lang=3DFR-BE
  style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi <span class=3DSpellE>Belgium</span></span><=
span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>Tl/Tel: <span
  style=3D'layout-grid-mode:line'>+32 (0)2 710 54 00<o:p></o:p></span></spa=
n></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLT style=3D'mso-ansi-language:LT'>Li=
etuva<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>UAB
  sanofi-aventis Lietuva</span><span lang=3DFR style=3D'mso-ansi-language:F=
R'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+370 5
  2755224<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><span class=3DSpellE><b><span lang=3DEN-GB>&#1041;&#=
1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></span><b><span
  lang=3DIT style=3D'mso-ansi-language:IT'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT;mso-no=
-proof:
  yes'>Sanofi Bulgaria EOOD<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  BG;mso-bidi-font-weight:bold'>&#1058;&#1077;&#1083;</span><span lang=3DIT
  style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT;mso-bidi-font-wei=
ght:
  bold'>.</span><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
  BG;mso-bidi-font-weight:bold'>: +</span><span lang=3DIT style=3D'mso-bidi=
-font-size:
  11.0pt;mso-ansi-language:IT;mso-bidi-font-weight:bold'>359 (0)2</span><sp=
an
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial;
  mso-ansi-language:IT'> 970 53 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR-LU style=3D'mso-ansi-language:FR-=
LU'>Luxembourg/Luxemburg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi <span class=3DSpellE>Belgium</span> <o:p></=
o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-LU style=3D'mso-ansi-language:FR-LU'=
>Tl/Tel: </span><span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;layout-grid-mode:line'>+32 =
(0)2 710
  54 00 (</span><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>Belgiq=
ue/<span
  class=3DSpellE>Belgien</span>)<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DHU style=3D'mso-ansi-language:HU'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>&#=
268;esk
  republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis,
  s.r.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+420 233
  086 111<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DHU style=3D'mso-ansi-language:HU'>Ma=
gyarorszg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>SANOF=
I-AVENTIS
  Zrt.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel.:=
 +36 1 </span><span
  lang=3DHU style=3D'mso-ansi-language:HU'>505 0050<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Da=
nmark<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i A/S<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+45 45 16
  70 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Ma=
lta<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+39 02
  39394275<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>De=
utschland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i-Aventis Deutschland
  GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
0800 52 52
  010<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel. =
aus dem
  Ausland: +49 69 305 21 131<o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Ne=
derland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Genzy=
me Europe B.V.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+31 20 245
  4000</span><span lang=3DNL style=3D'mso-ansi-language:NL'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DET style=3D'mso-ansi-language:ET'>Ee=
sti<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Estonia O<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+372 627
  34 88<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>No=
rge<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Norge AS<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+47 67 10
  71 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
917;&#955;&#955;&#940;&#948;&#945;</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  AEBE</span><span lang=3DET style=3D'mso-ansi-language:ET'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'>: +30 210 900 16 00<o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>s=
terreich<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>sanof=
i-aventis
  GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Tel: =
+43 1 80
  185  0<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DES style=3D'mso-ansi-language:ES'>Es=
paa<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>sanof=
i-aventis,
  S.A.<span style=3D'font-variant:small-caps'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tel: =
+34 93 485
  94 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>Po=
lska<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>sanof=
i-aventis
  Sp. z o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel.:=
 +48
  22&nbsp;280 00 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:8;page-break-inside:avoid'>
  <td width=3D312 colspan=3D2 valign=3Dtop style=3D'width:233.9pt;padding:0=
in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Fr=
ance<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
  France</span><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tl: =
0 800 222
  555<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Appel=
 depuis
  ltranger : +33 1 57 63 23 23<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DPT style=3D'mso-ansi-language:PT'>Po=
rtugal<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Sanof=
i -
  Produtos Farmacuticos, Lda<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+351 21 35
  89 400<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:9;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'page-break-after:avoid'><b><span lang=3DIT
  style=3D'mso-fareast-font-family:SimSun;mso-ansi-language:IT'>Hrvatska<o:=
p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:IT'>sanofi-aventis Croatia d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:FR'>Tel: +385 1 600 34 00</span><span lang=3DFR
  style=3D'mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<b
  style=3D'mso-bidi-font-weight:normal'><span lang=3DIT style=3D'mso-bidi-f=
ont-size:
  11.0pt;mso-ansi-language:IT;mso-no-proof:yes'>Romnia<o:p></o:p></span></=
b></p>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<span
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT'>Sanofi=
 Romania
  SRL<span style=3D'mso-no-proof:yes'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  IT;mso-no-proof:yes'>Tel: +40 </span><span lang=3DIT style=3D'mso-bidi-fo=
nt-size:
  11.0pt;mso-ansi-language:IT'>(0) 21 317 31 36<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:10;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Ir=
eland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
  Ireland Ltd. T/A SANOFI<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+353 (0) 1
  403 56 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSL style=3D'mso-ansi-language:SL'>Sl=
ovenija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+386 1 560
  48 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:11;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIS style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:IS'>sland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Vistor hf.</span><span lang=3DIS style=3D'mso-bidi-font-size:11.0pt;
  mso-ansi-language:IS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0p=
t;
  mso-no-proof:yes'>Smi</span><span lang=3DCS style=3D'mso-bidi-font-size:=
11.0pt;
  mso-ansi-language:CS'>: +354 535 7000<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSK style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:SK'>Slovensk republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'>sanofi-</span><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;mso-=
ansi-language:
  CS'>aventis Slovakia </span><span lang=3DSK style=3D'mso-bidi-font-size:1=
1.0pt;
  mso-ansi-language:SK'>s.r.o.</span><span lang=3DCS style=3D'mso-bidi-font=
-size:
  11.0pt;mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Tel: +</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
  SK'>421 2 </span><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>3=
3 100
  100</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-ansi-lan=
guage:
  SK'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:12;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>It=
alia<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Tel: =
</span><span
  lang=3DCS style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:CS'>800 53=
6389</span><span
  lang=3DIT style=3D'mso-ansi-language:IT'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>Su=
omi/Finland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i Oy<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Puh/T=
el: +358
  (0) 201 200 300<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:13;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
922;&#973;&#960;&#961;&#959;&#962;</span></b><b><span
  lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis <span
  class=3DSpellE>Cyprus</span> Ltd.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;:
  +</span><span lang=3DFR style=3D'mso-ansi-language:FR'>357 22 871600<o:p>=
</o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Sv=
erige<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i AB<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+46 (0)8
  634 50 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:14;mso-yfti-lastrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>La=
tvija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>sanof=
i-aventis
  Latvia SIA<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Tel: =
+371 67 33
  24 51<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Un=
ited
  Kingdom<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+44 (0)
  845 372 7101<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <![if !supportMisalignedColumns]>
 <tr height=3D0>
  <td width=3D2 style=3D'border:none'></td>
  <td width=3D310 style=3D'border:none'></td>
  <td width=3D312 style=3D'border:none'></td>
 </tr>
 <![endif]>
</table>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>This
leaflet was last revised in</span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icine is
available on the European Medicines Agency web site: http://www.ema.europa.=
eu/</span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'page-break-before:always'>
</span>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Package leaflet:
Information for the user<o:p></o:p></span></b></p>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><span
class=3DSpellE><b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>=
Karvea</span></b></span><span
lang=3DEN-GB>&nbsp;<b style=3D'mso-bidi-font-weight:normal'>75</b>&nbsp;<b
style=3D'mso-bidi-font-weight:normal'>mg film-coated tablets<o:p></o:p></b>=
</span></p>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><span la=
ng=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Read all of this leaflet careful=
ly
before you start taking this medicine because it contains important informa=
tion
for you.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>If you have any further questions, ask your doctor or pharmaci=
st.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>This medicine has been prescribed for you only. Do not pass it=
 on to
others. It may harm them, even if their signs of illness are the same as yo=
urs.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>If you get any side effects, talk to your doctor or pharmacist=
. This
includes any possible side effects not listed in this leaflet. See section =
4.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><u><span lang=3DEN-GB>What is in this leaflet<o:p><=
/o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>What
<span class=3DSpellE>Karvea</span> is and what it is used for</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>What
you need to know before you take <span class=3DSpellE>Karvea</span></span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>How
to take <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>Possible
side effects</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>How
to store <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1=
'> </span>Contents
of the pack and other information</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>1.<span
style=3D'mso-tab-count:1'> </span>What <span class=3DSpellE>Karvea</s=
pan> is
and what it is used for<o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> belongs to a group of medicines known as angiotensin-II recep=
tor antagonists.
Angiotensin-II is a substance produced in the body which binds to receptors=
 in
blood vessels causing them to tighten. This results in an increase in blood
pressure. <span class=3DSpellE>Karvea</span> prevents the binding of
angiotensin-II to these receptors, causing the blood vessels to relax and t=
he
blood pressure to lower. <span class=3DSpellE>Karvea</span> slows the decre=
ase of
kidney function in patients with high blood pressure and type&nbsp;2 diabet=
es.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is used in adult patients</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to treat high blood pressure (<i style=3D'mso-bidi-font-style:=
normal'>essential
hypertension</i>)</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</=
span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span></span><span
lang=3DEN-GB style=3D'font-family:"Times New Roman Bold",serif;mso-bidi-fon=
t-family:
"Times New Roman";text-transform:none'>What you need to know before you tak=
e</span><span
lang=3DEN-GB> </span><span class=3DSpellE><span lang=3DEN-GB style=3D'text-=
transform:
none'>Karvea</span></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Do not take <span class=3DSpellE=
>Karvea</span></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>allergic</=
b> to
irbesartan or any other ingredients of this medicine (listed in section 6)<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>more than
3&nbsp;months pregnant</b>. (It is also better to avoid <span class=3DSpell=
E>Karvea</span>
in early pregnancy  see pregnancy section)</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l11 level1 lfo10;tab-stops:list 27.5pt'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings;color:black'><span style=3D'mso-list:Ignore'=
><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>if you have diabet=
es or
impaired kidney function </span></b><span lang=3DEN-GB>and you are treated =
with a
blood pressure lowering medicine containing <span class=3DSpellE>aliskiren<=
/span>.
<i style=3D'mso-bidi-font-style:normal'><span style=3D'color:red'><o:p></o:=
p></span></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Warnings and precautions</span><=
/p>

<p class=3DEMEAHeading3><span lang=3DEN-GB style=3D'font-weight:normal'>Tal=
k to your
doctor before taking <span class=3DSpellE>Karvea</span></span><span lang=3D=
EN-GB> </span><span
lang=3DEN-GB style=3D'font-weight:normal'>and </span><span lang=3DEN-GB>if =
any of the
following apply to you:</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you get <b style=3D'mso-bidi-font-weight:normal'>excessive =
vomiting
or diarrhoea</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>ki=
dney
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>he=
art
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you receive <span class=3DSpellE>Karvea</span> for <b
style=3D'mso-bidi-font-weight:normal'>diabetic kidney disease</b>. In this =
case
your doctor may perform regular blood tests, especially for measuring blood
potassium levels in case of poor kidney function</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you develop <b>low blood sugar levels</b> (symptoms may inc=
lude
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>going to h=
ave an
operation</b> (surgery) or <b style=3D'mso-bidi-font-weight:normal'>be given
anaesthetics<o:p></o:p></b></span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l4 level1 lfo13'><![if !supportLists]><span lang=3DEN-GB
style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-f=
ont-family:
Wingdings;color:black'><span style=3D'mso-list:Ignore'><span style=3D'font=
:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>if you are taking any of =
the
following medicines used to treat high blood pressure:</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:1.0in;text-indent:-.25in;
mso-list:l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:"Courier New";mso-fareast-font-family:"Co=
urier New"'><span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>an ACE-inhibitor (for exa=
mple
enalapril, lisinopril, ramipril), in particular if you have diabetes-related
kidney problems.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-.25in;mso-l=
ist:
l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span lang=3DEN-=
GB
style=3D'font-family:"Courier New";mso-fareast-font-family:"Courier New"'><=
span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span class=3DSpellE><span lang=3DEN-GB>alis=
kiren</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>See also information under the h=
eading
Do not take <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. <span class=3DSpellE>Karvea</spa=
n> is
not recommended in early pregnancy, and must not be taken if you are more t=
han
3&nbsp;months pregnant, as it may cause serious harm to your baby if used at
that stage (see pregnancy section).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Children and adolescents</span><=
/p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>This medici=
nal
product should not be used in children and adolescents because the safety a=
nd
efficacy have not&nbsp;yet been&nbsp;fully established.</span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Other medicines and <span class=
=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor or pharmacist i=
f you
are taking, have recently taken or might take any other medicines.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may need to change y=
our dose
and/or to take other precautions:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><span style=3D'mso-spacerun:yes'=
></span>If
you are taking an ACE-inhibitor or <span class=3DSpellE>aliskiren</span> (s=
ee
also information under the headings Do not take <span class=3DSpellE>Karve=
a</span>
and Warnings and precautions).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>You
may need to have blood checks if you take:</span></b></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium supplements</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>salt substitutes containing potassium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium-sparing medicines (such as certain diuretics)</span>=
</p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>medicines containing lithium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3;mso-prop-ch=
ange:
Author 19000000T0000'><![if !supportLists]><span lang=3DEN-GB style=3D'font=
-family:
Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'=
><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>repaglinide (medication u=
sed
for lowering blood sugar levels)</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you take certain painkillers,=
 called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be redu=
ced.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> with food and drink</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> can be taken with or without food.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Pregnancy and breast-feeding</sp=
an></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Pregnancy</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise=
 you
to stop taking <span class=3DSpellE>Karvea</span> before you become pregnan=
t or
as soon as you know you are pregnant and will advise you to take another
medicine instead of <span class=3DSpellE>Karvea</span>. <span class=3DSpell=
E>Karvea</span>
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used a=
fter
the third month of pregnancy.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Breast-feeding</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. <span class=3DSpellE>Karve=
a</span>
is not recommended for mothers who are breast-feeding, and your doctor may
choose another treatment for you if you wish to breast-feed, especially if =
your
baby is <span class=3DSpellE>newborn</span>, or was born prematurely.</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Driving and using machines</span=
></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is unlikely to affect your ability to drive or use machines.
However, occasionally dizziness or weariness may occur during treatment of =
high
blood pressure. If you experience these, talk to your doctor before attempt=
ing
to drive or use machines.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains lactose</span></b><span lang=3DEN-GB>. If you have b=
een told
by your doctor that you have an intolerance to some sugars (e.g. lactose),
contact your doctor before taking this medicinal product.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains sodium. </span></b><span lang=3DEN-GB style=3D'mso-b=
idi-font-weight:
bold'>This medicine contains less than 1 mmol sodium (23 mg) per tablet, th=
at is
to say essentially sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>3.<span
style=3D'mso-tab-count:1'> </span>How to take <span class=3DSpellE>Ka=
rvea</span><o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Always take this medicine exactl=
y as
your doctor has told you. Check with your doctor or pharmacist if you are n=
ot
sure.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Method of administration</span><=
/p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is for <b style=3D'mso-bidi-font-weight:normal'>oral use</b>.=
 Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take <span class=3DSpellE>Karvea</span> with or without food. Try to ta=
ke
your daily dose at about the same time each day. It is important that you
continue to take <span class=3DSpellE>Karvea</span> until your doctor tells=
 you
otherwise.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure<o:p></o:p></span></b></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>Th=
e usual
dose is 150&nbsp;mg once a day (two tablets a day). The dose may later be
increased to 300&nbsp;mg (four tablets a day) once daily depending on blood=
 pressure
response.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure and type&nbsp;2 diabetes with kidney disease<o:p></o:p></span></b>=
</p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>In=
 patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg (four tablet=
s a
day) once daily is the preferred maintenance dose for the treatment of
associated kidney disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The doctor may advise a lower do=
se,
especially when starting treatment in certain patients such as those on <b
style=3D'mso-bidi-font-weight:normal'>haemodialysis</b>, or those <b
style=3D'mso-bidi-font-weight:normal'>over the age of 75&nbsp;years.<o:p></=
o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The maximal blood pressure lower=
ing
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Use in children and adolescents<=
/span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> should not be given to children under 18&nbsp;years of age. I=
f a
child swallows some tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you take more <span class=3DS=
pellE>Karvea</span>
than you should:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally take too man=
y tablets,
contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you forget to take <span
class=3DSpellE>Karvea</span>:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally miss a daily=
 dose,
just take the next dose as normal. Do not take a double dose to make up for=
 a
forgotten dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:NL=
'>If you
have any further questions on the use of this medicine, ask your doctor or
pharmacist.</span><span lang=3DEN-GB style=3D'font-size:10.0pt;font-family:=
"TimesNewRoman\,Italic";
mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"TimesNewRoman=
\,Italic";
mso-fareast-language:NL'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>4.<span
style=3D'mso-tab-count:1'> </span>Possible side effects<o:p></o:p></s=
pan></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Like all medicines, this medicin=
e can
cause side effects, although not everybody gets them.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Some of these effects may be ser=
ious and
may require medical attention.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As with similar medicines, rare =
cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of=
 the
face, lips and/or tongue have been reported in patients taking irbesartan. =
If
you get any of these symptoms or get short of breath, <b style=3D'mso-bidi-=
font-weight:
normal'>stop taking <span class=3DSpellE>Karvea</span> and contact your doc=
tor
immediately.<o:p></o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of the side effect=
s listed
below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Very common: </span><span lang=
=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt'>may affect more than 1 in 10 people</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Common: may affect up to 1 in 10=
 people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Uncommon: may affect up to 1 in =
100
people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Side effects reported in clinical
studies for patients treated with <span class=3DSpellE>Karvea</span> were:<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Very common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-=
size:11.0pt'>may
affect more than 1 in 10 people)</span><span lang=3DEN-GB>: if you suffer f=
rom
high blood pressure and type&nbsp;2 diabetes with kidney disease, blood tes=
ts
may show an increased level of potassium.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-size:=
11.0pt'>may
affect up to 1 10 people)</span><span lang=3DEN-GB>: dizziness, feeling sic=
k/vomiting,
fatigue and blood tests may show raised levels of an enzyme that measures t=
he
muscle and heart function (creatine kinase enzyme). In patients with high b=
lood
pressure and type&nbsp;2 diabetes with kidney disease, dizziness when getti=
ng
up from a lying or sitting position, low blood pressure when getting up fro=
m a
lying or sitting position, pain in joints or muscles and decreased levels o=
f a
protein in the red blood cells (haemoglobin) were also reported.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Uncommon (</span><span lang=3DEN-GB style=3D'mso-bidi-font-siz=
e:11.0pt'>may
affect up to 1 in 100 people)</span><span lang=3DEN-GB>: heart rate increas=
ed,
flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (prob=
lems
with sexual performance), chest pain.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB>Some undesirable effects have been =
reported
since marketing of <span class=3DSpellE>Karvea</span>. Undesirable effects =
where
the frequency is not known are: feeling of spinning, headache, taste
disturbance, ringing in the ears, </span><span lang=3DEN-GB style=3D'mso-bi=
di-font-size:
11.0pt'>muscle cramps, </span><span lang=3DEN-GB>pain in joints and muscles=
, </span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>decreased number of red bl=
ood
cells (anaemia  symptoms may include tiredness, headaches, being short of
breath when exercising, dizziness and looking pale), </span><span lang=3DEN=
-GB>reduced
number of platelets, abnormal liver function, increased blood potassium lev=
els,
impaired kidney function, inflammation of small blood vessels</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> </span><span lang=3DEN-GB
style=3D'mso-bidi-font-style:italic'>mainly affecting the skin</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> (a condition known as <sp=
an
class=3DSpellE>leukocytoclastic</span> vasculitis),</span><span lang=3DEN-GB
style=3D'mso-ansi-language:EN-US'> </span><span style=3D'mso-ansi-language:=
EN-US'>severe
allergic reactions (anaphylactic shock)</span><span style=3D'mso-bidi-font-=
size:
11.0pt'> <span lang=3DEN-GB>and </span></span><span lang=3DEN-GB>low blood =
sugar
levels. Uncommon cases of jaundice (yellowing of the skin and/or whites of =
the
eyes) have also been reported.</span><span style=3D'mso-ansi-language:EN-US=
'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of side effects<o:p=
></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you get any side effects, tal=
k to
your doctor or pharmacist. This includes any possible side effects not list=
ed
in this leaflet. You can also report side effects directly via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in </span></span><span class=3DMsoHyperlink><span lang=3DES-TRAD
style=3D'mso-bidi-font-size:12.0pt;background:silver;mso-highlight:silver;
mso-ansi-language:ES-TRAD;mso-fareast-language:ZH-CN;mso-no-proof:yes;
text-decoration:none;text-underline:none'>Appendix V</span></span><span
lang=3DEN-GB>. By reporting side <span class=3DSpellE>effects you</span> ca=
n help
provide more information on the safety of this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>5.<span
style=3D'mso-tab-count:1'> </span>How to store <span class=3DSpellE>K=
arvea</span><o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Keep this medicine out of the si=
ght and
reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not use this medicine after t=
he
expiry date which is stated on the carton and on the blister after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not store above 30C.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not throw away any medicines =
via
wastewater or household waste. Ask your pharmacist how to throw away medici=
nes
you no longer use. These measures will help protect the environment.</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>6.<span
style=3D'mso-tab-count:1'> </span>Contents of the pack and other info=
rmation<o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
contains</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>The active substance is irbesartan. Each tablet of <span
class=3DSpellE>Karvea</span>&nbsp;75&nbsp;mg contains 75&nbsp;mg irbesartan=
.</span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'font-family:Wingdings'><s=
pan
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB>The other ingr=
edients
are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium,=
 <span
class=3DSpellE>hypromellose</span>, silicon dioxide, magnesium stearate, ti=
tanium
dioxide, macrogol 3000, carnauba wax. </span><span style=3D'mso-ansi-langua=
ge:
EN-US'>Please see section 2 <span class=3DSpellE>Karvea</span> contains
lactose.<o:p></o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB><o=
:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
looks like and contents of the pack</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg film-coated tablets are white to off-white,
biconvex, and oval-shaped with a heart debossed on one side and the
number&nbsp;2871 engraved on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;75&nbsp;mg film-coated tablets are supplied in blister p=
acks
of 14, 28, 30, 56, 84, 90 or 98&nbsp;film-coated tablets. <span class=3DSpe=
llE>Unidose</span>
blister packs of 56&nbsp;x&nbsp;1&nbsp;film-coated tablet for delivery in
hospitals are also available.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Not all pack sizes may be market=
ed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Mark=
eting <span
class=3DSpellE>Authorisation</span> Holder:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris</span><span lang=3DFR-BE style=3D'mso-ansi-language:FR'> </sp=
an><span
lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>-&nbsp;France<o:p></o:p></sp=
an></p>

<p class=3DEMEABodyText><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE=
'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Manu=
facturer:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
<span class=3DSpellE>Ambars</span> &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DEN-GB>SANOFI&nbsp;<st1:City w:st=3D"on"=
>WINTHROP</st1:City>&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;<st1:City w:st=3D"on"><st1:place w:st=3D"on">Tours</st1:place>=
</st1:City>&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France</span></p>

<p class=3DEMEAAddress><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For any information about this m=
edicinal
product, please contact the local representative of the Marketing Authorisa=
tion
Holder.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D624
 style=3D'margin-left:-1.7pt;border-collapse:collapse;mso-table-layout-alt:=
fixed;
 mso-padding-alt:0in 5.4pt 0in 5.4pt'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Be=
lgi/</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'>Belgique</span></b><b><span lang=
=3DMT
  style=3D'mso-ansi-language:MT'>/Belgien</span></b><b><span lang=3DFR-BE
  style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi <span class=3DSpellE>Belgium</span></span><=
span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>Tl/Tel: <span
  style=3D'layout-grid-mode:line'>+32 (0)2 710 54 00<o:p></o:p></span></spa=
n></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLT style=3D'mso-ansi-language:LT'>Li=
etuva<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>UAB
  sanofi-aventis Lietuva</span><span lang=3DFR style=3D'mso-ansi-language:F=
R'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+370 5
  2755224<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><span class=3DSpellE><b><span lang=3DEN-GB>&#1041;&#=
1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></span><b><span
  lang=3DIT style=3D'mso-ansi-language:IT'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT;mso-no=
-proof:
  yes'>Sanofi Bulgaria EOOD<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  BG;mso-bidi-font-weight:bold'>&#1058;&#1077;&#1083;</span><span lang=3DIT
  style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT;mso-bidi-font-wei=
ght:
  bold'>.</span><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
  BG;mso-bidi-font-weight:bold'>: +</span><span lang=3DIT style=3D'mso-bidi=
-font-size:
  11.0pt;mso-ansi-language:IT;mso-bidi-font-weight:bold'>359 (0)2</span><sp=
an
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial;
  mso-ansi-language:IT'> 970 53 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR-LU style=3D'mso-ansi-language:FR-=
LU'>Luxembourg/Luxemburg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi <span class=3DSpellE>Belgium</span> <o:p></=
o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-LU style=3D'mso-ansi-language:FR-LU'=
>Tl/Tel: </span><span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;layout-grid-mode:line'>+32 =
(0)2 710
  54 00 (</span><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>Belgiq=
ue/<span
  class=3DSpellE>Belgien</span>)<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DHU style=3D'mso-ansi-language:HU'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>&#=
268;esk
  republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis,
  s.r.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+420 233
  086 111<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DHU style=3D'mso-ansi-language:HU'>Ma=
gyarorszg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>SANOF=
I-AVENTIS
  Zrt.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel.:=
 +36 1 </span><span
  lang=3DHU style=3D'mso-ansi-language:HU'>505 0050<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Da=
nmark<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i A/S<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+45 45 16
  70 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Ma=
lta<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+39 02
  39394275<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>De=
utschland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i-Aventis
  Deutschland GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
0800 52 52
  010<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel. =
aus dem Ausland:
  +49 69 305 21 131<o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Ne=
derland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Genzy=
me Europe B.V.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+31 20 245
  4000</span><span lang=3DNL style=3D'mso-ansi-language:NL'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DET style=3D'mso-ansi-language:ET'>Ee=
sti<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Estonia O<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+372 627
  34 88<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>No=
rge<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Norge AS<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+47 67 10
  71 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
917;&#955;&#955;&#940;&#948;&#945;</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  AEBE</span><span lang=3DET style=3D'mso-ansi-language:ET'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'>: +30 210 900 16 00<o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>s=
terreich<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>sanof=
i-aventis
  GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Tel: =
+43 1 80
  185  0<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DES style=3D'mso-ansi-language:ES'>Es=
paa<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>sanof=
i-aventis,
  S.A.<span style=3D'font-variant:small-caps'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tel: =
+34 93 485
  94 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>Po=
lska<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>sanof=
i-aventis
  Sp. z o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel.:=
 +48
  22&nbsp;280 00 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:8;page-break-inside:avoid'>
  <td width=3D312 colspan=3D2 valign=3Dtop style=3D'width:233.9pt;padding:0=
in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Fr=
ance<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
  France</span><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tl: =
0 800 222
  555<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Appel=
 depuis
  ltranger : +33 1 57 63 23 23<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DPT style=3D'mso-ansi-language:PT'>Po=
rtugal<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Sanof=
i -
  Produtos Farmacuticos, Lda<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+351 21 35
  89 400<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:9;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'page-break-after:avoid'><b><span lang=3DIT
  style=3D'mso-fareast-font-family:SimSun;mso-ansi-language:IT'>Hrvatska<o:=
p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:IT'>sanofi-aventis Croatia d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:FR'>Tel: +385 1 600 34 00</span><span lang=3DFR
  style=3D'mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 67.25pt'=
><b
  style=3D'mso-bidi-font-weight:normal'><span lang=3DIT style=3D'mso-bidi-f=
ont-size:
  11.0pt;mso-ansi-language:IT;mso-no-proof:yes'>Romnia<span style=3D'mso-t=
ab-count:
  1'> </span><o:p></o:p></span></b></p>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<span
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT'>Sanofi=
 Romania
  SRL<span style=3D'mso-no-proof:yes'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  IT;mso-no-proof:yes'>Tel: +40 </span><span lang=3DIT style=3D'mso-bidi-fo=
nt-size:
  11.0pt;mso-ansi-language:IT'>(0) 21 317 31 36<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:10;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Ir=
eland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
  Ireland Ltd. T/A SANOFI<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+353 (0) 1
  403 56 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSL style=3D'mso-ansi-language:SL'>Sl=
ovenija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+386 1 560
  48 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:11;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIS style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:IS'>sland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Vistor hf.</span><span lang=3DIS style=3D'mso-bidi-font-size:11.0pt;
  mso-ansi-language:IS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0p=
t;
  mso-no-proof:yes'>Smi</span><span lang=3DCS style=3D'mso-bidi-font-size:=
11.0pt;
  mso-ansi-language:CS'>: +354 535 7000<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSK style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:SK'>Slovensk republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'>sanofi-</span><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;mso-=
ansi-language:
  CS'>aventis Slovakia </span><span lang=3DSK style=3D'mso-bidi-font-size:1=
1.0pt;
  mso-ansi-language:SK'>s.r.o.</span><span lang=3DCS style=3D'mso-bidi-font=
-size:
  11.0pt;mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Tel: +</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
  SK'>421 2 </span><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>3=
3 100
  100</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-ansi-lan=
guage:
  SK'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:12;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>It=
alia<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
800 536389<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>Su=
omi/Finland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i Oy<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Puh/T=
el: +358
  (0) 201 200 300<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:13;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
922;&#973;&#960;&#961;&#959;&#962;</span></b><b><span
  lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis <span
  class=3DSpellE>Cyprus</span> Ltd.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;:
  +</span><span lang=3DFR style=3D'mso-ansi-language:FR'>357 22 871600<o:p>=
</o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Sv=
erige<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i AB<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+46 (0)8
  634 50 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:14;mso-yfti-lastrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>La=
tvija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>sanof=
i-aventis
  Latvia SIA<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Tel: =
+371 67 33
  24 51<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Un=
ited
  Kingdom<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+44 (0)
  845 372 7101<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <![if !supportMisalignedColumns]>
 <tr height=3D0>
  <td width=3D2 style=3D'border:none'></td>
  <td width=3D310 style=3D'border:none'></td>
  <td width=3D312 style=3D'border:none'></td>
 </tr>
 <![endif]>
</table>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>This
leaflet was last revised in</span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icine is
available on the European Medicines Agency web site: http://www.ema.europa.=
eu/</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'page-break-before:always'>
</span>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Package leaflet:
Information for the user<o:p></o:p></span></b></p>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><span
class=3DSpellE><b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>=
Karvea</span></b></span><span
lang=3DEN-GB>&nbsp;<b style=3D'mso-bidi-font-weight:normal'>150</b>&nbsp;<b
style=3D'mso-bidi-font-weight:normal'>mg film-coated tablets<o:p></o:p></b>=
</span></p>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><span la=
ng=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Read all of this leaflet careful=
ly
before you start taking this medicine because it contains important informa=
tion
for you.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>If you have any further questions, ask your doctor or pharmaci=
st.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>This medicine has been prescribed for you only. Do not pass it=
 on to
others. It may harm them, even if their signs of illness are the same as yo=
urs.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>If you get any side effects, talk to your doctor or pharmacist=
. This
includes any possible side effects not listed in this leaflet. See section =
4.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><u><span lang=3DEN-GB>What is in this leaflet<o:p><=
/o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>What
<span class=3DSpellE>Karvea</span> is and what it is used for</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>What
you need to know before you take <span class=3DSpellE>Karvea</span></span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>How
to take <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>Possible
side effects</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>How
to store <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1=
'> </span>Contents
of the pack and other information</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>1.<span
style=3D'mso-tab-count:1'> </span>What <span class=3DSpellE>Karvea</s=
pan> is
and what it is used for<o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> belongs to a group of medicines known as angiotensin-II recep=
tor antagonists.
Angiotensin-II is a substance produced in the body which binds to receptors=
 in
blood vessels causing them to tighten. This results in an increase in blood
pressure. <span class=3DSpellE>Karvea</span> prevents the binding of
angiotensin-II to these receptors, causing the blood vessels to relax and t=
he
blood pressure to lower. <span class=3DSpellE>Karvea</span> slows the decre=
ase of
kidney function in patients with high blood pressure and type&nbsp;2 diabet=
es.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is used in adult patients</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to treat high blood pressure (<i style=3D'mso-bidi-font-style:=
normal'>essential
hypertension</i>)</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</=
span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>2.<span style=3D'mso-spacerun:ye=
s'>
</span><span style=3D'mso-tab-count:1'> </span><span style=3D'text-tran=
sform:
uppercase'>What you need to know before you take <span class=3DSpellE>Karve=
a<span
style=3D'text-transform:none'>Do</span></span></span> not take <span
class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you are <span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'>allergic</b>to</span>
irbesartan or any other ingredients of this medicine (listed in section 6)<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>more than =
3&nbsp;months
pregnant</b>. (It is also better to avoid <span class=3DSpellE>Karvea</span=
> in
early pregnancy  see pregnancy section)</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l5 level1 lfo11;tab-stops:list 27.5pt'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings;color:black'><span style=3D'mso-list:Ignore'=
><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>if you have diabet=
es or
impaired kidney function</span></b><span lang=3DEN-GB> and you are treated =
with a
blood pressure lowering medicine containing <span class=3DSpellE>aliskiren<=
/span>.<i
style=3D'mso-bidi-font-style:normal'><span style=3D'color:red'><o:p></o:p><=
/span></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Warnings and precautions</span><=
/p>

<p class=3DEMEAHeading3><span lang=3DEN-GB style=3D'font-weight:normal'>Tal=
k to your
doctor before taking <span class=3DSpellE>Karvea</span></span><span lang=3D=
EN-GB> </span><span
lang=3DEN-GB style=3D'font-weight:normal'>and </span><span lang=3DEN-GB>if =
any of the
following apply to you:</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you get <b style=3D'mso-bidi-font-weight:normal'>excessive =
vomiting
or diarrhoea</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>ki=
dney
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>he=
art
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you receive <span class=3DSpellE>Karvea</span> for <b
style=3D'mso-bidi-font-weight:normal'>diabetic kidney disease</b>. In this =
case
your doctor may perform regular blood tests, especially for measuring blood
potassium levels in case of poor kidney function</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you develop <b>low blood sugar levels</b> (symptoms may inc=
lude
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>going to h=
ave an
operation</b> (surgery) or <b style=3D'mso-bidi-font-weight:normal'>be given
anaesthetics<o:p></o:p></b></span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l4 level1 lfo13'><![if !supportLists]><span lang=3DEN-GB
style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-f=
ont-family:
Wingdings;color:black'><span style=3D'mso-list:Ignore'><span style=3D'font=
:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>if you are taking any of =
the
following medicines used to treat high blood pressure:</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:1.0in;text-indent:-.25in;
mso-list:l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:"Courier New";mso-fareast-font-family:"Co=
urier New"'><span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>an ACE-inhibitor (for exa=
mple
enalapril, lisinopril, ramipril), in particular if you have diabetes-related
kidney problems.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-.25in;mso-l=
ist:
l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span lang=3DEN-=
GB
style=3D'font-family:"Courier New";mso-fareast-font-family:"Courier New"'><=
span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span class=3DSpellE><span lang=3DEN-GB>alis=
kiren</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>See also information under the h=
eading
Do not take <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. <span class=3DSpellE>Karvea</spa=
n> is
not recommended in early pregnancy, and must not be taken if you are more t=
han
3&nbsp;months pregnant, as it may cause serious harm to your baby if used at
that stage (see pregnancy section).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Children and adolescents</span><=
/p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>This medici=
nal
product should not be used in children and adolescents because the safety a=
nd
efficacy have not&nbsp;yet been&nbsp;fully established.</span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Other medicines and <span class=
=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor or pharmacist i=
f you
are taking, have recently taken or might take any other medicines.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may need to change y=
our dose
and/or to take other precautions:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><span style=3D'mso-spacerun:yes'=
></span>If
you are taking an ACE-inhibitor or <span class=3DSpellE>aliskiren</span> (s=
ee
also information under the headings Do not take <span class=3DSpellE>Karve=
a</span>
and Warnings and precautions).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>You
may need to have blood checks if you take:</span></b></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium supplements</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>salt substitutes containing potassium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium-sparing medicines (such as certain diuretics)</span>=
</p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>medicines containing lithium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3;mso-prop-ch=
ange:
Author 19000000T0000'><![if !supportLists]><span lang=3DEN-GB style=3D'font=
-family:
Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'=
><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>repaglinide (medication u=
sed
for lowering blood sugar levels)</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you take certain painkillers,=
 called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be redu=
ced.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> with food and drink</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> can be taken with or without food.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Pregnancy and breast-feeding</sp=
an></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Pregnancy</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise=
 you
to stop taking <span class=3DSpellE>Karvea</span> before you become pregnan=
t or
as soon as you know you are pregnant and will advise you to take another
medicine instead of <span class=3DSpellE>Karvea</span>. <span class=3DSpell=
E>Karvea</span>
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used a=
fter
the third month of pregnancy.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Breast-feeding</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. <span class=3DSpellE>Karve=
a</span>
is not recommended for mothers who are breast-feeding, and your doctor may
choose another treatment for you if you wish to breast-feed, especially if =
your
baby is <span class=3DSpellE>newborn</span>, or was born prematurely.</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Driving and using machines</span=
></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is unlikely to affect your ability to drive or use machines.
However, occasionally dizziness or weariness may occur during treatment of =
high
blood pressure. If you experience these, talk to your doctor before attempt=
ing
to drive or use machines.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains lactose</span></b><span lang=3DEN-GB>. If you have b=
een told
by your doctor that you have an intolerance to some sugars (e.g. lactose),
contact your doctor before taking this medicinal product.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains sodium. </span></b><span lang=3DEN-GB style=3D'mso-b=
idi-font-weight:
bold'>This medicine contains less than 1 mmol sodium (23 mg) per tablet, th=
at is
to say essentially sodium-free.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>3.<span
style=3D'mso-tab-count:1'> </span>How to take <span class=3DSpellE>Ka=
rvea</span><o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Always take this medicine exactl=
y as
your doctor has told you. Check with your doctor or pharmacist if you are n=
ot
sure.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Method of administration</span><=
/p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is for <b style=3D'mso-bidi-font-weight:normal'>oral use</b>.=
 Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take <span class=3DSpellE>Karvea</span> with or without food. Try to ta=
ke
your daily dose at about the same time each day. It is important that you
continue to take <span class=3DSpellE>Karvea</span> until your doctor tells=
 you
otherwise.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure<o:p></o:p></span></b></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>Th=
e usual
dose is 150&nbsp;mg once a day. The dose may later be increased to 300&nbsp=
;mg
(two tablets a day) once daily depending on blood pressure response.</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure and type&nbsp;2 diabetes with kidney disease<o:p></o:p></span></b>=
</p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>In=
 patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg (two tablets=
 a
day) once daily is the preferred maintenance dose for the treatment of
associated kidney disease.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The doctor may advise a lower do=
se,
especially when starting treatment in certain patients such as those on <b
style=3D'mso-bidi-font-weight:normal'>haemodialysis</b>, or those <b
style=3D'mso-bidi-font-weight:normal'>over the age of 75&nbsp;years.<o:p></=
o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The maximal blood pressure lower=
ing
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Use in children and adolescents<=
/span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> should not be given to children under 18&nbsp;years of age. I=
f a
child swallows some tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you take more <span class=3DS=
pellE>Karvea</span>
than you should:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you forget to take <span
class=3DSpellE>Karvea</span>:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally miss a daily=
 dose,
just take the next dose as normal. Do not take a double dose to make up for=
 a
forgotten dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:NL=
'>If you
have any further questions on the use of this medicine, ask your doctor or
pharmacist.</span><span lang=3DEN-GB style=3D'font-size:10.0pt;font-family:=
"TimesNewRoman\,Italic";
mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"TimesNewRoman=
\,Italic";
mso-fareast-language:NL'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>4.<span
style=3D'mso-tab-count:1'> </span>Possible side effects<o:p></o:p></s=
pan></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Like all medicines, this medicin=
e can
cause side effects, although not everybody gets them.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Some of these effects may be ser=
ious and
may require medical attention.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As with similar medicines, rare =
cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of=
 the
face, lips and/or tongue have been reported in patients taking irbesartan. =
If
you get any of these symptoms or get short of breath, <b style=3D'mso-bidi-=
font-weight:
normal'>stop taking <span class=3DSpellE>Karvea</span> and contact your doc=
tor
immediately.<o:p></o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of the side effect=
s listed
below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Very common: </span><span lang=
=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt'>may affect more than 1 in 10 people</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Common: may affect up to 1 in 10=
 people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Uncommon: may affect up to 1 in =
100
people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Side effects reported in clinical
studies for patients treated with <span class=3DSpellE>Karvea</span> were:<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Very common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-=
size:11.0pt'>may
affect more than 1 in 10 people)</span><span lang=3DEN-GB>: if you suffer f=
rom
high blood pressure and type&nbsp;2 diabetes with kidney disease, blood tes=
ts
may show an increased level of potassium.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-size:=
11.0pt'>may
affect up to 1 10 people)</span><span lang=3DEN-GB>: dizziness, feeling
sick/vomiting, fatigue and blood tests may show raised levels of an enzyme =
that
measures the muscle and heart function (creatine kinase enzyme). In patients
with high blood pressure and type&nbsp;2 diabetes with kidney disease,
dizziness when getting up from a lying or sitting position, low blood press=
ure
when getting up from a lying or sitting position, pain in joints or muscles=
 and
decreased levels of a protein in the red blood cells (haemoglobin) were also
reported.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Uncommon (</span><span lang=3DEN-GB style=3D'mso-bidi-font-siz=
e:11.0pt'>may
affect up to 1 in 100 people)</span><span lang=3DEN-GB>: heart rate increas=
ed, flushing,
cough, diarrhoea, indigestion/heartburn, sexual dysfunction (problems with
sexual performance), chest pain.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB>Some undesirable effects have been =
reported
since marketing of <span class=3DSpellE>Karvea</span>. Undesirable effects =
where
the frequency is not known are: feeling of spinning, headache, taste
disturbance, ringing in the ears, </span><span lang=3DEN-GB style=3D'mso-bi=
di-font-size:
11.0pt'>muscle cramps, </span><span lang=3DEN-GB>pain in joints and muscles=
, </span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>decreased number of red bl=
ood
cells (anaemia  symptoms may include tiredness, headaches, being short of
breath when exercising, dizziness and looking pale), </span><span lang=3DEN=
-GB>reduced
number of platelets, abnormal liver function, increased blood potassium lev=
els,
impaired kidney function, inflammation of small blood vessels</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> </span><span lang=3DEN-GB
style=3D'mso-bidi-font-style:italic'>mainly affecting the skin</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> (a condition known as <sp=
an
class=3DSpellE>leukocytoclastic</span> vasculitis),</span><span lang=3DEN-GB
style=3D'mso-ansi-language:EN-US'> </span><span style=3D'mso-ansi-language:=
EN-US'>severe
allergic reactions (anaphylactic shock)</span><span style=3D'mso-bidi-font-=
size:
11.0pt'> <span lang=3DEN-GB>and </span></span><span lang=3DEN-GB>low blood =
sugar
levels. Uncommon cases of jaundice (yellowing of the skin and/or whites of =
the
eyes) have also been reported.</span><span style=3D'mso-ansi-language:EN-US=
'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of side effects<o:p=
></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you get any side effects, tal=
k to
your doctor or pharmacist. This includes any possible side effects not list=
ed
in this leaflet. You can also report side effects directly via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in </span></span><span class=3DMsoHyperlink><span lang=3DES-TRAD
style=3D'mso-bidi-font-size:12.0pt;background:silver;mso-highlight:silver;
mso-ansi-language:ES-TRAD;mso-fareast-language:ZH-CN;mso-no-proof:yes;
text-decoration:none;text-underline:none'>Appendix V</span></span><span
lang=3DEN-GB>. By reporting side <span class=3DSpellE>effects you</span> ca=
n help
provide more information on the safety of this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>5.<span
style=3D'mso-tab-count:1'> </span>How to store <span class=3DSpellE>K=
arvea</span><o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Keep this medicine out of the si=
ght and
reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not use this medicine after t=
he
expiry date which is stated on the carton and on the blister after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not store above 30C.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not throw away any medicines =
via
wastewater or household waste. Ask your pharmacist how to throw away medici=
nes
you no longer use. These measures will help protect the environment.</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>6.<span
style=3D'mso-tab-count:1'> </span>Contents of the pack and other
information<o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
contains</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>The active substance is irbesartan. Each tablet of <span
class=3DSpellE>Karvea</span>&nbsp;150&nbsp;mg contains 150&nbsp;mg irbesart=
an.</span></p>

<p class=3DMsoNormal><span lang=3DEN-GB style=3D'font-family:Wingdings'><s=
pan
style=3D'mso-tab-count:1'> </span></span><span lang=3DEN-GB>The other ingr=
edients
are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium,=
 <span
class=3DSpellE>hypromellose</span>, silicon dioxide, magnesium stearate, ti=
tanium
dioxide, macrogol 3000, carnauba wax. </span><span style=3D'mso-ansi-langua=
ge:
EN-US'>Please see section 2 <span class=3DSpellE>Karvea</span> contains
lactose.<o:p></o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB><o=
:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
looks like and contents of the pack</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg film-coated tablets are white to off-white,
biconvex, and oval-shaped with a heart debossed on one side and the
number&nbsp;2872 engraved on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;150&nbsp;mg film-coated tablets are supplied in blister =
packs
of 14, 28, 30, 56, 84, 90 or 98&nbsp;film-coated tablets. <span class=3DSpe=
llE>Unidose</span>
blister packs of 56&nbsp;x&nbsp;1&nbsp;film-coated tablet for delivery in
hospitals are also available.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Not all pack sizes may be market=
ed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Mark=
eting <span
class=3DSpellE>Authorisation</span> Holder:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris</span><span lang=3DFR style=3D'mso-ansi-language:FR'>&nbsp;</=
span><span
lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>-&nbsp;France<o:p></o:p></sp=
an></p>

<p class=3DEMEABodyText><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE=
'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Manu=
facturer:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
<span class=3DSpellE>Ambars</span> &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>SANOF=
I&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France<o:p></o:p></span></=
p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>CHINO=
IN PRIVATE
CO. LTD.<br>
<span class=3DSpellE>Lvai</span> u.5.<br>
2112 <span class=3DSpellE>Veresegyhz</span>&nbsp;-&nbsp;<span class=3DSpel=
lE>Hungary</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>SANO=
FI-AVENTIS,
S.A.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Ctra=
. C-35 (La
Batlloria-Hostalric), km. 63.09<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>17404 <span class=3DSpellE>Riell=
s</span> <span
class=3DSpellE>i</span> <span class=3DSpellE>Viabrea</span> (Girona)  Spai=
n</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For any information about this m=
edicinal
product, please contact the local representative of the Marketing Authorisa=
tion
Holder.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D624
 style=3D'margin-left:-1.7pt;border-collapse:collapse;mso-table-layout-alt:=
fixed;
 mso-padding-alt:0in 5.4pt 0in 5.4pt'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Be=
lgi/</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'>Belgique</span></b><b><span lang=
=3DMT
  style=3D'mso-ansi-language:MT'>/Belgien</span></b><b><span lang=3DFR-BE
  style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi <span class=3DSpellE>Belgium</span></span><=
span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>Tl/Tel: <span
  style=3D'layout-grid-mode:line'>+32 (0)2 710 54 00<o:p></o:p></span></spa=
n></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLT style=3D'mso-ansi-language:LT'>Li=
etuva<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>UAB
  sanofi-aventis Lietuva</span><span lang=3DFR style=3D'mso-ansi-language:F=
R'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+370 5 2755224<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><span class=3DSpellE><b><span lang=3DEN-GB>&#1041;&#=
1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></span><b><span
  lang=3DIT style=3D'mso-ansi-language:IT'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT;mso-no=
-proof:
  yes'>Sanofi Bulgaria EOOD<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  BG;mso-bidi-font-weight:bold'>&#1058;&#1077;&#1083;</span><span lang=3DIT
  style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT;mso-bidi-font-wei=
ght:
  bold'>.</span><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
  BG;mso-bidi-font-weight:bold'>: +</span><span lang=3DIT style=3D'mso-bidi=
-font-size:
  11.0pt;mso-ansi-language:IT;mso-bidi-font-weight:bold'>359 (0)2</span><sp=
an
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial;
  mso-ansi-language:IT'> 970 53 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR-LU style=3D'mso-ansi-language:FR-=
LU'>Luxembourg/Luxemburg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi <span class=3DSpellE>Belgium</span> <o:p></=
o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-LU style=3D'mso-ansi-language:FR-LU'=
>Tl/Tel: </span><span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;layout-grid-mode:line'>+32 =
(0)2 710
  54 00 (</span><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>Belgiq=
ue/<span
  class=3DSpellE>Belgien</span>)<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DHU style=3D'mso-ansi-language:HU'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>&#=
268;esk
  republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis,
  s.r.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+420 233
  086 111<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DHU style=3D'mso-ansi-language:HU'>Ma=
gyarorszg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>SANOF=
I-AVENTIS
  Zrt.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel.:=
 +36 1 </span><span
  lang=3DHU style=3D'mso-ansi-language:HU'>505 0050<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Da=
nmark<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i A/S<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+45 45 16
  70 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Ma=
lta<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+39 02
  39394275<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>De=
utschland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i-Aventis
  Deutschland GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
0800 52 52
  010<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel. =
aus dem
  Ausland: +49 69 305 21 131<o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Ne=
derland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Genzy=
me Europe B.V.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+31 20 245
  4000</span><span lang=3DNL style=3D'mso-ansi-language:NL'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DET style=3D'mso-ansi-language:ET'>Ee=
sti<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Estonia O<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+372 627
  34 88<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>No=
rge<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Norge AS<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+47 67 10
  71 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
917;&#955;&#955;&#940;&#948;&#945;</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  AEBE</span><span lang=3DET style=3D'mso-ansi-language:ET'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'>: +30 210 900 16 00<o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>s=
terreich<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>sanof=
i-aventis
  GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Tel: =
+43 1 80
  185  0<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DES style=3D'mso-ansi-language:ES'>Es=
paa<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>sanof=
i-aventis,
  S.A.<span style=3D'font-variant:small-caps'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tel: =
+34 93 485
  94 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>Po=
lska<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>sanof=
i-aventis
  Sp. z o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel.:=
 +48
  22&nbsp;280 00 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:8;page-break-inside:avoid'>
  <td width=3D312 colspan=3D2 valign=3Dtop style=3D'width:233.9pt;padding:0=
in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Fr=
ance<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
  France</span><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tl: =
0 800 222
  555<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Appel=
 depuis
  ltranger : +33 1 57 63 23 23<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DPT style=3D'mso-ansi-language:PT'>Po=
rtugal<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Sanof=
i -
  Produtos Farmacuticos, Lda<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+351 21 35
  89 400<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:9;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'page-break-after:avoid'><b><span lang=3DIT
  style=3D'mso-fareast-font-family:SimSun;mso-ansi-language:IT'>Hrvatska<o:=
p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:IT'>sanofi-aventis Croatia d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:FR'>Tel: +385 1 600 34 00</span><span lang=3DFR
  style=3D'mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<b
  style=3D'mso-bidi-font-weight:normal'><span lang=3DPL style=3D'mso-bidi-f=
ont-size:
  11.0pt;mso-ansi-language:PL;mso-no-proof:yes'>Romnia<o:p></o:p></span></=
b></p>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<span
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT'>Sanofi=
 Romania
  SRL<span style=3D'mso-no-proof:yes'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DPL style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  PL;mso-no-proof:yes'>Tel: +40 </span><span lang=3DFR style=3D'mso-bidi-fo=
nt-size:
  11.0pt;mso-ansi-language:FR'>(0) 21 317 31 36<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:10;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Ir=
eland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
  Ireland Ltd. T/A SANOFI<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+353 (0) 1
  403 56 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSL style=3D'mso-ansi-language:SL'>Sl=
ovenija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+386 1 560
  48 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:11;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIS style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:IS'>sland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Vistor hf.</span><span lang=3DIS style=3D'mso-bidi-font-size:11.0pt;
  mso-ansi-language:IS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0p=
t;
  mso-no-proof:yes'>Smi</span><span lang=3DCS style=3D'mso-bidi-font-size:=
11.0pt;
  mso-ansi-language:CS'>: +354 535 7000<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSK style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:SK'>Slovensk republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'>sanofi-</span><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;mso-=
ansi-language:
  CS'>aventis Slovakia </span><span lang=3DSK style=3D'mso-bidi-font-size:1=
1.0pt;
  mso-ansi-language:SK'>s.r.o.</span><span lang=3DCS style=3D'mso-bidi-font=
-size:
  11.0pt;mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Tel: +</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
  SK'>421 2 </span><span lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
  IT'>33 100 100</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;
  mso-ansi-language:SK'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:12;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>It=
alia<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Sanofi S.r.l.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Tel: 800 536389<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>Su=
omi/Finland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i Oy<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Puh/T=
el: +358
  (0) 201 200 300<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:13;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
922;&#973;&#960;&#961;&#959;&#962;</span></b><b><span
  lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis <span
  class=3DSpellE>Cyprus</span> Ltd.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;:
  +</span><span lang=3DFR style=3D'mso-ansi-language:FR'>357 22 871600<o:p>=
</o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Sv=
erige<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i AB<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+46 (0)8
  634 50 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:14;mso-yfti-lastrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>La=
tvija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>sanof=
i-aventis
  Latvia SIA<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+371 67 33
  24 51<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Un=
ited
  Kingdom<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+44 (0)
  845 372 7101<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <![if !supportMisalignedColumns]>
 <tr height=3D0>
  <td width=3D2 style=3D'border:none'></td>
  <td width=3D310 style=3D'border:none'></td>
  <td width=3D312 style=3D'border:none'></td>
 </tr>
 <![endif]>
</table>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>This
leaflet was last revised in</span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icine is
available on the European Medicines Agency web site: http://www.ema.europa.=
eu/</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>

<span lang=3DEN-GB style=3D'font-size:11.0pt;mso-bidi-font-size:10.0pt;font=
-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-=
language:
EN-GB;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'page-break-before:always'>
</span>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Package leaflet:
Information for the user<o:p></o:p></span></b></p>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><span
class=3DSpellE><b style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>=
Karvea</span></b></span><span
lang=3DEN-GB>&nbsp;<b style=3D'mso-bidi-font-weight:normal'>300</b>&nbsp;<b
style=3D'mso-bidi-font-weight:normal'>mg film-coated tablets<o:p></o:p></b>=
</span></p>

<p class=3DEMEABodyText align=3Dcenter style=3D'text-align:center'><span la=
ng=3DEN-GB>irbesartan</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Read all of this leaflet careful=
ly
before you start taking this medicine because it contains important informa=
tion
for you.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>If you have any further questions, ask your doctor or pharmaci=
st.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>This medicine has been prescribed for you only. Do not pass it=
 on to
others. It may harm them, even if their signs of illness are the same as yo=
urs.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>If you get any side effects, talk to your doctor or pharmacist=
. This
includes any possible side effects not listed in this leaflet. See section =
4.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><u><span lang=3DEN-GB>What is in this leaflet<o:p><=
/o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>1.<span style=3D'mso-tab-count:1=
'> </span>What
<span class=3DSpellE>Karvea</span> is and what it is used for</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span>What
you need to know before you take <span class=3DSpellE>Karvea</span></span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB>3.<span style=3D'mso-tab-count:1=
'> </span>How
to take <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>4.<span style=3D'mso-tab-count:1=
'> </span>Possible
side effects</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>5.<span style=3D'mso-tab-count:1=
'> </span>How
to store <span class=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>6.<span style=3D'mso-tab-count:1=
'> </span>Contents
of the pack and other information</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>1.<span
style=3D'mso-tab-count:1'> </span>What <span class=3DSpellE>Karvea</s=
pan> is
and what it is used for<o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> belongs to a group of medicines known as angiotensin-II recep=
tor antagonists.
Angiotensin-II is a substance produced in the body which binds to receptors=
 in
blood vessels causing them to tighten. This results in an increase in blood
pressure. <span class=3DSpellE>Karvea</span> prevents the binding of
angiotensin-II to these receptors, causing the blood vessels to relax and t=
he
blood pressure to lower. <span class=3DSpellE>Karvea</span> slows the decre=
ase of
kidney function in patients with high blood pressure and type&nbsp;2 diabet=
es.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is used in adult patients</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to treat high blood pressure (<i style=3D'mso-bidi-font-style:=
normal'>essential
hypertension</i>)</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>to protect the kidney in patients with high blood pressure,
type&nbsp;2 diabetes and laboratory evidence of impaired kidney function.</=
span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB>2.<span style=3D'mso-tab-count:1=
'> </span></span><span
lang=3DEN-GB style=3D'font-family:"Times New Roman Bold",serif;mso-bidi-fon=
t-family:
"Times New Roman";text-transform:none'>What you need to know before you tak=
e</span><span
lang=3DEN-GB> </span><span class=3DSpellE><span lang=3DEN-GB style=3D'text-=
transform:
none'>Karvea</span></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Do not take <span class=3DSpellE=
>Karvea</span></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>allergic</=
b> to
irbesartan or any other ingredients of this medicine (listed in section 6)<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>more than
3&nbsp;months pregnant</b>. (It is also better to avoid <span class=3DSpell=
E>Karvea</span>
in early pregnancy  see pregnancy section)</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l6 level1 lfo12;tab-stops:list 27.5pt'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings;color:black'><span style=3D'mso-list:Ignore'=
><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>if you have diabet=
es or
impaired kidney function</span></b><span lang=3DEN-GB> and you are treated =
with a
blood pressure lowering medicine containing <span class=3DSpellE>aliskiren<=
/span>.<i
style=3D'mso-bidi-font-style:normal'><span style=3D'color:red'><o:p></o:p><=
/span></i></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Warnings and precautions</span><=
/p>

<p class=3DEMEAHeading3><span lang=3DEN-GB style=3D'font-weight:normal'>Tal=
k to your
doctor before taking <span class=3DSpellE>Karvea</span></span><span lang=3D=
EN-GB> </span><span
lang=3DEN-GB style=3D'font-weight:normal'>and </span><span lang=3DEN-GB>if =
any of the
following apply to you:</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you get <b style=3D'mso-bidi-font-weight:normal'>excessive =
vomiting
or diarrhoea</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>ki=
dney
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you suffer from <b style=3D'mso-bidi-font-weight:normal'>he=
art
problems</b></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you receive <span class=3DSpellE>Karvea</span> for <b
style=3D'mso-bidi-font-weight:normal'>diabetic kidney disease</b>. In this =
case
your doctor may perform regular blood tests, especially for measuring blood
potassium levels in case of poor kidney function</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you develop <b>low blood sugar levels</b> (symptoms may inc=
lude
sweating, weakness, hunger, dizziness, trembling, headache, flushing or
paleness, numbness, having a fast, pounding heart beat), particularly if you
are being treated for diabetes.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>if you are <b style=3D'mso-bidi-font-weight:normal'>going to h=
ave an
operation</b> (surgery) or <b style=3D'mso-bidi-font-weight:normal'>be given
anaesthetics<o:p></o:p></b></span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:27.5pt;text-indent:-27.5=
pt;
mso-list:l4 level1 lfo13'><a name=3D"_BPDC_LN_INS_1001"></a><![if !supportL=
ists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings;color:black'><span style=3D'mso-list:Ignore'=
><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>if you are taking <span style=3D'mso-spacerun:yes'></span>any=
 of the
following medicines used to treat high blood pressure:</span></p>

<p class=3DEMEABodyTextIndent style=3D'margin-left:1.0in;text-indent:-.25in;
mso-list:l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span
lang=3DEN-GB style=3D'font-family:"Courier New";mso-fareast-font-family:"Co=
urier New"'><span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>an ACE-inhibitor (for exa=
mple
enalapril, lisinopril, ramipril), in particular if you have diabetes-related
kidney problems.</span></p>

<p class=3DEMEABodyText style=3D'margin-left:1.0in;text-indent:-.25in;mso-l=
ist:
l4 level2 lfo13;tab-stops:list 1.0in'><![if !supportLists]><span lang=3DEN-=
GB
style=3D'font-family:"Courier New";mso-fareast-font-family:"Courier New"'><=
span
style=3D'mso-list:Ignore'>o<span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;
</span></span></span><![endif]><span class=3DSpellE><span lang=3DEN-GB>alis=
kiren</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may check your kidney
function, blood pressure, and the amount of electrolytes (e.g. potassium) in
your blood at regular intervals.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>See also information under the h=
eading
Do not take <span class=3DSpellE>Karvea</span>.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. <span class=3DSpellE>Karvea</spa=
n> is
not recommended in early pregnancy, and must not be taken if you are more t=
han
3&nbsp;months pregnant, as it may cause serious harm to your baby if used at
that stage (see pregnancy section).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Children and adolescents</span><=
/p>

<p class=3DEMEABodyText><span style=3D'mso-ansi-language:EN-US'>This medici=
nal
product should not be used in children and adolescents because the safety a=
nd
efficacy have not&nbsp;yet been&nbsp;fully established.</span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Other medicines and <span class=
=3DSpellE>Karvea</span></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor or pharmacist i=
f you
are taking, have recently taken or might take any other medicines.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Your doctor may need to change y=
our dose
and/or to take other precautions:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><span style=3D'mso-spacerun:yes'=
></span>If
you are taking an ACE-inhibitor or <span class=3DSpellE>aliskiren</span> (s=
ee
also information under the headings Do not take <span class=3DSpellE>Karve=
a</span>
and Warnings and precautions).</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>You
may need to have blood checks if you take:</span></b></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium supplements</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>salt substitutes containing potassium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>potassium-sparing medicines (such as certain diuretics)</span>=
</p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>medicines containing lithium</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3;mso-prop-ch=
ange:
Author 19000000T0000'><![if !supportLists]><span lang=3DEN-GB style=3D'font=
-family:
Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:Wingdings'=
><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DEN-GB>repaglinide (medication u=
sed
for lowering blood sugar levels)</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you take certain painkillers,=
 called
non-steroidal anti-inflammatory drugs, the effect of irbesartan may be redu=
ced.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> with food and drink</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> can be taken with or without food.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Pregnancy and breast-feeding</sp=
an></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Pregnancy</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>You must tell your doctor if you=
 think
you are (<u>or might become</u>) pregnant. Your doctor will normally advise=
 you
to stop taking <span class=3DSpellE>Karvea</span> before you become pregnan=
t or
as soon as you know you are pregnant and will advise you to take another
medicine instead of <span class=3DSpellE>Karvea</span>. <span class=3DSpell=
E>Karvea</span>
is not recommended in early pregnancy, and must not be taken when more than
3&nbsp;months pregnant, as it may cause serious harm to your baby if used a=
fter
the third month of pregnancy.</span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB><o:p>&nbsp;</o:p></span></b></p>

<p class=3DEMEAHeading2><span lang=3DEN-GB>Breast-feeding</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Tell your doctor if you are
breast-feeding or about to start breast-feeding. <span class=3DSpellE>Karve=
a</span>
is not recommended for mothers who are breast-feeding, and your doctor may
choose another treatment for you if you wish to breast-feed, especially if =
your
baby is <span class=3DSpellE>newborn</span>, or was born prematurely.</span=
></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Driving and using machines</span=
></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is unlikely to affect your ability to drive or use machines.
However, occasionally dizziness or weariness may occur during treatment of =
high
blood pressure. If you experience these, talk to your doctor before attempt=
ing
to drive or use machines.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains lactose</span></b><span lang=3DEN-GB>. If you have b=
een told
by your doctor that you have an intolerance to some sugars (e.g. lactose),
contact your doctor before taking this medicinal product.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><b style=3D'mso-bidi-font-weig=
ht:normal'><span
lang=3DEN-GB>Karvea</span></b></span><b style=3D'mso-bidi-font-weight:norma=
l'><span
lang=3DEN-GB> contains sodium. </span></b><span lang=3DEN-GB style=3D'mso-b=
idi-font-weight:
bold'>This medicine contains less than 1 mmol sodium (23 mg) per tablet, th=
at is
to say essentially sodium-free.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>3.<span
style=3D'mso-tab-count:1'> </span>How to take <span class=3DSpellE>Ka=
rvea</span><o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Always take this medicine exactl=
y as
your doctor has told you. Check with your doctor or pharmacist if you are n=
ot
sure.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Method of administration</span><=
/p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> is for <b style=3D'mso-bidi-font-weight:normal'>oral use</b>.=
 Swallow
the tablets with a sufficient amount of fluid (e.g. one glass of water). You
can take <span class=3DSpellE>Karvea</span> with or without food. Try to ta=
ke
your daily dose at about the same time each day. It is important that you
continue to take <span class=3DSpellE>Karvea</span> until your doctor tells=
 you
otherwise.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure<o:p></o:p></span></b></p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>Th=
e usual
dose is 150&nbsp;mg once a day. The dose may later be increased to 300&nbsp=
;mg
once daily depending on blood pressure response.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-GB>Patients with high=
 blood
pressure and type&nbsp;2 diabetes with kidney disease<o:p></o:p></span></b>=
</p>

<p class=3DEMEABodyText style=3D'margin-left:28.35pt'><span lang=3DEN-GB>In=
 patients
with high blood pressure and type&nbsp;2 diabetes, 300&nbsp;mg once daily is
the preferred maintenance dose for the treatment of associated kidney disea=
se.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The doctor may advise a lower do=
se,
especially when starting treatment in certain patients such as those on <b
style=3D'mso-bidi-font-weight:normal'>haemodialysis</b>, or those <b
style=3D'mso-bidi-font-weight:normal'>over the age of 75&nbsp;years.<o:p></=
o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The maximal blood pressure lower=
ing
effect should be reached 4-6&nbsp;weeks after beginning treatment.</span></=
p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>Use in children and adolescents<=
/span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB> should not be given to children under 18&nbsp;years of age. I=
f a
child swallows some tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you take more <span class=3DS=
pellE>Karvea</span>
than you should:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally take too many
tablets, contact your doctor immediately.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>If you forget to take <span
class=3DSpellE>Karvea</span>:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you accidentally miss a daily=
 dose,
just take the next dose as normal. Do not take a double dose to make up for=
 a
forgotten dose.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB style=3D'mso-fareast-language:NL=
'>If you
have any further questions on the use of this medicine, ask your doctor or
pharmacist.</span><span lang=3DEN-GB style=3D'font-size:10.0pt;font-family:=
"TimesNewRoman\,Italic";
mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"TimesNewRoman=
\,Italic";
mso-fareast-language:NL'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>4.<span
style=3D'mso-tab-count:1'> </span>Possible side effects<o:p></o:p></s=
pan></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Like all medicines, this medicin=
e can
cause side effects, although not everybody gets them.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Some of these effects may be ser=
ious and
may require medical attention.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>As with similar medicines, rare =
cases of
allergic skin reactions (rash, urticaria), as well as localised swelling of=
 the
face, lips and/or tongue have been reported in patients taking irbesartan. =
If
you get any of these symptoms or get short of breath, <b style=3D'mso-bidi-=
font-weight:
normal'>stop taking <span class=3DSpellE>Karvea</span> and contact your doc=
tor
immediately.<o:p></o:p></b></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>The frequency of the side effect=
s listed
below is defined using the following convention:</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Very common: </span><span lang=
=3DEN-GB
style=3D'mso-bidi-font-size:11.0pt'>may affect more than 1 in 10 people</sp=
an></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Common: may affect up to 1 in 10=
 people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Uncommon: may affect up to 1 in =
100
people</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Side effects reported in clinical
studies for patients treated with <span class=3DSpellE>Karvea</span> were:<=
/span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Very common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-=
size:11.0pt'>may
affect more than 1 in 10 people)</span><span lang=3DEN-GB>: if you suffer f=
rom
high blood pressure and type&nbsp;2 diabetes with kidney disease, blood tes=
ts
may show an increased level of potassium.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Common (</span><span lang=3DEN-GB style=3D'mso-bidi-font-size:=
11.0pt'>may
affect up to 1 10 people)</span><span lang=3DEN-GB>: dizziness, feeling
sick/vomiting, fatigue and blood tests may show raised levels of an enzyme =
that
measures the muscle and heart function (creatine kinase enzyme). In patients
with high blood pressure and type&nbsp;2 diabetes with kidney disease,
dizziness when getting up from a lying or sitting position, low blood press=
ure
when getting up from a lying or sitting position, pain in joints or muscles=
 and
decreased levels of a protein in the red blood cells (haemoglobin) were also
reported.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:l10 level1 lfo3'><![if !sup=
portLists]><span
lang=3DEN-GB style=3D'font-family:Wingdings;mso-fareast-font-family:Wingdin=
gs;
mso-bidi-font-family:Wingdings'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span></s=
pan><![endif]><span
lang=3DEN-GB>Uncommon (</span><span lang=3DEN-GB style=3D'mso-bidi-font-siz=
e:11.0pt'>may
affect up to 1 in 100 people)</span><span lang=3DEN-GB>: heart rate increas=
ed,
flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (prob=
lems
with sexual performance), chest pain.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DEN-GB>Some undesirable effects have been =
reported
since marketing of <span class=3DSpellE>Karvea</span>. Undesirable effects =
where
the frequency is not known are: feeling of spinning, headache, taste distur=
bance,
ringing in the ears, </span><span lang=3DEN-GB style=3D'mso-bidi-font-size:=
11.0pt'>muscle
cramps, </span><span lang=3DEN-GB>pain in joints and muscles, </span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>decreased number of red bl=
ood
cells (anaemia  symptoms may include tiredness, headaches, being short of
breath when exercising, dizziness and looking pale), </span><span lang=3DEN=
-GB>reduced
number of platelets, abnormal liver function, increased blood potassium lev=
els,
impaired kidney function, inflammation of small blood vessels</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> </span><span lang=3DEN-GB
style=3D'mso-bidi-font-style:italic'>mainly affecting the skin</span><span
lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'> (a condition known as <sp=
an
class=3DSpellE>leukocytoclastic</span> vasculitis),</span><span lang=3DEN-GB
style=3D'mso-ansi-language:EN-US'> </span><span style=3D'mso-ansi-language:=
EN-US'>severe
allergic reactions (anaphylactic shock)</span><span style=3D'mso-bidi-font-=
size:
11.0pt'> <span lang=3DEN-GB>and </span></span><span lang=3DEN-GB>low blood =
sugar
levels. Uncommon cases of jaundice (yellowing of the skin and/or whites of =
the
eyes) have also been reported.</span><span style=3D'mso-ansi-language:EN-US=
'><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><u><span lang=3DEN-GB>Reporting of side effects<o:p=
></o:p></span></u></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>If you get any side effects, tal=
k to
your doctor or pharmacist. This includes any possible side effects not list=
ed
in this leaflet. You can also report side effects directly via <span
style=3D'background:silver;mso-highlight:silver'>the national reporting sys=
tem
listed in </span></span><span class=3DMsoHyperlink><span lang=3DES-TRAD
style=3D'mso-bidi-font-size:12.0pt;background:silver;mso-highlight:silver;
mso-ansi-language:ES-TRAD;mso-fareast-language:ZH-CN;mso-no-proof:yes;
text-decoration:none;text-underline:none'>Appendix V</span></span><span
lang=3DEN-GB>. By reporting side <span class=3DSpellE>effects you</span> ca=
n help
provide more information on the safety of this medicine.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>5.<span
style=3D'mso-tab-count:1'> </span>How to store <span class=3DSpellE>K=
arvea</span><o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Keep this medicine out of the si=
ght and
reach of children.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not use this medicine after t=
he
expiry date which is stated on the carton and on the blister after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not store above 30C.</span><=
/p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Do not throw away any medicines =
via
wastewater or household waste. Ask your pharmacist how to throw away medici=
nes
you no longer use. These measures will help protect the environment.</span>=
</p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB style=3D'font-family:"Times New =
Roman Bold",serif;
mso-bidi-font-family:"Times New Roman";text-transform:none'>6.<span
style=3D'mso-tab-count:1'> </span>Contents of the pack and other
information<o:p></o:p></span></p>

<p class=3DEMEAHeading1><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
contains</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>The active substance is irbesartan. Each tablet of <span
class=3DSpellE>Karvea</span>&nbsp;300&nbsp;mg contains 300&nbsp;mg irbesart=
an.</span></p>

<p class=3DEMEABodyTextIndent style=3D'mso-list:none'><span lang=3DEN-GB
style=3D'font-family:Wingdings'><span style=3D'mso-tab-count:1'> </span><=
/span><span
lang=3DEN-GB>The other ingredients are lactose monohydrate, microcrystalline
cellulose, croscarmellose sodium, <span class=3DSpellE>hypromellose</span>,
silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3000, carna=
uba
wax. </span><span style=3D'mso-ansi-language:EN-US'>Please see section 2 <=
span
class=3DSpellE>Karvea</span> contains lactose.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DEN-GB>What <span class=3DSpellE>Karvea=
</span>
looks like and contents of the pack</span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg film-coated tablets are white to off-white,
biconvex, and oval-shaped with a heart debossed on one side and the
number&nbsp;2873 engraved on the other side.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span class=3DSpellE><span lang=3DEN-GB>Karvea</spa=
n></span><span
lang=3DEN-GB>&nbsp;300&nbsp;mg film-coated tablets are supplied in blister =
packs
of 14, 28, 30, 56, 84, 90 or 98&nbsp;film-coated tablets. <span class=3DSpe=
llE>Unidose</span>
blister packs of 56&nbsp;x&nbsp;1&nbsp;film-coated tablet for delivery in
hospitals are also available.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Not all pack sizes may be market=
ed.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Mark=
eting <span
class=3DSpellE>Authorisation</span> Holder:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
groupe<br>
54, rue La Botie<br>
F-75008 Paris</span><span lang=3DFR-BE style=3D'mso-ansi-language:FR'> </sp=
an><span
lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>-&nbsp;France<o:p></o:p></sp=
an></p>

<p class=3DEMEABodyText><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE=
'><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEAHeading3><span lang=3DFR style=3D'mso-ansi-language:FR'>Manu=
facturer:<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>SANOFI&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
1, rue de la Vierge<br>
<span class=3DSpellE>Ambars</span> &amp; Lagrave<br>
F-33565&nbsp;Carbon Blanc Cedex&nbsp;-&nbsp;France<o:p></o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>SANOF=
I&nbsp;WINTHROP&nbsp;INDUSTRIE<br>
30-36&nbsp;Avenue Gustave Eiffel, BP&nbsp;7166<br>
F-37071&nbsp;Tours&nbsp;Cedex&nbsp;2&nbsp;-&nbsp;France<o:p></o:p></span></=
p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>

<p class=3DEMEAAddress><span lang=3DFR style=3D'mso-ansi-language:FR'>CHINO=
IN PRIVATE
CO. LTD.<br>
<span class=3DSpellE>Lvai</span> u.5.<br>
2112 <span class=3DSpellE>Veresegyhz</span>&nbsp;-&nbsp;<span class=3DSpel=
lE>Hungary</span><o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>SANO=
FI-AVENTIS,
S.A.<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DIT style=3D'mso-ansi-language:IT'>Ctra=
. C-35 (La
Batlloria-Hostalric), km. 63.09<o:p></o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>17404 <span class=3DSpellE>Riell=
s</span> <span
class=3DSpellE>i</span> <span class=3DSpellE>Viabrea</span> (Girona)  Spai=
n</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>For any information about this m=
edicinal
product, please contact the local representative of the Marketing Authorisa=
tion
Holder.</span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D624
 style=3D'margin-left:-1.7pt;border-collapse:collapse;mso-table-layout-alt:=
fixed;
 mso-padding-alt:0in 5.4pt 0in 5.4pt'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Be=
lgi/</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'>Belgique</span></b><b><span lang=
=3DMT
  style=3D'mso-ansi-language:MT'>/Belgien</span></b><b><span lang=3DFR-BE
  style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi <span class=3DSpellE>Belgium</span></span><=
span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>Tl/Tel: <span
  style=3D'layout-grid-mode:line'>+32 (0)2 710 54 00<o:p></o:p></span></spa=
n></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLT style=3D'mso-ansi-language:LT'>Li=
etuva<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>UAB
  sanofi-aventis Lietuva</span><span lang=3DFR style=3D'mso-ansi-language:F=
R'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+370 5 2755224<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><span class=3DSpellE><b><span lang=3DEN-GB>&#1041;&#=
1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></span><b><span
  lang=3DIT style=3D'mso-ansi-language:IT'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT;mso-no=
-proof:
  yes'>Sanofi Bulgaria EOOD<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  BG;mso-bidi-font-weight:bold'>&#1058;&#1077;&#1083;</span><span lang=3DIT
  style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT;mso-bidi-font-wei=
ght:
  bold'>.</span><span lang=3DBG style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
  BG;mso-bidi-font-weight:bold'>: +</span><span lang=3DIT style=3D'mso-bidi=
-font-size:
  11.0pt;mso-ansi-language:IT;mso-bidi-font-weight:bold'>359 (0)2</span><sp=
an
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial;
  mso-ansi-language:IT'> 970 53 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR-LU style=3D'mso-ansi-language:FR-=
LU'>Luxembourg/Luxemburg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;
  layout-grid-mode:line'>Sanofi <span class=3DSpellE>Belgium</span> <o:p></=
o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR-LU style=3D'mso-ansi-language:FR-LU'=
>Tl/Tel: </span><span
  lang=3DFR-BE style=3D'mso-ansi-language:FR-BE;layout-grid-mode:line'>+32 =
(0)2 710
  54 00 (</span><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'>Belgiq=
ue/<span
  class=3DSpellE>Belgien</span>)<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DHU style=3D'mso-ansi-language:HU'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>&#=
268;esk
  republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis,
  s.r.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+420 233
  086 111<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DHU style=3D'mso-ansi-language:HU'>Ma=
gyarorszg<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>SANOF=
I-AVENTIS
  Zrt.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel.:=
 +36 1 </span><span
  lang=3DHU style=3D'mso-ansi-language:HU'>505 0050<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Da=
nmark<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i A/S<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+45 45 16
  70 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DMT style=3D'mso-ansi-language:MT'>Ma=
lta<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+39 02
  39394275<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>De=
utschland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Sanof=
i-Aventis
  Deutschland GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
0800 52 52
  010<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel. =
aus dem
  Ausland: +49 69 305 21 131<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>Ne=
derland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Genzy=
me Europe B.V.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+31 20 245
  4000</span><span lang=3DNL style=3D'mso-ansi-language:NL'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DET style=3D'mso-ansi-language:ET'>Ee=
sti<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Estonia O<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+372 627
  34 88<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DET style=3D'mso-ansi-language:ET'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>No=
rge<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  Norge AS<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tlf: =
+47 67 10
  71 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
917;&#955;&#955;&#940;&#948;&#945;</span></b><b><span
  lang=3DCS style=3D'mso-ansi-language:CS'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  AEBE</span><span lang=3DET style=3D'mso-ansi-language:ET'><o:p></o:p></sp=
an></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;</span><span
  lang=3DCS style=3D'mso-ansi-language:CS'>: +30 210 900 16 00<o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DCS style=3D'mso-ansi-language:CS'>s=
terreich<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>sanof=
i-aventis
  GmbH<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Tel: =
+43 1 80
  185  0<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DES style=3D'mso-ansi-language:ES'>Es=
paa<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>sanof=
i-aventis,
  S.A.<span style=3D'font-variant:small-caps'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tel: =
+34 93 485
  94 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>Po=
lska<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>sanof=
i-aventis
  Sp. z o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel.:=
 +48
  22&nbsp;280 00 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:8;page-break-inside:avoid'>
  <td width=3D312 colspan=3D2 valign=3Dtop style=3D'width:233.9pt;padding:0=
in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Fr=
ance<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR-BE style=3D'mso-ansi-language:FR-BE'=
>sanofi-aventis
  France</span><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></=
span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Tl: =
0 800 222
  555<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Appel=
 depuis
  ltranger : +33 1 57 63 23 23<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DPT style=3D'mso-ansi-language:PT'>Po=
rtugal<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DPT style=3D'mso-ansi-language:PT'>Sanof=
i -
  Produtos Farmacuticos, Lda<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+351 21 35
  89 400<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:9;page-break-inside:avoid;mso-row-margin-left:1=
.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'page-break-after:avoid'><b><span lang=3DIT
  style=3D'mso-fareast-font-family:SimSun;mso-ansi-language:IT'>Hrvatska<o:=
p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:IT'>sanofi-aventis Croatia d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-fareast-font-family:Sim=
Sun;
  mso-ansi-language:FR'>Tel: +385 1 600 34 00</span><span lang=3DFR
  style=3D'mso-ansi-language:FR'><o:p></o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<b
  style=3D'mso-bidi-font-weight:normal'><span lang=3DIT style=3D'mso-bidi-f=
ont-size:
  11.0pt;mso-ansi-language:IT;mso-no-proof:yes'>Romnia<o:p></o:p></span></=
b></p>
  <p class=3DMsoNormal style=3D'mso-hyphenate:none;tab-stops:-.5in 3.15in'>=
<span
  lang=3DIT style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:IT'>Sanofi=
 Romania
  SRL<span style=3D'mso-no-proof:yes'><o:p></o:p></span></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  IT;mso-no-proof:yes'>Tel: +40 </span><span lang=3DIT style=3D'mso-bidi-fo=
nt-size:
  11.0pt;mso-ansi-language:IT'>(0) 21 317 31 36<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:10;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DFR style=3D'mso-ansi-language:FR'>Ir=
eland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis
  Ireland Ltd. T/A SANOFI<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>Tel: =
+353 (0) 1
  403 56 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSL style=3D'mso-ansi-language:SL'>Sl=
ovenija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>sanof=
i-aventis
  d.o.o.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-ansi-language:CS'>Tel: =
+386 1 560
  48 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'><o:p>&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:11;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIS style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:IS'>sland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Vistor hf.</span><span lang=3DIS style=3D'mso-bidi-font-size:11.0pt;
  mso-ansi-language:IS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0p=
t;
  mso-no-proof:yes'>Smi</span><span lang=3DCS style=3D'mso-bidi-font-size:=
11.0pt;
  mso-ansi-language:CS'>: +354 535 7000<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSK style=3D'mso-bidi-font-size:11.0p=
t;
  mso-ansi-language:SK'>Slovensk republika<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  SK'>sanofi-</span><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;mso-=
ansi-language:
  CS'>aventis Slovakia </span><span lang=3DSK style=3D'mso-bidi-font-size:1=
1.0pt;
  mso-ansi-language:SK'>s.r.o.</span><span lang=3DCS style=3D'mso-bidi-font=
-size:
  11.0pt;mso-ansi-language:CS'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DCS style=3D'mso-bidi-font-size:11.0pt;m=
so-ansi-language:
  CS'>Tel: +</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
  SK'>421 2 </span><span lang=3DEN-GB style=3D'mso-bidi-font-size:11.0pt'>3=
3 100
  100</span><span lang=3DSK style=3D'mso-bidi-font-size:11.0pt;mso-ansi-lan=
guage:
  SK'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:12;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>It=
alia<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i S.r.l.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Tel: =
</span><span
  lang=3DFR style=3D'mso-ansi-language:FR'>800 536389</span><span lang=3DIT
  style=3D'mso-ansi-language:IT'><o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DIT style=3D'mso-ansi-language:IT'>Su=
omi/Finland<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Sanof=
i Oy<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Puh/T=
el: +358
  (0) 201 200 300<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:13;page-break-inside:avoid;mso-row-margin-left:=
1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DEL style=3D'mso-ansi-language:EL'>&#=
922;&#973;&#960;&#961;&#959;&#962;</span></b><b><span
  lang=3DFR style=3D'mso-ansi-language:FR'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'>sanof=
i-aventis <span
  class=3DSpellE>Cyprus</span> Ltd.<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DEL style=3D'mso-ansi-language:EL'>&#932=
;&#951;&#955;:
  +</span><span lang=3DFR style=3D'mso-ansi-language:FR'>357 22 871600<o:p>=
</o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Sv=
erige<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i AB<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+46 (0)8
  634 50 00<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:14;mso-yfti-lastrow:yes;page-break-inside:avoid;
  mso-row-margin-left:1.7pt'>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0in 0in 0in=
 0in'
  width=3D2><p class=3D'MsoNormal'>&nbsp;</td>
  <td width=3D310 valign=3Dtop style=3D'width:232.2pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DLV style=3D'mso-ansi-language:LV'>La=
tvija<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>sanof=
i-aventis
  Latvia SIA<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DIT style=3D'mso-ansi-language:IT'>Tel: =
+371 67 33
  24 51<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
  <td width=3D312 valign=3Dtop style=3D'width:233.9pt;padding:0in 5.4pt 0in=
 5.4pt'>
  <p class=3DMsoNormal><b><span lang=3DSV style=3D'mso-ansi-language:SV'>Un=
ited
  Kingdom<o:p></o:p></span></b></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Sanof=
i<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DSV style=3D'mso-ansi-language:SV'>Tel: =
+44 (0)
  845 372 7101<o:p></o:p></span></p>
  <p class=3DMsoNormal><span lang=3DLV style=3D'mso-ansi-language:LV'><o:p>=
&nbsp;</o:p></span></p>
  </td>
 </tr>
 <![if !supportMisalignedColumns]>
 <tr height=3D0>
  <td width=3D2 style=3D'border:none'></td>
  <td width=3D310 style=3D'border:none'></td>
  <td width=3D312 style=3D'border:none'></td>
 </tr>
 <![endif]>
</table>

<p class=3DMsoNormal><span lang=3DFR style=3D'mso-ansi-language:FR'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DEMEABodyText><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DEN-GB>This
leaflet was last revised in</span></b></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB>Detailed information on this med=
icine is
available on the European Medicines Agency web site: http://www.ema.europa.=
eu/</span><span
lang=3DEN-GB style=3D'font-size:9.0pt;font-family:"Verdana",sans-serif;mso-=
fareast-font-family:
Verdana;mso-bidi-font-family:Verdana;mso-fareast-language:EN-GB'> <o:p></o:=
p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

<p class=3DEMEABodyText><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

</div>

</body>

</html>

------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/item0001.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"utf-8"?><ct:contentTypeSchema ct:_=3D"" m=
a:_=3D"" ma:contentTypeName=3D"Document" ma:contentTypeID=3D"0x010100726F91=
DD1AE57B44B1BCEB7F1056F5D0" ma:contentTypeVersion=3D"6" ma:contentTypeDescr=
iption=3D"Create a new document." ma:contentTypeScope=3D"" ma:versionID=3D"=
80d1dd17cb0c17b7740334051d5d16b2" xmlns:ct=3D"http://schemas.microsoft.com/=
office/2006/metadata/contentType" xmlns:ma=3D"http://schemas.microsoft.com/=
office/2006/metadata/properties/metaAttributes">
<xsd:schema targetNamespace=3D"http://schemas.microsoft.com/office/2006/met=
adata/properties" ma:root=3D"true" ma:fieldsID=3D"c170dc105f61f60cf84b7b3e6=
d807e4f" ns2:_=3D"" ns3:_=3D"" xmlns:xsd=3D"http://www.w3.org/2001/XMLSchem=
a" xmlns:xs=3D"http://www.w3.org/2001/XMLSchema" xmlns:p=3D"http://schemas.=
microsoft.com/office/2006/metadata/properties" xmlns:ns2=3D"a6a35199-84b7-4=
ca5-aa1c-39e9ca4c46ff" xmlns:ns3=3D"0ac2e3cc-46bd-4320-b2ac-d7f7d167e1a9">
<xsd:import namespace=3D"a6a35199-84b7-4ca5-aa1c-39e9ca4c46ff"/>
<xsd:import namespace=3D"0ac2e3cc-46bd-4320-b2ac-d7f7d167e1a9"/>
<xsd:element name=3D"properties">
<xsd:complexType>
<xsd:sequence>
<xsd:element name=3D"documentManagement">
<xsd:complexType>
<xsd:all>
<xsd:element ref=3D"ns2:MediaServiceMetadata" minOccurs=3D"0"/>
<xsd:element ref=3D"ns2:MediaServiceFastMetadata" minOccurs=3D"0"/>
<xsd:element ref=3D"ns2:MediaServiceAutoKeyPoints" minOccurs=3D"0"/>
<xsd:element ref=3D"ns2:MediaServiceKeyPoints" minOccurs=3D"0"/>
<xsd:element ref=3D"ns3:SharedWithUsers" minOccurs=3D"0"/>
<xsd:element ref=3D"ns3:SharedWithDetails" minOccurs=3D"0"/>
</xsd:all>
</xsd:complexType>
</xsd:element>
</xsd:sequence>
</xsd:complexType>
</xsd:element>
</xsd:schema>
<xsd:schema targetNamespace=3D"a6a35199-84b7-4ca5-aa1c-39e9ca4c46ff" elemen=
tFormDefault=3D"qualified" xmlns:xsd=3D"http://www.w3.org/2001/XMLSchema" x=
mlns:xs=3D"http://www.w3.org/2001/XMLSchema" xmlns:dms=3D"http://schemas.mi=
crosoft.com/office/2006/documentManagement/types" xmlns:pc=3D"http://schema=
s.microsoft.com/office/infopath/2007/PartnerControls">
<xsd:import namespace=3D"http://schemas.microsoft.com/office/2006/documentM=
anagement/types"/>
<xsd:import namespace=3D"http://schemas.microsoft.com/office/infopath/2007/=
PartnerControls"/>
<xsd:element name=3D"MediaServiceMetadata" ma:index=3D"8" nillable=3D"true"=
 ma:displayName=3D"MediaServiceMetadata" ma:hidden=3D"true" ma:internalName=
=3D"MediaServiceMetadata" ma:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note"/>
</xsd:simpleType>
</xsd:element>
<xsd:element name=3D"MediaServiceFastMetadata" ma:index=3D"9" nillable=3D"t=
rue" ma:displayName=3D"MediaServiceFastMetadata" ma:hidden=3D"true" ma:inte=
rnalName=3D"MediaServiceFastMetadata" ma:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note"/>
</xsd:simpleType>
</xsd:element>
<xsd:element name=3D"MediaServiceAutoKeyPoints" ma:index=3D"10" nillable=3D=
"true" ma:displayName=3D"MediaServiceAutoKeyPoints" ma:hidden=3D"true" ma:i=
nternalName=3D"MediaServiceAutoKeyPoints" ma:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note"/>
</xsd:simpleType>
</xsd:element>
<xsd:element name=3D"MediaServiceKeyPoints" ma:index=3D"11" nillable=3D"tru=
e" ma:displayName=3D"KeyPoints" ma:internalName=3D"MediaServiceKeyPoints" m=
a:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note">
<xsd:maxLength value=3D"255"/>
</xsd:restriction>
</xsd:simpleType>
</xsd:element>
</xsd:schema>
<xsd:schema targetNamespace=3D"0ac2e3cc-46bd-4320-b2ac-d7f7d167e1a9" elemen=
tFormDefault=3D"qualified" xmlns:xsd=3D"http://www.w3.org/2001/XMLSchema" x=
mlns:xs=3D"http://www.w3.org/2001/XMLSchema" xmlns:dms=3D"http://schemas.mi=
crosoft.com/office/2006/documentManagement/types" xmlns:pc=3D"http://schema=
s.microsoft.com/office/infopath/2007/PartnerControls">
<xsd:import namespace=3D"http://schemas.microsoft.com/office/2006/documentM=
anagement/types"/>
<xsd:import namespace=3D"http://schemas.microsoft.com/office/infopath/2007/=
PartnerControls"/>
<xsd:element name=3D"SharedWithUsers" ma:index=3D"12" nillable=3D"true" ma:=
displayName=3D"Shared With" ma:internalName=3D"SharedWithUsers" ma:readOnly=
=3D"true">
<xsd:complexType>
<xsd:complexContent>
<xsd:extension base=3D"dms:UserMulti">
<xsd:sequence>
<xsd:element name=3D"UserInfo" minOccurs=3D"0" maxOccurs=3D"unbounded">
<xsd:complexType>
<xsd:sequence>
<xsd:element name=3D"DisplayName" type=3D"xsd:string" minOccurs=3D"0"/>
<xsd:element name=3D"AccountId" type=3D"dms:UserId" minOccurs=3D"0" nillabl=
e=3D"true"/>
<xsd:element name=3D"AccountType" type=3D"xsd:string" minOccurs=3D"0"/>
</xsd:sequence>
</xsd:complexType>
</xsd:element>
</xsd:sequence>
</xsd:extension>
</xsd:complexContent>
</xsd:complexType>
</xsd:element>
<xsd:element name=3D"SharedWithDetails" ma:index=3D"13" nillable=3D"true" m=
a:displayName=3D"Shared With Details" ma:internalName=3D"SharedWithDetails"=
 ma:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note">
<xsd:maxLength value=3D"255"/>
</xsd:restriction>
</xsd:simpleType>
</xsd:element>
</xsd:schema>
<xsd:schema targetNamespace=3D"http://schemas.openxmlformats.org/package/20=
06/metadata/core-properties" elementFormDefault=3D"qualified" attributeForm=
Default=3D"unqualified" blockDefault=3D"#all" xmlns=3D"http://schemas.openx=
mlformats.org/package/2006/metadata/core-properties" xmlns:xsd=3D"http://ww=
w.w3.org/2001/XMLSchema" xmlns:xsi=3D"http://www.w3.org/2001/XMLSchema-inst=
ance" xmlns:dc=3D"http://purl.org/dc/elements/1.1/" xmlns:dcterms=3D"http:/=
/purl.org/dc/terms/" xmlns:odoc=3D"http://schemas.microsoft.com/internal/ob=
d">
<xsd:import namespace=3D"http://purl.org/dc/elements/1.1/" schemaLocation=
=3D"http://dublincore.org/schemas/xmls/qdc/2003/04/02/dc.xsd"/>
<xsd:import namespace=3D"http://purl.org/dc/terms/" schemaLocation=3D"http:=
//dublincore.org/schemas/xmls/qdc/2003/04/02/dcterms.xsd"/>
<xsd:element name=3D"coreProperties" type=3D"CT_coreProperties"/>
<xsd:complexType name=3D"CT_coreProperties">
<xsd:all>
<xsd:element ref=3D"dc:creator" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element ref=3D"dcterms:created" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element ref=3D"dc:identifier" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element name=3D"contentType" minOccurs=3D"0" maxOccurs=3D"1" type=3D"x=
sd:string" ma:index=3D"0" ma:displayName=3D"Content Type"/>
<xsd:element ref=3D"dc:title" minOccurs=3D"0" maxOccurs=3D"1" ma:index=3D"4=
" ma:displayName=3D"Title"/>
<xsd:element ref=3D"dc:subject" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element ref=3D"dc:description" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element name=3D"keywords" minOccurs=3D"0" maxOccurs=3D"1" type=3D"xsd:=
string"/>
<xsd:element ref=3D"dc:language" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element name=3D"category" minOccurs=3D"0" maxOccurs=3D"1" type=3D"xsd:=
string"/>
<xsd:element name=3D"version" minOccurs=3D"0" maxOccurs=3D"1" type=3D"xsd:s=
tring"/>
<xsd:element name=3D"revision" minOccurs=3D"0" maxOccurs=3D"1" type=3D"xsd:=
string">
<xsd:annotation>
<xsd:documentation>
                        This value indicates the number of saves or revisio=
ns. The application is responsible for updating this value after each revis=
ion.
                    </xsd:documentation>
</xsd:annotation>
</xsd:element>
<xsd:element name=3D"lastModifiedBy" minOccurs=3D"0" maxOccurs=3D"1" type=
=3D"xsd:string"/>
<xsd:element ref=3D"dcterms:modified" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element name=3D"contentStatus" minOccurs=3D"0" maxOccurs=3D"1" type=3D=
"xsd:string"/>
</xsd:all>
</xsd:complexType>
</xsd:schema>
<xs:schema targetNamespace=3D"http://schemas.microsoft.com/office/infopath/=
2007/PartnerControls" elementFormDefault=3D"qualified" attributeFormDefault=
=3D"unqualified" xmlns:pc=3D"http://schemas.microsoft.com/office/infopath/2=
007/PartnerControls" xmlns:xs=3D"http://www.w3.org/2001/XMLSchema">
<xs:element name=3D"Person">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:DisplayName" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:AccountId" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:AccountType" minOccurs=3D"0"></xs:element>
</xs:sequence>
</xs:complexType>
</xs:element>
<xs:element name=3D"DisplayName" type=3D"xs:string"></xs:element>
<xs:element name=3D"AccountId" type=3D"xs:string"></xs:element>
<xs:element name=3D"AccountType" type=3D"xs:string"></xs:element>
<xs:element name=3D"BDCAssociatedEntity">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:BDCEntity" minOccurs=3D"0" maxOccurs=3D"unbounded"></=
xs:element>
</xs:sequence>
<xs:attribute ref=3D"pc:EntityNamespace"></xs:attribute>
<xs:attribute ref=3D"pc:EntityName"></xs:attribute>
<xs:attribute ref=3D"pc:SystemInstanceName"></xs:attribute>
<xs:attribute ref=3D"pc:AssociationName"></xs:attribute>
</xs:complexType>
</xs:element>
<xs:attribute name=3D"EntityNamespace" type=3D"xs:string"></xs:attribute>
<xs:attribute name=3D"EntityName" type=3D"xs:string"></xs:attribute>
<xs:attribute name=3D"SystemInstanceName" type=3D"xs:string"></xs:attribute>
<xs:attribute name=3D"AssociationName" type=3D"xs:string"></xs:attribute>
<xs:element name=3D"BDCEntity">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:EntityDisplayName" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityInstanceReference" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId1" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId2" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId3" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId4" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId5" minOccurs=3D"0"></xs:element>
</xs:sequence>
</xs:complexType>
</xs:element>
<xs:element name=3D"EntityDisplayName" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityInstanceReference" type=3D"xs:string"></xs:elemen=
t>
<xs:element name=3D"EntityId1" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityId2" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityId3" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityId4" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityId5" type=3D"xs:string"></xs:element>
<xs:element name=3D"Terms">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:TermInfo" minOccurs=3D"0" maxOccurs=3D"unbounded"></x=
s:element>
</xs:sequence>
</xs:complexType>
</xs:element>
<xs:element name=3D"TermInfo">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:TermName" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:TermId" minOccurs=3D"0"></xs:element>
</xs:sequence>
</xs:complexType>
</xs:element>
<xs:element name=3D"TermName" type=3D"xs:string"></xs:element>
<xs:element name=3D"TermId" type=3D"xs:string"></xs:element>
</xs:schema>
</ct:contentTypeSchema>
------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/props002.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{3E493170-E3CC-4F09-8581-D558CA301396}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.microsoft.com/office/20=
06/metadata/contentType"/><ds:schemaRef ds:uri=3D"http://schemas.microsoft.=
com/office/2006/metadata/properties/metaAttributes"/><ds:schemaRef ds:uri=
=3D"http://www.w3.org/2001/XMLSchema"/><ds:schemaRef ds:uri=3D"http://schem=
as.microsoft.com/office/2006/metadata/properties"/><ds:schemaRef ds:uri=3D"=
a6a35199-84b7-4ca5-aa1c-39e9ca4c46ff"/><ds:schemaRef ds:uri=3D"0ac2e3cc-46b=
d-4320-b2ac-d7f7d167e1a9"/><ds:schemaRef ds:uri=3D"http://schemas.microsoft=
.com/office/2006/documentManagement/types"/><ds:schemaRef ds:uri=3D"http://=
schemas.microsoft.com/office/infopath/2007/PartnerControls"/><ds:schemaRef =
ds:uri=3D"http://schemas.openxmlformats.org/package/2006/metadata/core-prop=
erties"/><ds:schemaRef ds:uri=3D"http://purl.org/dc/elements/1.1/"/><ds:sch=
emaRef ds:uri=3D"http://purl.org/dc/terms/"/><ds:schemaRef ds:uri=3D"http:/=
/schemas.microsoft.com/internal/obd"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/item0003.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?mso-contentType?><FormTemplates xmlns=3D"http://schemas.microsoft.com/sha=
repoint/v3/contenttype/forms"><Display>DocumentLibraryForm</Display><Edit>D=
ocumentLibraryForm</Edit><New>DocumentLibraryForm</New></FormTemplates>
------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/props004.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{BF8FCB15-0182-438A-B9C3-A1664BB818DB}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.microsoft.com/sharepoin=
t/v3/contenttype/forms"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/item0005.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?><b:Sources Sele=
ctedStyle=3D"\APA.XSL" StyleName=3D"APA" xmlns:b=3D"http://schemas.openxmlf=
ormats.org/officeDocument/2006/bibliography" xmlns=3D"http://schemas.openxm=
lformats.org/officeDocument/2006/bibliography"></b:Sources>
------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/props006.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{3EC7A98C-0945-4A11-A5D4-B141FE6A9555}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.openxmlformats.org/offi=
ceDocument/2006/bibliography"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/item0007.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"utf-8"?><p:properties xmlns:p=3D"http://s=
chemas.microsoft.com/office/2006/metadata/properties" xmlns:xsi=3D"http://w=
ww.w3.org/2001/XMLSchema-instance" xmlns:pc=3D"http://schemas.microsoft.com=
/office/infopath/2007/PartnerControls"><documentManagement/></p:properties>
------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/props008.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{EA1EF326-798A-46DE-B7FB-E921A1345A1D}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.microsoft.com/office/20=
06/metadata/properties"/><ds:schemaRef ds:uri=3D"http://schemas.microsoft.c=
om/office/infopath/2007/PartnerControls"/></ds:schemaRefs></ds:datastoreIte=
m>
------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme
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------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/header.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1252"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
2">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 15">
<meta name=3DOriginator content=3D"Microsoft Word 15">
<link id=3DMain-File rel=3DMain-File href=3D"../Karvea_clean.htm">
<![if IE]>
<base href=3D"file:///C:/0467A08E/Karvea_clean_files/header.htm"
id=3D"webarch_temp_base_tag">
<![endif]><o:SmartTagType
 namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags" name=3D"City"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"place"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"PersonName"/>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"3074"/>
</xml><![endif]-->
</head>

<body lang=3DEN-US link=3Dblue vlink=3D"#954F72">

<div style=3D'mso-element:footnote-separator' id=3Dfs>

<p class=3DMsoNormal><span lang=3DEN-GB><span style=3D'mso-special-characte=
r:footnote-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-separator' id=3Dfcs>

<p class=3DMsoNormal><span lang=3DEN-GB><span style=3D'mso-special-characte=
r:footnote-continuation-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:endnote-separator' id=3Des>

<p class=3DMsoNormal><span lang=3DEN-GB><span style=3D'mso-special-characte=
r:footnote-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-separator' id=3Decs>

<p class=3DMsoNormal><span lang=3DEN-GB><span style=3D'mso-special-characte=
r:footnote-continuation-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:footer' id=3Def1>

<div style=3D'mso-element:frame;mso-element-wrap:around;mso-element-anchor-=
vertical:
paragraph;mso-element-anchor-horizontal:margin;mso-element-left:center;
mso-element-top:.05pt;mso-height-rule:exactly'>

<table cellspacing=3D0 cellpadding=3D0 hspace=3D0 vspace=3D0 align=3Dcenter>
 <tr>
  <td valign=3Dtop align=3Dleft style=3D'padding-top:0in;padding-right:0in;
  padding-bottom:0in;padding-left:0in'>
  <p class=3DMsoFooter style=3D'mso-element:frame;mso-element-wrap:around;
  mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:margi=
n;
  mso-element-left:center;mso-element-top:.05pt;mso-height-rule:exactly'><!=
--[if supportFields]><span
  class=3DMsoPageNumber><span lang=3DEN-GB><span style=3D'mso-element:field=
-begin'></span>PAGE<span
  style=3D'mso-spacerun:yes'> </span></span></span><![endif]--><!--[if sup=
portFields]><span
  class=3DMsoPageNumber><span lang=3DEN-GB><span style=3D'mso-element:field=
-end'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span lang=3DEN-GB><o:p></o:p></span></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoFooter><span lang=3DEN-GB><o:p>&nbsp;</o:p></span></p>

</div>

<div style=3D'mso-element:footer' id=3Df1>

<div style=3D'mso-element:frame;mso-element-wrap:around;mso-element-anchor-=
vertical:
paragraph;mso-element-anchor-horizontal:margin;mso-element-left:center;
mso-element-top:.05pt;mso-height-rule:exactly'>

<table cellspacing=3D0 cellpadding=3D0 hspace=3D0 vspace=3D0 align=3Dcenter>
 <tr>
  <td valign=3Dtop align=3Dleft style=3D'padding-top:0in;padding-right:0in;
  padding-bottom:0in;padding-left:0in'>
  <p class=3DMsoFooter style=3D'mso-element:frame;mso-element-wrap:around;
  mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:margi=
n;
  mso-element-left:center;mso-element-top:.05pt;mso-height-rule:exactly'><!=
--[if supportFields]><span
  class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-size:8.0pt;mso-bid=
i-font-size:
  10.0pt;font-family:"Arial",sans-serif'><span style=3D'mso-element:field-b=
egin'></span>PAGE<span
  style=3D'mso-spacerun:yes'> </span><span style=3D'mso-element:field-sepa=
rator'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-size:8.0pt;mso-bid=
i-font-size:
  10.0pt;font-family:"Arial",sans-serif'><span style=3D'mso-no-proof:yes'>2=
</span></span></span><!--[if supportFields]><span
  class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-size:8.0pt;mso-bid=
i-font-size:
  10.0pt;font-family:"Arial",sans-serif'><span style=3D'mso-element:field-e=
nd'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-size:8.0pt;mso-bid=
i-font-size:
  10.0pt;font-family:"Arial",sans-serif'><o:p></o:p></span></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoFooter><span lang=3DEN-GB style=3D'font-size:8.0pt;mso-bidi-f=
ont-size:
10.0pt;font-family:"Arial",sans-serif'><o:p>&nbsp;</o:p></span></p>

</div>

<div style=3D'mso-element:footer' id=3Dff1>

<p class=3DMsoFooter align=3Dcenter style=3D'margin-right:4.8pt;text-align:=
center;
tab-stops:center 3.0in right 6.0in 446.55pt'><!--[if supportFields]><span
lang=3DEN-GB><span style=3D'mso-element:field-begin'></span><span
style=3D'mso-spacerun:yes'></span>EQ </span><![endif]--><!--[if supportFie=
lds]><span
lang=3DEN-GB><span style=3D'mso-element:field-end'></span></span><![endif]-=
-><!--[if supportFields]><span
class=3DMsoPageNumber><span lang=3DEN-GB><span style=3D'mso-element:field-b=
egin'></span>PAGE<span
style=3D'mso-spacerun:yes'> </span><span style=3D'mso-element:field-separa=
tor'></span></span></span><![endif]--><span
class=3DMsoPageNumber><span lang=3DEN-GB><span style=3D'mso-no-proof:yes'>1=
</span></span></span><!--[if supportFields]><span
class=3DMsoPageNumber><span lang=3DEN-GB><span style=3D'mso-element:field-e=
nd'></span></span></span><![endif]--></p>

</div>

</body>

</html>

------=_NextPart_01D74B3E.EF6E2E70
Content-Location: file:///C:/0467A08E/Karvea_clean_files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../Karvea_clean.htm"/>
 <o:File HRef=3D"item0001.xml"/>
 <o:File HRef=3D"props002.xml"/>
 <o:File HRef=3D"item0003.xml"/>
 <o:File HRef=3D"props004.xml"/>
 <o:File HRef=3D"item0005.xml"/>
 <o:File HRef=3D"props006.xml"/>
 <o:File HRef=3D"item0007.xml"/>
 <o:File HRef=3D"props008.xml"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"header.htm"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01D74B3E.EF6E2E70--
